<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002229.pub4" GROUP_ID="VASC" ID="704300052310324063" MERGED_FROM="" MODIFIED="2015-08-19 12:02:01 +0100" MODIFIED_BY="Nicole Martin" REVIEW_NO="9908" REVMAN_SUB_VERSION="5.3.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="15.0">
<COVER_SHEET MODIFIED="2015-08-19 12:02:01 +0100" MODIFIED_BY="Nicole Martin">
<TITLE MODIFIED="2013-03-18 14:27:36 +0000" MODIFIED_BY="Diane Horsley">Hormone therapy for preventing cardiovascular disease in post-menopausal women</TITLE>
<CONTACT MODIFIED="2015-08-19 12:02:01 +0100" MODIFIED_BY="Nicole Martin"><PERSON ID="z1211291154102651428747101421744" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Henry</FIRST_NAME><MIDDLE_INITIALS>MP</MIDDLE_INITIALS><LAST_NAME>Boardman</LAST_NAME><POSITION>Clinical Research Fellow</POSITION><EMAIL_1>Harry.Boardman@cochrane.nhs.uk</EMAIL_1><EMAIL_2>hboardman@doctors.org.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Cardiovascular Medicine</DEPARTMENT><ORGANISATION>University of Oxford, John Radcliffe Hospital</ORGANISATION><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-08-19 12:02:01 +0100" MODIFIED_BY="Nicole Martin"><PERSON ID="z1211291154102651428747101421744" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Henry</FIRST_NAME><MIDDLE_INITIALS>MP</MIDDLE_INITIALS><LAST_NAME>Boardman</LAST_NAME><POSITION>Clinical Research Fellow</POSITION><EMAIL_1>Harry.Boardman@cochrane.nhs.uk</EMAIL_1><EMAIL_2>hboardman@doctors.org.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Cardiovascular Medicine</DEPARTMENT><ORGANISATION>University of Oxford, John Radcliffe Hospital</ORGANISATION><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="71031742632037279824110616111954" ROLE="AUTHOR"><FIRST_NAME>Louise</FIRST_NAME><LAST_NAME>Hartley</LAST_NAME><POSITION>Cochrane Systematic Reviewer</POSITION><EMAIL_1>Lu_Hartley@yahoo.co.uk</EMAIL_1><EMAIL_2>l.c.hartley@warwick.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Division of Health Sciences</DEPARTMENT><ORGANISATION>Warwick Medical School, University of Warwick</ORGANISATION><CITY>Coventry</CITY><ZIP>CV4 7AL</ZIP><REGION>Warwickshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>02476 151592</PHONE_1></ADDRESS></PERSON><PERSON ID="7094" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Eisinga</LAST_NAME><EMAIL_1>anne.eisinga@cochrane.nhs.uk</EMAIL_1><ADDRESS><ORGANISATION>UK Cochrane Centre</ORGANISATION><ADDRESS_1>National Institute for Health Research</ADDRESS_1><ADDRESS_2>Summertown Pavilion, Middle Way</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 7LG</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 516300</PHONE_1><FAX_1>+44 1865 516311</FAX_1></ADDRESS></PERSON><PERSON ID="ED4B84A982E26AA20078D4E61F090D9E" ROLE="AUTHOR"><FIRST_NAME>Caroline</FIRST_NAME><LAST_NAME>Main</LAST_NAME><POSITION>Systematic Reviewer</POSITION><EMAIL_1>carriemain24@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Cancer Research UK Clinical Trials Unit (CRCTU), School of Cancer Sciences</DEPARTMENT><ORGANISATION>University of Birmingham</ORGANISATION><CITY>Birmingham</CITY><ZIP>B15 2TT</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="AAD7845D82E26AA20130726F85E76FD4" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Marta</FIRST_NAME><LAST_NAME>Roqué i Figuls</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>mroque@santpau.cat</EMAIL_1><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 171</ADDRESS_1><ADDRESS_2>Edifici Casa de Convalescència</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08041</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935 537 814</PHONE_1><PHONE_2>+34 935 537 808</PHONE_2><FAX_1>+34 935 537 809</FAX_1></ADDRESS></PERSON><PERSON ID="D3B1F77E82E26AA200831C1940F4DA2E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xavier</FIRST_NAME><LAST_NAME>Bonfill Cosp</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>xbonfill@santpau.cat</EMAIL_1><EMAIL_2>director@cochrane.es, XBonfill@hsp.santpau.es</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret, 167</ADDRESS_1><ADDRESS_2>Pavilion 18 (D-13)</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 553 78 10</PHONE_1><PHONE_2>+34 93 553 78 14</PHONE_2><FAX_1>+34 93 553 78 09</FAX_1></ADDRESS></PERSON><PERSON ID="18932" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rafael</FIRST_NAME><LAST_NAME>Gabriel Sanchez</LAST_NAME><POSITION>Head</POSITION><EMAIL_1>rgabriel.hulp@salud.madrid.org</EMAIL_1><EMAIL_2>rgsanchez@hup.es</EMAIL_2><ADDRESS><DEPARTMENT>Instituto de Investigacion IdiPAZ, Red Espanola de Investigacion Cardiovascular RD/12/0042/0008</DEPARTMENT><ORGANISATION>Hospital Universitario de la Paz, Universidad Autónoma de Madrid</ORGANISATION><ADDRESS_1>Diego De Leon 62</ADDRESS_1><ADDRESS_2>Planta 9</ADDRESS_2><CITY>Madrid</CITY><ZIP>28006</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 91 520 2338</PHONE_1><FAX_1>+34 91 520 2338</FAX_1></ADDRESS></PERSON><PERSON ID="66340690609787759129100917125752" ROLE="AUTHOR"><FIRST_NAME>Beatrice</FIRST_NAME><LAST_NAME>Knight</LAST_NAME><EMAIL_1>B.A.Knight@exeter.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>NIHR Exeter Clinical Research Facility</DEPARTMENT><ORGANISATION>University of Exeter Medical School</ORGANISATION><CITY>Exeter</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-03-04 16:06:45 +0000" MODIFIED_BY="Henry Boardman">
<UP_TO_DATE>
<DATE DAY="25" MONTH="2" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="2" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="25" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-08-19 11:54:36 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-08-19 11:54:32 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>Feedback and response included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-08-19 11:54:36 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-08-19 11:54:36 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>Minor edit in footnotes of Summary of Findings table. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-05-18 13:40:13 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="2" YEAR="2014"/>
<DESCRIPTION>
<P>We included six new trials, with a total of 2239 participants in this review update. The review now includes 40,410 women randomised to either hormone therapy or no treatment/placebo. Nine trials were primary prevention and ten were secondary prevention trials.</P>
<P>We updated the searches to February 2014 and combined the cardiovascular outcomes of coronary artery bypass graft and angioplasty under "Revascularisation". We excluded health-related quality of life from the outcomes. We combined single and combination therapy for analysis. We have presented subgroup analysis results for the timing hypothesis. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-18 13:40:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="2" YEAR="2014"/>
<DESCRIPTION>
<P>Date of search February 2014.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-02-01 05:34:51 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>We updated the searches to April 2010, and included the cardiovascular outcomes of angina, coronary artery bypass graft, angioplasty, and health-related quality of life as further relevant additional outcomes.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-02-01 05:30:03 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>We included four new trials, with a total of 15,984 participants in the review update. We included one trial in the previous review and excluded the open-label long-term follow-up of another trial. The review update therefore included 13 randomised controlled trials with a total of 38,171 women randomised to either hormone therapy or placebo. Five trials were primary prevention and eight were secondary prevention trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-01 05:25:50 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>The results and conclusion of the update review have not changed from those of the original review. However, there is further substantive evidence that treatment with hormone therapy in post-menopausal women for either primary or secondary prevention of cardiovascular disease events is not effective, and causes an increase in the risk of stroke, and venous thromboembolic events.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-02-03 13:08:33 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2015-02-03 13:08:33 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-02-03 13:08:33 +0000" MODIFIED_BY="[Empty name]">
<NAME>UK Cochrane Centre</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Cochrane Fellowship Grant</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-12-02 15:48:23 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-12-02 15:48:23 +0000" MODIFIED_BY="[Empty name]">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Cochrane Programme Grant</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-05-18 09:35:22 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-03-06 15:16:05 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-02-09 13:58:17 +0000" MODIFIED_BY="[Empty name]">Hormone therapy for preventing cardiovascular disease in both healthy post-menopausal women and post-menopausal women with pre-existing cardiovascular disease</TITLE>
<SUMMARY_BODY MODIFIED="2015-03-06 15:16:05 +0000" MODIFIED_BY="[Empty name]">
<P>Hormone therapy is used for controlling menopausal symptoms. It has also been used for the prevention of cardiovascular disease in post-menopausal women. The present review assessed the effects of using hormone therapy for six months or more. Nineteen randomised controlled trials (involving 40,410 women) compared oral hormone therapy (oestrogen, with or without progestogen) with placebo. Most participants were from the Unites States (US), and the mean age in most studies was over 60 years. The length of time women were on treatment varied across the trials from 7 months to 10.1 years. The studies were generally well conducted with overall low risk of bias.<BR/>
<BR/>Overall, results showed no evidence that hormone therapy provides any protective effects against death from any cause, death specifically from cardiovascular disease, non-fatal heart attack or angina, either in healthy women or women with pre-existing heart disease. Rather, in post-menopausal women hormone therapy increased the risk of stroke and obstruction of a vein by a blood clot (venous thromboembolism).</P>
<P>We are confident that the results of are review are close to the true effects for most of the outcomes we looked at. The studies were large, well-designed and the results were generally consistent across the studies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-03-06 15:14:13 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-02-03 15:21:29 +0000" MODIFIED_BY="[Empty name]">
<P>Evidence from systematic reviews of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of cardiovascular disease events in post-menopausal women, however the results of randomised controlled trials (RCTs) have had mixed results. This is an updated version of a Cochrane review published in 2013.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-02-01 05:52:00 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of hormone therapy for the prevention of cardiovascular disease in post-menopausal women, and whether there are differential effects between use in primary or secondary prevention.<BR/>
<BR/>Secondary aims were to undertake exploratory analyses to (i) assess the impact of time since menopause that treatment was commenced (&#8805; 10 years versus &lt; 10 years), and where these data were not available, use age of trial participants at baseline as a proxy (&#8805; 60 years of age versus &lt; 60 years of age); and (ii) assess the effects of length of time on treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-02-03 15:44:15 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the following databases on 25 February 2014: Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I>, MEDLINE, EMBASE and LILACS. We also searched research and trials registers, and conducted reference checking of relevant studies and related systematic reviews to identify additional studies. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-02-02 00:58:48 +0000" MODIFIED_BY="[Empty name]">
<P>RCTs of women comparing orally administered hormone therapy with placebo or a no treatment control, with a minimum of six months follow-up.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-02-01 06:04:58 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed study quality and extracted data. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for each outcome. We combined results using random effects meta-analyses, and undertook further analyses to assess the effects of treatment as primary or secondary prevention, and whether treatment was commenced more than or less than 10 years after menopause.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-03-03 14:59:56 +0000" MODIFIED_BY="[Empty name]">
<P>We identified six new trials through this update. Therefore the review includes 19 trials with a total of 40,410 post-menopausal women. On the whole, study quality was good and generally at low risk of bias; the findings are dominated by the three largest trials. We found high quality evidence that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality, cardiovascular death, non-fatal myocardial infarction, angina, or revascularisation. However, there was an increased risk of stroke in those in the hormone therapy arm for combined primary and secondary prevention (RR 1.24, 95% CI 1.10 to 1.41). Venous thromboembolic events were increased (RR 1.92, 95% CI 1.36 to 2.69), as were pulmonary emboli (RR 1.81, 95% CI 1.32 to 2.48) on hormone therapy relative to placebo.</P>
<P>The absolute risk increase for stroke was 6 per 1000 women (number needed to treat for an additional harmful outcome (NNTH) = 165; mean length of follow-up: 4.21 years (range: 2.0 to 7.1)); for venous thromboembolism 8 per 1000 women (NNTH = 118; mean length of follow-up: 5.95 years (range: 1.0 to 7.1)); and for pulmonary embolism 4 per 1000 (NNTH = 242; mean length of follow-up: 3.13 years (range: 1.0 to 7.1)).</P>
<P>We performed subgroup analyses according to when treatment was started in relation to the menopause. Those who started hormone therapy less than 10 years after the menopause had lower mortality (RR 0.70, 95% CI 0.52 to 0.95, moderate quality evidence) and coronary heart disease (composite of death from cardiovascular causes and non-fatal myocardial infarction) (RR 0.52, 95% CI 0.29 to 0.96; moderate quality evidence), though they were still at increased risk of venous thromboembolism (RR 1.74, 95% CI 1.11 to 2.73, high quality evidence) compared to placebo or no treatment. There was no strong evidence of effect on risk of stroke in this group. In those who started treatment more than 10 years after the menopause there was high quality evidence that it had little effect on death or coronary heart disease between groups but there was an increased risk of stroke (RR 1.21, 95% CI 1.06 to 1.38, high quality evidence) and venous thromboembolism (RR 1.96, 95% CI 1.37 to 2.80, high quality evidence).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-03-06 15:14:13 +0000" MODIFIED_BY="[Empty name]">
<P>Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women overall, for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-03-06 15:25:34 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-03-06 15:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Despite falling incidence of coronary heart disease and stroke, which makes up the majority of cardiovascular disease, there is increasing prevalence due to lower case-fatality. It remains the leading cause of death in both high- and middle-income countries (<LINK REF="REF-WHO-2008" TYPE="REFERENCE">WHO 2008</LINK>), and is increasingly the cause in low-income countries. In 2013, cardiovascular disease caused an estimated 30% of all global deaths, and killed 17.3 million people worldwide (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). In the United Kingdom (UK), in 2010, cardiovascular disease caused 32% of deaths, and killed just over 179,000 people. Analysing this data according to gender demonstrates no significant overall difference in numbers between men and women; 31% of women died from cardiovascular disease in 2010 in the UK (<LINK REF="REF-British-Heart-Foundation-Statistics-Database-2012" TYPE="REFERENCE">British Heart Foundation Statistics Database 2012</LINK>).<BR/>
</P>
<P>The burden of coronary heart disease is costly, both in terms of reduced patient health-related quality of life, and healthcare costs in the management of these conditions. Morbidity statistics indicate that cardiovascular disease is the leading single cause of disability in Europe, with a prevalence of 6.0% to 6.5% in men and 4.0% to 4.5% in women within the UK. Cardiovascular disease is therefore costly in terms of both direct and indirect healthcare costs, accounting for 9.8% of total disability-adjusted years (<LINK REF="REF-Townsend-2012" TYPE="REFERENCE">Townsend 2012</LINK>). In 2009, it was estimated that cardiovascular disease cost the UK healthcare system approximately GBP 8.6 billion, equating to approximately just under GBP 141 per capita. Overall, the cost from cardiovascular disease in the UK is estimated to be GBP 19 billion, the balance attributed to lost productivity and caring for those with cardiovascular disease (<LINK REF="REF-British-Heart-Foundation-Statistics-Database-2012" TYPE="REFERENCE">British Heart Foundation Statistics Database 2012</LINK>).</P>
<CONDITION MODIFIED="2015-02-02 01:14:52 +0000" MODIFIED_BY="[Empty name]">
<P>Whilst the overall risk of cardiovascular disease is matched in men and women, this risk varies according to age. The risk is higher in men compared to women in younger age groups, with women&#8217;s cardiovascular disease incidence rates found to lag approximately ten years behind those of men. Most women experience the menopause (the last menstrual period) in their early fifties, after a phase of changing ovarian function (the peri-menopause) that may last several years and which is characterised by irregular menstrual cycles (<LINK REF="REF-Greendale-1999" TYPE="REFERENCE">Greendale 1999</LINK>). Following menopause and loss of endogenous oestradiol (major ovarian oestrogen), these gender-based differences narrow (<LINK REF="REF-Barrett_x002d_Connor-1997" TYPE="REFERENCE">Barrett-Connor 1997</LINK>; <LINK REF="REF-Maxwell-1998" TYPE="REFERENCE">Maxwell 1998</LINK>). Most women who enter menopause are asymptomatic for cardiovascular disease, and 95% of women who develop cardiovascular disease do so after menopause. Evidence suggests that younger age at natural menopause is associated with cardiovascular disease (<LINK REF="REF-Hu-1999" TYPE="REFERENCE">Hu 1999</LINK>) and cardiovascular disease mortality (<LINK REF="REF-Jacobsen-1997" TYPE="REFERENCE">Jacobsen 1997</LINK>; <LINK REF="REF-van-der-Schouw-1996" TYPE="REFERENCE">van der Schouw 1996</LINK>). Post-menopausal women have 2.6 times the rate of cardiovascular events compared to their age-matched pre-menopausal peers (<LINK REF="REF-Kannel-1976" TYPE="REFERENCE">Kannel 1976</LINK>). There are many possible explanations for this associated increase in risk. The menopause has an adverse effect on lipid profile; low-density lipoprotein and triglyceride levels rise after the menopause, and high-density lipoprotein falls (<LINK REF="REF-Kilim-2013" TYPE="REFERENCE">Kilim 2013</LINK>). Weight gain and a change in body fat distribution, increases in blood pressure and a host of other metabolic factors are amongst the other changes seen. The management and prognosis of women with cardiovascular disease is not aided by their being under-represented in trials (<LINK REF="REF-Melloni-2010" TYPE="REFERENCE">Melloni 2010</LINK>) and are more likely to present atypically with lower cardiovascular revascularisation rates (<LINK REF="REF-Rathore-2003" TYPE="REFERENCE">Rathore 2003</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-02-02 01:20:45 +0000" MODIFIED_BY="[Empty name]">
<P>The term 'hormone replacement therapy' has been replaced by 'hormone therapy', as the older term infers that hormone therapy is replacing the function of a defective organ. Hormone therapy includes either oestrogen alone (oestrogen-only hormone therapy) or oestrogen in combination with a progestogen (combined hormone therapy). It is used in a variety of formulations and doses which can be taken orally, vaginally, intranasally or as an implant, skin patch, cream or gel. The clinical effects vary according to the type of hormone therapy and the duration of its use. Formulations of oral oestrogen may include oestradiol (an oestrogen derived from wild Mexican yam), oestradiol valerate (a pro-drug for oestradiol), or conjugated equine oestrogen, a blend of equine oestrogens extracted from horse urine. Historically, larger doses were prescribed but doses have fallen in the past two decades as prescribers aim to minimise side effects associated with larger doses. The progestogens used for hormone therapy include synthetic derivatives of progesterone, synthetic derivatives of testosterone, and natural progesterones derived from plants. These differ in their metabolic action and potential for adverse effects, and the risk-benefit profile of each type of progestogen for use in hormone therapy is currently unclear. In combined hormone therapy, progestogen can be taken either every day (continuous combined therapy), cyclically with oestrogens taken daily and progestogens taken for part of the month (sequentially combined hormone therapy), or less frequently.<BR/>
<BR/>The addition of a progestogen to oestrogen reduces the risk of endometrial hyperplasia associated with the use of oestrogen alone in women with a uterus (<LINK REF="REF-Furness-2009" TYPE="REFERENCE">Furness 2009</LINK>). However, the addition of progestogens can be problematic as they have adverse effects on blood lipid profiles and may cause symptoms such as headaches, bloating and breast tenderness (<LINK REF="REF-McKinney-1998" TYPE="REFERENCE">McKinney 1998</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-02-02 01:32:12 +0000" MODIFIED_BY="[Empty name]">
<P>The finding that cardiovascular disease rates in women rise sharply after the menopause has led to the suggestion that endogenous oestradiol may attenuate age-related vascular remodelling in pre-menopausal women. Age-associated vascular remodelling involves endothelial dysfunction, enhanced growth of intimal smooth muscle cells, and increased prevalence of vascular plaques. The same cellular processes participate in atherosclerosis (<LINK REF="REF-Lakatta-2003" TYPE="REFERENCE">Lakatta 2003</LINK>). The decline in oestradiol levels during menopause leads to a higher androgen-to-oestradiol ratio. Androgens induce vasoconstriction and smooth muscle cell growth and exacerbate diet-induced atherosclerosis, plaque formation, and pro-atherosclerotic arterial remodelling. This suggests that the increase in the androgen-to-oestradiol ratio in post-menopausal women may be another mechanism which contributes to the observed acceleration of atherosclerosis. The exact mechanism by which cardiovascular disease risk may be reduced by oestrogen is not completely understood, but leading hypotheses involve inhibition of vascular remodelling, lowering cholesterol and improving vascular tone (<LINK REF="REF-Dubey-2001" TYPE="REFERENCE">Dubey 2001</LINK>; <LINK REF="REF-Mendelsohn-1999" TYPE="REFERENCE">Mendelsohn 1999</LINK>; <LINK REF="STD-PEPI-1995" TYPE="STUDY">PEPI 1995</LINK>; <LINK REF="REF-Walsh-1991" TYPE="REFERENCE">Walsh 1991</LINK>). Other factors that may play a role are changes in coagulation factors, blood pressure, insulin, and body fat distribution (<LINK REF="REF-Koh-2004" TYPE="REFERENCE">Koh 2004</LINK>; <LINK REF="REF-Lieberman-1994" TYPE="REFERENCE">Lieberman 1994</LINK>; <LINK REF="STD-PEPI-1995" TYPE="STUDY">PEPI 1995</LINK>).</P>
<P>Hormone therapy to treat menopausal oestrogen deficiency has been in widespread use for more than 60 years (<LINK REF="REF-Wallach-1959" TYPE="REFERENCE">Wallach 1959</LINK>). Long-term treatment was assumed to prevent atherosclerosis, and the increased cardiovascular disease and mortality risk observed following the menopausal transition (<LINK REF="REF-Robinson-1959" TYPE="REFERENCE">Robinson 1959</LINK>; <LINK REF="REF-Wallach-1959" TYPE="REFERENCE">Wallach 1959</LINK>; <LINK REF="REF-Wilson-1963" TYPE="REFERENCE">Wilson 1963</LINK>), either in the form of primary prevention (prevention of disease before it has first presented) or secondary prevention (preventing the progression or recurrence of disease). Since the early 1980s, several observational studies have consistently shown that hormone therapy users, many of whom started treatment shortly after menopause, had a reduction in total mortality and risk of cardiovascular disease events of approximately 30% to 50% relative to women who did not use hormone therapy (<LINK REF="REF-Grady-1992" TYPE="REFERENCE">Grady 1992</LINK>; <LINK REF="REF-Grodstein-1999" TYPE="REFERENCE">Grodstein 1999</LINK>; <LINK REF="REF-Grodstein-2000" TYPE="REFERENCE">Grodstein 2000</LINK>; <LINK REF="REF-Mann-1994" TYPE="REFERENCE">Mann 1994</LINK>; <LINK REF="REF-Psaty-1994" TYPE="REFERENCE">Psaty 1994</LINK>; <LINK REF="REF-Rosenberg-1993" TYPE="REFERENCE">Rosenberg 1993</LINK>; <LINK REF="REF-Stampfer-1991" TYPE="REFERENCE">Stampfer 1991</LINK>). However, most observational data sets suggest that the risk reduction in mortality and coronary heart disease events, is coupled with a higher impact of the risk of venous thromboembolic events and an apparent increased incidence of stroke, but lower stroke mortality (<LINK REF="REF-Paganini_x002d_Hill-2001" TYPE="REFERENCE">Paganini-Hill 2001</LINK>). Overall, the accumulated available epidemiological evidence supported the use of hormone therapy to increase longevity in post-menopausal women (<LINK REF="REF-Mishell-1989" TYPE="REFERENCE">Mishell 1989</LINK>). Following these observational studies two large RCTs, the Heart and Estrogen/progestin Replacement Study, assessing secondary prevention (<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>) and the Women&#8217;s Health Initiative, assessing primary prevention (<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>) were carried out and both appeared to contradict the evidence from observational studies.<BR/>
</P>
<P>In light of these trials not confirming a cardioprotective effect of oestrogen, attention was focused on the age of the women enrolled in both <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK> and <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> (mean age: 67 and 63 years, respectively), as non-significant data trends suggested hormone therapy did not lead to excess coronary risk when started shortly after the menopause and interest alighted upon the timing of initiation of hormone therapy in relation to the time of menopause. This &#8216;timing hypothesis&#8217;, first proposed in 2002, states that there may be a window of opportunity where hormone therapy is beneficial for prevention of cardiovascular disease in women when started in early menopause, with this benefit lost in older women. This hypothesis is supported by the Clarkson primate model, where conjugated equine oestrogen prevented atherosclerosis only in animals treated early after surgically induced menopause (within the calculated equivalent of six human post-menopausal years) before the onset of diet-induced atherosclerosis (<LINK REF="REF-Mikkola-2002" TYPE="REFERENCE">Mikkola 2002</LINK>). The reasoning behind the &#8216;timing hypothesis&#8217; is that oestrogen effects differ with the presence and severity of atherosclerosis and that this is linked to the timing of the menopause and age. This may be due to fewer oestrogen receptors in the artery wall (<LINK REF="REF-Losordo-1994" TYPE="REFERENCE">Losordo 1994</LINK>) and reduced vasodilatory effects of oestrogen with progressing atherosclerosis (<LINK REF="REF-Campisi-2002" TYPE="REFERENCE">Campisi 2002</LINK>). When there is minimal or no atherosclerosis, oestrogen leads to reduced platelet and inflammatory activation. It also enables nitric oxide mediated vasodilatation, an important component of healthy endothelial function (<LINK REF="REF-Mendelsohn-1999" TYPE="REFERENCE">Mendelsohn 1999</LINK>). When there is established atherosclerosis, many of these beneficial physiological changes are attenuated or even reversed, with reduced vasodilatation and increased inflammatory activation (<LINK REF="REF-Ouyang-2006" TYPE="REFERENCE">Ouyang 2006</LINK>). It is also hypothesised that although hormone therapy reduces the risk of plaque formation, it increases plaque instability and the risk of plaque erosion or rupture, through production of matrix metalloproteinases (<LINK REF="REF-Phillips-2005" TYPE="REFERENCE">Phillips 2005</LINK>). Therefore, as it is known that cardiovascular risk (including atherosclerosis) increases significantly after the menopause (<LINK REF="REF-Kannel-1976" TYPE="REFERENCE">Kannel 1976</LINK>) the &#8216;timing hypothesis&#8217; suggests that if hormone therapy is instigated many years after menopause, it is much more likely that there will be established atherosclerosis, and therefore the benefit of reduced plaque formation will be abrogated by the increased risk of plaque erosion or rupture. In support of the &#8216;timing hypothesis&#8217;, reanalysis of the Nurses&#8217; Health Study (<LINK REF="REF-Grodstein-2006" TYPE="REFERENCE">Grodstein 2006</LINK>) demonstrated a benefit to starting treatment less than four years after the menopause compared to more than 10 years after the menopause. A stratified meta-analysis by <LINK REF="REF-Salpeter-2004" TYPE="REFERENCE">Salpeter 2004</LINK> also indicated differential treatment effects with hormone therapy relative to placebo, according to the participants' baseline age, favouring use in women under 60 years of age.</P>
<P>
<BR/>
</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-03-06 15:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>The previous Cochrane Review on hormone therapy for the prevention of cardiovascular disease in post-menopausal women (<LINK REF="REF-Main-2013" TYPE="REFERENCE">Main 2013</LINK>) identified a total of 13 RCTs which included 38,171 post-menopausal women (19,302 randomised to hormone therapy and 18,869 to placebo). The review reported no protective cardiovascular effects for hormone therapy observed in either healthy women or women with one or more pre-existing cardiovascular disease risk factors, but a higher risk of stroke, venous thromboembolic events and pulmonary embolism was observed.</P>
<P>Since the literature search for the previous Cochrane review (<LINK REF="REF-Main-2013" TYPE="REFERENCE">Main 2013</LINK>), the BMJ (October 2012) reported the results of the cardiovascular outcomes of the Danish Osteoporosis Prevention Study (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>). This trial was designed to assess the long-term impact of hormone therapy on bone mineral density and predefined adverse cardiovascular endpoints in healthy women compared to a no treatment control group. The trial had over 10 years of randomised follow-up and a further 5.7 years of post-interventional follow-up, the longest of any comparable trial. The trial had some noticeable differences to the majority of previous studies that used hormone therapy to prevent cardiovascular disease, other than its long follow-up; the women included were younger and the hormone preparation was different to that used in the majority of previous trials. The results indicated that women receiving hormone therapy early after menopause had a reduced risk of the composite endpoint of mortality, heart failure or myocardial infarction, without any apparent increase in risk of cancer, venous thromboembolism, or stroke. This led to great media interest and a revival of the debate on whether hormone therapy is safe, when it should be prescribed and in whom it should be prescribed.</P>
<P>However, the DOPS trial had many criticisms levelled against it; the low event rate, open-label design and the higher mean age in the control group. To bring clarity to the subject, we felt it was important to update the review to assess whether this new trial altered the balance of evidence on hormone therapy and its effect on cardiovascular disease.</P>
<P>There are also further data not available to the previous review, which reported events by year of treatment and also by participants&#8217; age from trials. Additionally, it has become increasingly clear that the risk from hormone therapy is not constant for the time for which it is taken. Whether women are taking it to treat symptoms or reduce the risk of other diseases, it is important that they are informed regarding the risks as accurately as possible for them as individuals, and this varies according to duration of therapy, their age and when their menopause started.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-02-01 05:54:43 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of hormone therapy for the prevention of cardiovascular disease in post-menopausal women, and whether there are differential effects between use in primary or secondary prevention.<BR/>
<BR/>Secondary aims were to undertake exploratory analyses to (i) assess the impact of time since menopause that treatment was commenced (&#8805; 10 years versus &lt; 10 years), and where these data were not available, use age of trial participants at baseline as a proxy (&#8805; 60 years of age versus &lt; 60 years of age); and (ii) assess the effects of length of time on treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-02-11 22:15:17 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-02-03 12:27:25 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-02-02 01:40:18 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) comparing oral hormone therapy with either placebo or a no treatment control for a follow-up duration of six months or longer. We included RCTs which compared two or more different types of oral hormone therapy, provided that they were additionally compared with a placebo or a no treatment control arm.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-02-01 05:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Post-menopausal women (with either spontaneous or induced cessation of menstrual bleeding for a continuous period of six months or more), either with or without evidence of existing cardiovascular disease. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-02-02 01:47:02 +0000" MODIFIED_BY="[Empty name]">
<P>Oral hormone therapy, consisting of either oestrogen alone or in combination with a progestogen, compared with either a placebo or a no treatment control. Combined hormone therapy (oestrogen plus progestogen) could be delivered continuously daily (continuous combined hormone therapy) or sequentially (oestrogen taken daily with progestogens taken for part of the month).<BR/>
<BR/>In accordance with the inclusion criteria from the previous review (<LINK REF="REF-Main-2013" TYPE="REFERENCE">Main 2013</LINK>), we excluded RCTs in which hormone therapy was delivered to the body via either patches, tablets, creams, troches, an intrauterine device, vaginal ring, gels or injections compared with placebo or no treatment. Likewise, we excluded RCTs assessing the effects of selective oestrogen receptor modulators (e.g. raloxifene) compared to placebo or a no treatment control.  </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-02-03 12:27:25 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-05-30 13:39:00 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death from any cause</LI>
<LI>Cardiovascular death</LI>
<LI>Non-fatal myocardial infarction</LI>
<LI>Stroke</LI>
<LI>Angina</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-02-03 12:27:25 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Venous thromboemboli (pulmonary emboli plus deep vein thromboses)</LI>
<LI>Pulmonary emboli</LI>
<LI>Revascularisation (coronary artery bypass grafting and angioplasty (with or without a stent))</LI>
</UL>
<P>We reviewed trials which were above a given size (based on number of participants and length of follow-up) to see if relevant outcomes were reported as adverse events. We reviewed trials which included 1000 or more participants (where the participants were followed up for six months or more) and all other trials of comparable or larger size. For example, we reviewed trials which included 500 participants (where the participants were followed up for one year or more). We also included trials with 250 participants or more (where the participants were followed up for two years or more). All the trials which were reviewed due to their size to assess whether they reported relevant outcomes as adverse events are listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Outcomes with zero events in one or more arms of a trial were not included from the trial in question. This was done to minimise bias.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-02-09 15:06:30 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-02-09 15:06:30 +0000" MODIFIED_BY="[Empty name]">
<P>We identified randomised controlled trials (RCTs) that assessed the effects of hormone therapy compared to placebo or no treatment with a minimum of six months duration through searching the following electronic databases on 25 February 2014:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL; Issue 1, 2014) in <I>The Cochrane Library</I>,</LI>
<LI>MEDLINE (Ovid; 1946 to week 9 2014),</LI>
<LI>EMBASE (Ovid; 1980 to week 9 2014),</LI>
<LI>LILACS (<A HREF="http://lilacs.bvsalud.org/en/">http://lilacs.bvsalud.org/en/</A>) (1982 to 25 February 2014).</LI>
</UL>
<P>Additionally, we searched the following trials and research registers for any ongoing trials on cardiovascular disease on 25 February 2014: ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>), the World Health Organization (WHO) International Clinical Trials Registry Platform (<A HREF="http://www.who.int/ictrp/">www.who.int/ictrp/</A>&#8206;), the UK Clinical Research Network Portfolio Database (<A HREF="http://public.ukcrn.org.uk">http://public.ukcrn.org.uk</A>) and Centerwatch (<A HREF="http://www.centerwatch.com">www.centerwatch.com</A>).<BR/>
<BR/>We did not apply any language restrictions. The full search strategies, designed and run in each database, are presented in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (original review), <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> (2010) and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> (2014).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-02-02 02:01:50 +0000" MODIFIED_BY="[Empty name]">
<P>We searched reference lists of all eligible RCTs and relevant systematic reviews for additional trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-02-11 22:15:17 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-02-02 02:43:33 +0000" MODIFIED_BY="[Empty name]">
<P>We identified relevant studies in two stages. Two review authors (HB and LH) independently screened the titles and abstracts returned by the database searches for relevance. The full text of any references that were considered as potentially relevant by either author were obtained. They then independently assessed the relevance of each paper, according to the review's prespecified eligibility criteria. This assessment was performed unblinded. Any discrepancies between the authors were resolved by recourse to the papers, and if necessary, a third author was consulted. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-02-02 02:45:21 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (HB and LH) independently extracted data from the included studies using a standardised data extraction form in Microsoft Word. The data extraction was checked for agreement and any discrepancies were resolved through recourse to the papers. We assessed the following study details.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial characteristics</HEADING>
<OL>
<LI>Method of randomisation</LI>
<LI>Method of allocation concealment</LI>
<LI>Use of stratification</LI>
<LI>Adequacy of double-blinding</LI>
<LI>Means of recruitment</LI>
<LI>Number of participants screened for eligibility, randomised, analysed, excluded, lost to follow-up or dropped-out (i.e. withdrew from the trial but were followed-up)</LI>
<LI>Baseline equality of treatment groups</LI>
<LI>Level of adherence to therapy</LI>
<LI>Whether analyses were conducted on an intention-to-treat basis</LI>
<LI>Study design (parallel versus multi-arm, single centre or multi-centre)</LI>
<LI>Funding source</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of the trial participants</HEADING>
<OL>
<LI>Inclusion and exclusion criteria</LI>
<LI>Age and other recorded prognostic baseline variables</LI>
<LI>Menopausal status (definition of menopause and how this was defined, surgical or natural menopause) of participants</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<OL>
<LI>Type of hormone therapy (oestrogen-only or combination oestrogen and progestogen)</LI>
<LI>Dosage</LI>
<LI>Duration of therapy (minimum six months)</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<OL>
<LI>Which relevant primary and secondary outcomes were measured</LI>
<LI>How relevant outcomes were defined and measured</LI>
</OL>
<P>See <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>; <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> </P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-02-02 02:47:08 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed risk of bias according to the risk of bias assessment criteria detailed in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). These criteria focus upon the quality of random sequence generation and allocation concealment, blinding (participants, trial personnel and outcome assessors), incomplete outcome data, selective outcome reporting, and other sources of bias. Assessment of risk of bias was undertaken by two review authors (HB and LH) independently, with any disagreements resolved by discussion.</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-02-03 01:51:52 +0000" MODIFIED_BY="[Empty name]">
<P>We explored heterogeneity between studies qualitatively (by comparing the characteristics of included studies) and quantitatively using the Chi<SUP>2</SUP> test of heterogeneity and the I<SUP>2</SUP> statistic. We considered trials with a Chi<SUP>2</SUP> test resulting in a P value &lt; 0.10 indicative of significant statistical heterogeneity. In order to assess and quantify the possible magnitude of heterogeneity between trials, and the potential impact for undertaking meta-analyses, we interpreted an I<SUP>2</SUP> statistic of 0% to 40% as potentially not being important; 30% to 60% as representing moderate heterogeneity; 50% to 90% as representing substantial heterogeneity; and 75% to 100% as being considerably heterogeneous and potentially unsuitable for meta-analyses (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). Published graphs display the results of analysis using the random-effects model. We assessed reporting bias through the examination of funnel plots.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-02-02 02:57:16 +0000" MODIFIED_BY="[Empty name]">
<P>We undertook statistical analyses following the guidelines in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). </P>
<P>For dichotomous data, we generated two-by-two tables for each study and expressed the data as a risk ratio (RR) with 95% confidence intervals (CIs). We grouped the data according to whether the intervention was primary or secondary prevention. We undertook further analyses to assess the effect of both single and combination therapy in the overall patient population (both primary and secondary prevention) and commencement of treatment according to time since the menopause (&lt; 10 years and &#8805; 10 years). Where time since menopause data was not available then mean age of the population at baseline was used (&lt; 60 years old and &#8805; 60 years old). We combined data for meta-analysis in Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), using the Peto-modified Mantel-Haenszel method with a random-effects model to provide an overall estimate of treatment effect. We chose the random-effects model due to the wide variety in sample sizes between studies and the heterogeneity found for some outcomes. For comparisons showing statistically significant differences between treatment groups, we calculated the absolute risk reduction and number needed to treat, or absolute risk increase and number needed to harm using the pooled RR data.<BR/>
<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-02-11 22:15:17 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effect of duration of treatment, we compared data in two different ways. Where data were reported by year of follow-up, we analysed the data both non-cumulatively (year-by-year), as well as cumulatively, incorporating the remainder of the trials where data were not reported by year of follow-up, according to the total duration of trial follow-up. We classified these trials <I>a priori</I> as exploratory given the heterogeneity between the different hormone therapy regimens assessed and the patient populations in the different trials.</P>
<P>To assess the timing hypothesis and the potential impact of the time since menopause that treatment was commenced, we stratified trials according to when treatment was started. This was characterised as starting treatment either &lt; 10 or &#8805; 10 years after the menopause, or if these data were not available, then we used mean age of participants at baseline (&gt; 60 years of age versus &lt; 60 years of age) as a surrogate.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of Findings tables</HEADING>
<P>We used methods developed by the <A HREF="http://www.gradeworkinggroup.org/">GRADE working group</A> to rate the quality of the evidence for the following outcomes: </P>
<OL>
<LI>Death (all causes)</LI>
<LI>Coronary heart disease</LI>
<LI>Stroke</LI>
<LI>Venous thromboembolism</LI>
<LI>Pulmonary embolism</LI>
</OL>
<P>We have presented the quality ratings in Summary of Findings tables for the comparison of HT and placebo in primary and secondary prevention of cardiovascular disease and for the subgroup analysis addressing the timing hypothesis.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-03-06 13:14:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-03-06 13:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>; <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2015-03-03 14:59:18 +0000" MODIFIED_BY="[Empty name]">
<P>For this update, we retrieved 3930 records from the database searches and found 33 additional records through other sources, bringing the total results to 3963. Of these, we excluded 3866 records after assessment of titles and abstracts. We considered the full text of 97 references for inclusion.</P>
<P>We found six new trials (12 papers) for inclusion and additional 25 papers on ten previously included studies. We excluded 58 papers. One study has completed and is awaiting classification (<LINK REF="STD-NCT00154180" TYPE="STUDY">NCT00154180</LINK>) and one study is ongoing (<LINK REF="STD-NCT00114517" TYPE="STUDY">NCT00114517</LINK>). The process of study selection for the original review in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and for this updated review is presented in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-03-06 13:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>In total we identified 19 RCTs with at least six-months follow-up that compared hormone therapy to placebo or no treatment published between 1979 and 2012 (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>). Thirteen of the identified trials had been included in the previous review. Six new trials were therefore identified for this update (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>).<BR/>
<BR/>The 19 trials included 40,410 post-menopausal women; 20,517 randomised to receive some form of hormone therapy and 19,893 to receive either placebo or a no treatment control. <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK> also included a group randomised to calcitriol who were not included in this review. Likewise, <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK> also included a further 1307 women randomised to a comparison of two active hormone therapies, and <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>, also included 1001 women randomised to either open-label hormone therapy, or a no treatment control. The data from these further 2306 women randomised into either of these trials (<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>) were not included in this review.<BR/>
<BR/>The trials varied considerably in size, ranging from 40 (<LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>) to 16,608 (<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>). Likewise, there was large variation in the length of follow-up within the trials ranging from seven months (<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>) to 10.1 years (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>). Overall, three large trials (<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>) with a mean follow-up duration of 5.6 years (range: 4.1 to 7.1) randomised 30,110 women to either hormone therapy treatment or placebo, and therefore contributed approximately 75% of the included participants from the 19 trials.<BR/>
<BR/>The majority of the trials (n = 11) had been conducted in the US, two were conducted in more than one country (one in the US and Canada, and one in England, New Zealand and Australia), two trials were conducted in the UK, with one trial conducted in each of the following countries: Norway, Denmark, Sweden, and Estonia.<BR/>
<BR/>Seven trials were stopped early (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>); either as other trial results were published showing no beneficial effect, or a detrimental effect of hormone therapy on cardiovascular disease outcomes (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>), or due to it being established that the overall risks (adverse events) associated with hormone therapy use were unlikely to be outweighed by any potential benefits of hormone therapy use on cardiovascular disease outcomes within the time frame of the trial (<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>).<BR/>
<BR/>A summary of the main characteristics of the included trials is displayed in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>All the trials included post-menopausal women, irrespective of whether the absence of menses was natural or an artefact of hysterectomy or oophorectomy, with a mean age of 64 years. In 14 of the 19 trials the mean participant age was over 60 years at baseline. The hysterectomy status of the women in four of the trials was related to the inclusion criteria and therefore in <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK> and <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> was 0%, and in <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> it was 100%. In the nine trials in which baseline hysterectomy status was reported, this ranged from 10% to 61% (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>). Six studies did not report data on hysterectomy status (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>).<BR/>
<BR/>The trial inclusion criteria varied according to the primary study objectives. Six of the trials were designed to assess the effects of hormone therapy in the primary prevention of cardiovascular disease and therefore enrolled predominantly healthy patient populations (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>). Ten of the trials aimed to assess the impact of hormone therapy in secondary prevention, and therefore enrolled women with established cardiovascular disease (<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>) or after a designated specific cardiovascular disease event of interest, such as coronary artery bypass graft (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>), angina (<LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>), acute coronary syndrome (<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>), myocardial infarction or transient ischaemic attack (<LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>), or pulmonary embolism or deep vein thrombosis (<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>). Three trials were designed to assess non-cardiovascular endpoints but reported relevant outcomes as adverse events, safety of long-term hormone therapy (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>), bone mineral density (<LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>), physical performance, functional ability, falls and cognitive function (<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary prevention trials</HEADING>
<P>Nine studies enrolled relatively healthy women (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>). Although one of the studies enrolled women with one cardiovascular disease risk factor, namely hypercholesterolaemia (<LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>) and a small minority (approximately &#8804; 5%) of women within all trials had a history of cardiovascular disease, the trial participants were representative of population samples of fit women in this age group without overt disease. Four of these trials (<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>) assessed the impact of hormone therapy on both cardiovascular disease, as well as a wide range of other endpoints, including cancer, osteoporosis and gallbladder disease, and therefore reported detailed lists of participant inclusion and exclusion criteria. One study included only participants who were admitted for the entire duration of the study (ten years) in a hospital for patients with chronic illnesses (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>). The illnesses of the participants are not reported. However, it specified that acute heart disease and hypertension were exclusion criteria. Three studies, mentioned above, were designed to assess non-cardiovascular outcomes but reported relevant outcomes as adverse events (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>).<BR/>
<BR/>The two biggest primary prevention trials (<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>) both set enrolment targets to establish set fractions for baseline age categories and to achieve racial and ethnic group representation within participant groups in the proportions recorded in the US census for the 50 to 79 year old age group. This was achieved, with it being noted that baseline cardiovascular risk factors in the trial participants in both <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> were low and consistent with those observed in a generally healthy population of post-menopausal women (<LINK REF="REF-Manson-2003" TYPE="REFERENCE">Manson 2003</LINK>; <LINK REF="REF-Stefanick-2003" TYPE="REFERENCE">Stefanick 2003</LINK>). <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK> recruited women with no major health problems from general practice registers in England, Australia and New Zealand, whilst <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK> included healthy women with no major health problems drawn from population samples in Estonia. In both trials, participant baseline cardiovascular risk factors were low and consistent with those observed in the general population of post-menopausal women within this age group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary prevention trials</HEADING>
<P>Ten studies included women with established cardiovascular disease (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>). <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>, <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK> and <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK> included women who had coronary artery stenosis evidenced by angiogram. <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK> and <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK> both included women who had undergone a revascularisation procedure (coronary artery bypass graft or percutaneous coronary intervention), whilst <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>, <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK> and <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK> included women who had had a previous acute coronary syndrome or a transient ischaemic attack (TIA). <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK> included women previously hospitalised with angina, and <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK> included women who had suffered a thromboembolic event, pulmonary embolism or deep vein thrombosis.<BR/>
<BR/>The largest of the ten trials (<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>) compared the baseline characteristics of the trial participants with a similar group of women presumed to have coronary heart disease who were participants in a survey designed to produce nationally representative data. The <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK> participants had significantly fewer smokers, women with hypertension and diabetes than the comparison group but were comparable with respect to blood pressure, body mass index, physical activity and cholesterol levels (<LINK REF="REF-Grady-1998" TYPE="REFERENCE">Grady 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>A number of different oestrogen alone or oestrogen and progestogen combinations had been assessed in the different trials. Two trials (<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>) were three-armed trials, and therefore assessed both oestrogen alone and in combination with a progestogen versus placebo. Most of the included comparisons used a moderate dose of oestrogen, for example, oestradiol 1 mg or conjugated equine oestrogen 0.625 mg daily. We assessed the following interventions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oestrogen-alone hormone therapy</HEADING>
<UL>
<LI>1 mg 17-ß oestradiol  (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>).</LI>
<LI>2 mg 17-ß oestradiol (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>).</LI>
<LI>2 mg oestradiol valerate (<LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>).</LI>
<LI>0.625 mg conjugated equine oestrogen (<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Combined hormone therapy regimes</HEADING>
<P>Combined hormone therapy regimens included one of the above types of oestrogen in combination with one of the two progestogens:</P>
<UL>
<LI>medroxyprogesterone acetate (MPA);</LI>
<LI>norethisterone.</LI>
</UL>
<P>The continuous combined regimens were composed of the following.</P>
<UL>
<LI>Conjugated equine oestrogen 0.625 mg with MPA 2.5 mg daily (<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>).</LI>
<LI>Oestradiol 2 mg with 1 mg norethisterone daily (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>).</LI>
</UL>
<P>Whist the combined sequential regimes included:</P>
<UL>
<LI>oestradiol 1 mg daily with MPA 5 mg for 12 days each month (<LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>);</LI>
<LI>conjugated equine oestrogen 0.625 mg for 18 days followed by a combination with oral 5 mg MPA (<LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>);</LI>
<LI>conjugated equine oestrogen 2.5 mg with MPA 10 mg for seven days each month (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>); and</LI>
<LI>oestradiol 1 mg daily with 0.5 mg norethisterone daily (<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>).</LI>
</UL>
<P>The control arm in each of the trials received placebo tablets, except <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK> which used a no treatment control.<BR/>
<BR/>The duration of hormone therapy use varied widely across the trials, with follow-up duration ranging from seven months (<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>) to 10.1 years (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>). Four trials reported outcomes after hormone therapy use for around one year (<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>); two trials for two years (<LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>), and eight trials for approximately three years (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>). <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK> measured outcomes after 4.1 years, and continued the study unblinded for a further 2.7 years follow-up (<LINK REF="STD-HERS-II" TYPE="STUDY">HERS II</LINK>). Both the <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> trials were planned to continue for 8.5 years, but both trials were terminated early. Outcomes in <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> were reported at 5.2 years and subsequently for a further four months of follow-up (total follow-up 5.6 years) for primary and selected secondary outcome measures. <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> reported outcomes at 6.8 years and for a subsequent further three months of follow-up (7.1 years) for primary and selected secondary outcomes, with a median time of 5.9 and 5.8 years on treatment for the hormone therapy and placebo groups, respectively. <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK> measured outcomes at 10 years. <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK> measured outcomes after 10.1 years, and continued the study unblinded for a further 5.7 years (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>
<U>)</U>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The outcomes assessed in the individual trials varied according to the trial objectives. One primary prevention trial (<LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>) and five secondary prevention trials (<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>) aimed to assess the effects of hormone therapy upon intermediate outcomes: carotid artery intima-media thickness, lipid and coagulation biomarkers and the impact on coronary atherosclerosis as measured by angiographic coronary stenosis. Two trials, including populations free from cardiovascular disease assessed bone mineral density, physical and cognitive parameters (<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>), and one study did not state any outcomes but reported a range of adverse events seen in the participants over a ten year follow-up period (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>).</P>
<P>The primary aim in the largest two trials, <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>, was to assess the potential cardioprotective effect of hormone therapy in relatively healthy post-menopausal women, and therefore both trials reported cardiovascular clinical endpoints as the primary outcome. Invasive breast cancer was the designated primary adverse outcome in both trials, with the incidence of other cancers, fractures, gallbladder disease and death reported as secondary outcomes. A further two primary prevention trials (<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>) also measured similar outcomes, with cardiovascular disease outcomes designated as the primary ones of interest. A further primary prevention study (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>) had a primary outcome of osteoporotic fractures but had a predefined safety composite endpoint of death, admission to hospital for myocardial infarction and heart failure; it also reported a number of cardiovascular endpoints individually. The remaining five secondary prevention trials aimed to examine the effects of hormone therapy in women with already established clinical disease, with the primary outcome designated according to the underlying patient pathology. Their primary outcomes were myocardial infarction or death (<LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>), thromboembolism (<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>), stroke (<LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>), and angina (<LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>). Adverse events due to hormone therapy were not analysed other than those prespecified as primary or secondary outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Funding Source</HEADING>
<P>Eighteen out of 19 trials reported the funding source. Only one of the trials, <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK> was exclusively funded by the pharmaceutical industry (Wyeth-Ayerst), whilst <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK> and <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK> were part funded by a grant from Novo-Nordisk Pharmaceutical. <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK> was mainly funded by the US National Institutes of Health (NIH) but was additionally supported by Wyeth-Ayerst, Hoffman-LaRoche, Inc. Pharm. and Pharmacia and Upjohn. The study medication for <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>, <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> was provided by Wyeth-Ayerst Research, for <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK> by Schering AG and for <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK> by Mead Johnson laboratories. <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK> was supported by study medication from Novo Nordisk, Novartis and Leo Pharma Denmark, <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK> by medication from Wyeth-Ayerst Laboratories and Merck Research Laboratories and <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK> by medication from Mead Johnson Laboratries and Pharmacia and Upjohn.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-02-02 07:24:34 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded fifty papers. The primary reasons for the exclusion were:</P>
<UL>
<LI>thirty-seven studies reported no relevant outcomes of interest to this review;</LI>
<LI>three assessed a different intervention;</LI>
<LI>five were not RCTs;</LI>
<LI>two did not investigate the relevant population;</LI>
<LI>one reported the open-label follow-up of an included study; and</LI>
<LI>two had insufficient duration of intervention or follow-up.</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-02-02 07:29:21 +0000" MODIFIED_BY="[Empty name]">
<P>The design and methods within the trials were generally well reported. The review authors&#8217; judgements about the risk of bias in the included studies are presented in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<ALLOCATION MODIFIED="2013-05-30 14:06:13 +0100" MODIFIED_BY="[Empty name]">
<P>The generation of randomised sequence was adequate in 15 out of the 19 trials; in all but three of these 15 trials (<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>) it was computer-generated. Three trials (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>) did not report the methods used to generate random allocation, and therefore it is unclear as to whether the method used was satisfactory. One trial used a research nurse to randomly assign matched pairs of participants to treatment or placebo (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>).</P>
<P>Thirteen trials described a satisfactory method of allocation concealment. One of these thirteen trials, <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK> randomised women who expressed an interest in participating, but did not open the randomisation envelope until their eligibility had been checked and they had consented. Five of the trials (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>) did not report methods of allocation concealment. One trial reported inadequate methods for allocation concealment (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-02-01 05:06:44 +0000" MODIFIED_BY="[Empty name]">
<P>All the trials except <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK> and <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK> were described as double-blind. Twelve of the trials explicitly stated that all participants, clinical staff and outcome assessors were blinded to treatment allocation, and all 19 trials reported &#8216;hard&#8217; outcomes; the verification of which is unlikely to be affected by blinding. Unblinding of participants occurred in 331 women initially randomised into the active single hormone therapy treatment arm in <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>, who, after a protocol change, were unblinded and changed arms into the <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> combined therapy arm. Eight of the trials additionally described an unblinding mechanism to be used in the management of adverse events (<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-02-02 07:29:21 +0000" MODIFIED_BY="[Empty name]">
<P>Thirteen of the trials analysed all participants on an intention-to-treat basis at least for the outcomes of interest in the present review, whilst data in <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK> were analysed on an ITT basis for over 97% of participants. Drop-out rates (medication non-compliance) were generally high, particularly in the active treatment groups, and tended to increase over time. In the 15 trials that reported data on adherence, these ranged from greater than 90% compliance rates in <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK> and <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK> at two and three years follow-up, respectively, to less than 40% compliance in <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK> at four-years follow-up. In the two WHI trials with the greatest number of participants, 42% of the active treatment group and 38% of the placebo group were no longer taking their allocated treatment at 5.2 years in <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>, and 10.7% of the placebo group had initiated active hormone therapy treatment outside of the trial. Whilst in <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>, 53% of participants overall were no longer taking their allocated treatment at 6.8 years, and a further 5.7% had initiated hormone use outside the study. The two studies with longest follow-up duration did not report adherence, <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK> and <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>. However the latter is likely to have very high, if not complete adherence, as all patients were inpatients for the duration of the study. A summary of medication compliance within the trials is given in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.<BR/>
<BR/>Losses to follow-up were low in most of the trials, with no women lost to follow-up in nine trials (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>) and between 0.1% to 5.2% lost in six other trials (<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>); two trials with significant levels of participants lost to follow-up were <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK> (14.9%) and <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK> (19%).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-05-20 14:25:38 +0100" MODIFIED_BY="[Empty name]">
<P>Two trials (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>
<U>)</U> may have been subject to selective reporting. The remaining 17 trials reported all expected outcomes.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-02-11 22:15:17 +0000" MODIFIED_BY="[Empty name]">
<P>Results are reported below. It was not possible to conduct analyses for all outcomes stratified by time of hormone therapy commenced since menopause (&lt; 10 years or &#8805; 10 years), where these data were not available, participants' mean age at baseline was used (&lt; 60 years of age or &#8805; 60 years of age), as <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>
<U>,</U> which contributed the majority of events to this analysis, only reported some of the outcomes of interest in these subgroups.</P>
<SUBSECTION>
<HEADING LEVEL="3">Hormone therapy versus placebo in primary prevention</HEADING>
<P>This comparison was assessed in nine trials (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>) with a total of 34,767 participants. A summary of the trials reporting each outcome is presented in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> and a summary of the outcomes and their relative risks are presented in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>There was no strong evidence that hormone therapy has an effect on all-cause mortality (RR 1.00, 95% CI 0.89 to 1.12; 34,422 participants in 8 studies) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), or any cardiovascular disease outcomes, including death by cardiovascular causes (RR 0.81, 95% CI 0.47 to 1.40; 28,353 participants in 3 studies) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), non-fatal myocardial infarction (RR 1.02, 95% CI 0.80 to 1.31; 29,482 participants in 7 studies) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), angina (RR 0.90, 95% CI 0.74 to 1.08; 27,347 participants in 2 studies) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>), or revascularisation (RR 0.96, 95% CI 0.85 to 1.09; 27,569 participants in 3 studies) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). However there was an increased risk of stroke (RR 1.32, 95% CI 1.12 to 1.56; 28,719 participants in 4 studies) relative to placebo (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> authors noted that the excess risk of stroke in the intervention arm was due to an increased risk of ischaemic rather than haemorrhagic stroke, which became apparent after four years of follow-up (<LINK REF="REF-Hendrix-2006" TYPE="REFERENCE">Hendrix 2006</LINK>). There was also an increased risk of venous thromboembolism (RR 1.92, 95% CI 1.24 to 2.99; 33,477 participants in 6 studies) relative to placebo (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), and also of pulmonary embolism (RR 1.89, 95% CI 1.17 to 3.04; 31,732 participants in 3 studies) relative to placebo (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). The absolute risk increase for stroke was 0.006 (number needed to treat to harm (NNTH)) = 165; mean length of follow-up: 4.21 years (range: 2.0 to 7.1), for venous thromboembolism 0.008 (NNTH = 118; mean length of follow-up: 5.95 years (range: 1.0 to 7.1), and for pulmonary embolism 0.004 (NNTH = 242; mean length of follow-up: 3.13 years (range: 1.0 to 7.1)). There was substantial heterogeneity in the studies assessing the outcome of death from cardiovascular causes (I<SUP>2</SUP> = 69%). There was also moderate heterogeneity in the studies assessing the outcome of venous thromboembolism and pulmonary embolism (I<SUP>2</SUP> = 56% and 54%, respectively). There was no significant heterogeneity between studies for the remaining outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hormone therapy versus placebo in secondary prevention</HEADING>
<P>This comparison was assessed in ten trials (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>) with a total of 5766 participants. A summary of the outcomes assessed in each of the trials is presented in <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
<P>There was no strong evidence that hormone therapy has an effect on all-cause mortality (RR 1.04, 95% CI 0.87 to 1.24; 5445 participants in 7 studies) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), death by cardiovascular causes (RR 1.00, 95% CI 0.78 to 1.29; 5259 participants in 6 studies) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), non-fatal myocardial infarction (RR 0.98, 95% CI 0.81 to 1.18; 5359 participants in 7 studies) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), angina (RR 0.91, 95% CI 0.74 to 1.12; 3155 participants in 3 studies) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), revascularisation (RR 0.98, 95% CI 0.63 to 1.53; 3155 participants in 3 studies) (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>), stroke RR 1.09 (95% CI 0.89 to 1.33; 5172 participants in 5 studies) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), or pulmonary embolism (RR 2.48, 95% CI 0.92 to 6.70; 3920 participants in 3 studies) (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>). However there was an increased risk of venous thromboembolism (RR 2.02, 95% CI 1.13 to 3.62; 4399 participants in 6 studies) relative to placebo (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). The absolute risk increase was 0.014 (NNTH = 71; mean length of follow-up: 2.46 years (range: 1.3 to 4.1)) for venous thromboembolism. There was substantial heterogeneity in studies reporting revascularisation (I² = 60%). There was no significant heterogeneity between studies for the remaining outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hormone therapy versus placebo in both primary and secondary prevention</HEADING>
<P>Consistent with effects observed in both primary and secondary prevention, there was no strong evidence that hormone therapy overall had an effect on the outcomes of death (RR 1.01, 95% CI 0.92 to 1.11; 35,483 participants in 14 studies) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), death from cardiovascular causes (RR 0.96, 95% CI 0.78 to 1.18; 33,613 participants in 9 studies) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>), non-fatal myocardial infarction (RR 1.01, 95% CI 0.89 to 1.14; 34,841 participants in 14 studies) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>), angina (RR 0.90, 95% CI 0.79 to 1.03; 30,502 participants in 5 studies) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>), or revascularisation procedures (RR 0.95, 95% CI 0.85 to 1.05; 30,724 participants in 6 studies) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>) compared to placebo. Again, an increased risk of stroke (RR 1.24, 95% CI 1.10 to 1.41; 34,672 participants in 10 studies), venous thromboembolism (RR 1.92, 95% CI 1.36 to 2.69; 37,313 participants in 10 studies) and pulmonary embolism (RR 1.81, 95% CI 1.32 to 2.48; 36,316 participants in 7 studies) relative to placebo was observed (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). An absolute risk increase of 0.006 (NNTH = 165; mean length of follow-up: 4.21 years (range: 2.0 to 7.1)) for stroke, an absolute risk increase of 0.008 (NNTH = 118; mean length of follow-up: 5.95 years (range: 1.0 to 7.1)) for venous thromboembolism, and an absolute risk increase of 0.004 (NNTH = 242; mean length of follow-up: 3.13 years (range: 1.0 to 7.1)) for pulmonary embolism were observed. There was moderate statistical heterogeneity present between trials for the outcome of venous thromboembolism (I<SUP>2</SUP> = 40%). There was no significant heterogeneity between studies in the remaining outcomes. There was no evidence of funnel plot asymmetry (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity Analysis</HEADING>
<P>Five trials assessing hormone therapy in primary prevention were stopped early (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>). To assess what effect this may have had, we performed a subgroup analysis on trials which did not stop early to see if the effect was significantly changed. There was no strong evidence of change in the balance of effect for the outcomes of death from any cause, non-fatal myocardial infarction or revascularisation. It was not possible to perform this analysis for death from cardiovascular causes, angina or pulmonary embolism as there were no studies which reported these outcomes which did not stop early. However, there were changes in the remaining outcomes. For the outcome of stroke, once the studies which stopped early were removed (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>) the outcome changed (from: RR 1.32, 95% CI 1.12 to 1.56 to: RR 1.69, 95% CI 0.47 to 6.02) due to only one study remaining in the analysis (<LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>). The outcome of venous thromboembolism also changed (from: RR 1.92, 95% CI 1.24 to 2.99 to: RR 2.01, 95% CI 0.40 to 10.06) with only two trials remaining in the analysis (<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>).</P>
<P>Two trials assessing hormone therapy in secondary prevention were stopped early (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>). To assess what effect this may have had, we performed a subgroup analysis on trials which did not stop early to see if the effect was significantly changed. There was no strong evidence of change in the balance of effect for the outcomes of death from cardiovascular causes, non-fatal myocardial infarction, angina, venous thromboembolism, pulmonary embolism or revascularisation. It was not possible to perform this analysis for death from any cause or stroke as there were no studies which reported these outcomes which stopped early.</P>
<P>Seven trials assessing hormone therapy in primary and secondary prevention were stopped early (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>). To assess what effect this may have had, we performed a subgroup analysis on trials which did not stop early to see if the effect was significantly changed. There was no strong evidence of change in the balance of effect for the outcomes of death from any cause, death from cardiovascular causes, non-fatal myocardial infarction, angina, venous thromboembolism or revascularisation. For the outcome of stroke, once the studies which stopped early were removed (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>) the outcome changed (from: RR 1.24, 95% CI 1.10 to 1.41 to: RR 1.14, 95% CI 0.94 to 1.39). The outcome of pulmonary embolism, once the studies which stopped early were removed (<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>) changed (from: RR 1.81, 95% CI 1.32 to 2.48 to: RR 1.57, 95% CI 0.62 to 3.95).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Duration of treatment</HEADING>
<P>To assess the effect of duration of treatment, we compared data in two different ways. Where data were reported by year of follow-up (<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>), we analysed them both non-cumulatively (year-by-year), as well as cumulatively, incorporating the remainder of the trials where data were not reported by year of follow-up, according to the total duration of trial follow-up. We classified these analyses <I>a priori</I> as exploratory, given the heterogeneity between the different hormone therapy regimens assessed and the patient populations in the different trials. To conduct the analyses, we had to round up or down the time points for the reporting of outcomes in the trials. We rounded data as follows: <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK> and <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK> reported results after a median follow-up of 7 months and 11.9 months (range 7.1 to 19.6), respectively; results were therefore reported at one-year follow-up. <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK> was conducted for a 1.3 year period; results from this trial were therefore also reported for one-year follow-up. <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>, <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK> and <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK> were all reported for two years of follow-up. <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK> and <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK> both reported three years of follow-up, <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK> had a median follow-up of 3.3 years, <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK> (median length of follow-up: 3.4 years (range: 2 to 4.9)), <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK> (mean follow-up: 3.5 years (range: 25 to 41)), <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK> (mean follow-up: 3.2 years (range: 2.8 to 3.8)), <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK> (mean follow-up: 2.8 years (range: 2.1 to 3.9)) and <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK> (mean follow-up: 2.8 years (range: 1.6 to 4.1)) were all classified as having a three-year follow-up period. Final outcome results within the blinded part of the <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK> trial were reported at a mean of 4.1 years and this was classified as having a four-year follow-up period. However there were selected clinical outcomes reported for each year of follow-up which were included in the analysis. Outcome data for the 4 to 6.8 years (unblinded, open-label) follow-up period were not included in the standard pair-wise meta-analyses. Final outcome results for <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> reported results after a mean follow-up of 5.6 years (range: 3.5 to 8.5), analysed as five years, however selected clinical outcomes were also reported for each year of follow-up to five years and this was included in the analysis. <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> reported results by year of follow-up for eight years for selected outcomes. <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK> reported a follow-up of 10 years. <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK> reported a mean follow-up of 10.1 years which was rounded down to 10 years.</P>
<P>We only assessed the outcome of death in this way as with other outcomes there was a risk of counting participants multiple times. By individual year of treatment from year one to eight, there was no strong evidence of difference between hormone therapy and placebo for any year analysed (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>). For the cumulative effect of treatment on the outcome of death, there was no strong evidence of difference between hormone therapy and control for years one up until eight. There were no data for nine years of treatment. Ten years of treatment showed a survival benefit in the hormone therapy group (RR 0.55, 95% CI 0.31 to 0.96) based on the results of two studies (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>) (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>). The absolute risk reduction for death was 0.003 (NNTH = 333). There was no statistically significant heterogeneity between the trials for any of the outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">The timing hypothesis</HEADING>
<P>To assess the timing hypothesis and the potential impact of the time since menopause that treatment was commenced, we stratified trials according to when treatment was started. This was characterised as starting treatment either &lt; 10 or &#8805;10 years after the menopause, or if these data were not available, then we used mean age of participants at baseline (&lt; 60 versus &#8805; 60 years of age) as a surrogate. In some cases, studies reported the results in subgroups, according to the time since the menopause that treatment was started, or age that treatment was started (<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>). For the remaining studies, we used mean time since menopause that treatment commenced or mean age that treatment commenced. It is not possible to say with absolute certainty that all individuals in these studies are correctly attributed to the correct treatment timing subgroup, however, with the reported standard deviations of the mean time since menopause or mean age that treatment was commenced, we can be confident that the vast majority are correctly assigned and this allows us to make an important subgroup analysis, though the limitations of this analysis must be borne in mind.</P>
<P>The reason we used a composite endpoint of coronary heart disease and did not report the remaining prespecified outcomes was due to the largest trials (<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>) reporting this composite endpoint according to number of decades after menopause at which treatment was started, and venous thromboembolism according to age in decades at which treatment was started. We did not include the remaining outcomes in this analysis as there were insufficient data reported according to time that treatment was started in relation to the menopause or age to allow for accurate analysis.</P>
<P>The results of the subgroup analysis provide some supportive evidence for the timing hypothesis for the outcomes of death from all causes and coronary heart disease. All cause death was lower in the subgroup of studies where treatment was started within 10 years of the menopause compared with studies where more than 10 had elapsed since the menopause had started (P = 0.01; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). The risk of coronary heart disease was also lower in women who had commenced therapy less than 10 since the start of the menopause (P = 0.02; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). We did not find evidence of a difference between the subgroups for the outcomes of stroke and venous thromboembolism (P = 0.66; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>, and P = 0.7; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK> respectively).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hormone therapy commenced less than 10 years after the menopause</HEADING>
<P>Six trials and 9629 participants were included in this analysis (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>) (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). Three trials reported a mean time since menopause for the study population at the start of the study of less than 10 years: <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK> (0.58 years), <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK> (4.6 years) and <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK> (8.8 years). One study which did not report number of years since menopause did report a mean age of the study population under 60 years (<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK> (55 years old)). Two studies reported events stratified by those participants who were less than 10 years since their menopause at the start of the study (<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>).</P>
<P>Hormone therapy in a population who, as a mean, started treatment less than 10 years after their menopause or were less than 60 years old, demonstrated an all-cause mortality benefit (RR 0.70, 95% CI 0.52 to 0.95; 9088 participants in 5 studies) and coronary heart disease benefit (composite of death from cardiovascular causes and non-fatal myocardial infarction) (RR 0.52, 95% CI 0.29 to 0.96; 8311 participants in 4 studies) compared to placebo (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). There was a statistically non-significant trend to increased risk of stroke (RR 1.37, 95% CI 0.80 to 2.34; 8143 participants in 3 studies) (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). There was, however, strong evidence of increased risk of venous thromboembolism (RR 1.74, 95% CI 1.11 to 2.73; 9838 participants in 3 studies) in the hormone therapy group compared to placebo (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). The absolute risk reduction for death (all-causes) was 0.007 (NNTH = 146) and coronary heart disease (death from cardiovascular causes and non-fatal myocardial infarction) was 0.007 (NNTH = 133). The absolute risk increase for venous thromboembolism was 0.005 (NNTH = 214). A summary of the outcomes and their relative risks are presented in <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>. There was moderate statistical heterogeneity present between trials for the outcome of coronary heart disease (I<SUP>2</SUP> = 48%). There was no strong evidence of statistically significant heterogeneity for the remaining analyses.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hormone therapy commenced more than 10 years after the menopause</HEADING>
<P>Fifteen trials and 28,705 participants were included in this analysis (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>) (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). Eight studies reported a mean time since menopause for the study population at the start of the study of more than 10 years: <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK> (12.5 years), <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK> (14.7 years), <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK> (16.1 years), <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK> (18 years), <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK> (18.2 years), <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK> (22.8 years), <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK> (23.0 years) and <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK> (25 years). Five studies did not report number of years since menopause, but did report a mean age of the study population &gt; 60 years (<LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK> (62.2 years old), <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK> (64 years old), <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK> (65 years old), <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK> (71 years old) and <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK> (71.2 years old). Two studies reported events stratified by participants who were &#8805; 10 years since their menopause at the start of the study <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>).</P>
<P>Hormone therapy in a population who as a mean started treatment 10 years or more after menopause or were more than 60 years old demonstrated no strong evidence that hormone therapy has an effect on death (RR 1.06, 95% CI 0.95 to 1.18; 27,750 participants in 12 studies) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) or coronary heart disease (RR 1.07, 95% CI 0.96 to 1.20; 23,491 participants in 12 studies) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). However, there was strong evidence that hormone therapy is associated with an increased risk of stroke (RR 1.21, 95% CI 1.06 to 1.38; 22,722 participants in 8 studies) (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>) and of venous thromboembolism (RR 1.96, 95% CI 1.37 to 2.80; 27,475 participants in 9 studies) (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). The absolute risk increase for stroke and venous thromboembolism was 0.01 (NNTH = 102) and 0.01 (NNTH = 101), respectively. A summary of the outcomes and their relative risks are presented in <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>. There was moderate statistical heterogeneity present between trials for the outcome of venous thromboembolism (I<SUP>2</SUP> = 41%) but not for any other outcomes.</P>
<P>
<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-03-06 15:25:34 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-02-03 06:21:26 +0000" MODIFIED_BY="[Empty name]">
<P>The stimulus for updating this review was the publication of <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>, however this trial only contributed 3.5% and 19.5% weight to the all-cause mortality and cardiovascular mortality, respectively, in the treatment of a primary prevention population. In the trial population as a whole, there is no evidence that hormone therapy has a role in either the prevention or treatment of cardiovascular disease. There was no strong evidence that treatment with hormone therapy had an effect on overall death rates, cardiovascular disease-related death, non-fatal myocardial infarction, angina, or the number of patients undergoing revascularisation procedures. On the contrary, it is associated with an increased risk of stroke, venous thromboembolism and pulmonary embolism.</P>
<P>The excess risk of stroke in our analyses was observed in the primary prevention analysis (which includes those randomised to either oestrogen alone or oestrogen in combination with progestogen compared to placebo). These findings are based on the two largest trials, <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>, with follow-up of 5.6 and 7.1 years, respectively. Whilst, no strong evidence of increased risk was observed in any of the secondary prevention trials, including the largest trial <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>, it is probable that the results from the primary prevention trials are applicable to secondary prevention populations, and that subgroup analyses of these trials were underpowered (due to small trial sizes, low event rates and shorter length of follow-up) to detect any statistically significant differences in stroke rates between hormone therapy and placebo treatment arms. In both <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>, the excess risk of stroke observed with hormone therapy use was driven by an excess of ischaemic rather than haemorrhagic stroke, with 79.8% and 80.3% of strokes, respectively, observed within the trials being ischaemic (<LINK REF="REF-Hendrix-2006" TYPE="REFERENCE">Hendrix 2006</LINK>; <LINK REF="REF-Wassertheil_x002d_Smoller-2003" TYPE="REFERENCE">Wassertheil-Smoller 2003</LINK>). In the same two trials, an increased risk of stroke was apparent after two years of treatment in women taking combination hormone therapy, and after four years for women randomised to oestrogen alone (<LINK REF="REF-Hendrix-2006" TYPE="REFERENCE">Hendrix 2006</LINK>). In both trials, the hazard ratios for ischaemic stroke did not differ significantly in subgroups based on age, years since menopause, prior cardiovascular disease, hypertension or diabetes mellitus status, body mass index, or statin or aspirin use at baseline (<LINK REF="REF-Hendrix-2006" TYPE="REFERENCE">Hendrix 2006</LINK>; <LINK REF="REF-Wassertheil_x002d_Smoller-2003" TYPE="REFERENCE">Wassertheil-Smoller 2003</LINK>).</P>
<P>The finding of increased risk for both venous thromboembolism and pulmonary embolism within the overall trial populations appears in our analyses to be driven largely by the excess risk observed in combination hormone therapy (oestrogen combined with progestogen) trials. The greatest risk in primary prevention populations was shown in <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK> and <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>, both testing combination hormone therapy. In secondary prevention populations, the greatest risk was demonstrated in <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>, also assessing combination hormone therapy. Subgroup analysis of <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> for the outcome of venous thromboembolism demonstrated the greatest risk with combination hormone therapy in the first year of treatment (HR 4.01), with lower risk in subsequent years (<LINK REF="REF-Cushman-2004" TYPE="REFERENCE">Cushman 2004</LINK>). <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> also demonstrated a tendency to higher risk early on with only modest increased risk after two years of treatment with oestrogen alone (<LINK REF="REF-Curb-2006" TYPE="REFERENCE">Curb 2006</LINK>). When comparing the two studies (combination hormone therapy compared to oestrogen alone), the difference in risk was most apparent after year two when the higher risk in combination hormone therapy was most noticeable (<LINK REF="REF-Curb-2006" TYPE="REFERENCE">Curb 2006</LINK>).</P>
<P>Both <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> undertook further prespecified subgroup analyses to evaluate the association between participant baseline characteristics and venous thromboembolism and pulmonary embolism risk. Not surprisingly, given the fact that no excess risk was observed within the trial, <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> investigators found no strong evidence of interactions between oestrogen alone use and age, body mass index, or most other venous thromboembolism risk factors. The authors did however note, that hazard ratios for combination therapy in <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> were significantly higher than those for oestrogen alone, even after adjusting for venous thromboembolism risk factors (<LINK REF="REF-Curb-2006" TYPE="REFERENCE">Curb 2006</LINK>). In <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>, increasing age, being overweight and obese, and having a factor V Leiden mutation (a blood coagulation disorder) were associated with a higher risk of venous thromboembolism compared to placebo (<LINK REF="REF-Cushman-2004" TYPE="REFERENCE">Cushman 2004</LINK>). Both <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> undertook prespecified subgroup analyses to evaluate whether any clinical characteristics of the trial populations may potentially moderate the effects of hormone therapy. The potential predictor variables examined included: age, time since menopause, presence or absence of vasomotor symptoms, prior hormone use, coronary heart disease risk factor status and presence or absence of preexisting cardiovascular disease (<LINK REF="REF-Hsia-2006" TYPE="REFERENCE">Hsia 2006</LINK>; <LINK REF="REF-Manson-2003" TYPE="REFERENCE">Manson 2003</LINK>). None of these variables significantly affected results, although we observed a non-significant trend for a reduction in coronary heart disease risk for women who initiated hormone therapy use within ten years of menopause.</P>
<P>Subgroup analysis of time of treatment commencement in relation to the menopause, found a benefit in overall survival and coronary heart disease (composite of death from cardiovascular causes and non-fatal myocardial infarction) in the hormone therapy group in those who started less than 10 years after their menopause (or before the age of 60). This is similar to the trend in coronary heart disease events in <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> shown in <LINK REF="REF-Hsia-2006" TYPE="REFERENCE">Hsia 2006</LINK>. There was no strong evidence of effect on stroke. There was, however, strong evidence of increased risk of venous thromboembolism, whether started before or after the age of 60.</P>
<P>There was no strong evidence of effect on death or coronary heart disease for the group who started treatment at 10 years or more after the menopause, however there was an increased risk of stroke and venous thromboembolism. We did not analyse any other outcomes, as these analyses relied significantly on subgroup reporting from <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>, which only reported these outcomes according to time since the menopause, or age that treatment was started. There were insufficient data from other trials to make reliable analyses of other outcomes.</P>
<P>It is worth noting that the benefit seen in survival and coronary heart disease for the group starting treatment less than 10 years after the menopause is from combining five trials all performed in primary prevention populations and all with quite long follow-up, ranging from 3.4 years to 10.1 years. Looking at the event rates in these individual trials it can be seen that the greatest benefit is in those trials with the longest follow-up. It is possible that this could be due to an interaction with time on treatment, whereby coronary heart disease events occur in predisposed individuals early as opposed to later on with hormone therapy treatment, and therefore any risk reduction is observed in the later stages of treatment. This is consistent with the hazard ratio for coronary heart disease for the one-year intervals of follow-up observed in <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> (<LINK REF="REF-Manson-2003" TYPE="REFERENCE">Manson 2003</LINK>). Therefore, it is not possible to say if short duration hormone therapy is beneficial in this population, only that hormone therapy taken for between 3.4 to 10 years is beneficial in this population.</P>
<P>In analysis of death according to year of treatment, there was no strong evidence of difference between treatment groups by individual year of treatment. There was also no strong evidence of difference in survival comparing cumulative years of treatment, until ten years of treatment, where there was a small survival benefit in the hormone therapy group. However, this was based on two relatively small primary prevention trials, where treatment was started shortly after the menopause (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>). One of the trials had poor methodology (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>). It is possible that there are other explanations for the benefit seen in this analysis, other than the duration of treatment, such as the timing of commencing treatment.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-03-06 14:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>There are a number of limitations to the evidence base reviewed. Firstly, it should be highlighted that the results are based on those obtained in 19 RCTs, with the majority of statistically significant findings derived from the results of the three largest trials, <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>, <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>, which dominate the results. These three trials all evaluated oral conjugated equine oestrogen 0.625 mg, with or without continuous medroxyprogesterone (MPA) 2.5 mg. Other trials evaluating different types of hormone therapy tended to be much smaller with a shorter duration of follow-up, and reported few if any major clinical events. There is some debate regarding the external validity of the findings of <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>, and the degree to which they apply to any type of hormone therapy, other than continuous combined oral conjugated equine oestrogen 0.625 mg with or without MPA 2.5 mg. The effects of hormone therapy may vary with different oestrogens and progestogens, different doses and routes of administration. However, in order to pool the results of different studies statistically, we had to make assumptions regarding a &#8216;class effect&#8217; of hormone therapy, which may not be warranted.<BR/>
</P>
<P>The clinical outcomes of interest in the review were secondary outcomes in five of the trials (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>) and reported as adverse events in five more (<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>). It can therefore be postulated that these trials may not have been sufficiently powered in order to detect differences in clinical treatment effects between the hormone therapy and placebo arms, as this was not the primary aim of these trials. Furthermore, as previously highlighted, seven of the trials were stopped early (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>), either as other trial results were published showing no beneficial effects on cardiovascular disease outcomes for hormone therapy relative to placebo, or observation of a detrimental effect either on cardiovascular disease outcomes or adverse events was shown. The mean length of trial follow-up therefore ranged considerably from seven months to 10.1 years, with a mean duration of follow-up of 3.6 (median of three) years across the trials. The early stopping of the trials has implications both for the power to detect differences in treatment effects between the hormone therapy and placebo arms (as the sample size will have been predicated based on the original proposed length of follow-up, and assumptions regarding the number of events observed), and also for limiting the availability of evidence on the longer-term treatment effects of hormone therapy compared to placebo. A further limitation of the evidence base reviewed relates to the impact of patient medication compliance, which ranged considerably between the trials. A high proportion of women in the trials did not receive the treatment to which they were randomised. Overall, the number of women who discontinued their medication or took less than 80% was disproportionately high in the hormone therapy trial arms, presumably due to medication side effects. The authors of <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> noted that if discontinuation of treatment and initiation of non-study treatment occurred independently of risk factors for clinical outcomes, their intention-to-treat analysis underestimates both the harms and benefits of hormone therapy among women who adhere to treatment.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-03-06 15:25:12 +0000" MODIFIED_BY="[Empty name]">
<P>A summary of the findings and strength of evidence can be found in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK> and <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>. In the primary prevention population, the quality of evidence for death and cardiovascular disease was high. We downgraded the quality of the evidence by one level for venous thromboembolism and pulmonary embolism due to inconsistency of effect across the study results. When HT considered as a secondary prevention strategy, the quality of the evidence was also high for death and venous thromboembolism. The confidence intervals for the estimated effect on stroke and pulmonary embolism could not exclude small decreases or large increases in risk. For the subgroup of studies addressing the effects of HT started less than 10 years since the menopause the quality of evidence was downgraded one level for the outcomes of mortality and coronary heart disease as the results of the analysis were dominated by the results of a few large trials. Overall study quality was high (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The vast majority of trials had adequate generation of randomised sequences (15 out of 19), 17 out of 19 were double-blinded and 13 out of 19 were analysed on an intention-to-treat basis. Participants lost to follow-up were generally low, except in two trials: 14.9% in <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK> and 19% in <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>, though these provided relatively low weight to the analysis. Only two out of 19 trials were at risk of selective outcome reporting.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-03-06 15:25:34 +0000" MODIFIED_BY="[Empty name]">
<P>There are a number of potential biases in the review process, although we made attempts to limit these. The bias of most concern is that of patient selection bias which limits external validity. Nearly all of the included trials had a mean participant age of over 60 years at baseline, and only one trial (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>) focused on women who were either peri-menopausal or around the time of the menopause. Whilst these inclusion criteria reflected the aims of the trials, it does not reflect usual clinical practice, in which hormone therapy is prescribed for the relief of vasomotor symptoms at the time of menopause.</P>
<P>Despite extensive searches it is possible that we failed to identify all relevant studies. However, given the dominance of <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> and <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK> on the results of the review, it is unlikely that we missed any trials large enough to impact substantially on the results. Additionally, as already indicated, assumptions had to be made in the analyses regarding the effects of different HT preparations in order to undertake meta-analyses. These assumptions may not be warranted, as it is as yet unclear how different preparations and doses may differ.</P>
<P>Our assessment of the timing hypothesis could be considered a post-hoc change to the original protocol for this review. The data for events since menopause (stratified in decades) were only available for two studies (<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>) and for the remaining studies baseline characteristics for eleven studies (<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>; <LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>; <LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>; <LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>; <LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>) were available for us to allocate the study population as a whole to either commencing treatment less than 10 years since the menopause or 10 years or more since the menopause. For six studies (<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>; <LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>; <LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>) these data were not available. However, age was reported and therefore whole study populations were allocated accordingly to those less than 60 years of age or those 60 years of age or older when they commenced treatment. It is highly likely that trial populations were distributed across a range of ages and time since menopause, and it is therefore likely that a proportion of study populations were incorrectly allocated. This will be more of a problem in study samples with large standard deviations for time since menopause, or age, and also in those who have a mean or median age or time since menopause close to the cut-off (10 years since the menopause and 60 years of age). Although we remain confident that the subgroups are broadly representative of the study populations of interest, subgroup level data for each study or individual participant data would represent more robust approaches to testing the timing hypothesis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-02-03 06:55:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="REF-Magliano-2006" TYPE="REFERENCE">Magliano 2006</LINK> pooled results from seven of the trials included in the current review (<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>; <LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>; <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>; <LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>; <LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>; <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>; <LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>), and concluded that there was no impact of hormone therapy compared to placebo on total mortality or non-fatal myocardial infarction, but strong evidence of an increased risk in the number of strokes (RR 1.29, 95% CI 1.13 to 1.48) observed with hormone therapy use. Likewise, a meta-analysis by <LINK REF="REF-Bath-2005" TYPE="REFERENCE">Bath 2005</LINK>, pooling 28 RCTs, reported  hormone therapy was associated with an increase in the risk of stroke, particularly ischaemic stroke. Furthermore, those participants who had a stroke in the hormone therapy groups appeared to have a worse outcome.  However, it is unclear to what degree the results of this review are applicable to post-menopausal women, as the review had very broad inclusion criteria, and pooled a wide range of trials which used different types of hormone therapy for a range of indications, some of which included male participants.   <BR/>
<BR/>
<LINK REF="REF-Salpeter-2006" TYPE="REFERENCE">Salpeter 2006</LINK>, in a meta-analysis aimed to examine the effect of hormone therapy on coronary heart disease events in younger and older post-menopausal women (defined as participants with a mean time from menopause of less than or greater than ten years, or mean age less than or greater than 60 years). The analyses of 23 trials (ten trials with younger women and 11 trials with older women), included the relevant Women's Health Initiative age-specific subgroup data in one or the other group as though they had originated from separate RCTs. The results showed that hormone therapy reduced coronary heart disease events in younger women, but not in older women. This is comparable with our findings in this review.</P>
<P>
<LINK REF="REF-Miller-2002" TYPE="REFERENCE">Miller 2002</LINK> performed a meta-analysis of venous thromboembolic outcomes in post-menopausal women using oestrogen replacement. The review included both oestrogen alone and combination therapy and RCTs, case-control studies and a cohort study. They found an increased risk with hormone therapy (RR 2.14, 95% CI 1.64 to 2.81). The analysis was published in 2002 and did not include either Women's Health Initiative studies, which contributed the largest portion of our included population, but the risk is comparable with our findings. They also found that the risk was highest in the first year, but in the majority of studies remained elevated for the duration of follow-up.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-03-06 15:15:16 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-03-06 15:14:29 +0000" MODIFIED_BY="[Empty name]">
<P>Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women for either primary or secondary prevention of cardiovascular disease events has little if any benefit overall, and causes an increase in the risk of stroke, or venous thromboembolic events. <BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-03-06 15:15:16 +0000" MODIFIED_BY="[Empty name]">
<P>Currently there is a lack of evidence regarding factors that may modulate the risks involved in hormone therapy treatment, such as different oestrogen and progestogen preparations, different durations, doses and routes of administration (for example, skin patches and creams). There is one recently published study (<LINK REF="STD-NCT00154180" TYPE="STUDY">NCT00154180</LINK>) and one ongoing study (<LINK REF="STD-NCT00114517" TYPE="STUDY">NCT00114517</LINK>) that assess the timing hypothesis through surrogate endpoints. They should lay the foundation for future research in this area, especially as supportive evidence for the timing hypothesis in this review comes from post-protocol subgroup analyses. Future updates of this review will look to incorporate their findings fully, but it may be that analysis of data at the level of individual participants from the existing trials is needed to evaluate the credibility of the timing hypothesis on mortality and coronary heart disease. Due to low event rates, definitive studies assessing the timing hypothesis through hard endpoints would likely need a very large study population, estimated at 30,000 with 10 to 15 years follow-up, and hence be very costly (<LINK REF="REF-Rossouw-2013" TYPE="REFERENCE">Rossouw 2013</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-12-17 20:19:08 +0000" MODIFIED_BY="[Empty name]">
<P>We should like to acknowledge the contributions by Alma Adler, Diane Horsley, Fiona Taylor, Juan-Pablo Casas, Karen Rees and Shah Ebrahim who all gave methodological assistance and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-05-18 09:35:22 +0100" MODIFIED_BY="[Empty name]">
<P>No potential conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-11-26 09:31:00 +0000" MODIFIED_BY="[Empty name]">
<P>Anne Eisinga developed and ran the search strategies. Study selection, quality assessment and data extraction were performed by Henry Boardman and Louise Hartley. Caroline Main calculated the absolute risk increases/decreases and the numbers needed to treat/harm. Henry Boardman wrote the first draft of the review, and all co-authors commented on this and contributed to the final draft of the review. All authors have approved the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-03-06 15:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>In this updated review the outcomes of coronary artery bypass graft (CABG) and angioplasty were combined into a single outcome measure "revascularisation". This treatment options are closely related and their combination gives increased power to assessing the effect of HT upon them.</P>
<P>Health-related quality of life (HRQoL) was excluded from outcomes to focus on cardiovascular endpoints and relevant subgroup analysis on time of commencing of HT in relation to the menopause.</P>
<P>We have presented subgroup analysis results based on the timing hypothesis in this version of the review. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-02-03 15:58:17 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-DOPS-2012" MODIFIED="2015-02-03 15:57:29 +0000" MODIFIED_BY="[Empty name]" NAME="DOPS 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-02-02 20:54:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bladbjerg E, Madsen J, Kristensen S, Abrahamsen B, Brixen K, Mosekilde L, et al</AU>
<TI>Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>6</NO>
<PG>1208-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 20:55:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristensen S, Abrahamsen B, Madsen J, Gram J, Rejnmark L, Rud B, et al</AU>
<TI>Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS)</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2006</YR>
<VL>95</VL>
<PG>915-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 20:55:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madsen J, Kristensen S, Gram J, Bladbjerg E, Henriksen F, Christensen K, et al</AU>
<TI>Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>9</NO>
<PG>1984-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-02 14:08:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schierbeck L, Rejnmark L, Tofteng C, Stilgren L, Eiken P, Mosekilde L, et al</AU>
<TI>Hormone replacement treatment in early postmenopausal women reduces cardiovascular events - A randomized controlled study</TI>
<SO>Circulation</SO>
<YR>2011</YR>
<VL>124</VL>
<PG>A11380</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 15:57:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al</AU>
<TI>Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>345</VL>
<PG>e6409</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:00:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tofteng C, Jensen J, Abrahamsen B, Odum L, Brot C</AU>
<TI>Two polymorphisms in the vitamin D receptor gene-association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>8</NO>
<PG>1535-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:02:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Maat M, Madsen J, Langdal B, Bladbjerg E, Tofteng C, Abrahamsen L, et al</AU>
<TI>Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>97</VL>
<NO>2</NO>
<PG>234-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EAGAR-2006" MODIFIED="2015-02-02 21:02:46 +0000" MODIFIED_BY="[Empty name]" NAME="EAGAR 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-02-02 21:02:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ouyang  P, Tardif J, Herrington D, Stewart K, Thompson P, Walsh M, et al</AU>
<TI>Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries</TI>
<SO>Atherosclerosis</SO>
<YR>2006</YR>
<VL>189</VL>
<NO>2</NO>
<PG>375-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EPAT-2001" MODIFIED="2015-02-03 15:57:45 +0000" MODIFIED_BY="[Empty name]" NAME="EPAT 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-02 15:35:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hodis H, Mack W, Lobo R, Mahrer P, Liu C R, Liu C H</AU>
<TI>Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT)</TI>
<SO>Circulation</SO>
<YR>2002</YR>
<VL>106</VL>
<NO>19 Suppl II</NO>
<PG>II-744</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 15:57:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al</AU>
<TI>Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>939-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EPHT-2006" MODIFIED="2015-02-02 21:05:22 +0000" MODIFIED_BY="[Empty name]" NAME="EPHT 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-15 15:19:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hemminki E, Hovi S, Veerus P, Sevón T, Tuimala R, Rahu M, et al</AU>
<TI>Blinding decreased recruitment in a prevention trial of postmenopausal women</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2004</YR>
<VL>57</VL>
<PG>1237-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:19:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veerus P, Fischer K, Hovi S-L, Karro H, Rahu M, Hemminki E</AU>
<TI>Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial</TI>
<SO>BMC Women&#8217;s Health</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:05:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Veerus P, Hovi S, Fischer K, Rahu M, Hakama M, Hemminki E</AU>
<TI>Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]</TI>
<SO>Maturitas</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>2</NO>
<PG>162-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ERA-2000" MODIFIED="2015-02-02 21:06:04 +0000" MODIFIED_BY="[Empty name]" NAME="ERA 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-01-26 21:34:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Herrington DM, Reboussin DM, Bridget Brosnihan K, Sharp PC, Shumaker SA, Snyder TE, et al</AU>
<TI>Effects of estrogen replacement on the progression of coronary-artery atherosclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>8</NO>
<PG>522-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-03 21:00:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrington DM, Reboussin DM, Klein KP, Sharp PC, Shumaker SA, Snyder TE, et al</AU>
<TI>The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>3</NO>
<PG>257-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:06:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nair G, Herrington D</AU>
<TI>The ERA trial: findings and implications for the future</TI>
<SO>Climacteric</SO>
<YR>2000</YR>
<VL>3</VL>
<PG>227-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ERT-II-1979" MODIFIED="2015-02-02 21:06:24 +0000" MODIFIED_BY="[Empty name]" NAME="ERT II 1979" YEAR="1979">
<REFERENCE MODIFIED="2015-02-02 21:06:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM</AU>
<TI>Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems</TI>
<SO>Obstetrics Gynecology</SO>
<YR>1979</YR>
<VL>54</VL>
<NO>1</NO>
<PG>74-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ESPRIT-2002" MODIFIED="2013-03-15 15:20:51 +0000" MODIFIED_BY="[Empty name]" NAME="ESPRIT 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-15 15:20:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The ESPRIT Team</AU>
<TI>Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>2001-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EVTET-2000" MODIFIED="2015-02-03 15:58:02 +0000" MODIFIED_BY="[Empty name]" NAME="EVTET 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-02-03 15:58:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hoibraaten E, Arnesen H, Larsen S, Wickstrom E, Sandset PM</AU>
<TI>Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2000</YR>
<VL>84</VL>
<PG>961-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:08:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qvigtad, Hoibraaten H, Arnesen H, Larsen S, Wickstrom E, Sandset P</AU>
<TI>Recurrent venous thromboembolism during hormone replacement therapy - results of the estrogen in venous thromboembolism trial</TI>
<SO>XVI FIGO World Congress of O and G</SO>
<YR>2000</YR>
<VL>Abstract book 1</VL>
<PG>58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-2005" MODIFIED="2015-02-02 21:09:23 +0000" MODIFIED_BY="[Empty name]" NAME="Greenspan 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-02-02 21:09:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan SL, Resnick NM, Parker RA</AU>
<TI>The effect of hormone replacement on physical performance in community-dwelling elderly women</TI>
<SO>The American Journal of Medicine</SO>
<YR>2005</YR>
<VL>118</VL>
<PG>1232-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HALL-1998" MODIFIED="2013-03-15 14:20:30 +0000" MODIFIED_BY="[Empty name]" NAME="HALL 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-03-15 14:20:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall G, Pripp U, Schenk-Gustafsson K, Landgren BM</AU>
<TI>Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease</TI>
<SO>Maturitas</SO>
<YR>1998 </YR>
<VL>28 </VL>
<PG>235-42 </PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HERS-I-1998" MODIFIED="2015-02-02 21:15:25 +0000" MODIFIED_BY="[Empty name]" NAME="HERS I 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-05-02 14:35:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley S, Grady D, et al</AU>
<TI>Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease</TI>
<SO>American Journal of Cardiology</SO>
<YR>2005</YR>
<VL>95</VL>
<NO>2</NO>
<PG>289-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:10:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giddings L</AU>
<TI>Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease</TI>
<SO>Evidence Based Nursing</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>4</NO>
<PG>123</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:21:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley S, et al</AU>
<TI>Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>4</NO>
<PG>314-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:22:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady D, Herrington D, Bittner V, Davidson M, Hlatky M, Hsia J, et al</AU>
<TI>Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>1</NO>
<PG>49-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:11:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady D, Wenger N, Herrington D, Khan S, Furberg C, Hunninghake, et al</AU>
<TI>Postmenopausal hormone therapy increases risk for venous thromboembolic disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>132</VL>
<PG>689-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:23:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hlatky M, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA</AU>
<TI>Quality-of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>5</NO>
<PG>591-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:11:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al</AU>
<TI>Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group</TI>
<SO>Obstetrical and Gynecological Survey</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>1</NO>
<PG>41-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:11:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al</AU>
<TI>Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>280</VL>
<NO>7</NO>
<PG>605-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:11:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan M, Hlatky M, Liu M, Lin F, Rogers W, Shlipak M</AU>
<TI>Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty</TI>
<SO>The American Journal of Cardiology</SO>
<YR>2003</YR>
<VL>91</VL>
<NO>8</NO>
<PG>989-91, A7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-02 16:10:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shlipak M, Simon J, Vittinghoff E, Lin F, Barrett-Connor E, Knopp R</AU>
<TI>Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>14</NO>
<PG>1845-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-03 21:15:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al</AU>
<TI>Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS)</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<NO>5</NO>
<PG>638-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:13:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon JA, Lin F, Vittinghoff E, Bittner V; Heart and Estrogen-Progestin Replacement Study (HERS) Research Group</AU>
<TI>The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen-progestin replacement study (HERS)</TI>
<SO>Annals of Epidemiology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>2</NO>
<PG>138-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:15:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speroff L</AU>
<TI>The heart and estrogen/progestin replacement study (HERS)</TI>
<SO>Maturitas</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>1</NO>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STOP-IT-2001" MODIFIED="2015-02-03 15:58:17 +0000" MODIFIED_BY="[Empty name]" NAME="STOP IT 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-02-02 21:19:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher J, Rapuri B, Haynatzki G, Detter R</AU>
<TI>Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>11</NO>
<PG>4914-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 15:58:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher JC, Fowler SE, Detter JR, Sherman SS</AU>
<TI>Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2001</YR>
<VL>86</VL>
<NO>8</NO>
<PG>3618-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-02 15:30:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapuri P, Gallagher J, Knezetic J, Haynatzka V</AU>
<TI>Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen</TI>
<SO>Maturitas</SO>
<YR>2006</YR>
<VL>53</VL>
<NO>4</NO>
<PG>371-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:20:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sai A, Gallagher J, Fang X</AU>
<TI>Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor-alpha genotypes</TI>
<SO>Menopause</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>10</NO>
<PG>1101-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:21:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yalamanchili V, Gallagher J</AU>
<TI>Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms</TI>
<SO>Menopause</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>6</NO>
<PG>697-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WAVE-2002" MODIFIED="2015-02-02 21:23:22 +0000" MODIFIED_BY="[Empty name]" NAME="WAVE 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-15 15:23:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsia J, Alderman EL, Verter JI, Rogers WJ, Thompson P, Howard BV, et al</AU>
<TI>Women&#8217;s angiographic vitamin and estrogen trial: design and methods</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>708-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:23:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waters D, Alderman E, Hsia J, Howard B, Cobb F, Rogers W, et al</AU>
<TI>Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>288</VL>
<NO>19</NO>
<PG>2432-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WELL_x002d_HART-2003" MODIFIED="2015-02-02 21:23:37 +0000" MODIFIED_BY="[Empty name]" NAME="WELL-HART 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-02-02 21:23:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al</AU>
<TI>Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>6</NO>
<PG>535-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WEST-2001" MODIFIED="2015-02-02 21:24:48 +0000" MODIFIED_BY="[Empty name]" NAME="WEST 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-02-02 21:24:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kernan WN, Brass LM, Viscoli CM, Sarrell PM, Makuch R, Horwitz RI</AU>
<TI>Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial</TI>
<SO>Journal of Stroke and Cerebrovascular Diseases</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>1</NO>
<PG>85-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:24:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viscoli C, Brass L, Kernan, Sarrel P, Suissa S, Horwitz R</AU>
<TI>Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST)</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>2</NO>
<PG>387-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:24:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI</AU>
<TI>A clinical trial of estrogen-replacement therapy after ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>17</NO>
<PG>1243-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHI-I-2002" MODIFIED="2015-02-02 22:08:36 +0000" MODIFIED_BY="[Empty name]" NAME="WHI I 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-15 15:25:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson GI, Manson J, Wallace R, Lund B, Hall D, Davis S, et al</AU>
<TI>Implementation of the womens health initiative study design</TI>
<SO>Annals of Epidemiology</SO>
<YR>2003</YR>
<VL>13</VL>
<PG>S5-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:25:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al</AU>
<TI>Estrogen plus progestin and risk of venous thrombosis</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>292</VL>
<NO>13</NO>
<PG>1573-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:26:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hays J, Hunt JR, Hubbell, FA, Anderson GL, Limacher M, Allen C, et al</AU>
<TI>The Women's Health Initiative recruitment methods and results</TI>
<SO>Annals of Epidemiology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>Suppl 9</NO>
<PG>S18-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:26:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al</AU>
<TI>Effects of estrogen plus progestin on health-related quality of life</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>104</NO>
<PG>1839-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-18 14:12:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SAA, Brzyski R, et al</AU>
<TI>Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>299</VL>
<NO>9</NO>
<PG>1036&#8211;45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:28:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf A, Lasser N, et al; Women's Health Initiative Investigators</AU>
<TI>Estrogen plus progestin and the risk of coronary heart disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>6</NO>
<PG>523-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:29:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M</AU>
<TI>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>3</NO>
<PG>321-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:41:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al</AU>
<TI>Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>297</VL>
<NO>13</NO>
<PG>1465&#8211;77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 22:08:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR, et al</AU>
<TI>The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants</TI>
<SO>Annals of Epidemiology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>Suppl 9</NO>
<PG>S78-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 22:08:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Womens Health Initiative Study Group</AU>
<TI>Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>1</NO>
<PG>61-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-15 15:43:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg C, Baird A, et al</AU>
<TI>Effect of estrogen plus progestin on stroke in postmenopausal women</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>20</NO>
<PG>2673-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:30:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Writing Group for the Women's Health Initiative Investigators</AU>
<TI>Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>3</NO>
<PG>321-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHI-II-2004" MODIFIED="2015-02-02 21:54:56 +0000" MODIFIED_BY="[Empty name]" NAME="WHI II 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-02-02 21:52:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al; Women's Health Initiative Steering Committee</AU>
<TI>Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>14</NO>
<PG>1701-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:31:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, et al; Women's Health Initiative Investigators</AU>
<TI>Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2005</YR>
<VL>165</VL>
<NO>17</NO>
<PG>1976-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:32:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn K, Barnabei VM, et al</AU>
<TI>Venous thrombosis and conjugated equine estrogen in women without a uterus</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<NO>7</NO>
<PG>772-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:54:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al; WHI Investigators</AU>
<TI>Effects of conjugated equine estrogen on stroke in the Women's Health Initiative</TI>
<SO>Circulation</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>20</NO>
<PG>2425-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:34:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsia J, Langer R, Manson J, Kuller L, Johnson K, Hendrix S, et al; Women's Health Initiative Investigators</AU>
<TI>Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<NO>3</NO>
<PG>357-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 21:35:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al; Women's Health Initiative Investigators</AU>
<TI>Conjugated equine estrogens and coronary heart disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>291</VL>
<PG>1701-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHISP-2006" MODIFIED="2015-02-02 21:59:26 +0000" MODIFIED_BY="[Empty name]" NAME="WHISP 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-02-02 21:59:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins P, Flather M, Lees B, Mister R, Proudler A, Stevenson JC; WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators</AU>
<TI>Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study</TI>
<SO>European Heart Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>17</NO>
<PG>2046-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WISDOM-2007" MODIFIED="2015-02-02 22:05:39 +0000" MODIFIED_BY="[Empty name]" NAME="WISDOM 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-02-02 22:00:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vickers MR, MacLacLennan A, Lawton B, Ford D, Martin J, Meredith S, et al; WISDOM group</AU>
<TI>Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>335</VL>
<NO>7613</NO>
<PG>239</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 22:05:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vickers MR, Martin J, Meade TW; WISDOM study team</AU>
<TI>The Women&#8217;s international study of long-duration of estrogen after menopause (WISDOM): a randomised controlled trial</TI>
<SO>BMC Women's Health</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-02 22:04:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, MacLennan AH, et al; WISDOM team</AU>
<TI>Health related quality of life after combined hormone replacement therapy: randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>337</VL>
<PG>a1190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-02-05 22:30:44 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aitken-1973" MODIFIED="2015-02-02 22:14:02 +0000" MODIFIED_BY="[Empty name]" NAME="Aitken 1973" YEAR="1973">
<REFERENCE MODIFIED="2015-02-02 22:14:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aitken JM, Hart DM, Lindsay R</AU>
<TI>Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>3</VL>
<PG>515-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aloia-1995" MODIFIED="2015-02-02 22:14:55 +0000" MODIFIED_BY="[Empty name]" NAME="Aloia 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-02-02 22:14:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aloia JF, Vaswani A, Russo L, Sheehan M, Flaster E</AU>
<TI>The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>172</VL>
<NO>3</NO>
<PG>896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angerer-2001" MODIFIED="2013-03-15 15:49:01 +0000" MODIFIED_BY="[Empty name]" NAME="Angerer 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-03-15 15:49:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angerer P, Störk S, Kothny W, Scmitt P, von Schacky C</AU>
<TI>Effect of oral postmenopausal hormone replacement on progression of atherosclerosis</TI>
<SO>Arteriosclerosis, Thrombosis and Vascular Biology</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>262-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angerer-2002" MODIFIED="2015-02-02 22:15:08 +0000" MODIFIED_BY="[Empty name]" NAME="Angerer 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-02 22:15:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angerer P, Stork S, Kothny W, Schacky C</AU>
<TI>Effect of postmenopausal hormone replacement on atherosclerosis in femoral arteries</TI>
<SO>Maturitas</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>1</NO>
<PG>51-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bui-Minh-2002" MODIFIED="2015-02-02 22:15:33 +0000" MODIFIED_BY="[Empty name]" NAME="Bui Minh 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-02 22:15:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bui Minh N, Arai A, Hathaway L, Waclawiw M, Csako G, Cannon R</AU>
<TI>Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women</TI>
<SO>The American Journal of Cardiology</SO>
<YR>2002</YR>
<VL>90</VL>
<NO>1</NO>
<PG>82-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CHART-2006" MODIFIED="2015-02-03 16:00:20 +0000" MODIFIED_BY="[Empty name]" NAME="CHART 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-02-03 16:00:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rowan J, Simon J, Speroff L, Ellman H</AU>
<TI>Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 mug) in women with postmenopausal symptoms: Updated analysis of three randomized, controlled trials</TI>
<SO>Clinical Therapeutics</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>6</NO>
<PG>921-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-02 16:39:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speroff L, Rowan J, Symons J, Genant H, Wilborn W</AU>
<TI>The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>17</NO>
<PG>1397-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-1982" MODIFIED="2015-02-02 22:16:15 +0000" MODIFIED_BY="[Empty name]" NAME="Christensen 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-02-02 22:16:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrsitensen MS, Hagen C, Christiansen C, Transbøl IB</AU>
<TI>Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: Placebo-controlled trial of its gynecologic and metabolic actions</TI>
<SO>Gynecology</SO>
<YR>1982</YR>
<VL>144</VL>
<NO>8</NO>
<PG>873-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1981" MODIFIED="2015-02-02 22:17:34 +0000" MODIFIED_BY="[Empty name]" NAME="Christiansen 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-02-02 22:17:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen C, Christiansen MD, Rødbro P, Hagen C, Transbøl I</AU>
<TI>Effect of 1,25-dihydroxy-vitamin D<SUB>3</SUB> in itself or combined with hormone treatment in preventing postmenopausal osteoporosis</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1981</YR>
<VL>11</VL>
<NO>4</NO>
<PG>305-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1984" MODIFIED="2015-02-02 22:18:00 +0000" MODIFIED_BY="[Empty name]" NAME="Christiansen 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-02-02 22:18:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen C, Christensen M, Grande P, Transbøl I</AU>
<TI>Low-risk lipoprotein pattern in post-menopausal women on sequential oestrogen/progestogen treatment</TI>
<SO>Maturitas</SO>
<YR>1984</YR>
<VL>5</VL>
<NO>3</NO>
<PG>193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1990" MODIFIED="2015-02-02 22:18:26 +0000" MODIFIED_BY="[Empty name]" NAME="Christiansen 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-02-02 22:18:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen C, Riis BJ</AU>
<TI>17ß-Estradiol and continuous norethistrone: a unique treatment for established osteoporosis in elderly women</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1990</YR>
<VL>71</VL>
<PG>836-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2002" MODIFIED="2013-03-15 15:50:54 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-15 15:50:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM</AU>
<TI>A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study</TI>
<SO>BJOG</SO>
<YR>2001</YR>
<VL>109</VL>
<NO>9</NO>
<PG>1056-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coope-1981" MODIFIED="2015-02-02 22:20:10 +0000" MODIFIED_BY="[Empty name]" NAME="Coope 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-02-02 22:20:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coope J</AU>
<TI>Is oestrogen therapy effective in the treatment of menopausal depression?</TI>
<SO>The Menopause</SO>
<YR>1981</YR>
<VL>31</VL>
<PG>134-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1997" MODIFIED="2015-02-02 22:25:17 +0000" MODIFIED_BY="[Empty name]" NAME="Davidson 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-02-02 22:25:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Davidson MH, Maki KC, Cyrwski MS, Maki AC</AU>
<TI>Rationale and design of a trial to evaluate the impact of continuous combined hormone replacement therapy on the cardiovascular disease risk profile</TI>
<SO>11th International Symposium on Atherosclerosis; 1997 Oct; Paris</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2000" MODIFIED="2015-02-02 22:26:16 +0000" MODIFIED_BY="[Empty name]" NAME="Davidson 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-02-02 22:26:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Maki K, Marx P, Maki A, Cyrowski M, Nanavati N, et al</AU>
<TI>Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>21</NO>
<PG>3315-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enderle-1999" MODIFIED="2013-05-10 09:11:51 +0100" MODIFIED_BY="[Empty name]" NAME="Enderle 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-05-10 09:11:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enderle M, Sayer R, Balletshofer B, Meisner C, Mueck A, Haasis R, et al</AU>
<TI>Improved peripheral endothelial function in postmenopausal women with coronary artery disease after acute oral intake of 17 ß-Estradiol Valerate</TI>
<SO>Atherosclerosis</SO>
<YR>1999</YR>
<VL>144</VL>
<NO>1</NO>
<PG>33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallagher-1991" MODIFIED="2015-02-02 22:26:50 +0000" MODIFIED_BY="[Empty name]" NAME="Gallagher 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-02-02 22:26:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher JC, Kable WT, Goldgar D</AU>
<TI>Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen</TI>
<SO>The American Journal of Medicine</SO>
<YR>1991</YR>
<VL>90</VL>
<PG>171-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genant-1990" MODIFIED="2015-02-02 22:27:12 +0000" MODIFIED_BY="[Empty name]" NAME="Genant 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-02-02 22:27:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M</AU>
<TI>Effect of estrone sulphate on postmenopausal bone loss</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>76</VL>
<NO>4</NO>
<PG>579-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genant-1997" MODIFIED="2015-02-02 22:27:25 +0000" MODIFIED_BY="[Empty name]" NAME="Genant 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-02-02 22:27:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, et al</AU>
<TI>Low-dose esterified estrogen therapy</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1997</YR>
<VL>157</VL>
<PG>2609-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grady-1997" MODIFIED="2015-02-02 22:27:32 +0000" MODIFIED_BY="[Empty name]" NAME="Grady 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-02-02 22:27:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady D, Hulley S, Furberg C</AU>
<TI>Venous thromboembolic events associated with hormone replacement therapy</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>278</VL>
<NO>6</NO>
<PG>477</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hart-1984" MODIFIED="2015-02-02 22:27:42 +0000" MODIFIED_BY="[Empty name]" NAME="Hart 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-02-02 22:27:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hart D, Farish E, Fletcher C, Howie C, Kitchener H</AU>
<TI>Ten years post-menopausal hormone replacement therapy-effect on lipoproteins</TI>
<SO>Maturitas</SO>
<YR>1984</YR>
<VL>5</VL>
<NO>4</NO>
<PG>271-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hassager-1987" MODIFIED="2015-02-02 22:27:57 +0000" MODIFIED_BY="[Empty name]" NAME="Hassager 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-02-02 22:27:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hassager C, Riis BJ, Strøm V, Guyene TT, Christiansen C</AU>
<TI>The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure</TI>
<SO>Circulation</SO>
<YR>1987</YR>
<VL>76</VL>
<NO>4</NO>
<PG>753-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heikkinen-1997" MODIFIED="2015-02-02 22:28:08 +0000" MODIFIED_BY="[Empty name]" NAME="Heikkinen 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-02-02 22:28:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heikkinen A, Tuppurainen M, Niskanen L, Komulainen M, Penttila I, Saarikoski S</AU>
<TI>Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy</TI>
<SO>European Journal of Endocrinology</SO>
<YR>1997</YR>
<VL>137</VL>
<NO>5</NO>
<PG>495-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrington-1996" MODIFIED="2015-02-02 22:38:00 +0000" MODIFIED_BY="[Empty name]" NAME="Herrington 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-02-02 22:38:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Herrington D</AU>
<TI>Estrogen Replacement and Progression or Regression of Coronary Atherosclerosis</TI>
<SO>Proceedings of the 8th International Congress on the Menopause; 1996 Nov 3-7; Sydney</SO>
<YR>1996</YR>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HERS-II" MODIFIED="2015-02-03 00:39:32 +0000" MODIFIED_BY="[Empty name]" NAME="HERS II" YEAR="2002">
<REFERENCE MODIFIED="2015-02-03 00:39:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al; HERS Research Group</AU>
<TI>Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>1</NO>
<PG>49-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holmberg-2004" MODIFIED="2015-02-03 00:40:08 +0000" MODIFIED_BY="[Empty name]" NAME="Holmberg 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-02-03 00:40:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holmberg L, Anderson H</AU>
<TI>HABITS (hormonal replacement therapy after breast cancer - is it safe?): a randomised comparison: trial stopped</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9407</NO>
<PG>453-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HOPE-2002" MODIFIED="2015-02-03 16:00:41 +0000" MODIFIED_BY="[Empty name]" NAME="HOPE 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-03 16:00:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindsay R, Gallagher J, Kleerekoper M, Pickar H</AU>
<TI>Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>20</NO>
<PG>2668-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 00:40:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobo R, Bush T, Carr B, Pickar J</AU>
<TI>Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>76</VL>
<NO>1</NO>
<PG>13-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 00:40:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Utian W, Shoupe D, Bachmann G, Pinkerton J, Pickar J</AU>
<TI>Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>75</VL>
<NO>6</NO>
<PG>1065-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsia-2003" MODIFIED="2013-03-15 15:52:21 +0000" MODIFIED_BY="[Empty name]" NAME="Hsia 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-15 15:52:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsia J, Bittner V, Tripputi M, Howard BV</AU>
<TI>Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin &amp; Estrogen trial</TI>
<SO>American Heart Journal</SO>
<YR>2003</YR>
<VL>146</VL>
<NO>3</NO>
<PG>439-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsia-2004" MODIFIED="2013-03-15 15:52:32 +0000" MODIFIED_BY="[Empty name]" NAME="Hsia 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-03-15 15:52:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsia JM, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, et al</AU>
<TI>Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>109</VL>
<NO>5</NO>
<PG>620-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2009" MODIFIED="2015-02-03 00:43:26 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-03 00:43:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D</AU>
<TI>Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women</TI>
<SO>Menopause</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>4</NO>
<PG>639-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoi-2000" MODIFIED="2015-02-03 00:47:44 +0000" MODIFIED_BY="[Empty name]" NAME="Itoi 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-02-03 00:47:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoi H, Minakami H, Iwasaki R, Watanabe T, Araki S, Sato I</AU>
<TI>Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipids in postmenopausal women</TI>
<SO>Proceedings of the XVI FIGO World Congress of Gynecology and Obstetrics; 2000 Sept 3-8; Washington</SO>
<YR>2000</YR>
<VL>Abstract book 2</VL>
<PG>149</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-1989" MODIFIED="2015-02-03 00:48:24 +0000" MODIFIED_BY="[Empty name]" NAME="Jensen 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-02-03 00:48:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen J, Riis BJ, Strøm, Christiansen C</AU>
<TI>Long-term and withdrawal effects of two different osetrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women.</TI>
<SO>Maturitas</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>117-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karim-2008" MODIFIED="2015-02-03 00:48:35 +0000" MODIFIED_BY="[Empty name]" NAME="Karim 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-02-03 00:48:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ</AU>
<TI>Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2008</YR>
<VL>93</VL>
<NO>1</NO>
<PG>131-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-1996" MODIFIED="2013-05-02 16:38:23 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-05-02 16:38:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim C, Min Y, Ryu W, Kwak J, Ryoo U</AU>
<TI>Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: Influence of various progestogens and duration of therapy</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>15</NO>
<PG>1693-1700</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komulainen-1999" MODIFIED="2015-02-03 00:49:05 +0000" MODIFIED_BY="[Empty name]" NAME="Komulainen 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-02-03 00:49:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komulainen M, Kroger H, Tuppurainen M, Heikkinen A, Alhava E, Honkanen R</AU>
<TI>Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>2</NO>
<PG>546-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamon_x002d_Fava-2009" MODIFIED="2013-03-15 15:53:13 +0000" MODIFIED_BY="[Empty name]" NAME="Lamon-Fava 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-15 15:53:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamon-Fava S, Herrington DSM, Reboussin DM, Sherman M, Horvath K, Schaefer EJ, et al</AU>
<TI>Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women</TI>
<SO>Atherosclerosis</SO>
<YR>2009</YR>
<VL>205</VL>
<NO>1</NO>
<PG>325-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamon_x002d_Fava-2010" MODIFIED="2015-02-03 00:49:58 +0000" MODIFIED_BY="[Empty name]" NAME="Lamon-Fava 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-02-03 00:49:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamon-Fava S, Asztalos B, Howard T, Reboussin D, Horvath K, Schaefer E, et al</AU>
<TI>Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women</TI>
<SO>Clinical Endocrinology</SO>
<YR>2010</YR>
<VL>72</VL>
<NO>2</NO>
<PG>169-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leggate-1984" MODIFIED="2015-02-03 00:50:55 +0000" MODIFIED_BY="[Empty name]" NAME="Leggate 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-02-03 00:50:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leggate J, Farish E, Fletcher C, McIntosh W, Hart D, Sommerville JM</AU>
<TI>Calcitonin and postmenopausal osteoporosis</TI>
<SO>Clinical Endocrinology</SO>
<YR>1984</YR>
<VL>20</VL>
<NO>1</NO>
<PG>85-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindsay-1984" MODIFIED="2015-02-03 00:52:38 +0000" MODIFIED_BY="[Empty name]" NAME="Lindsay 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-02-03 00:52:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindsay R, Hart DM, Clark DM</AU>
<TI>The minimum effective dose of estrogen for prevention of postmenopausal bone loss</TI>
<SO>Journal of the American College of Obstetricians and Gynecologists</SO>
<YR>1984</YR>
<VL>63</VL>
<NO>6</NO>
<PG>759-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madsen-2003" MODIFIED="2015-02-03 00:52:54 +0000" MODIFIED_BY="[Empty name]" NAME="Madsen 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-02-03 00:52:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madsen J, Kristensen S, Gram J, Bladbjerg E, Henriksen F, Christensen K, et al</AU>
<TI>Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>9</NO>
<PG>1984-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marsden-2002" MODIFIED="2013-03-15 15:53:26 +0000" MODIFIED_BY="[Empty name]" NAME="Marsden 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-15 15:53:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marsden J, Sacks N</AU>
<TI>The national randomised trial of hormone replacement therapy in women with a history of early stage breast cancer: an update</TI>
<SO>Journal of the British Menopause Society</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>4</NO>
<PG>129</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molander-1990" MODIFIED="2015-02-03 00:53:13 +0000" MODIFIED_BY="[Empty name]" NAME="Molander 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-02-03 00:53:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molander U, Milsom I, Ekelund P, Mellstrom, Eriksson O</AU>
<TI>Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause</TI>
<SO>Maturitas</SO>
<YR>1990</YR>
<VL>12</VL>
<PG>113-120</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moriyama-2008" MODIFIED="2013-03-15 15:53:37 +0000" MODIFIED_BY="[Empty name]" NAME="Moriyama 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-03-15 15:53:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moriyama CK, Oneda B, Bernardo FR, Cardoso CG, Forjaz CL, Abrahao SB</AU>
<TI>A randomized, placebo-controlled trial of the effects of physical exercises and estrogen therapy on health-related quality of life in postmenopausal women</TI>
<SO>Menopause</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>4</NO>
<PG>613-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mosca-2009" MODIFIED="2013-03-15 15:53:49 +0000" MODIFIED_BY="[Empty name]" NAME="Mosca 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-15 15:53:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mosca L, Grady D, Barrettt-Connor E, Collins P, Wenger N, Amramson B, et al</AU>
<TI>Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>1</NO>
<PG>147-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nair-2005" MODIFIED="2015-02-03 16:01:08 +0000" MODIFIED_BY="[Empty name]" NAME="Nair 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-09 16:23:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nair G, Waters D, Rogers W, Kowalchuk G, Stuckey T and Herrington D</AU>
<TI>Pulse pressure and coronary atherosclerosis progression in postmenopausal women</TI>
<SO>Hypertension</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>1</NO>
<PG>53-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 16:01:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nair GV, Chaput LA, Vittinghoff E, Herrington DM; Heart and Estrogen/Progestin Replacement Study Investigators</AU>
<TI>Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>127</VL>
<NO>5</NO>
<PG>1498-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neuhouser-2009" MODIFIED="2013-03-15 15:54:13 +0000" MODIFIED_BY="[Empty name]" NAME="Neuhouser 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-15 15:54:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neuhouser ML, Wassertheil-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE, et al</AU>
<TI>Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>3</NO>
<PG>294-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nikolov-1999" MODIFIED="2015-02-03 00:57:52 +0000" MODIFIED_BY="[Empty name]" NAME="Nikolov 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-02-03 00:57:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nikolov R, Golbs S, Schneider H</AU>
<TI>Estrogen replacement therapy (ERT) and hormone replacement therapy (HRT) in the prevention of cardiovascular diseases</TI>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1999</YR>
<VL>121</VL>
<NO>2</NO>
<PG>101-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nordin-1980" MODIFIED="2015-02-03 00:58:03 +0000" MODIFIED_BY="[Empty name]" NAME="Nordin 1980" YEAR="1980">
<REFERENCE MODIFIED="2015-02-03 00:58:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nordin B, Jones M, Crilly R, Marshall D, Brooke R</AU>
<TI>A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women</TI>
<SO>Maturitas</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>3</NO>
<PG>247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Obel-1993" MODIFIED="2015-02-03 00:58:57 +0000" MODIFIED_BY="[Empty name]" NAME="Obel 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-02-03 00:58:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Obel EB, Munk-Jensen N, Svenstrup B, Bennett P, Micic S, Henrik-Nielsen R, et al</AU>
<TI>A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment</TI>
<SO>Maturitas</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>1</NO>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-OPAL-2006" MODIFIED="2015-02-03 16:01:29 +0000" MODIFIED_BY="[Empty name]" NAME="OPAL 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-02-03 16:01:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bots M, Evans G, Riley W, McBride K, Paskett E, Helmond FA, et al; OPAL Investigators</AU>
<TI>The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study</TI>
<SO>European Heart Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>6</NO>
<PG>746-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 01:01:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meijer R, Störk S, Evans GW, Grobbee DE, Bots ML</AU>
<TI>Striking increases in carotid artery wall thickness in healthy subjects</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>5</NO>
<PG>448-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagliaro-1999" MODIFIED="2015-02-03 01:06:48 +0000" MODIFIED_BY="[Empty name]" NAME="Pagliaro 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-02-03 01:06:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pagliaro D, Tangalakis K, Kingwell B, Craven R, Carey M, Stojanovska L</AU>
<TI>The effects of hormone replacement therapy (HRT) on performance, cardiovascular parameters and bone resorption in post menopausal 'masters' athletes</TI>
<SO>Proceedings of the 3rd Congress of the Australasian Menopause Society; 1999; Cairns</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEPI-1995" MODIFIED="2015-02-03 16:01:48 +0000" MODIFIED_BY="[Empty name]" NAME="PEPI 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-05-02 16:32:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson S, et al</AU>
<TI>The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women</TI>
<SO>Maturitas</SO>
<YR>1997</YR>
<VL>27</VL>
<NO>3</NO>
<PG>261-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 01:07:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Espeland M, Hogan P, Fineberg S, Howard G, Schrott H, Waclawiw M, et al</AU>
<TI>Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1589-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-02 16:29:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Espeland M, Marcovina S, Miller V, Wood P, Wasilauskas C, Sherwin R, et al</AU>
<TI>Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>10</NO>
<PG>979-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 01:08:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson S, Mebane-Sims I, Hogan P, Soy D</AU>
<TI>Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S20-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 01:08:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith N, Wiley J, Legault C, Rice K, Heckbert S, Psaty B, et al</AU>
<TI>Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study</TI>
<SO>Menopause</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>6</NO>
<PG>1145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 16:01:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The Writing Group for the PEPI Trial</AU>
<TI>Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>3</NO>
<PG>199-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinkerton-2009" MODIFIED="2015-02-03 01:09:52 +0000" MODIFIED_BY="[Empty name]" NAME="Pinkerton 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-03 01:09:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH</AU>
<TI>Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: A randomized, controlled trial</TI>
<SO>Menopause</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>6</NO>
<PG>1116-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Post-2003" MODIFIED="2015-02-03 01:10:11 +0000" MODIFIED_BY="[Empty name]" NAME="Post 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-02-03 01:10:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Post M, Thomassen M, Mooren M, Baal W, Rosing J, Kenemans P, et al</AU>
<TI>Route of HRT administration and risk factors for venous thrombosis: A randomized, placebo-controlled study in healthy postmenopausal women</TI>
<SO>International Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>83</VL>
<NO>Suppl 3</NO>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prentice-2008" MODIFIED="2015-02-03 01:10:29 +0000" MODIFIED_BY="[Empty name]" NAME="Prentice 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-02-03 01:10:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prentice R</AU>
<TI>Women's health initiative studies of postmenopausal breast cancer</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>2009</YR>
<VL>617</VL>
<PG>151-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prentice-2009" MODIFIED="2015-02-03 01:11:27 +0000" MODIFIED_BY="[Empty name]" NAME="Prentice 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-03 01:11:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, et al</AU>
<TI>Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>170</VL>
<NO>1</NO>
<PG>2-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riggs-1982" MODIFIED="2015-02-03 01:11:57 +0000" MODIFIED_BY="[Empty name]" NAME="Riggs 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-02-03 01:11:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM</AU>
<TI>Effect of the fluoride/calcium regimen on vertebral fracture occurence in postmenopausal osteoporosis</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>306</VL>
<NO>8</NO>
<PG>446-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SMART_x002d_5-2012" MODIFIED="2015-02-03 16:02:26 +0000" MODIFIED_BY="[Empty name]" NAME="SMART-5 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-02-03 16:02:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher JC, Lindsay R, Pan K, Ryan KA, Mirkin S, Chines AA</AU>
<TI>Bazedoxifene/conjugated estrogens: Effects on bone mineral density and bone turnover markers in a double-blind, randomised, placebo- and active-controlled phase 3 study</TI>
<SO>Osteoporosis International</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>S2</NO>
<PG>S63-S64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 01:13:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mirkin S, Archer D, Lobo R, Pan K, Chines A</AU>
<TI>Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: Findings from a 1-year, randomized, placebo- and active-controlled, phase 3 TRIAL</TI>
<SO>Maturitas</SO>
<YR>2012</YR>
<VL>71</VL>
<PG>S43-S44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-02 13:57:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mirkin S, Harvey J, Pinkerton J, Pan K, Thompson J, Chines A</AU>
<TI>The effects of bazedoxifene/conjugated estrogens on breast density in postmenopausal women</TI>
<SO>Maturitas</SO>
<YR>2012</YR>
<VL>71</VL>
<PG>S44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-02 13:59:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mirkin S, Ryan K, Thompson J, Chines A</AU>
<TI>Effects of bazedoxifene/conjugated estrogens on coagulation parameters in a 1-year, randomized, placebo-and active-controlled, phase 3 trial of postmenopausal women</TI>
<SO>Endocrine Reviews</SO>
<YR>2012</YR>
<VL>33</VL>
<PG>3 Meeting Abstracts</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soma-1991" MODIFIED="2013-05-10 09:55:27 +0100" MODIFIED_BY="[Empty name]" NAME="Soma 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-05-10 09:55:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soma M, Fumagalli R, Paoletti R, Meschia M, Maini M, Crosignani P, et al</AU>
<TI>Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<NO>8741</NO>
<PG>612</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-2007" MODIFIED="2015-02-03 01:13:53 +0000" MODIFIED_BY="[Empty name]" NAME="Steiner 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-02-03 01:13:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiner A, Xiang M, Mack W, Shoupe D, Felix J, Lobo R, et al</AU>
<TI>Unopposed estradiol therapy in postmenopausal women: results from two randomized trials</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>109</VL>
<PG>581-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevenson-2005" MODIFIED="2013-05-02 14:38:12 +0100" MODIFIED_BY="[Empty name]" NAME="Stevenson 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-02 14:38:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevenson J, Rioux J, Komer L, Gelfand M</AU>
<TI>1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women</TI>
<SO>Climacteric</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>4</NO>
<PG>352-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svendsen-1992" MODIFIED="2015-02-03 01:14:44 +0000" MODIFIED_BY="[Empty name]" NAME="Svendsen 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-02-03 01:14:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svendsen OL, Hassager C, Marslew U, Christiansen C</AU>
<TI>Changes in calcanean bone mineral occurring spontaneously and during hormone replacement therapy in early post-menopausal women</TI>
<SO>Scandinavian Journal of Clinical and Laboratory Investigation</SO>
<YR>1992</YR>
<VL>52</VL>
<PG>831-836</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toh-2010" MODIFIED="2013-03-15 15:54:54 +0000" MODIFIED_BY="[Empty name]" NAME="Toh 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-15 15:54:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toh S, Hernandez-Diaz S, Logan R, Rossouw JE, Hernan MA</AU>
<TI>Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010</YR>
<VL>152</VL>
<NO>4</NO>
<PG>I-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuppurainen--1995" MODIFIED="2015-02-03 01:14:58 +0000" MODIFIED_BY="[Empty name]" NAME="Tuppurainen  1995" YEAR="1995">
<REFERENCE MODIFIED="2015-02-03 01:14:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuppurainen M, Heikkinen A, Penttila I, Saarikoski S</AU>
<TI>Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3</TI>
<SO>Maturitas</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>1</NO>
<PG>55-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulloa-2000" MODIFIED="2013-05-10 09:09:46 +0100" MODIFIED_BY="[Empty name]" NAME="Ulloa 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-05-10 09:09:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ulloa N, Bustos P, Arteaga E, Duran D, Castro G, Fruchart J, et al</AU>
<TI>Estrogen-progestin replacement therapy raises Lp A-i particles, HDL lipids and cholesterol efflux from Fu5AH cells</TI>
<SO>Atherosclerosis</SO>
<YR>2000</YR>
<VL>151</VL>
<NO>1</NO>
<PG>204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walter-1977" MODIFIED="2015-02-03 01:15:19 +0000" MODIFIED_BY="[Empty name]" NAME="Walter 1977" YEAR="1977">
<REFERENCE MODIFIED="2015-02-03 01:15:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walter S, Jensen H</AU>
<TI>The effect of treatment with oestradiol and oestriol on fasting serum cholesterol and triglyceride levels in postmenopausal women</TI>
<SO>British journal of Obstetrics and Gynaecology</SO>
<YR>1977</YR>
<VL>84</VL>
<NO>11</NO>
<PG>869-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHIMS-2009" MODIFIED="2015-02-03 16:02:49 +0000" MODIFIED_BY="[Empty name]" NAME="WHIMS 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-03 01:15:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casanova R, Espeland M, Goveas J, Davatzikos C, Gaussoin S, Maldjian J, et al</AU>
<TI>Application of machine learning methods to describe the effects of conjugated equine estrogens therapy on region-specific brain volumes</TI>
<SO>Magnetic Resonance Imaging</SO>
<YR>2011</YR>
<VL>29</VL>
<PG>546-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 16:02:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coker L, Hogan P, Bryan N, Kuller L, Margolis K, Betterman K, et al</AU>
<TI>Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>72</VL>
<PG>125-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-09 16:28:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Espeland M, Rapp S, Shumaker S, Brunner R, Manson J, Sherwin B, et al</AU>
<TI>Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>24</NO>
<PG>2959-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 01:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Espeland M, Tindle H, Bushnell C, Jaramillo S, Kuller L, Margolis K</AU>
<TI>Brain volumes, cognitive impairment, and conjugated equine estrogens</TI>
<SO>The Journals of Gerontology</SO>
<YR>2009</YR>
<VL>64</VL>
<PG>1243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wimalawansa-1995" MODIFIED="2015-02-03 01:17:07 +0000" MODIFIED_BY="[Empty name]" NAME="Wimalawansa 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-02-03 01:17:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wimalawansa SJ</AU>
<TI>Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomised study</TI>
<SO>The American Journal of Medicine</SO>
<YR>1995</YR>
<VL>99</VL>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeboah-2008" MODIFIED="2013-03-15 15:55:03 +0000" MODIFIED_BY="[Empty name]" NAME="Yeboah 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-03-15 15:55:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeboah J, Klein K, Brosniham B, Reboussin D, Herrington D</AU>
<TI>Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease</TI>
<SO>Menopause 2008</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>6</NO>
<PG>1060-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ylikorkala-1999" MODIFIED="2015-02-03 01:17:23 +0000" MODIFIED_BY="[Empty name]" NAME="Ylikorkala 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-02-03 01:17:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ylikorkala O, Caubel P, Lim P</AU>
<TI>Effects of a 1-year pulsed progestogen, constant estrogen hormone replacement therapy regimen, Prefest, on serum lipid levels in postmenopausal women</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>1999</YR>
<VL>86</VL>
<NO>Suppl</NO>
<PG>S18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00154180" MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00154180" YEAR="2005">
<REFERENCE MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>NCT00154180</AU>
<TI>Kronos Early Estrogen Prevention Study (KEEPS)</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00154180</SO>
<YR>(accessed 15 March 2013)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00154180"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naftolin F, Harman SM, Black D, Brinton E, Budoff M, et al</AU>
<TI>Adverse events during four years of daily oral conjugated estrogen or transdermal estradiol plus cyclic oral progesterone treatment in recently menopausal women: The KRONOS early estrogen prevention study (KEEPS)</TI>
<SO>Menopause</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1402-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naftolin F</AU>
<TI>The kronos early estrogen prevention study (KEEPS)</TI>
<SO>Climacteric</SO>
<YR>2011</YR>
<VL>14</VL>
<PG>35-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00114517" MODIFIED="2015-02-03 16:03:23 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00114517" YEAR="2004">
<REFERENCE MODIFIED="2015-02-03 01:32:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howard H</AU>
<TI>The early versus late intervention trial with estradiol (ELITE)</TI>
<SO>Climacteric</SO>
<YR>2011</YR>
<VL>14</VL>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-03 16:03:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>NCT00114517</AU>
<TI>ELITE: early versus late intervention trial with estradiol</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00114517</SO>
<YR>(accessed 15 March 2013)</YR>
<IDENTIFIERS MODIFIED="2013-03-15 15:58:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-15 15:58:16 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00114517"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-03-15 15:57:15 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-02-09 15:22:00 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-02-09 15:22:00 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barrett_x002d_Connor-1997" MODIFIED="2013-03-15 16:00:59 +0000" MODIFIED_BY="[Empty name]" NAME="Barrett-Connor 1997" TYPE="JOURNAL_ARTICLE">
<AU>Barrett-Connor E</AU>
<TI>Sex differences in coronary heart disease. Why are women so superior?</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>95</VL>
<PG>252&#8211;64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bath-2005" MODIFIED="2013-03-15 16:01:17 +0000" MODIFIED_BY="[Empty name]" NAME="Bath 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bath PMW, Gray LJ</AU>
<TI>Association between hormone replacement therapy and subsequent stroke: a meta-analysis</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>330</VL>
<PG>342</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-British-Heart-Foundation-Statistics-Database-2012" MODIFIED="2015-02-03 01:42:59 +0000" MODIFIED_BY="[Empty name]" NAME="British Heart Foundation Statistics Database 2012" TYPE="OTHER">
<AU>British Heart Foundation Statistics Database 2012</AU>
<TI>Number dying from CVD and CHD</TI>
<SO>www.bhf.org.uk/publications/view-publication.aspx?ps=1002097</SO>
<YR>(accessed 14 May 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burnam-1988" MODIFIED="2013-03-15 16:02:42 +0000" MODIFIED_BY="[Empty name]" NAME="Burnam 1988" TYPE="JOURNAL_ARTICLE">
<AU>Burnam MA, Wells KB, Leake B, Landsverk J</AU>
<TI>Development of a brief screening instrument for detecting depressive disorders</TI>
<SO>Medical Care</SO>
<YR>1998</YR>
<VL>26</VL>
<PG>775-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campisi-2002" MODIFIED="2015-02-03 01:45:17 +0000" MODIFIED_BY="[Empty name]" NAME="Campisi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Campisi R, Nathan L, Pampaloni MH, Schöder H, Sayre JW, Chaudhuri G, et al</AU>
<TI>Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration</TI>
<SO>Circulation</SO>
<YR>2002</YR>
<VL>105</VL>
<NO>4</NO>
<PG>425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curb-2006" MODIFIED="2013-05-20 14:45:20 +0100" MODIFIED_BY="[Empty name]" NAME="Curb 2006" TYPE="JOURNAL_ARTICLE">
<AU>Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn K, Barnabei VM, et al</AU>
<TI>Venous thrombosis and conjugated equine estrogen in women without a uterus</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<PG>772-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cushman-2004" MODIFIED="2013-05-20 14:45:43 +0100" MODIFIED_BY="[Empty name]" NAME="Cushman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al</AU>
<TI>Estrogen plus progestin and risk of venous thrombosis</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>292</VL>
<NO>13</NO>
<PG>1573-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Maat-2007" MODIFIED="2015-02-09 15:22:00 +0000" MODIFIED_BY="[Empty name]" NAME="de Maat 2007" TYPE="JOURNAL_ARTICLE">
<AU>de Maat M, Madsen J, Langdahl B, Bladberg E, Tofteng C et al</AU>
<TI>Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after long term hormone replacement therapy</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>97</VL>
<NO>2</NO>
<PG>234-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2015-02-03 01:51:52 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dubey-2001" MODIFIED="2013-03-15 16:04:17 +0000" MODIFIED_BY="[Empty name]" NAME="Dubey 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dubey RK, Jackson EK</AU>
<TI>Estrogen-induced cardiorenal protection:potential cellular, biochemical, and molecular mechanisms</TI>
<SO>American Journal of Physiology. Renal Physiology</SO>
<YR>2001</YR>
<VL>280</VL>
<PG>365&#8211;88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furness-2009" MODIFIED="2013-03-11 16:10:13 +0000" MODIFIED_BY="[Empty name]" NAME="Furness 2009" TYPE="COCHRANE_REVIEW">
<AU>Furness S, Roberts H, Marjoribanks J, Lethaby A, HickeyM, Farquhar C</AU>
<TI>Hormone therapy in postmenopausal women and risk of endometrial hyperplasia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000402.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grady-1992" MODIFIED="2015-02-03 01:53:03 +0000" MODIFIED_BY="[Empty name]" NAME="Grady 1992" TYPE="JOURNAL_ARTICLE">
<AU>Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al</AU>
<TI>Hormone therapy to prevent disease and prolong life in postmenopausal women</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>117</VL>
<NO>12</NO>
<PG>1016-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grady-1998" MODIFIED="2013-05-20 14:12:59 +0100" MODIFIED_BY="[Empty name]" NAME="Grady 1998" TYPE="JOURNAL_ARTICLE">
<AU>Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley S, et al</AU>
<TI>Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>4</NO>
<PG>314-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greendale-1999" MODIFIED="2013-03-15 16:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Greendale 1999" TYPE="JOURNAL_ARTICLE">
<AU>Greendale GA, Lee NP, Arriola ER</AU>
<TI>The menopause</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>571&#8211;80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grodstein-1999" MODIFIED="2013-03-15 16:05:28 +0000" MODIFIED_BY="[Empty name]" NAME="Grodstein 1999" TYPE="JOURNAL_ARTICLE">
<AU>Grodstein F, Stampfer MJ, Falkeborn M, Naessen T, Persson I</AU>
<TI>Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women</TI>
<SO>Epidemiology</SO>
<YR>1999</YR>
<VL>10</VL>
<PG>476-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grodstein-2000" MODIFIED="2015-02-03 01:53:44 +0000" MODIFIED_BY="[Empty name]" NAME="Grodstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Grodstein F, Manson JE, Colditz GA, Willet WC, Speizer FE, Stampfer MJ</AU>
<TI>A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>133</VL>
<PG>933-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grodstein-2006" MODIFIED="2015-02-03 01:54:29 +0000" MODIFIED_BY="[Empty name]" NAME="Grodstein 2006" TYPE="JOURNAL_ARTICLE">
<AU>Grodstein F, Manson JE, Stampfer MJ</AU>
<TI>Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation</TI>
<SO>Journal of Womens Health</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>1</NO>
<PG>35-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hendrix-2006" MODIFIED="2013-05-20 14:27:57 +0100" MODIFIED_BY="[Empty name]" NAME="Hendrix 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al</AU>
<TI>Effects of conjugated equine estrogen on stroke in the women's health initiative</TI>
<SO>Circulation</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>2425-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-02-03 01:56:42 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hsia-2006" MODIFIED="2015-02-03 01:57:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hsia 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hsia J, Langer R, Manson J, Kuller L, Johnson K, Hendrix S, et al</AU>
<TI>Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<NO>3</NO>
<PG>357-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hu-1999" MODIFIED="2013-03-15 16:08:56 +0000" MODIFIED_BY="[Empty name]" NAME="Hu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JE, et al</AU>
<TI>Age at natural menopause and risk of cardiovascular disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<PG>1061&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobsen-1997" MODIFIED="2013-03-15 16:10:30 +0000" MODIFIED_BY="[Empty name]" NAME="Jacobsen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsen BK, Nilssen S, Heuch I, Kvale G</AU>
<TI>Does age at natural menopause affect mortality from ischemic heart disease?</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1997</YR>
<VL>50</VL>
<PG>475&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kannel-1976" MODIFIED="2015-02-03 01:58:09 +0000" MODIFIED_BY="[Empty name]" NAME="Kannel 1976" TYPE="JOURNAL_ARTICLE">
<AU>Kannel W, Hjortland M, McNamara P, Gordon T</AU>
<TI>Menopause and risk of cardiovascular disease: the Framingham study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1976</YR>
<VL>85</VL>
<PG>447-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kilim-2013" MODIFIED="2015-02-03 01:59:36 +0000" MODIFIED_BY="[Empty name]" NAME="Kilim 2013" TYPE="JOURNAL_ARTICLE">
<AU>Kilim SR, Chandala SR</AU>
<TI>A comparative study of lipid profile and oestradiol in pre- and post-menopausal women</TI>
<SO>Journal of Clinical and Diagnostic Research</SO>
<YR>2013</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1596-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koh-2004" MODIFIED="2015-02-03 02:00:34 +0000" MODIFIED_BY="[Empty name]" NAME="Koh 2004" TYPE="JOURNAL_ARTICLE">
<AU>Koh KK, Shin MS, Sakuma I, Ahn JY, Jin DK, Kim HS, et al</AU>
<TI>Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women</TI>
<SO>Arteriosclerosis, Thrombosis and Vascualr Biology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>8</NO>
<PG>1516-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lakatta-2003" MODIFIED="2013-03-15 16:11:21 +0000" MODIFIED_BY="[Empty name]" NAME="Lakatta 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lakatta EG</AU>
<TI>Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III. Cellular and molecular clues to heart and arterial aging</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<PG>490&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-1994" MODIFIED="2015-02-03 02:01:41 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al</AU>
<TI>Estrogen improves endothelium-dependent, flow mediated vasodilation in postmenopausal women</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<NO>12</NO>
<PG>936-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Losordo-1994" MODIFIED="2015-02-03 02:02:16 +0000" MODIFIED_BY="[Empty name]" NAME="Losordo 1994" TYPE="JOURNAL_ARTICLE">
<AU>Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM</AU>
<TI>Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women</TI>
<SO>Circulation</SO>
<YR>1994</YR>
<VL>89</VL>
<PG>1501-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magliano-2006" MODIFIED="2013-03-06 14:28:05 +0000" MODIFIED_BY="[Empty name]" NAME="Magliano 2006" TYPE="JOURNAL_ARTICLE">
<AU>Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM</AU>
<TI>Hormone therapy and cardiovascular disease: a systematic review and meta-analysis</TI>
<SO>BJOG</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>5-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Main-2013" MODIFIED="2015-02-03 02:10:15 +0000" MODIFIED_BY="[Empty name]" NAME="Main 2013" TYPE="COCHRANE_REVIEW">
<AU>Main C, Knight B, Moxham T, Gabriel Sanchez R, Sanchez Gomez LM, Roqué i Figuls M, et al</AU>
<TI>Hormone therapy for preventing cardiovascular disease in post-menopausal women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2015-02-03 02:09:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-02-03 02:09:47 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002229.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mann-1994" MODIFIED="2013-03-15 16:12:28 +0000" MODIFIED_BY="[Empty name]" NAME="Mann 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mann RD, Lis Y, Chukwujindu J, Chanter DO</AU>
<TI>A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1994</YR>
<VL>47</VL>
<PG>307-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manson-2003" MODIFIED="2015-02-03 02:11:12 +0000" MODIFIED_BY="[Empty name]" NAME="Manson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Manson, JE, Hsia J, Johnson KC, Rossouw JE, Assaf A, Lasser N, et al</AU>
<TI>Estrogen plus progestin and the risk of coronary heart disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<PG>523-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maxwell-1998" MODIFIED="2015-02-03 02:11:30 +0000" MODIFIED_BY="[Empty name]" NAME="Maxwell 1998" TYPE="JOURNAL_ARTICLE">
<AU>Maxwell SR</AU>
<TI>Women and heart disease</TI>
<SO>Basic Research in Cardiology</SO>
<YR>1998</YR>
<VL>934</VL>
<NO>93 (Suppl 2)</NO>
<PG>79&#8211;84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKinney-1998" MODIFIED="2015-02-03 02:11:38 +0000" MODIFIED_BY="[Empty name]" NAME="McKinney 1998" TYPE="JOURNAL_ARTICLE">
<AU>McKinney KA, Thompson W</AU>
<TI>A practical guide to prescribing hormone replacement therapy</TI>
<SO>Drugs</SO>
<YR>2009</YR>
<VL>56</VL>
<NO>1</NO>
<PG>49-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melloni-2010" MODIFIED="2015-02-03 02:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Melloni 2010" TYPE="JOURNAL_ARTICLE">
<AU>Melloni C, Berger J, Wang T, Gunes F, Stebbins A, Pieper K, et al</AU>
<TI>Representation of women in randomized clinical trials of cardiovascular disease prevention</TI>
<SO>Circulation</SO>
<YR>2010</YR>
<VL>3</VL>
<NO>2</NO>
<PG>135-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mendelsohn-1999" MODIFIED="2013-03-15 16:13:48 +0000" MODIFIED_BY="[Empty name]" NAME="Mendelsohn 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mendelsohn ME, Karas RH</AU>
<TI>The protective effects of estrogen on the cardiovascular system</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<PG>1801&#8211;11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mikkola-2002" MODIFIED="2013-03-15 16:13:58 +0000" MODIFIED_BY="[Empty name]" NAME="Mikkola 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mikkola TS, Clarkson TB</AU>
<TI>Estrogen replacement therapy,atherosclerosis, and vascular function</TI>
<SO>Cardiovascular Research</SO>
<YR>2002</YR>
<VL>53</VL>
<PG>605&#8211;19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2002" MODIFIED="2015-02-03 02:12:22 +0000" MODIFIED_BY="[Empty name]" NAME="Miller 2002" TYPE="JOURNAL_ARTICLE">
<AU>Miller J, Chan B, Nelson H</AU>
<TI>Postmenopausal Estrogen Replacement and Risk for VenousThromboembolism: A Systematic Review and Meta-Analysis for the U.S. Preventive Services Task Force</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002</YR>
<VL>136</VL>
<PG>680-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mishell-1989" MODIFIED="2013-03-15 16:14:29 +0000" MODIFIED_BY="[Empty name]" NAME="Mishell 1989" TYPE="JOURNAL_ARTICLE">
<AU>Mishell DR Jr</AU>
<TI>Estrogen replacement therapy: an overview</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>161</VL>
<NO>6 Pt 2</NO>
<PG>1825-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ouyang-2006" MODIFIED="2015-02-03 02:14:24 +0000" MODIFIED_BY="[Empty name]" NAME="Ouyang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ouyang P, Michos E, Karas R</AU>
<TI>Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>9</NO>
<PG>1741-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paganini_x002d_Hill-2001" MODIFIED="2013-03-15 16:14:36 +0000" MODIFIED_BY="[Empty name]" NAME="Paganini-Hill 2001" TYPE="JOURNAL_ARTICLE">
<AU>Paganini-Hill A</AU>
<TI>Hormone replacement therapy and stroke: risk protection or no effect?</TI>
<SO>Maturitas</SO>
<YR>2001</YR>
<VL>38</VL>
<PG>243-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Phillips-2005" MODIFIED="2015-02-03 02:16:08 +0000" MODIFIED_BY="[Empty name]" NAME="Phillips 2005" TYPE="JOURNAL_ARTICLE">
<AU>Phillips LS, Langer RD</AU>
<TI>Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>83</VL>
<PG>558-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Psaty-1994" MODIFIED="2015-02-03 02:17:05 +0000" MODIFIED_BY="[Empty name]" NAME="Psaty 1994" TYPE="JOURNAL_ARTICLE">
<AU>Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al</AU>
<TI>The risk of myocardial infarction associated with the combined use of estrogen and progestins in postmenopausal women</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<NO>12</NO>
<PG>1333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rathore-2003" MODIFIED="2015-02-03 02:17:15 +0000" MODIFIED_BY="[Empty name]" NAME="Rathore 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rathore S, Foody J, Radford M, Krumholz H</AU>
<TI>Sex differences in use of coronary revascularization in elderly patients after acute myocardial infarction: a tale of two therapies</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>6</NO>
<PG>2079-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-02-02 02:56:38 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.4</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-1959" MODIFIED="2013-03-15 16:16:10 +0000" MODIFIED_BY="[Empty name]" NAME="Robinson 1959" TYPE="JOURNAL_ARTICLE">
<AU>Robinson RW, Higano N, Cohen WD</AU>
<TI>Increased incidence of coronary heart disease in women castrated prior to the menopause</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1959</YR>
<VL>104</VL>
<PG>908-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenberg-1993" MODIFIED="2013-03-15 16:16:44 +0000" MODIFIED_BY="[Empty name]" NAME="Rosenberg 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg L, Palmer JR, Shapiro S</AU>
<TI>A case-control study of myocardial infarction in relation to use of estrogen supplements</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1993</YR>
<VL>137</VL>
<PG>54-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossouw-2013" MODIFIED="2015-02-03 02:17:44 +0000" MODIFIED_BY="[Empty name]" NAME="Rossouw 2013" TYPE="JOURNAL_ARTICLE">
<AU>Rossouw JE, Manson JE, Kaunitz AM, Anderson GL</AU>
<TI>Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2013</YR>
<VL>121</VL>
<PG>172-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salpeter-2004" MODIFIED="2013-03-15 16:17:36 +0000" MODIFIED_BY="[Empty name]" NAME="Salpeter 2004" TYPE="JOURNAL_ARTICLE">
<AU>Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE</AU>
<TI>Mortality associated with hormone replacement therapy in younger and older women</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2004</YR>
<VL>19</VL>
<PG>791-804</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salpeter-2006" MODIFIED="2013-03-15 16:18:15 +0000" MODIFIED_BY="[Empty name]" NAME="Salpeter 2006" TYPE="JOURNAL_ARTICLE">
<AU>Salpeter SR, Walsh JME, Greyber E, Salpeter EE</AU>
<TI>Coronary heart disease events associated with hormone therapy in younger and older women</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>363-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stampfer-1991" MODIFIED="2013-03-15 16:18:26 +0000" MODIFIED_BY="[Empty name]" NAME="Stampfer 1991" TYPE="JOURNAL_ARTICLE">
<AU>Stampfer M, Colditz G</AU>
<TI>Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence</TI>
<SO>Preventive Medicine</SO>
<YR>1991</YR>
<VL>20</VL>
<PG>47-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stefanick-2003" MODIFIED="2015-02-03 02:18:08 +0000" MODIFIED_BY="[Empty name]" NAME="Stefanick 2003" TYPE="JOURNAL_ARTICLE">
<AU>Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR, et al</AU>
<TI>The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants</TI>
<SO>Annals of Epidemiology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>Suppl 9</NO>
<PG>S78-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tofteng-2002" MODIFIED="2015-02-09 15:21:38 +0000" MODIFIED_BY="[Empty name]" NAME="Tofteng 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tofteng C, Jensen J, Abrahamsen B, Odum L and Brot C</AU>
<TI>Two Polymorphisms in the Vitamin D Receptor Gene&#8212;Association With Bone Mass and 5-Year Change in BoneMass With or Without Hormone-Replacement Therapy inPostmenopausal Women: The Danish OsteoporosisPrevention Study</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>8</NO>
<PG>1535-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Townsend-2012" MODIFIED="2013-03-15 16:19:37 +0000" MODIFIED_BY="[Empty name]" NAME="Townsend 2012" TYPE="BOOK">
<AU>Townsend N, Wickramasinghe K, Bhatnagar P, Smolina K, Nichols M, Leal J, et al</AU>
<SO>Coronary Heart Disease Statistics</SO>
<YR>2012</YR>
<PB>British Heart Foundation</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Schouw-1996" MODIFIED="2015-02-03 02:18:49 +0000" MODIFIED_BY="[Empty name]" NAME="van der Schouw 1996" TYPE="JOURNAL_ARTICLE">
<AU>van der Schouw YT, van der Graaf GY, Steyerberg EW, Eijkemans JD, Banga JD</AU>
<TI>Age at menopause as a risk factor for cardiovascular mortality</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>714&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wallach-1959" MODIFIED="2013-03-15 16:21:02 +0000" MODIFIED_BY="[Empty name]" NAME="Wallach 1959" TYPE="JOURNAL_ARTICLE">
<AU>Wallach S, Henneman PH</AU>
<TI>Prolonged estrogen therapy in postmenopausal women</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1959</YR>
<VL>171</VL>
<PG>1637-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh-1991" MODIFIED="2015-02-03 02:19:09 +0000" MODIFIED_BY="[Empty name]" NAME="Walsh 1991" TYPE="JOURNAL_ARTICLE">
<AU>Walsh B, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks F</AU>
<TI>Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<PG>1196-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wassertheil_x002d_Smoller-2003" MODIFIED="2013-05-20 14:44:08 +0100" MODIFIED_BY="[Empty name]" NAME="Wassertheil-Smoller 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg C, Baird A, et al</AU>
<TI>Effect of estrogen plus progestin on stroke in postmenopausal women</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>20</NO>
<PG>2673-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2008" MODIFIED="2015-02-03 02:20:31 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2008" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Leading causes of death according to income group</TI>
<SO>http://who.int/mediacentre/factsheets/fs310/en/index.html</SO>
<YR>(accessed 20 May 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2015-02-03 12:45:17 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2011" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Global status report on noncommunicable diseases 2010</TI>
<SO>www.who.int/nmh/publications/ncd_report2010/en/</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1963" MODIFIED="2013-03-15 16:22:54 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 1963" TYPE="JOURNAL_ARTICLE">
<AU>Wilson RA, Brevetti RE, Wilson TA</AU>
<TI>Specific procedures for the elimination of the menopause</TI>
<SO>Western Journal of Surgery, Obstetrics, and Gynecology</SO>
<YR>1963</YR>
<VL>71</VL>
<PG>110-21</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-03-15 15:15:28 +0000" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2013-03-11 16:09:13 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-03-06 13:15:15 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-03-06 13:15:15 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-02-03 12:28:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DOPS-2012">
<CHAR_METHODS MODIFIED="2015-02-03 12:28:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B> To assess the effects of hormone therapy for the prevention of osteoporotic fractures in healthy young post- and peri-menopausal women. The primary outcome was therefore incidence of osteoporotic fracture. Prespecified clinical cardiovascular and cancer outcomes were assessed as secondary outcomes. Multicentre randomised open-label controlled trial (RCT) conducted in Denmark. The trial was conducted from 1990-2008, randomised follow-up period with mean duration of 10.1 years (trial terminated early due to results of WHI I), non-randomised follow-up continued for a further 5.7 years. The analysis in this review includes the data reported from the randomised 10.1 years of follow-up. This was chosen over the extended follow-up to reduce bias</P>
<P>
<B>Recruitment: </B>direct mailing to a random selection of the general population</P>
<P>
<B>Screening: </B>physical examination and biochemical screening at baseline</P>
<P>
<B>Randomisation: </B>sequence generation was undertaken using stratified (study centre) blocked (n = 10) computer-generated randomisation</P>
<P>
<B>Stratification: </B>not reported</P>
<P>
<B>Allocation: </B>paper states "open label" suggesting that allocation was not concealed, however, later in the paper it is stated that sealed envelopes were used</P>
<P>
<B>Baseline equality of treatment groups: </B>similar apart from the treatment group who were on average six months younger than the control group</P>
<P>
<B>Blinding: </B>open-label</P>
<P>
<B>Analysis</B>: intention to treat (ITT)</P>
<P>
<B>Funding Source: </B>Funded by the University of Aarhus, Karen Elise Jensen&#8217;s Foundation, Novo Nordic, Novartis, and LEO Pharma. Novo Nordisk, Novartis, and Leo Pharma Denmark provided the study drug free of charge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 11:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>1006 healthy white peri- or post-menopausal women aged 45-58 years, with a mean age of 49.5 years (SD ± 2.7 years), underwent treatment with HT or no treatment. The participants had a mean age of 0.58 years (SD ± 0.63 years) since menopause, 95 of 502 (18.9%) participants had undergone a hysterectomy, and 2% had used HT previously, for a median duration of 1 year.</P>
<P>In terms of risk factors for cardiovascular disease: Mean body mass index (kg/m<SUP>2</SUP>) = 25.3 (SD ± 4.3); hip: waist ratio = 1.27 (SD ± 0.11); total cholesterol concentration (mmol/L) = 6.26 (SD ± 1.10); LDL concentration (mmol/L) = 3.85 (SD ± 1.04); HDL concentration (mmol/L) = 1.71 (SD ± 0.42); triglyceride concentration (mmol/L) = 1.14 (SD ± 0.53) and fasting glucose concentration (mmol/L) = 4.7 (SD ± 0.7). </P>
<P>In the treatment arm mean systolic blood pressure (mm Hg) = 129 (SD ± 18); diastolic blood pressure (mm Hg) = 81 (SD ±11); 169 (33.6%) with vitamin D deficiency and 212 (42.3%) were current smokers</P>
<P>There were no statistically significant differences in baseline characteristics between the HT treatment group and the no treatment controls for any of the reported variables apart from age.  Participants in the HT group were slightly younger with a mean age of 49.5 (SD ± 2.7) years compared to a mean age of 50.0 (SD ± 2.8) years in the control group (P = 0.007)</P>
<P> </P>
<P>
<B>Inclusion criteria:</B>
</P>
<UL>
<LI>Recent post-menopausal or peri-menopausal symptoms in combination with recorded postmenopausal serum follicle stimulating hormone values</LI>
<LI>Healthy white women</LI>
<LI>Last menstrual bleeding 3-24 months before study entry or peri-menopausal symptoms (including irregular menstruations)</LI>
<LI>Recorded post-menopausal serum follicle stimulating hormone values (&gt; 2 SD over the pre-menopausal mean)</LI>
<LI>Women who had had a hysterectomy were included if they were 45 to 52 years old and had records showing an increase in serum follicle stimulating hormone level</LI>
</UL>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>history of bone disease</LI>
<LI>uncontrolled chronic disease</LI>
<LI>previous or current cancer</LI>
<LI>previous or current thromboembolic disease</LI>
<LI>current or past treatment with glucocorticoids for more than 6 months</LI>
<LI>current or previous use of hormone therapy within the past 3 months</LI>
<LI>alcohol or drug dependency</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 07:20:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen:</B>
</P>
<P> </P>
<P>
<B>1) </B>     Sequentially combined HT: 2 mg synthetic 17-&#946;-oestradiol for 12 days, 2 mg 17-&#946;-oestradiol plus 1 mg norethisterone acetate for 10 days, and 1 mg 17-&#946;-oestradiol for six days (women with intact uterus)</P>
<P>
<B>2) </B>     HT Monotherapy: 2 mg 17-&#946;-oestradiol a day (women whom had had a hysterectomy)</P>
<P> </P>
<P>
<B>Comparator:</B>  No treatment control</P>
<P> </P>
<P>Other treatment modalities were offered to those who experienced side effects of insufficient relief of symptoms.</P>
<P>Participants were classified as medication compliant if they took &#8805;80% of their medication throughout the trial. However, rates of medication compliance were not reported </P>
<P> </P>
<P>
<B>Follow-up times: </B>
</P>
<P>All participants underwent a physical examination and biochemical screening at baseline. They were subsequently followed-up at six months, one year, two, three, five and 10 years. Study drugs were posted to the women randomised to HT, and they were offered an annual visit. Women were advised to visit their own GP or gynaecologist if they had any health concerns. No participants were lost to follow-up, but two women were censored at time of emigration (one in each treatment group)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 12:18:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes</B>:</P>
<P>Composite of all-cause mortality and hospitalisation for MI or heart failure</P>
<P>
<B>Secondary outcomes: </B>
</P>
<P>Stroke</P>
<P>Pulmonary embolism</P>
<P>Venous thromboembolism</P>
<P>
<B>Adverse events: </B>
</P>
<P>Cancer</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 07:22:11 +0000" MODIFIED_BY="[Empty name]">
<P>Methods for verifying medication compliance, and actual compliance rates were not reported. Follow-up was annual within the first five years of the trial and then only on a five-year basis thereafter, therefore it is likely that this was patient self report rather than ascertained by pill count. Patient medication compliance rates (if self reported) may therefore be overestimated, which would potentially underestimate the treatment effect in the HT group relative to the no treatment control</P>
<P>Attrition rates were only reported for year 10 follow-up visit: HT group: 15%; no treatment control group: 17.7%  </P>
<P> </P>
<P>At 10.1 year follow-up 266/502 (53%) of the women randomised to HT therapy had stopped treatment, whilst 236/502 (47%) continued taking some form of HT treatment. Amongst the 236 women continuing treatment, 104/236 (44%) continued to take the study medication to which they were randomised whilst 132/236 (56%) were taking &#8216;other&#8217; HT. In the no treatment control group, 290/506 (77%) never used HT, whilst 114/506 (23%) had started using some form of HT treatment during the 10.1 year follow-up period. Of these, 61/114 (53.5%) were still taking this at the 10.1 year follow-up whilst 53/114 (46.5%) had stopped taking any form of HT treatment</P>
<P>Although data were analysed on an intention-to-treat basis, the treatment cross-over between the two groups makes interpretation of the data more complex. However, overall it is likely that cross- over between treatment groups would potentially underestimate the relative treatment effect of HT compared to no treatment control</P>
<P> </P>
<P>The control group population started treatment on average 0.61 years (SD 0.65) after their menopause with the hormone group starting on average 0.58 years (SD 0.63) after. Events were not reported individually or according to starting treatment &lt; 10 or &gt; 10 years since the menopause. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment within 10 years of their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-06 13:14:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EAGAR-2006">
<CHAR_METHODS MODIFIED="2015-02-03 12:27:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B> To assess the effects in post-menopausal women of HT started after coronary artery bypass surgery (CABG) on saphenous vein graft (SVG) disease</P>
<P>Multicentre randomised controlled (RCT) trial involving eight hospital sites in the United States. The trial was conducted from 1998-2002 over a 3.5 year follow-up (mean duration 33 ± 8 months). The trial was stopped early after the Women&#8217;s Health Initiative (WHI 2002) reported an increased risk of breast cancer and no additional benefits for women on HT in terms of CVD risk on combined oestrogen and progestin combination therapy relative to placebo</P>
<P> </P>
<P>The primary outcome measure was SVG progression assessed by angiography and intravascular ultrasound (IVUS) on percent stenosis, minimal lumen diameter, and total plaque volume. Secondary outcomes (not specified a priori included death from CV disease, MI, angina and angioplasty</P>
<P>  </P>
<P>
<B>Recruitment:</B> Not reported</P>
<P>
<B>Screening:</B> Not reported</P>
<P>
<B>Randomisation:</B> Not reported</P>
<P>
<B>Stratification:</B> Not reported</P>
<P>
<B>Allocation:</B> Not reported</P>
<P>
<B>Baseline equality of treatment groups: </B>No substantive differences between study groups at baseline</P>
<P>
<B>Blinding:</B> Not reported</P>
<P>
<B>Analysis:</B> ITT for secondary clinical outcomes</P>
<P>
<B>Funding Source:</B> Research Council funded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 12:27:42 +0000" MODIFIED_BY="[Empty name]">
<P>Eighty-three post-menopausal women (HT: 40; placebo: 43) with a mean age of 64 (SD: ± 8.5 years) underwent treatment with either HT or placebo within six months following coronary artery bypass surgery. Post-menopausal status was defined as &gt; 55 years of age and amenorrhoea for &#8805; 1 year or follicle stimulating hormone &gt; 50 IU. The number of women who had previously undergone a hysterectomy was not reported. Included women were 78% white, and 22% from an ethnic minority group. 40% had a history of diabetes, 69% hypertension, 81% hyperlipidaemia and 40% MI. In terms of smoking status: 16.5% were current smokers; 59.5% past smokers and 24.5% never smokers. 35% had prior HT use. Mean BMI among the women was 30 kg/m<SUP>2</SUP> (SD: 30 ± 6). Mean systolic blood pressure at baseline was 135 (SD: 6) mm Hg and diastolic blood pressure was 72.5 (SD: 10.5) mm Hg.  There were no statistically significant differences between the two groups in terms of baseline demographics</P>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>current HT use (i.e.) within the three months before enrolment</LI>
<LI>contraindication to HT including a history of hormone sensitive neoplasia or severe liver disease</LI>
<LI>history of idiopathic deep venous thrombosis or pulmonary embolus</LI>
<LI>symptomatic gallbladder disease</LI>
<LI>creatine of &#8805; 2 mg/mL</LI>
<LI>or a life-expectancy of &lt; 4 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 07:28:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen:</B> 1 mg unopposed 17ß-oestradiol daily with or without daily 2.5 mg medroxyprogesterone depending on hysterectomy status (continuous dosage regimen)</P>
<P>
<B>Comparator:</B> identical placebo capsule daily</P>
<P>The overall compliance with study intervention assessed by pill count at each visit exceeded 80% in both arms up to 30 months of treatment </P>
<P>
<B>Follow-up times:</B>
</P>
<P>Six-months: angiogram (n = 83) (actual mean time of angiogram assessment 10.7 months post CABG); intravascular ultrasound assessment (IVUS) (n = 63);  42-months: angiogram (n = 45), IVUS (n = 20).  Actual mean time of participant follow-up was 33 (SD: 8) months before the study drug was stopped</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 07:28:41 +0000" MODIFIED_BY="[Empty name]">
<P>Per cent stenosis</P>
<P>Minimal lumen diameter</P>
<P>Total plaque volume</P>
<P>Death from CV disease (definition not provided)</P>
<P>Angina (definition not provided)</P>
<P>MI (definition not provided)</P>
<P>Angioplasty (definition not provided)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-06 13:14:17 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size calculation not reported, and therefore it is unclear whether the trial was powered adequately to detect significant differences in clinical event rates between the HT and placebo group. It was unclear how the CVD events were defined, and whether definitions may have varied between centres.  Additionally, it was unclear how these were corroborated, locally or centrally and whether outcome assessors were blinded to patient treatment status</P>
<P> </P>
<P>Patient attrition rates were high for both angiographic and intravascular ultrasound (IVUS), with only 24% and 54% of patients undergoing each investigation respectively at trial termination [mean length of follow-up: 33 months (SD: eight months)].  However, follow-up for all clinical events was completed for all patients.</P>
<P>Data were not published for this study on the time since menopause that treatment was started. The study author was contacted but we were informed that these data were not collected. The mean age of the control group population was 64 years (SD 9). The mean age of the treatment group population was 64 years (SD 8). Events were not reported individually or according to age &lt; 60 or &gt; 60 years. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment more than 10 years of their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 12:29:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EPAT-2001">
<CHAR_METHODS MODIFIED="2015-02-03 07:30:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B>  To determine the effect of oestrogen-alone HT on the progression of sub-clinical atherosclerosis in healthy post-menopausal women without pre-existing cardiovascular disease, as measured by changes in thickness of carotid artery wall.</P>
<P>University-based clinic randomised controlled (RCT) trial conducted in the United States over a two-year follow-up period (1994 to 1998).  The primary outcome measure was carotid intima-media thickness to assess the rate of progression of sub-clinical atherosclerosis; clinical outcomes were reported as secondary outcomes </P>
<P>
<B>Recruitment:</B>  Not reported</P>
<P>
<B>Screening:</B> Interested women screened by phone for eligibility, then attended three screening visits two to four weeks apart to determine final study eligibility. 1161 pre-screened by phone, 422 screened on site, of whom 52% randomised</P>
<P>
<B>Randomisation:</B> Computer-generated random numbers</P>
<P>
<B>Stratification:</B> By LDL cholesterol level (threshold &lt; 4.15 mmol/L), previous duration of HRT, (threshold &lt; 5 years),  and diabetes mellitus status</P>
<P>
<B>Allocation:</B> Blinded medication packets assigned sequentially and remotely after eligibility confirmed</P>
<P>
<B>Baseline equality of treatment groups:</B> No substantive differences between study groups at baseline apart from a significantly higher proportion of HT patients than placebo patients had undergone a complete or partial oophorectomy at baseline (P = 0.03)</P>
<P>
<B>Blinding:</B> Participants, gynaecologists, clinical staff, and image analysts. The data monitor and data analyst were blinded to treatment assignment until analyses were completed</P>
<P>
<B>Analysis:</B> ITT</P>
<P>
<B>Funding Source: </B>National Institute on Aging</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 11:34:09 +0000" MODIFIED_BY="[Empty name]">
<P>222 post-menopausal women (HT: 111; placebo: 111) with a mean age of 62.2 years (range: 46 to 80 years) underwent treatment with either HT or placebo. Post-menopausal status was not defined in the trial. The ethnic origins of the women included in the trial were: 57% White, 11% Black, 21% Hispanic, 10% Asian and 1% Other. 38% of women had undergone a hysterectomy, and 18% an oophorectomy&#8225;. In terms of smoking status: 53% were former smokers and 47% non-smokers. Mean BMI among the women was 29.4 kg/m<SUP>2</SUP>. Systolic blood pressure at baseline was 128 mm Hg and diastolic blood pressure was 76.1 mm Hg</P>
<P> </P>
<P>
<B>Inclusion criteria:  </B>Women were eligible if they were:</P>
<UL>
<LI>post-menopausal (serum oestradiol level &lt; 73.4 pmol/L [&lt; 20 pg/mL])</LI>
<LI>45 years of age or older</LI>
<LI>had a low-density lipoprotein (LDL) cholesterol level of 3.37 mmol/L or greater (&#8805; 130 mg/dL)</LI>
</UL>
<P>Women with diabetes were eligible for inclusion provided their fasting blood glucose level was less than 11.1 mmol/L (&lt; 200 mg/dL) </P>
<P>
<B>Exclusion criteria: </B>
</P>
<UL>
<LI>a diagnosis of breast or gynaecological cancer within the past five years or if these cancers were identified during screening</LI>
<LI>previous HT use for more than 10 years or if HT had been used within one month of the screening visit</LI>
<LI>five or more hot flushes daily that interfered with daily activity</LI>
<LI>diastolic blood pressure greater than 110 mm Hg</LI>
<LI>untreated thyroid disease</LI>
<LI>life-threatening disease with a survival prognosis less than 5 years</LI>
<LI>total triglyceride level of 4.25 mmol/L or greater (&#8804; 400 mg/dL)</LI>
<LI>high-density lipoprotein (HDL) cholesterol level less than 0.78 mmol/L (&lt; 30 mg/dL)</LI>
<LI>serum creatinine concentration greater than 221 µmol/L (&gt; 2.5 mg/dL)</LI>
<LI>current smokers</LI>
</UL>
<P>&#8225;a significantly higher proportion of HT patients than placebo patients had undergone a complete or partial oophorectomy at baseline (P = 0.03)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 12:29:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen: </B>1 mg unopposed micronised 17ß-oestradiol daily (continuous dosage regimen)</P>
<P>
<B>Comparator:</B> identical placebo capsule daily</P>
<P>Overall pill adherence in the trial was 95% in the HT group and 92% in the placebo group (P = 0.08).  This was maintained throughout the two year follow-up trial period</P>
<P>
<B>Follow-up times: </B>
</P>
<P>Patients were followed up every month for the first six months and then every other month for two years. Carotid artery ultrasonography in patients with a uterus was performed at baseline and then every six months. Pelvic examination, papanicolaou smear, and mammography were performed annually</P>
<P>During the trial, mean pill adherence was 95% in the oestradiol group and 92% in the placebo group (P = 0.08)</P>
<P>
<B>Losses to follow-up:</B> 33 women were not evaluable for primary study endpoints, but clinical endpoints were reported for all outcomes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 12:19:04 +0000" MODIFIED_BY="[Empty name]">
<P>Carotid intima-media thickness</P>
<P>All causes of death</P>
<P>Death from CV disease</P>
<P>MI</P>
<P>Coronary artery bypass</P>
<P>Angioplasty</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 07:34:17 +0000" MODIFIED_BY="[Empty name]">
<P>The sample size power calculation was based on potential differences in change in the intima-media thickness of the right distal common carotid artery far wall between the HT and placebo groups, and therefore it is unclear whether the trial was powered adequately to detect significant differences in clinical event rates between the HT and placebo group. It was unclear how the CVD events were defined, and whether these were corroborated locally or centrally. </P>
<P>Data were not published for this study on the time since menopause that treatment was started. The study author was contacted but we did not receive a reply. The mean age of the control group population was 62.1 years (SD 7.1). The mean age of the treatment group population was 60.9 years (SD 6.7). Events were not reported individually or according to age &lt; 60 or &gt; 60 years. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-06 13:14:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EPHT-2006">
<CHAR_METHODS MODIFIED="2015-02-03 07:35:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B>  To ascertain harms and benefits of combined HT among healthy post-menopausal Estonian women</P>
<P> </P>
<P>Multicentre four-armed randomised, placebo and non-treatment controlled trial (RCT) involving three primary care sites in Estonia. The trial was conducted from 1999 to 2001, with a mean follow-up of 3.4 years (range: 2 to 4.9). The trial was originally planned to be part of the Women&#8217;s International Study of Long Duration Oestrogen After Menopause (WISDOM) trial based primarily in the United Kingdom, and therefore no individual sample size was undertaken for the Estonian component of the trial. The trial was planned for five-year duration, but was stopped early after the reports from <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK> were published.</P>
<P> </P>
<P>The primary aim of the trial was to assess the effects of combined oestrogen and progestin HT among healthy post-menopausal women.  The trial also assessed the impact of blinding versus no blinding to treatment allocation on recruitment rates through including four trial arms: (1) blinded HT combination therapy; (2) blinded placebo therapy; (3) unblinded HT combination therapy; and (4) unblinded no treatment control groups. After adjustment of participants&#8217; age at recruitment and former oral contraceptive use between the blinded and non-blinded groups, the results were then combined, with HT therapy groups combined and placebo and no treatment control group combined, and the outcome data presented for both of the two groups</P>
<P>
<B>Recruitment:</B> Invitation sent to whole female population aged 50 to 64 of two areas of Estonia </P>
<P>
<B>Screening:</B> Number of women screened for eligibility: 39,713 (whole female pop aged 50 to 64 of two areas of Estonia)</P>
<P>
<B>Randomisation:</B> Remotely randomised in permuted block algorithm</P>
<P>
<B>Stratification:</B> By clinical centre</P>
<P>
<B>Allocation:</B> Non-transparent sealed envelopes</P>
<P>
<B>Baseline equality of treatment groups:</B>  More prior use of oral contraceptive in HT group 9.2% versus 6.4%; HT group older (59 versus 58.5)</P>
<P>
<B>Blinding:</B> Participants and investigators blinded</P>
<P>
<B>Analysis:</B> ITT</P>
<P>
<B>Funding Source: </B>Academic and government grants </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 11:32:29 +0000" MODIFIED_BY="[Empty name]">
<P>1778 healthy post-menopausal women were randomised to HT, placebo or a no treatment control group. The definition of post-menopausal was at least 12 months since last menses. (1) 404 women were randomised to blinded combination HT treatment; (2) 373 to blinded placebo; (3) 494 to unblinded combination HT therapy, and (4) 507 to no treatment control. Only the results reported for the blinded combination HT and placebo arms (n=777) included in the analyses.</P>
<P>The mean age of the women was 58.8 years (SD: ± 4.0), with a mean age of menopause of 50 years (SD: ± 3.9) years. 10% of the women had previously undergone a hysterectomy. Mean BMI was 27 kg/m2. In terms of risk factors for CVD: 15% were current smokers; 13.2% were being treated for hypertension; 8.5% had a history of angina; and 1.3% had a previous MI. Mean systolic blood pressure was 137 mm Hg and  mean diastolic blood pressure 86.2 mm Hg </P>
<P>
<B>Inclusion criteria</B>: Aged between 50 to 64 years and menopausal as defined above</P>
<P> </P>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>use of HT during the past six-months</LI>
<LI>untreated endometrial adenomatosis of atypical hyperplasia of the endometrium</LI>
<LI>a history of breast cancer, endometrial cancer or ovarian cancer or any other cancer treated less than five-years ago</LI>
<LI>a history of meningioma</LI>
<LI>MI within the last six months</LI>
<LI>a history of hepatitis of functional liver disorders in the last three months</LI>
<LI>a history of deep vein thrombosis, pulmonary embolism, cerebral infarction, porphyria</LI>
<LI>hypertension of more than 170/110 mm Hg despite medication</LI>
<LI>laparoscopically or histologically confirmed endometriosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 07:49:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimens :</B>
</P>
<P>1) 0.625 mg conjugated equine oestrogen and 2.5 mg medroxyprogesterone acetate daily (continuous dosage regimen). For women (n = 251) within three years of their last period 5.0 mg medroxyprogesterone acetate daily along with the standard dose of 0.625 mg conjugated equine oestrogen was prescribed</P>
<P>
<B>Comparator:</B>
</P>
<P>2) Placebo</P>
<P>3) No treatment control</P>
<P>Rates of medication compliance in the trial varied considerably with adherence &lt; 40% in HT group and &lt; 30% in placebo group by three years (estimated from graph)</P>
<P>
<B>Follow-up times: </B>baseline, seven months, and then annually. Patients underwent a Papanicolaou smear at baseline, and measurement of weight, arterial blood pressure, pelvic and breast examination annually. A Papanicolaou smear was taken every second year.</P>
<P>Thirteen patients were lost to follow-up, so the clinical status of all participants at trial exit was known for 97% of the women</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 07:49:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Coronary heart disease </B>(angina, acute MI, subsequent MI, current complications following acute MI, other acute ischaemic heart disease)</P>
<P>
<B>Cerebrovascular disease</B> (subarachnoid haemorrhage, intracerebral haemorrhage, other non-traumatic intracranial haemorrhage cerebral infarction, stroke, occlusion and stenosis of vertebral arteries, occlusion and stenosis of cerebral arteries, other cerebrovascular diseases, cerebrovascular disorders, sequelae of cerebrovascular disease)</P>
<P>Death from any cause</P>
<P>Non-fatal MI</P>
<P>Stroke </P>
<P>HRQoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-06 13:14:47 +0000" MODIFIED_BY="[Empty name]">
<P>No sample size calculation was performed so it is unclear whether the trial was powered to detect differences between the four treatment arms. Given the lack of patient treatment adherence which fell dramatically in the HT blinded, HT unblinded, and placebo groups from 70-76% at baseline, to 36-46% by one-year follow-up and 4-5% at four-year follow-up it is unlikely that enough clinical events associated with the use of HT relative to placebo would occur for the trial to have the power to detect any excess risks/benefits for the use of HT compared to placebo or no treatment</P>
<P>The overall study population started treatment 8.8 years after the menopause. The mean age of the menopause was 50.3 (SD 3.9) in the control group and 50.4 (SD 3.8) in the hormone group. The baseline age of participants was reported according to assigned treatment group, 54.1% of the control group and 62.6% of the hormone treatment group were &lt; 60 years. Events were not reported individually or according to starting treatment &lt; 10 or &gt; 10 years since the menopause. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment within 10 years of their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 11:32:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ERA-2000">
<CHAR_METHODS MODIFIED="2015-02-03 07:52:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective: </B>To evaluate the effects of HT on the progression of coronary atherosclerosis</P>
<P>Multicentered three-armed randomised controlled (RCT) trial involving six hospital sites in the United States. The trial was conducted from January 1996 to December 1997, with a mean follow-up of 3.2 ± 0.6 years. The primary aim of the trial was to assess the effects of oestrogen replacement therapy with or without low-dose progestin on angiographic progression or regression of coronary atherosclerosis in post-menopausal women. The primary outcome was therefore change in the minimum diameter of the major epicardial segments, as assessed by quantitative coronary angiography. Clinical CVD events were all assessed as secondary outcomes</P>
<P>
<B>Recruitment:</B> Media announcements, contact through hospital records and admissions, screening logs from other studies</P>
<P>
<B>Screening:</B> Not stated</P>
<P>
<B>Randomisation:</B> Computerised in random blocks</P>
<P>
<B>Stratification:</B> According to lipid lowering therapy at baseline and hospital where angiogram was performed</P>
<P>
<B>Allocation:</B> Computer displayed treatment assignment after eligible participant details entered</P>
<P>
<B>Baseline equality of treatment groups:</B> No substantive differences between study groups at baseline</P>
<P>
<B>Blinding:</B> Participants, clinic staff and all outcomes assessment blinded. Treatment assignment available to designated member of data management staff. Questions relating to adverse effects directed to gynaecology physician and nurse not connected with study</P>
<P>
<B>Analysis:</B> ITT</P>
<P>
<B>Funding Source: </B>Grants from National Heart, Lung and Blood Institute and NationalCenter for Research Resources General Clinical Research Center, study medications from Wyeth-Ayerst Research </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 11:32:40 +0000" MODIFIED_BY="[Empty name]">
<P>Three hundred and nine post-menopausal women with angiographically verified coronary disease were randomised to receive either (1) daily conjugated oestrogen alone (n = 100), (2) daily conjugated oestrogen in combination with medroxyprogesterone acetate (n = 105), or daily placebo (n = 105).  Coronary artery disease was defined as at least one stenosis of 30% in any single coronary artery.  </P>
<P>The mean age of the women was 65.8 years (range: 41.8 - 79.9), with a mean number of years since menopause of 22.5. Post-menopausal status was defined as the presence of one of the following conditions: (1) an age of at least 55 without natural menses for at least five years; (2) no natural menses for at least one year and a serum follicle-stimulating hormone level of more than 40 IU per litre; (3) documented bilateral oophorectomy; or self reported bilateral oophorectomy, a follicle-stimulating hormone level of more than 40 IU per litre, and a serum oestradiol level of less than 25 pg per mm (91.1 pmol/L). 61% of the women had undergone a hysterectomy and 30.4% an oophorectomy </P>
<P>At baseline 9% of women were taking oestrogen, and therefore underwent a three-month &#8216;wash out &#8216;period prior to randomisation</P>
<P>Included women were 82% White, 14% Black, and 4% of other racial origin. 49% had a history of MI and 47% a history of having undergone an angioplasty</P>
<P>In terms of risk factors for CVD: 28% had diabetes; 67% had hypertension; 18% were current smokers; and 57% had a BMI &gt; 27.5 kg/m<SUP>2</SUP>. The mean systolic blood pressure of the women was 130 mm Hg and the mean diastolic blood pressure 71.8 mm Hg. There were no statistically significant differences between the three treatment groups at baseline</P>
<P>
<B>Inclusion criteria:</B> Stated above, but only women who were 80% or more medication compliant in the one month prior to randomisation were eligible for participation in the trial </P>
<P>
<B>Exclusion criteria: </B>
</P>
<UL>
<LI>known or suspected breast cancer or endometrial carcinoma</LI>
<LI>previous or planned coronary artery bypass surgery</LI>
<LI>a history of deep vein thrombosis or pulmonary embolism</LI>
<LI>symptomatic gallstones</LI>
<LI>serum aspartate aminotransferase level more than 1.5 times the normal value</LI>
<LI>triglyceride level of more than 400 mg/dL (4.52 mmol/L) while fasting</LI>
<LI>serum creatinine level of more than 2.0 mg per decilitre (176.8 µmol per litre)</LI>
<LI>more than 70% stenosis of the left main coronary artery</LI>
<LI>uncontrolled hypertension</LI>
<LI>uncontrolled diabetes</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 07:55:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen:</B>
</P>
<P>1) 0.625 mg conjugated equine oestrogen daily and a placebo tablet daily (continuous dosage regimen)</P>
<P>2) 0.625 mg conjugated equine oestrogen plus medroxyprogesterone acetate and placebo tablet daily (continuous dosage regimen)</P>
<P>
<B>Comparator:</B> two placebo tablets daily (continuous dosage regimen)</P>
<P>Participants were classified as medication compliant if they took &#8805; 80% of their medication throughout the trial. Medication adherences in the 248 participants evaluated was: 74% in the oestrogen alone group (measured in 79% of participants); 84% in the combination therapy group (measured in the 84% of participants) and 86% in the placebo group (measured in 80% of participants). Additionally, five women in the placebo group initiated HT treatment outside the trial</P>
<P> </P>
<P>
<B>Follow-up times:</B> three months, six months and then every six months thereafter. Pre-treatment investigations included serum electrolytes, haemoglobin levels, hematocrit, platelet count and prothrombin, a 12-lead electrocardiogram and angiogram (if needed).  Other investigations included annual mammography and gynaecological examinations, including Papanicolaou smears and endometrial aspiration or vaginal ultrasound, to detect sub-clinical hyperplasia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 07:56:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes</B>:</P>
<P>Death from any cause</P>
<P>Death from CVD disease</P>
<P>Non-fatal MI</P>
<P>Fatal MI</P>
<P>Stroke</P>
<P>Angina (hospitalisation)</P>
<P>Any CVD event</P>
<P>
<B>Secondary outcomes</B>:</P>
<P>Venous thromboembolism</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 07:56:41 +0000" MODIFIED_BY="[Empty name]">
<P>The sample size calculation was predicated on the ability to detect differences between groups in the primary outcome measure, change in the minimum diameter of the major epicardial segments, as assessed by quantitative coronary angiography.  It is therefore possible that the trial was not powered to detect differences between the three treatment groups on clinical events.  It is therefore not possible to state whether there is any excess risk/benefit for the use of either oestrogen alone or in combination with medroxyprogesterone acetate compared to placebo on the basis of the results reported from the trial.</P>
<P>The control group population started treatment on average 23.1 years after their menopause with the oestrogen group starting on average 22.1 years and the combination oestrogen and medroxyprogesterone group starting 23.8 years after. Events were not reported individually or according to starting treatment &lt; 10 or &gt; 10 years since the menopause. For the subgroup analysis of when treatment was started the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 12:25:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ERT-II-1979">
<CHAR_METHODS MODIFIED="2015-02-03 07:59:00 +0000" MODIFIED_BY="[Empty name]">
<P>Single centre 10 year double-blind randomised control trial with matched pair design to evaluate the effects of oestrogen replacement therapy. Run at a hospital for chronic diseases where the participants were inpatients for the duration of the study.</P>
<P>The study ran at Goldwater Memorial Hospital NYC from: 1965 to 1976. Follow-up duration was 10 years</P>
<P>
<B>Recruitment: </B>from female hospitalised patients at Goldwater Memorial Hospital in New York City (a hospital for chronic diseases)</P>
<P>
<B>Screening: </B>history, physical examination and medical record review</P>
<P>
<B>Randomisation: </B>a research nurse was given matched pairs of participants and randomly selected which member of the pair would be assigned to the treatment group</P>
<P>
<B>Stratification: </B>not reported</P>
<P>
<B>Allocation: </B>by research nurse's discretion</P>
<P>
<B>Baseline equality of treatment groups: </B>all the participants were inpatients with chronic diseases, the matched pairs were identical for their primary diagnosis. The number of years since menopause were matched but gravidity and parity were not matched. Blood pressure, age and weight were not significantly different between groups</P>
<P>
<B>Blinding: </B>&#8220;a serious attempt was made to prevent the research physicians from knowing&#8221; however the code was broken in major medical complications 13 times (HRT) and 17 times (control). However the research nurse who did the allocating was not blinded</P>
<P>
<B>Analysis</B>: all participants included</P>
<P>
<B>Funding Source: </B>not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 12:25:16 +0000" MODIFIED_BY="[Empty name]">
<P>168 women with long-term chronic disease who were hospitalised for the entire study duration</P>
<P>
<B>Inclusion criteria:</B>
</P>
<UL>
<LI>last menstrual period two or more years previously</LI>
<LI>never taken HT</LI>
<LI>FSH &gt; 105.5 mU</LI>
<LI>urinary oestrogen levels &lt; 10 µg/dl</LI>
</UL>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>acute heart disease</LI>
<LI>hypertension (&gt; 160/94 mm Hg)</LI>
<LI>any malignancy</LI>
<LI>prior hysterectomy</LI>
</UL>
<P>84 matched pairs selected from pool of 329 eligible participants</P>
<P>Mean age was 55.3 years in the HRT group and 54.9 in the control group (P = 0.001)</P>
<P>Number of years since last menstrual period was 4.7 years in the HT group and 4.5 years in the control group (P = 0.001)</P>
<P>Mean blood pressure was 122/79 in the HT group and 122/80 in the control group (P = 0.498)</P>
<P>The number of participants with diabetes mellitus was 14 (16.6%) in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 08:00:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen: </B>conjugated oestrogen (Premarin) 2.5 mg daily and medroxyprogesterone acetate (Provera) 10 mg daily for 7 days in each month</P>
<P>
<B>Comparator: </B>matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-03 10:47:35 +0100" MODIFIED_BY="[Empty name]">
<P>Unspecified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 08:01:21 +0000" MODIFIED_BY="[Empty name]">
<P>The chronic diseases which the participants were admitted for were unspecified as was any specialty that the hospital focused upon</P>
<P>
<B>Medication compliance:</B> not reported but as all were inpatients for duration, likely to be high</P>
<P>
<B>How often assessed</B>: formally assessed on annual basis</P>
<P>The code for blinding was broken 13 times in the treated group and 17 times in the control group. When the code was broken the complication was noted and the patient was evaluated to that point of the study. No events were considered if they were recorded after the code was broken.</P>
<P>The control group population started treatment on average 4.5 years after their menopause with the hormone group starting on average 4.7 years after. Events were not reported individually or according to starting treatment &lt; 10 or &gt; 10 years since the menopause. For the subgroup analysis of when treatment was started the entirety of events in this study were analysed as if all participants had started treatment within 10 years of their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-06 13:14:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ESPRIT-2002">
<CHAR_METHODS MODIFIED="2015-03-06 13:14:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective: </B> To assess whether unopposed oestrogen reduces the risk of further cardiac events in post-menopausal women who survive a first myocardial infarction</P>
<P>Multicentre RCT involving 35 hospital sites in England and Wales. The trial was conducted over a two-year follow-up period (with recruitment beginning in July 1996 and ending in February 2000). All participants had suffered a first MI and were recruited within 31 days of the index event. MI was defined as two or more of: typical chest pain; ST elevation of 0.1 mV or more in at least one standard, or two precordial, leads of a 12-lead ECG; or biochemical makers indicative of MI (serum concentrations of creatinine kinase or aspartate transaminase greater than twice the normal laboratory value, or serum troponin concentration greater than the locally defined threshold for MI. The primary outcome measures were non-fatal reinfarction or cardiac death, and all-cause mortality</P>
<P>
<B>Recruitment:</B> Research nurses checked hospital case notes, approached potentially eligible women if their family doctor agreed to collaborate</P>
<P>
<B>Screening:</B> Not reported</P>
<P>
<B>Randomisation:</B> List of random numbers generated by trial statistician in blocks of four</P>
<P>
<B>Stratification:</B> By clinical centre site</P>
<P>
<B>Allocation: </B>Women assigned consecutively to numbers kept on list accessible to statistician only</P>
<P>
<B>Baseline equality of treatment groups:</B> No substantive differences between study groups at baseline</P>
<P>
<B>Blinding:</B> Participants, clinicians, outcome assessors. Pharmaceutical company dispensed medication/placebo in identical numbered packages Unblinding occurred on request of family doctor or if participant withdrew from treatment (in later stages of study, only if withdrawing participant had not had a hysterectomy). Outcome assessors remained blinded throughout</P>
<P>
<B>Analysis:</B> ITT</P>
<P>
<B>Funding Source: </B>Schering AG provided medication</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 08:04:58 +0000" MODIFIED_BY="[Empty name]">
<P>1017 post-menopausal women (HT: 513; placebo: 504) after a first MI with a mean age of 62.6 years (range: 50 - 69) underwent treatment with either HT or placebo. Post-menopausal status was defined as no vaginal bleeding in the previous 12 months.  The mean age at last menstrual period was 46.5 years of age. 24% of women (n = 245) had undergone a hysterectomy. </P>
<P>In terms of ethnic origin and risk factors for a further CVD event: 97% of the women were White; 53% were smokers at the time of admission; mean BMI was 40 kg/m2; 27% had angina; 44% had high blood pressure (not defined); 7.5% had suffered a previous stroke; 15% had diabetes, and 11% had used HT&gt; 12 months before admission to the trial</P>
<P>
<B>Inclusion criteria: </B>
</P>
<UL>
<LI>women aged 50 to 69 years admitted to hospital who had experienced a first MI, who were discharged alive within 31 days of admission</LI>
</UL>
<P> </P>
<P>
<B>Exclusion criteria:</B> </P>
<UL>
<LI>use of HT or vaginal bleeding in the 12 months before admission</LI>
<LI>history of breast, ovarian, or endometrial carcinoma</LI>
<LI>active thrombophlebitis or a history of deep-vein thrombosis or pulmonary embolism</LI>
<LI>acute or chronic liver disease</LI>
<LI>Rotor syndrome, Dubin-Johnson syndrome, or severe renal disease</LI>
</UL>
<P>Both HT and placebo groups had similar baseline characteristics, including those identified a priori (and listed above) as potential confounders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 08:05:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen:</B> 2 mg daily tablet of oestradiol valerate (continuous dosage regimen)</P>
<P>
<B>Comparator:</B> identical placebo capsule daily</P>
<P>Treatment compliance was not formally assessed, but patient reported to the treating physician at follow-up times.  Medication compliance rates were poor, and were lower in the HT group than in the placebo group.  At one year 51% of participants on the HT arm and 31% on the placebo arm were not taking their allocated tablets regularly. At two years, 57% of participants on the HT arm and 37% on the placebo arm were not taking their allocated tablets regularly</P>
<P> </P>
<P>Drop-outs included 43 women in the HT group (8%) and 57 in the placebo group (11%) who did not take any of the trial medication</P>
<P> </P>
<P>
<B>Follow-up times:</B> patients were followed-up at 3, 6, 12, 18 months and at study exit at 24 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-25 15:21:22 +0100" MODIFIED_BY="[Empty name]">
<P>Death from CVD</P>
<P>All causes of death</P>
<P>Death from CVD</P>
<P>MI (non-fatal)</P>
<P>Stoke</P>
<P>Deep vein thrombosis</P>
<P>Pulmonary embolism</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 08:05:45 +0000" MODIFIED_BY="[Empty name]">
<P>The sample size power calculation was originally based on recruiting 1700 patients to achieve 80% power with a two-sided test and a 5% significance rate predicated on HT reducing the rate of non-fatal reinforcing or cardiac death by 13%.  Due to financial constraints the trial was based on a total of 1017 women being randomised, and the power to detect a difference between treatment groups with this number was calculated as 56% assuming full treatment compliance in both of the treatment groups.  Due to poor treatment compliance it is likely that the trial was underpowered to detect differences between treatment groups for some outcomes, and therefore the point estimates of differences between the groups are likely to be conservative. </P>
<P>The overall study population started treatment on average 16.1 years after their menopause. Events were not reported individually or according to starting treatment &lt; 10 or &gt; 10 years since the menopause. For the subgroup analysis of when treatment was started the entirety of events in this study were analysed as if all participants had started treatment within 10 years of their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 11:34:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EVTET-2000">
<CHAR_METHODS MODIFIED="2015-02-03 08:07:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B>  To determine if HT alters the risk of venous thromboembolism in high risk women</P>
<P> </P>
<P>Multicentre RCT with a double triangular sequential design involving four hospital sites in Norway. The trial was conducted over a 1.3 year period between February 1996 and March 1998, but stopped early as other published trial results (<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>) indicated an increased risk of venous thromboembolism (VTE) with use of HT. The primary outcome measure was VTE and the secondary outcome measure pulmonary embolisms. VTE was verified by objective tests (i.e. venography or ultrasound in the case of DVT, and lung-scan, angiography, or<BR/>helical computed tomography, in the case of pulmonary embolism).</P>
<P>At baseline, all participants underwent a clinical examination including breast and pelvic examinations with cytological smear test and evaluation of the endometrium with transvaginal ultrasound.  A screening mammogram was also performed, as were routine haematological and clinical chemistry screening including blood lipids</P>
<P> </P>
<P>
<B>Recruitment:</B> letters to family doctors, gynaecologists and hospitals, health bulletins and media</P>
<P>
<B>Screening: </B>Not reported</P>
<P>
<B>Randomisation:</B> computer-generated 1:1 block randomisation with fixed block sizes of ten</P>
<P>
<B>Stratification:</B> By age &lt; 60 years or &gt; 60 years 37 (23 HT and 14 placebo) women did not attend all visits due to premature termination of the study</P>
<P>
<B>Allocation:</B> Not reported</P>
<P>
<B>Baseline equality of treatment groups: </B>No substantive differences between study groups at baseline</P>
<P>
<B>Blinding:</B> Double-blind</P>
<P>
<B>Analysis</B>: ITT</P>
<P>
<B>Funding Source: </B>Novo-Nordisk Pharmaceutical and research forum Ulleval University Hospital</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 11:34:22 +0000" MODIFIED_BY="[Empty name]">
<P>140 post-menopausal women who had previously had either VTE or PE (HT: 71; placebo: 69) with a mean age of 55.8 years (range: 42 to 69 years) underwent treatment with either HT or placebo.   Post-menopausal status was defined as no natural menstruation for at least one year. The ethnic origin of the women included in the trial was not reported.  In terms of risk factors for CVD 0.7% of women had previous/concomitant MI; 3% had angina; 1.4% had thromboembolic stroke; 3% had a transient ischaemic attack; 17% had hypertension and 2% had diabetes.  The time since last DVT was four years (range: 0 - 37 years) and last PE five years (range: 0 - 34 years). There were no statistically significant differences between the two groups in terms of risk factors for CVD. In terms of smoking status: 39% were never smokers; 36% were previous smokers; 14% smoked between one to 10 cigarettes daily, whilst 10% smoked &gt; 10 cigarettes per day.  Mean BMI among the women was 27.1 kg/m2.  Systolic blood pressure at baseline was 138 mm Hg and diastolic blood pressure was 83 mm Hg. </P>
<P>
<B>Inclusion criteria: </B>
</P>
<UL>
<LI>Post-menopausal women younger than 70 years who had suffered previous DVT or PE</LI>
</UL>
<P>Twenty-eight women were also enrolled into the trial without objective testing as they had a typical history and had subsequently been treated for VTE.  </P>
<P>
<B>Exclusion criteria:</B> </P>
<UL>
<LI>Current use or use of anti-coagulants within the last three months</LI>
<LI>familial anti-thrombin deficiency</LI>
<LI>any type of malignant diseases including known, suspected or past history of breast carcinoma</LI>
<LI>acute or chronic liver disease or history of liver disease in which tests had failed to return as normal</LI>
<LI>porphyries</LI>
<LI>known drug abuse or alcoholism</LI>
<LI>life expectancy less than two years</LI>
<LI>participation in other clinical trials within 12 weeks before study entry</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 08:08:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen: </B>2 mg oestradiol plus 1 mg norethisterone acetate (1 tablet) daily (continuous dosage regimen)</P>
<P>
<B>Comparator:</B> identical placebo capsule daily</P>
<P>Medication compliance in terms of pill counts was conducted at each follow-up visit</P>
<P>
<B>Follow-up times:</B> patients were followed up at three months, 12 months and 24 months</P>
<P>Treatment adherence was not reported</P>
<P>
<B>Loss to follow-up: </B> zero, but 37 (23 HT and 14 placebo) women did not attend all visits due to premature termination of the study.</P>
<P>There were 33 dropouts, 10 in HT group (two wanted to be sure of being treated with oestrogen for post-menopausal symptoms, eight had adverse effects), and 23 in the placebo group (11 wanted to be sure of being treated with oestrogen for post-menopausal symptoms, 10 had adverse effects, two no reason stated)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 12:08:17 +0000" MODIFIED_BY="[Empty name]">
<P>Venous thrombosis<BR/>Myocardial infarction<BR/>Stroke</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 08:09:09 +0000" MODIFIED_BY="[Empty name]">
<P>Study terminated early, only 140 women enrolled of 240 planned due to the results from HERS I (1998) being made available. </P>
<P>Power calculation: At a significance level of 5% and a power of 90% the sample size was estimated to a maximum of 240 women</P>
<P>Data on timing of the menopause or starting treatment in relation to the menopause was not reported. The study author was emailed but no response was received. Baseline age was reported for each treatment group, control group 55.7 (SD 5.9) and 55.8 (SD 7.0) years. Events were not reported individually or according to starting treatment &lt; 10 or &gt; 10 years since the menopause, or age. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment within 10 years of their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 08:12:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenspan-2005">
<CHAR_METHODS MODIFIED="2015-02-03 08:09:46 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial using 2 X 2 factorial design to compare HT and alendronate on physical performance, functional ability, physical activity, falls and cognitive function in elderly women. The study ran from January 1996 to May 2001.</P>
<P>Randomised follow-up duration was three years and run at a single centre.</P>
<P>
<B>Recruitment: </B>Newspaper advertisements, targeted mailings, presentations to senior groups and physician referrals of community-dwelling women aged 65 and older from the greater Boston Area</P>
<P>
<B>Screening: </B>Medical history, physical examination, bone densitometry, mammography and laboratory evaluation</P>
<P>
<B>Randomisation: </B>All participants took part in a three-month run-in phase, where they all took hormone therapy alendronate, calcium and vitamin D. Once completed, they were randomised according to randomised lists prepared by the study statistician</P>
<P>
<B>Stratification: </B>By prior hysterectomy and three levels of total hip bone mineral density</P>
<P>
<B>Allocation: </B>By research pharmacist</P>
<P>
<B>Baseline equality of treatment groups: </B>No substantive differences between study groups at baseline</P>
<P>
<B>Blinding: </B>Block sizes (four, eight or 12) were randomly determined to enhance blinding. Those who administered the intervention and measured the outcomes were blinded to treatment group assignment</P>
<P>
<B>Analysis</B>: ITT</P>
<P>
<B>Funding Source: </B>NIH, Wyeth-Ayerst Laboratories provided the Premarin and Preprom matching placebo and the Os-Cal plus D. Merck Research laboratories provided the alendronate and matching placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 08:10:30 +0000" MODIFIED_BY="[Empty name]">
<P>485 women entered three-month open-label run-in phase with HT, alendronate, placebo, calcium and vitamin D, 373 completed the run-in phase and were randomised</P>
<P> </P>
<P>
<B>Inclusion criteria:</B>
</P>
<UL>
<LI>Community-dwelling women</LI>
<LI>Aged 65 years and older</LI>
<LI>From the greater Boston area</LI>
</UL>
<P> </P>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>Any illness which could affect bone metabolism (e.g. hyperthyroidism, hyperparathyroidism, renal failure, hepatic failure, active malignancy</LI>
<LI>Participants taking medications known to alter bone metabolism</LI>
<LI>Participants who had previously been treated with anti-osteoporosis medications (i.e. HT or bisphosphonates) within one year of screening</LI>
<LI>Known contraindication to HT</LI>
</UL>
<P>The mean age of the women were: 71.2 years (SD ± 5.6) receiving HT, 71.3 years (SD ± 4.8) in the control group (P = 0.43). The number of participants who had had a hysterectomy were 66 (35%) and 64 (34%) in those receiving HT and the control group, respectively (P = 0.91). The body mass indices were comparable 27.5 (SD ± 4.8) in those receiving HT and 27.7 (SD ± 6.5) in the control group (P = 0.76)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 08:11:01 +0000" MODIFIED_BY="[Empty name]">
<P>All women in the trial received a calcium and vitamin D supplement (OsCal Plus D) and a multivitamin tablet to ensure their calcium intake was greater than 1000 mg/d and their vitamin D was between 400 and 800 IU/day</P>
<P> </P>
<P>
<B>HT regimen:</B>
</P>
<P>
<B>1. </B>Conjugated equine oestrogen 0.625 mg/d (Premarin)</P>
<P>(Medroxyprogesterone 2.5 mg/d was given to those women with an intact uterus) (n = 93)</P>
<P> </P>
<P>
<B>2. </B>Conjugated equine oestrogen 0.625 mg/d (Premarin)</P>
<P>(Medroxyprogesterone 2.5 mg/d was given to those women with an intact uterus)</P>
<P>Plus alendronate (dose not specified) (n = 94)</P>
<P>
<B>Comparators:</B>  </P>
<P>
<B>1. </B>Alendronate alone (dose not specified) (n = 93)</P>
<P> </P>
<P>
<B>2. </B>Placebo alone (n = 93)</P>
<P> </P>
<P>
<B>Follow-up time: </B>three years</P>
<P> </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 20:25:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes:</B>
</P>
<UL>
<LI>Clinical characteristic &#8211; weight, height, BMI, hematocrit, albumin, 25- hydroxyvitamin D and number of medications</LI>
<LI>Physical performance assessment</LI>
<LI>Physical activity scale of the elderly</LI>
<LI>Instrumental activities of daily living</LI>
<LI>Folstein mini-mental status</LI>
</UL>
<P> </P>
<P>
<B>Adverse events: </B>
</P>
<P>Menstrual spotting</P>
<P>Menstrual cramping</P>
<P>Endometrial biopsy</P>
<P>Endometrial cancer</P>
<P>Breast tenderness</P>
<P>Breast cancer</P>
<P>Bloating</P>
<P>Peripheral oedema</P>
<P>DVT</P>
<P>Weight gain</P>
<P>High blood pressure</P>
<P>Hospitalisations</P>
<P>MI</P>
<P>Chest pain</P>
<P>Clinical fractures</P>
<P>Colon cancer</P>
<P>Diabetes</P>
<P>Gallstones</P>
<P>Depression</P>
<P>Stress incontinence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 08:12:07 +0000" MODIFIED_BY="[Empty name]">
<P>Methods for verifying medication compliance, not specified.</P>
<P>Medication adherence was defined as women taking at least 80% of the medication at least 80% of the entire study period and present in 115 (61%) of those in the HT group and 124 (67%) in the control group (P = 0.33). Retention was defined as a participant who had a bone mineral density scan at least 33 months after randomisation, this took place in 169 (90%) in the HT allocated group and 168 (90%) of the control group (P = 1.00). Participant visits occurred every six months.</P>
<P>Data on timing of the menopause or starting treatment in relation to the menopause was not reported. The study author was emailed but no response was received. Baseline age was reported for each treatment group, control group 71.3 (SD 4.8) and 71.2 (SD 5.6) years. Events were not reported individually or according to starting treatment &lt; 10 or &gt; 10 years since the menopause, or age. For the subgroup analysis of when treatment was started the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 12:25:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HALL-1998">
<CHAR_METHODS MODIFIED="2015-02-03 08:12:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective: </B> to assess the effects of HT on angina and HRQoL in women with ischaemic heart disease</P>
<P> </P>
<P>Single-centre, randomised, controlled (RCT) trial involving one hospital site in Sweden. The trial was a three-arm trial comprising: one group who received 50 µg transdermal 17ß-oestradiol daily for 18 days followed by 5 mg of combined treatment with medroxyprogesterone acetate orally; the second group who received 0.625 mg conjugated oestrogens (CEE) orally for 18 days followed by a combination with oral 5 mg medroxyprogesterone acetate daily, and the third group who received placebo.  Due to not confounding the results of other trials in which oestrogens/progestins have been provided orally, the data presented in this trial are from the groups that received only oral medication (i.e. groups two and three). </P>
<P>The length of follow-up of the trial was one year.  The primary outcome was angina, with death from CVD causes, MI, and the number of angioplasties and CABG performed reported as secondary outcomes</P>
<P> </P>
<P>
<B>Recruitment:</B> Not reported</P>
<P>
<B>Screening:</B> Not reported</P>
<P>
<B>Randomisation:</B> Not reported</P>
<P>
<B>Stratification:</B> Not reported</P>
<P>
<B>Allocation:</B> Not reported</P>
<P>
<B>Baseline equality of treatment groups:</B>  Only limited baseline characteristics reported for the treatment groups, and no statistical comparisons made between groups.  Probable baseline imbalance between treatment groups for age (placebo group older than HT group); weight (placebo group heavier than HT group); number of years since menopause (placebo group higher number than HT group)</P>
<P>
<B>Blinding:</B> Not reported</P>
<P>
<B>Analysis: </B>Unclear. No statistical tests for between group differences conducted</P>
<P>
<B>Funding Source:</B> Hospital grant funded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 08:13:22 +0000" MODIFIED_BY="[Empty name]">
<P>Forty post-menopausal women with existing coronary artery disease (HT: 20; placebo: 20) with a mean age of 60 years (range: 44 - 75) underwent treatment with either HT or placebo for a year. No definition of what constituted post-menopausal status and whether the trial included patients with a hysterectomy was reported. The mean BMI among the 40 women included in the trial was 30 kg/m2 (range: 20.0 to 40.7 years); the mean time of menopause was 12.5 years (range: 2 to 26); 9.5% were former smokers, 5.5% were never smokers and 5.5% were present smokers. </P>
<P>In terms of diagnosis of CVD: 55% had a previous MI; 27.5% previous bypass surgery; 22.5% previous percutaneous transluminal coronary angioplasty (PTCA) (balloon dilation); 0% had type I diabetes; 10% had type II diabetes; 32.5% had hypertension, and 12.5% had claudication </P>
<P>
<B>Inclusion criteria:  </B>No inclusion criteria were reported</P>
<P>
<B>Exclusion criteria:</B> No inclusion criteria were reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 08:13:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen:</B> 0.625 mg conjugated oestrogens (CEE) orally for 18 days followed by a combination with oral 5 mg medroxyprogesterone acetate daily (sequential dosage regimen)</P>
<P>
<B>Comparator:</B> identical placebo capsule daily</P>
<P>The overall compliance with study intervention was not reported</P>
<P>
<B>Follow-up times</B>:  Baseline, three, six, 12 months and four to six weeks after completion of the trial. Pre-treatment investigations included gynaecological history and occurrence of climacteric symptoms, Pap smear and mammography (if not performed within two years prior to recruitment).  Blood samples were analysed for oestradiol, estrone, estrone sulphate and follicle stimulating hormone at baseline, three, six, 12 months and four to six weeks after trial completion.  Additionally, a cardiac history, physical examination, and symptoms of angina pectoris were performed using the Canadian Heart Association protocol before trial entry.  Minimal Health Related Quality of Life (HRQoL) data were measured at baseline and at one-year follow-up.  The domains covered were:  (1) well being; (2) mucous membrane changes; (3) climacteric symptoms; (4) breast tenderness; (5) negative mood changes; (6) headache, and (7) bleeding irregularities. The outcomes of these were not reported in the paper</P>
<P>
<B>Withdrawals:</B> 20%; 10% HT and 30% placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 08:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>Death from CVD cause</P>
<P>Angina</P>
<P>Fatal MI</P>
<P>Angioplasty</P>
<P>Coronary artery bypass</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 12:25:22 +0000" MODIFIED_BY="[Empty name]">
<P>No sample size calculation was performed and it is unlikely that the trial was powered adequately to detect significant differences in clinical event rates between the HT and placebo groups. No definition of how clinical events were defined or ascertained was reported.  Additionally, no statistical analyses to assess differences in clinical event rates between the groups were performed. It is therefore unclear, whether the groups differed significantly in the number and types of events experienced.  The length of trial follow-up (one year) was unlikely to be long enough to ascertain either the longer-term effects of HT use compared to placebo, or for other important CVD events to be assessed.</P>
<P>The control group population started treatment on average 13.3 (SD 7.8) years after their menopause with the hormone group starting on average 11.6 (SD 6.7) years after. Events were not reported individually or according to starting treatment &lt; 10 or &gt; 10 years since the menopause. For the subgroup analysis of when treatment was started the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 12:30:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HERS-I-1998">
<CHAR_METHODS MODIFIED="2015-02-03 12:29:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B> To assess whether combined HT alters the risk for CHD events in post-menopausal women with established coronary disease.</P>
<P>Multicentre, randomised, placebo-controlled, secondary prevention trial (RCT) involving 20 primary care sites in the United States. The trial recruitment was conducted from January 1993 to September 1994, with a mean follow-up of 4.1 years. The primary aim of the trial was to assess the effects of combined oestrogen and progestin therapy compared to placebo for the prevention of recurrent coronary heart disease (CHD) events in post-menopausal women with CHD.  Coronary heart disease was defined as evidenced by prior MI, coronary artery bypass graft surgery (CABG), percutaneous transluminal coronary angioplasty, or other mechanical revascularisation, or at least 50% occlusion of a major coronary artery.  The primary outcome was the occurrence of CHD events (CHD death or non-fatal MI). Secondary outcomes included stroke, venous thromboembolic events, angina, and breast and endometrial cancers</P>
<P> </P>
<P>
<B>Recruitment:</B> Lists of cardiac patients, mass mailing, direct advertising</P>
<P>
<B>Screening:</B> 3463 of whom 43% were excluded (ineligible, declined to participate, did not return for appointment or did not comply with placebo run-in period)</P>
<P>
<B>Randomisation:</B> Computer-generated random numbers in blocks of four</P>
<P>
<B>Stratification:</B> By clinical centre</P>
<P>
<B>Allocation:</B> Computer displayed after participant details entered</P>
<P>
<B>Baseline equality of treatment groups:</B> More women in control arm on statins at randomisation (67% versus 54%). When adjusted in analyses - made no statistically significant difference</P>
<P>
<B>Blinding:</B>  Participants, clinical centre staff, outcome assessors, data analysts, funders. Unblinding could occur when required for safety or symptom control, participants reported directly to gynaecology staff who were located separately from clinical staff, did not communicate with them about breast or gynaecological problems and were not involved in outcome ascertainment</P>
<P>
<B>Analysis:</B> ITT and also analysed by treatment received with inclusion limited to women with &gt; 80% compliance</P>
<P>
<B>Funding Source:</B> Pharmaceutical (Wyeth-Ayerst)</P>
<P> </P>
<P>
<B>HERS II</B>
</P>
<P>An unblinded, open-label observational continuation of HERS I in which 2321 women (93% of 2510 surviving HERS participants) followed up for a further 2.7 years (originally planned for additional four years but executive committee decided no further useful information likely to emerge). Number analysed: 2311 for vital status.  Losses to follow-up: ten women (1%) not contacted at final follow-up (two in HT arm; eight in control arm) of these, vital status known for five. Adherence to treatment: among women originally assigned to the HT group, 45% reported at least 80% compliance during the sixth year of follow-up. Among women originally assigned to placebo, 8% reported taking HT at six years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 12:30:04 +0000" MODIFIED_BY="[Empty name]">
<P>2763 post-menopausal women with verified CHD were randomised to receive either daily conjugated oestrogen in combination with medroxyprogesterone acetate (= 1380) or placebo (n = 1383). Post-menopausal status was defined as age at least 55 years and no natural menses for at least five years, or no natural menses for at least one year and serum follicle-stimulating hormone (FSH) level more than 40 IU/L, or documented bilateral oophorectomy, or reported bilateral oophorectomy with FSH level more than 40 IU/L and oestradiol level less than 92 pmol/L (25 pg/mL).  The mean age of the women was 67 years (range: 44 - 79), with a mean time of 18 years (SD: ± 8) since last menses.  </P>
<P>Included women were 89% White, 8% African-American, 2% Hispanic, &lt; 1% Asian, and &lt; 1% other.  In terms of risk factors for CVD: 13% were current smokers, 49% were past smokers and 38% had never smoked; 18.5% had diabetes and were on oral medication or insulin; mean systolic blood pressure was 135 (SD: ± 19) mm Hg and mean diastolic blood pressure was 73 (SD: ± 10). </P>
<P>56% of the women had a BMI &gt; 27 kg/m2 and 23.5% had previous post-menopausal oestrogen use (after menopause but not within three-months of initial screenings for HERS trial).</P>
<P>The CHD manifestations within the groups were: 9.5% had signs of congestive heart failure (presence of jugular venous distention more than 8 cm H20, S3 heart sound, rales, or pitting peripheral oedema); 17% had Q-wave MI; 45% had undergone percutaneous coronary revascularisation, and 41.5% had undergone coronary artery bypass graft surgery.  There were no statistically significant differences between treatment groups at baseline.</P>
<P>
<B>Inclusion criteria:</B> Stated above, plus &#8804; 79 years old with uterus present</P>
<P> </P>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>CHD event within six months of randomisation</LI>
<LI>serum triglyceride level higher than 3.39 mmol/L (300 mg/dL)</LI>
<LI>use of oral, parenteral, vaginal, or transdermal sex hormones within three months of the screening visit</LI>
<LI>history of deep vein thrombosis or pulmonary embolism</LI>
<LI>history of breast cancer or breast examination or mammogram suggestive of breast cancer</LI>
<LI>history of endometrial cancer</LI>
<LI>abnormal uterine bleeding, endometrial hyperplasia, or endometrium thickness greater than 5 mm on baseline evaluation</LI>
<LI>abnormal or unobtainable Papanicolaou test result</LI>
<LI>serum aspartate aminotransferase level more than 1.2 times normal</LI>
<LI>disease (other than CHD) judged likely to be fatal within four years</LI>
<LI>New York Heart Association class IV or severe class III congestive heart failure</LI>
<LI>alcoholism or other drug abuse</LI>
<LI>uncontrolled hypertension (diastolic blood pressure 105 mm Hg or systolic blood pressure 200 mm Hg)</LI>
<LI>uncontrolled diabetes (fasting blood glucose level 16.7 mmol/L [300 mg/dL])</LI>
<LI>less than 80% compliance with a placebo run-in prior to randomisation</LI>
<LI>history of intolerance to hormone therapy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 12:30:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimens:</B> 0.625 mg conjugated oestrogen plus 2.5 mg medroxyprogesterone acetate daily (continuous dosage regimen)</P>
<P> </P>
<P>
<B>Comparator:</B> identical placebo tablet daily.</P>
<P>Rates of medication compliance in the trial were reasonably high.  At the end of year-one, 82% of women in the HT group and 91% in the placebo group reported taking study medication.  At three years: 75% HT arm; 81% control arm. By pill count in HT arm: at one year: 79%; at three years: 70% HT arm</P>
<P> </P>
<P>
<B>Losses to follow-up:</B> Vital status known for all women at end of trial. 59 women did not complete follow-up (32 in experimental arm, 27 in placebo arm)</P>
<P> </P>
<P>
<B>Follow-up times: </B>Baseline, and then every four months.  At baseline, participants had a clinical examination, including breast and pelvic examination with Papanicolaou test and endometrial evaluation, a screening mammogram and standardised 12-lead electrocardiogram (ECG). Fasting total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were also measured.  Annual examinations included cardiac examination and ECG. Separate annual follow-up visits to the study gynaecologist included repeat breast and pelvic examinations with Papanicolaou smears and screening mammograms</P>
<P> </P>
<P>Health Related Quality of Life (HRQoL) was measured on four scales that assessed functional capacity, emotional health, vitality and depression.  These were assessed at baseline, four months, and then follow-up at years one, two, and three.  Physical function was assessed using the Duke Activity Status Index, energy/fatigue using a four-item RAND scale, mental health was measured by the RAND Mental Health Inventory, and depressive symptoms were assessed using an eight-item scale developed by <LINK REF="REF-Burnam-1988" TYPE="REFERENCE">Burnam 1988</LINK> to screen for depression in the National Study of Medical Outcomes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 08:17:42 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Death from CVD</P>
<P>Non-fatal MI</P>
<P>Secondary outcomes:-</P>
<P>Death from any cause</P>
<P>Fatal MI</P>
<P>Stroke</P>
<P>Angina (necessitating hospitalisation)</P>
<P>Pulmonary embolism</P>
<P>Venous thrombosis</P>
<P>Coronary artery bypass surgery </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 08:18:12 +0000" MODIFIED_BY="[Empty name]">
<P>Power calculation: 90% power to observe 24% reduction in coronary events at an average of 4.2 years (P = 0.05) follow-up.<BR/>Further unblinded follow up 2.7 years (HERS II) [included in original Sanchez review].</P>
<P>Data were not reported as events stratified to years since menopause. However, the mean age since menopause was 18 years and 84% of the study participants were &gt; 60 years old when enrolled. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 11:15:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-STOP-IT-2001">
<CHAR_METHODS MODIFIED="2015-02-03 11:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre, three-year, double-blinded, placebo-controlled trial run in North America. The primary aim of the trial was to examine the effect of HRT and calcitriol, separately or combined, on bone loss in healthy elderly women</P>
<P>
<B>Recruitment: </B>Mailout sent to women in the Omaha area, followed by a phone call</P>
<P>
<B>Screening: </B>Medical and medication history</P>
<P>
<B>Randomisation: </B>Not reported</P>
<P>
<B>Stratification: </B>Not reported</P>
<P>
<B>Allocation: </B>Not reported</P>
<P>
<B>Baseline equality of treatment groups: </B>No substantive differences between groups</P>
<P>
<B>Blinding: </B>Staff, investigators and participants were blinded throughout the treatment period</P>
<P>
<B>Analysis</B>: ITT</P>
<P>
<B>Funding Source: </B>NIH, Wyeth-Ayerst Laboratories, Inc. Pharm., Hoffman-LaRoche Inc. and Pharmacia and Upjohn</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-20 09:46:38 +0000" MODIFIED_BY="[Empty name]">
<P>489 healthy women were recruited</P>
<P>
<B>Inclusion criteria:</B>
</P>
<UL>
<LI>Femoral neck bone mineral density had to be within 2 SD of normal range for their age</LI>
<LI>Aged 65 to 77</LI>
<LI>female</LI>
</UL>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>Severe chronic illness</LI>
<LI>Primary hyperparathyroidism</LI>
<LI>Active renal stone disease</LI>
<LI>Taking particular medications including: bisphosphonates, anticonvulsants, oestrogen, fluoride, thiazide in the past six months</LI>
</UL>
<P>The mean age of the participants was 71 years (SD 4), range 65 to 77</P>
<P>Age in the placebo group 71 years (SD 4), calcitriol 72 years (SD 3), HRT 72 years (SD 4), HRT + calcitriol 71 years (SD 4)</P>
<P>Years since menopause: not specified</P>
<P>Previous HRT use: not specified but not allowed within six months prior to recruitment</P>
<P>
<B>CVS Risk Factors</B>
</P>
<P>Weight: placebo 69.4 kg (SD 13.0), calcitriol 68.3 kg (SD 13.0), HRT 69.5 kg (SD 12.4), HRT + calcitriol 67.3 kg (SD 12.0)</P>
<P>Hysterectomy numbers were comparable in each of the four groups; overall 199 (41%) had undergone a hysterectomy. Those women with an intact uterus assigned to HRT received medroxyprogesterone (MPA) in addition to conjugated equine oestrogen (CEE), those without a uterus received just CEE.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 11:14:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen:</B> conjugated oestrogen (Premarin) 0.625mg/d + Medroxyprogesterone (Provera) 2.5mg/d Hysterectomised women not given progestin</P>
<P>
<B>Comparator 1:</B>
</P>
<P>Calcitriol (Rocaltrol) 0.25 µg twice daily</P>
<P>
<B>Comparator 2:</B>
</P>
<P>HT + calcitriol</P>
<P>
<B>Comparator 3:</B>
</P>
<P>Matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-16 14:36:28 +0100" MODIFIED_BY="[Empty name]">
<P>Bone mineral density</P>
<P>Fractures</P>
<P>Falls</P>
<P>Biochemistry details</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 11:15:21 +0000" MODIFIED_BY="[Empty name]">
<P>After randomisation participants were assessed at six weeks, 12 weeks, six months and then every six months for three years.</P>
<P>They had bone mineral density assessed, blood tests and a questionnaire at six-monthly intervals.</P>
<P>Medication adherence assessed at 36 months was 78% in the placebo group, 70% in the calcitriol group, 65% in the HRT group and 62% in the HRT + calcitriol group.</P>
<P>Out of those still adherent, compliance at 36 months was: 92% in the placebo group, 93% in the calcitriol group, 92% in the oestrogen group and 94% taking MPA.</P>
<P>Major reasons for discontinuation were bleeding problems (n = 21), breast tenderness (n = 13), other significant health problems (n = 21), lost interest in the study (n = 19), cerebrovascular incident: cerebral thrombosis, cerebral haemorrhage or TIA (n = 15) and gastrointestinal problems (n = 14). Five participants died during study from causes unrelated to study medication.</P>
<P>Subjects were dispensed medication every six months and all returned pills were counted at that time to estimate compliance.</P>
<P>The calcitriol group was omitted from analysis. the HRT and HRT + calcitriol were combined for analysis.</P>
<P>Data were not collected on when treatment was started in relation to the menopause or when the menopause occurred. The study author was contacted but these data were not collected. The mean age in each treatment group was reported as follows, 72 years (SD 4) HRT, 71 years (SD 4) HRT and calcitriol and 71 years (SD 4). For the subgroup analysis of when treatment was started the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 11:17:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WAVE-2002">
<CHAR_METHODS MODIFIED="2015-02-03 11:15:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B>  To determine whether HT or antioxidant vitamin supplements, alone or in combination, influence the progress of coronary artery disease in post-menopausal women as measured by angiography.</P>
<P> </P>
<P>Multicentre, 2 x 2, randomised, factorial, placebo-controlled (RCT) trial involving seven hospital sites; five in the United States and two in Canada.  The trial recruitment was conducted from July 1997 to July 1999), with a mean follow-up of 2.8 (SD: ± 0.9 years.  The primary aim of the trial was to assess the effects of oestrogen and/or progestin with or without antioxidant vitamins for preventing angiographic progression of coronary artery disease. Coronary artery disease was defined as having al least one coronary segment with stenosis of &#8805; 15% and 75% in a vessel &#8805; 2 mm in diameter at baseline, with the angiograph conducted within four months of trial recruitment.  The primary outcome was therefore change in the minimum lumen diameter (MLD) of the vessels from baseline, as assessed by quantitative coronary angiography at follow-up. Clinical CVD events and health related quality of life were all assessed as secondary outcomes</P>
<P> </P>
<P>
<B>Recruitment:</B> Recruited at clinical sites in USA and Canada</P>
<P>
<B>Screening:</B> Not reported</P>
<P>
<B>Randomisation:</B> Computer-randomised, permuted block design with random blocks of two and four</P>
<P>
<B>Stratification:</B> Clinical centre, hysterectomy status</P>
<P>
<B>Allocation:</B> Remotely by phone call to study co-ordinating centre</P>
<P>
<B>Baseline equality of treatment groups:</B> Higher prevalence of diabetes and higher fasting blood glucose levels in the HT group</P>
<P>
<B>Blinding:</B> Participants, investigators and staff at clinical centres blinded except (when necessary) the study gynaecologist.  Adverse effects managed by gynaecologist not involved in outcome assessment who had access to treatment assignment if necessary, with permission of coordinating centre (unblinding).</P>
<P>
<B>Analysis:</B> No (98% of women analysed by ITT).</P>
<P>
<B>Funding Source:</B> National Heart, Lung and Blood Institute contract, General Clinical Research Center grant, USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 11:16:27 +0000" MODIFIED_BY="[Empty name]">
<P>Four hundred and twenty-three post-menopausal women with angiographically verified coronary disease were randomised to receive either (1) daily conjugated oestrogen alone for participants who had undergone a hysterectomy; (2) daily conjugated oestrogen in combination with medroxyprogesterone acetate; (3) vitamins E and C, or (4) placebo. Post-menopausal status was defined as having bilateral oophorectomy at any age, being younger than 55 years old with a follicle-stimulating hormone level of 40 IU/ml or higher, or being older than 55 years.  Included women were 66% White and 34% non-White (Black or other; specific origins not reported).</P>
<P>In terms of risk factors for CVD: 37% had diabetes; 76% had hypertension; 39% were current smokers; 43% had suffered a previous MI, and 37.5% were current HT users.  The mean BMI was 30.7 kg/m2; mean systolic blood pressure was 139 (SD: 21) mm Hg and the mean diastolic blood pressure 76 (SD: 10.5) mm Hg. The HT and placebo HT groups were well-balanced in terms of baseline characteristics, apart from the exception of the active HT group having a statistically significantly higher prevalence of diabetes and higher fasting blood glucose levels</P>
<P> </P>
<P>
<B>Exclusion criteria: </B>
</P>
<UL>
<LI>Use of oestrogen replacement therapy within the past three months apart from oestrogen vaginal cream if used no more than 25% of the time</LI>
<LI>use of vitamins C and E exceeding the recommended dietary allowance and unwillingness to stop taking them</LI>
<LI>evidence of potential breast, uterine, or cervical cancer;</LI>
<LI>any abnormal uterine bleeding or endometrial hyperplasia at baseline</LI>
<LI>MI less than four weeks prior to randomisation</LI>
<LI>prior or planned coronary artery bypass graft surgery</LI>
<LI>fasting triglycerides levels higher than 500 mg/dL (5.65 mmol/L)</LI>
<LI>creatinine level higher than 2.0 mg/dL (176.8 µmol/L0)</LI>
<LI>symptomatic gallstones</LI>
<LI>New York Heart Association class IV congestive heart failure or a left ventricular ejection fraction known to be less than 25%</LI>
<LI>history of hemorrhagic stroke, bleeding diathesis, pulmonary embolism, idiopathic deep venous thrombosis, or untreated osteoporosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 11:17:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimens:</B>
</P>
<P>1)  0.625 mg conjugated equine oestrogen daily plus placebo for women who had undergone a hysterectomy (continuous dosage regimen).</P>
<P>2)  0.625 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate daily plus placebo for women who had not undergone a hysterectomy (continuous dosage regimen).</P>
<P>3)  400 IU vitamin E twice daily (800 IU) plus 500 mg vitamin C twice daily (1 g)</P>
<P>
<B>Comparator: </B>two placebo tablets daily.</P>
<P>Adherence to treatment: Evaluated for 159/211 who had angiographic follow-up: HT group took 67% of medication, placebo group took 70%; 9/108 women in placebo group crossed to open-label oestrogen</P>
<P> </P>
<P>
<B>Losses to follow-up: </B>Five (three in HT group, two in placebo group)</P>
<P> </P>
<P>
<B>Follow-up times:</B> Baseline, three months, and then every six months. Patients underwent a coronary angiography at baseline and trial exit.  Other investigations performed at baseline were: 12-lead electrocardiogram; breast and pelvic examinations, mammography, Papanicolaou smears and fulfilment of the five health-related quality of life questionnaires (HRQoL). Baseline assays included: fasting glucose, insulin, HbA1c, fibrinogen, lipid profile, vitamins C and E and estrone.</P>
<P>HRQoL questionnaires: Five HRQoL questionnaires were completed at baseline and at 18 months by participants. The specific questionnaires completed were: (1) the Medical Outcome Study Short Form (SF-36); (2) Centre for Epidemiological Studies-Depression Scale; (3) Seattle Angina Questionnaire; (4) Duke Activity Scale Index, and (5) The Medical Outcomes Study Sleep Questionnaire</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 11:17:07 +0000" MODIFIED_BY="[Empty name]">
<P>Mean change from baseline in MLD of all qualifying angiographic segments</P>
<P>Death from any cause</P>
<P>Death from CVD</P>
<P>Non-fatal MI</P>
<P>Stroke</P>
<P>Secondary outcomes:</P>
<P>Deep vein thrombosis</P>
<P>Health-related quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 11:17:26 +0000" MODIFIED_BY="[Empty name]">
<P>The sample size calculation was predicated on the ability to detect differences between groups in the primary outcome measure, change in the minimum lumen diameter of all qualifying angiographic segments, as assessed by quantitative coronary angiography. The trial was therefore not powered to detect differences in CVD clinical events between the treatment groups. Additionally, as the factorial design revealed no interactions between treatment groups, results for the two HT versus placebo treatment groups (i.e. oestrogen alone or oestrogen in combination with progestin) were pooled and presented as aggregate numbers of events.  It is therefore not possible to state whether there is any excess risk/benefit for the use of either oestrogen alone or in combination with medroxyprogesterone acetate compared to placebo on the basis of the results reported from the trial.</P>
<P>Data were not published regarding the time that treatment was started in relation to the menopause or what age the menopause took place. The study author was contacted and advised that these data would be available from NIH. NIH were contacted but as yet these data have not been released. The mean age of study participants was reported, 65 years (SD 9) in the active group and 66 years (SD 9) in the control group. For the subgroup analysis of when treatment was started the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 12:43:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WELL_x002d_HART-2003">
<CHAR_METHODS MODIFIED="2015-02-03 12:42:50 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised, double-blinded, placebo-controlled trial run at 5 centres in North America. It was run from June 1995 to October 2000 and was designed to test the effects of oral micronised 17&#946;-oestradiol with or without sequential administered medroxyprogesterone acetate, compared to control, on the progression of atherosclerosis in postmenopausal women with angiographically documented coronary artery disease. Participants were stratified according to the presence or absence of diabetes</P>
<P>
<B>Recruitment: </B>Not reported</P>
<P>
<B>Screening: </B>Not reported</P>
<P>
<B>Randomisation: </B>Computerised random number generator in the data coordinating centre used and adaptive randomisation was used to correct for imbalances between treatment groups in total cholesterol</P>
<P>
<B>Stratification: </B>According to diabetes status</P>
<P>
<B>Allocation: </B>not reported</P>
<P>
<B>Baseline equality of treatment groups: </B>The age in the oestrogen treatment group was significantly lower than the other two treatment groups (P=0.02). Otherwise there were no substantive differences between groups</P>
<P>
<B>Blinding: </B>The participants, gynaecologists, clinical staff and image analysts were all blinded to treatment assignment</P>
<P>
<B>Analysis</B>:Only those who could be quantified by quantitative coronary angiography were included</P>
<P>
<B>Funding Source: </B>NHLBI, Mead Johnson laboratories and Pharmacia and Upjohn</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 12:43:27 +0000" MODIFIED_BY="[Empty name]">
<P>226 postmenopausal women who had at least one coronary artery lesion.</P>
<P>The mean age of the participants were: 64.2 years in the control group (SD 6.2), 61.8 years in the oestrogen group (SD 6.7) [E] and 64.4 years in the oestrogen-progestin group (SD 6.4) [EP] P = 0.02</P>
<P>Years since menopause: 18.3 years in the control group (SD 10.5), 16.7 years in the oestrogen group (SD 10.3) [E] and 19.7 years in the oestrogen-progestin group (SD 10.5) [EP] P = 0.23</P>
<P>
<B>CVS Risk Factors</B>
</P>
<P>Smoking status: P = 0.55</P>
<P>Current smoker:7 (9%) [control], 11 (14%) [E], 8 (11%) [EP]</P>
<P>Former smoker: 28 (37%) [control], 27 (36%) [E], 34 (46%) [EP]</P>
<P>Never smoked: 41 (54%) [control], 38 (50%) [E], 32 (43%) [EP]</P>
<P>Diabetes: 40 (53%) [control], 38 (50%) [E], 37 (50%) [EP] P = 0.93</P>
<P>Blood pressure &#8211; systolic: 141.6 (SD 22.4) [control], 138.1 (SD 21.7) [E], 142.3 (SD 24.6) [EP] P = 0.49</P>
<P>Blood pressure &#8211; diastolic: 75.9 (SD10.5) [control], 76.5 (SD 11.1) [E], 75.3 (SD 12.5) [EP] P = 0.82</P>
<P>BMI: 30.0 (SD 5.4) [control], 30.6 (SD 5.6) [E], 30.2 (SD 5.6) [EP] P = 0.83</P>
<P>
<B>Inclusion criteria:</B>
</P>
<UL>
<LI>Post-menopausal (as indicated by a serum oestradiol level below 20 pg per millilitre)</LI>
<LI>75 years or younger</LI>
<LI>LDL level of 100 to 250 mg per decilitre (2.59 to 6.46 mmol/L)</LI>
<LI>total triglyceride level of less than 400 mg per decilitre (4.52 mmol/L)</LI>
<LI>at least one coronary-artery lesion occluding 30 percent or more of the luminal diameter</LI>
<LI>Women who had undergone PTCA were eligible if they had at least 20 % stenosis in a segment of a coronary artery that was not crossed by the guidewire used for angioplasty</LI>
<LI>Women who had undergone CABG were eligible if they had at least 20 % stenosis in a segment of a coronary artery which was not proximal to a patent graft</LI>
</UL>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>women who smoked &gt; 15 cigarettes per day</LI>
<LI>a diagnosis of breast cancer or gynaecological cancer within 5 years before screening</LI>
<LI>a life-threatening disease and a projected survival of less than 5 years</LI>
<LI>a diastolic blood pressure &gt; 110 mm Hg</LI>
<LI>a fasting glucose of more than 200 mg per decilitre</LI>
<LI>thyroid disease</LI>
<LI>a serum creatinine more than 2.5 mg per decilitre (220 µmol/L)</LI>
<LI>heart failure (Killip class III or IV and an ejection fraction below 30%)</LI>
<LI>more than five hot flushes per day which interfered with their daily activities</LI>
<LI>plans to undergo revascularisation within six months of the screening visit</LI>
<LI>baseline coronary angiogram obtained before or less than six months after a revascularisation procedure</LI>
<LI>a MI less than six weeks before the screening visit</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 11:21:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen: </B>1 mg of oral micronised 17&#946;-oestradiol [E] (Estrace, Mea Johnson) daily, plus a placebo tablet matching medroxyprogesterone acetate for 12 consecutive days of every month</P>
<P>
<B>HT regimen 2: </B>1 mg of oral micronised 17&#946;-oestradiol (Estrace, Mea Johnson) daily, plus 5 mg medroxyprogesterone acetate [P] (Provera, Upjohn) for 12 consecutive days of every month</P>
<P>
<B>Comparator:</B> two placebo tablets, one matching each of the active drugs for 12 consecutive days of every month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 11:21:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes</B>:</P>
<P>Average (per-participant) change from baseline in the percent stenosis in all lesions evaluated by quantitative coronary angiography</P>
<P>
<B>Secondary outcomes:</B>
</P>
<P>Average (per-participant) change in minimal luminal diameter (on quantitative angiography)</P>
<P>Global change score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 12:43:37 +0000" MODIFIED_BY="[Empty name]">
<P>LDL was reduced to a target of less than 130 mg per decilitre (3.36 mmol/L) by means of dietary intervention and lipid lowering therapy (usually with a statin)</P>
<P>
<B>Follow-up times: </B>median duration 3.3 years</P>
<P>
<B>Medication compliance:</B> P = 0.28</P>
<P>Control group: 93.6% with oestrogen matched placebo and 98.4% with progestin matched placebo</P>
<P>Oestrogen group: 92.6% with oestrogen and 99.9% with progestin matched placebo</P>
<P>Oestrogen-Progestin group: 94.1% with oestrogen and 96.1% with progestin</P>
<P>Participants were assessed with visits every month for the first six months and then every other month up until 36 months</P>
<P>Methods for verifying medication compliance by pill counts at study visits</P>
<P>The number who dropped out or swapped medication: not clear, though four participants used open-label oestrogen</P>
<P>The mean time since menopause that treatment was started for the study population overall was 18.2 years. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-06 13:15:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WEST-2001">
<CHAR_METHODS MODIFIED="2015-02-03 12:30:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective: </B>To determine whether 17ß-oestradiol reduces the risk of recurrent stroke or death among post-menopausal women who have experienced a transient ischaemic attack or non-disabling ischaemic stroke.</P>
<P> </P>
<P>Multicentre, randomised, controlled (RCT) trial involving 21 hospital sites in the United States. The trial was conducted from December 1993 to May1998, with a mean follow-up duration of 2.8 years ± 17 months. The primary outcome measures were the number of strokes or deaths that occurred, with further clinical events of MI, and TIA also reported.</P>
<P>Medical testing for patients at baseline included computerised tomography (CT) scan, clinical breast examination, electrocardiogram, and a pelvic examination including a Papanicolaou smear (in women who had not undergone a hysterectomy).  Additionally, neurological examination was performed by a trained nurse using the National Institutes of Health (NIH) Stroke Scale, and tests on physical and cognitive performance, including the Boston Naming Test, a test of digit span recall, category work list generation, a depression screen, the Mini-Mental Status Examination and a test of delayed spatial recognition were undertaken.</P>
<P>
<B>Recruitment:</B> Admissions to 20 largest regional hospitals in Connecticut and Massachusetts; also via contact with selected neurology groups and direct referrals from physicians</P>
<P>
<B>Screening:</B> 5296 screened for eligibility (2772 ineligible, 1843 declined to participate, 17 unable to be randomised within protocol time frame)</P>
<P>
<B>Randomisation:</B> Computer generated at pharmacy, in blocks of four</P>
<P>
<B>Stratification:</B> By trial centre and risk level (three levels)</P>
<P>
<B>Allocation:</B> By remote contact with trial pharmacy</P>
<P>
<B>Baseline equality of treatment groups</B>: No substantive differences between study groups at baseline</P>
<P>
<B>Blinding:</B> Participants, investigators and endpoint assessors blinded.  Study internist unblinded in the case of overriding concern about a woman&#8217;s clinical care</P>
<P>
<B>Analysis:</B> ITT</P>
<P>
<B>Funding Source:</B> National Institute of Neurological Disorders and Stroke grant, Medical Research Council of Canada grant. Mead Johnson laboratories provided support and study drug</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 11:23:57 +0000" MODIFIED_BY="[Empty name]">
<P>664 post-menopausal women (HT: n = 337; placebo: n = 327) with a mean age of 71.5 (SD: ± 10 years) who had undergone either a non-disabling ischaemic stroke or a transient ischaemic attack in the previous 90 days prior to recruitment. Post-menopausal status was defined as amenorrhoea for at least 12 months or, for women who had undergone a hysterectomy without oophorectomy, an oestradiol level less than 40 pg/mL and a follicle-stimulating hormone level over 40 mIU/mL. The number of women who had previously undergone a hysterectomy was 44.5%. 29.5% of the women had previously used oestrogen-replacement therapy.   </P>
<P>In terms of ethnic background included women were: 83.5% White; 13% Black; and 3.5% other (unspecified). 24% had a previous MI; 14.5% congestive heart failure; 7% atrial fibrillation; 73.5% hypertension; and 28% diabetes. 12.5% were current cigarette smokers, and the mean BMI among the women was 28 kg/m2 (SD: ± 6).</P>
<P>In terms of neurological characteristics: 18.5% had a history of stroke before the index (ischaemic or TIA) event, and 75% had a stroke as the index event.  In relation to summary risk stratum of the occurrence of another event  [based on a validated instrument that included the five clinical features of age, blood pressure, diabetes, cardiac disease, and index event (stroke versus TIA)] 12.5% of women were classified as low risk, 67% as medium risk, and 20.5% as high risk </P>
<P>
<B>Inclusion criteria:</B>
</P>
<UL>
<LI>Age over 45 years</LI>
<LI>post-menopausal (at least 12 months since cessation of menstrual periods)</LI>
<LI>a qualifying neurological event of TIA or non-disabling ischaemic stroke within 90 days of randomisation</LI>
</UL>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>estimated survival less than five years</LI>
<LI>history of breast or uterine cancer</LI>
<LI>an identical twin with breast cancer</LI>
<LI>severe psychiatric illness</LI>
</UL>
<P>Temporary exclusion criteria that had to be resolved by the time of randomisation were moderate to severe neurological disability, or clinical suspicion of breast or uterine cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-06 13:15:11 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen:</B> 1 mg 17ß-oestradiol daily (plus a course of 5 mg medroxyprogesterone acetate once a year for 12 days or annual transvaginal ultrasound [to screen for endometrial hyperplasia] for women with a uterus) plus standard care (continuous dosage regimen)</P>
<P>
<B>Comparator:</B> identical placebo capsule daily plus standard care</P>
<P> </P>
<P>The overall compliance with study intervention assessed by pill count at each visit (including women who discontinued treatment) was 60% (56% in the HT group and 64% in the placebo group).  Compliance among women who did not discontinue the study drug was 90% in both treatment groups. </P>
<P>
<B>Dropouts:</B> 34% of the HT group and 24% of the placebo group </P>
<P>
<B>Losses to follow-up:</B> Zero</P>
<P>
<B>Follow-up times:</B> Baseline and then every three-months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 11:07:00 +0000" MODIFIED_BY="[Empty name]">
<P>Death</P>
<P>Stroke</P>
<P>Death from CVD cause</P>
<P>Non-fatal MI</P>
<P>Secondary outcomes:-</P>
<P>Venous thromboembolism</P>
<P>Pulmonary embolism</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 12:20:10 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size calculations and recruitment of participants were adequate to allow for drop-outs, and able to provide the power to detect any statistically significant differences between the HT and placebo group in terms of the primary outcomes of interest.  The clinical events of interest were defined according to standard criteria and verified by a neurologist blinded to treatment allocation, or by objective measures of disease such as positive results on a duplex ultrasonogram or venogram for the diagnosis of VTE. All events were centrally corroborated, and sensitivity analyses undertaken to examine the effect of including only medication compliant patients in the analyses.  Study publication pools results for women on unopposed and combined therapies.  Vital status was confirmed for all women at the conclusion of the trial.</P>
<P>Data were not stratified according to time since menopause that treatment was started, however the mean time since menopause for the study population as a whole was 25 years. The age of each treatment group was 71 years (SD 10) for the control group and 72 years (SD 10) for the hormone group. For the subgroup analysis of when treatment was started the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-06 13:15:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WHI-I-2002">
<CHAR_METHODS MODIFIED="2015-02-03 12:30:20 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B> To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States</P>
<P> </P>
<P>Multicentre, randomised, placebo-controlled, primary prevention trial (RCT) involving 40 primary care sites in the United States. The trial recruitment was conducted from January 1993 to September 1998, with a mean follow-up of 5.2 years (range: 3.5 to 8.5); planned duration 8.5 years. The primary aim of the trial was to assess the effects of oestrogen in combination with progestin compared to placebo on disease incident rates of CHD, hip fractures and deaths from all causes.  The primary outcome measure was CHD events (defined as non-fatal MI and CHD death), with invasive breast cancer as the primary adverse outcome.   </P>
<P>Secondary outcomes included stroke (both fatal and non-fatal), pulmonary embolism, DVT, angina (both hospitalisation due to and confirmed), revascularisation (CABG or percutaneous coronary intervention (PCI) combined), death from all causes, as well as a global index of risks and benefits defined as time to the first event among CHD, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture or death due to other causes to summarise overall effects. </P>
<P>Late in 1999, the National Institutes of Health Data and Safety Monitoring Board (DSMB) observed small but consistent early adverse effects in cardiovascular outcomes and in the global index.  However, none of the disease specific monitoring boundaries had been crossed. These adverse CV effects continued throughout 2000 and 2001, but the trial continued because the balance of risks and benefits remained uncertain.  The trial was finally stopped early after a mean follow-up of 5.2 years in May 2002, when the DSMB found that the adverse effects in CVD persisted, although these remained within the monitoring boundaries, but the weighted log-rank test statistic for breast cancer had crossed the designated stopping boundary, and the global index was supportive of a finding of overall harm.  The trial was therefore terminated at the end of May 2002</P>
<P> </P>
<P>
<B>Recruitment:</B> Letter of invitation in conjunction with media awareness programme.  Sampling method gave women from minority groups six-fold higher odds for selection than Caucasian women and resulted in sample with 84% racially/ethnically designated &#8220;white&#8221;, 16% non-&#8220;white&#8221;</P>
<P>
<B>Screening:</B> Interested women screened by phone or mail for eligibility, then attended three screening visits for history, clinical examination and tests. Three-month washout period before baseline evaluation of women using post-menopausal hormones at baseline screening. Lead-in placebo pills given for at least four weeks during screening process to establish compliance with pill taking</P>
<P>
<B>Randomisation:</B> Centrally randomised by permuted block algorithm</P>
<P>
<B>Stratification:</B> By clinical centre site and age group</P>
<P>
<B>Allocation:</B> By local access to remote study database</P>
<P>
<B>Baseline equality of treatment groups:</B> No substantive differences between study groups at baseline</P>
<P>
<B>Blinding:</B> All participants, clinic staff, and outcome assessors blinded, with the exception of 331 participants who were unblinded from the unopposed oestrogen arm and reassigned to combined HT arm due to change in protocol</P>
<P>
<B>Analysis:</B> ITT</P>
<P>
<B>Funding Source: </B>The National Heart, Lung, and Blood Institute. Wyeth-Ayerst Research provided the study medication</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 12:10:11 +0000" MODIFIED_BY="[Empty name]">
<P>16,608 healthy post-menopausal women were randomised to receive either daily conjugated equine oestrogen in combination with progestin (n = 8506) or placebo (n = 8102). Post-menopausal was defined as no vaginal bleeding for six months (12 months for 50 to 54 years), or having ever used post-menopausal hormones.  The mean age of the women was 63.25 years [(SD: 7.1) (range: 50 to 79]. Age ratio of 33%: 45%: 21% for the baseline age categories of 50 to 59, 60 to 69, 70 to 79, respectively (enrolment targeted to achieve ratio of 30: 45: 25)</P>
<P> </P>
<P>Included women were 84% White, 7% Black, 5% Hispanic, 0.4% American Indian, 2.2% Asian/Pacific Islander, and 1.4 % unknown. In terms of previous hormone use: 74% were &#8216;never&#8217; HT users, 20% were past users and 6% were current users (therefore requiring a three-month washout period prior to randomisation).  70% of women had used HT &lt; five years, 18% for five to &lt; ten years, and 12% for &#8805; 10 years</P>
<P> </P>
<P>In terms of risk factors for CVD: 50% were never smokers, 39.5% were past smokers, and 10.5% were current smokers. The mean BMI among the women was 28.5 kg/m<SUP>2</SUP>; mean systolic blood pressure was 128 (SD: ± 17.5) mm Hg and mean diastolic blood pressure was 75.7 (SD: ± 9.1)</P>
<P> </P>
<P>The CHD manifestations within the groups were: 4.4% were being treated for diabetes, 36% for hypertension or BP &#8805; 140/90 mm Hg, 1.8%  had a previous MI, 2.9% had angina, 1.3% had undergone either CABG/PTCA surgery, 0.9% had suffered a previous stroke, and 0.9% had DVT or PE.&#8224;; 12.7% had elevated cholesterol levels requiring medication, 6.7% were using statins at baseline, and 19.6% aspirin</P>
<P> </P>
<P>
<B>Inclusion criteria: </B>
</P>
<UL>
<LI>age 50 to 79 years at initial screening</LI>
<LI>post-menopausal</LI>
<LI>likelihood of residence in the area for three years</LI>
<LI>informed consent </LI>
</UL>
<P> </P>
<P>
<B>Exclusion criteria: </B>
</P>
<UL>
<LI>invasive cancer in the past ten years</LI>
<LI>breast cancer at any time or suspicion of breast cancer at baseline screening</LI>
<LI>endometrial cancer or endometrial hyperplasia at baseline</LI>
<LI>malignant melanoma</LI>
<LI>acute MI, stroke, TIA or pulmonary embolism or deep vein thrombosis that was nontraumatic or that had occurred in the previous six months &#8224;</LI>
<LI>known chronic active hepatitis or severe cirrhosis</LI>
<LI>blood counts indicative of disease</LI>
<LI>bleeding disorder</LI>
<LI>lipaemic serum and hypertriglyceridaemia diagnosis</LI>
<LI>current use of anticoagulants or tamoxifen</LI>
<LI>PAP smear or pelvic abnormalities</LI>
<LI>severe hypertension</LI>
<LI>current use of oral corticosteroids</LI>
<LI>reasons of adherence or retention: severe menopausal symptoms inconsistent with assignment to placebo</LI>
<LI>inability or unwillingness to discontinue current HT use or oral testosterone use</LI>
<LI>inadequate adherence with placebo run-in</LI>
<LI>unwillingness to have baseline or follow-up endometrial aspirations</LI>
<LI>alcoholism</LI>
<LI>drug dependency</LI>
<LI>mental illness</LI>
<LI>dementia</LI>
</UL>
<P> </P>
<P>&#8224;  Prior to the publication of the results of HERS I in 1997, (which led to a change in the inclusion criteria) women with a history of venous thromboembolism (VTE) were eligible for inclusion. From this point onwards women with indicated prior VTE were excluded. At this point 171 women with a history of VTE had been enrolled into the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-06 13:15:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HRT regimens: </B>0.625 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate (MPA) daily</P>
<P> </P>
<P>
<B>Comparator: </B>identical placebo tablet daily</P>
<P>Medication adherence was defined as participants taking &gt; 80 study pills, and was monitored by weighing medication bottles at each clinic visit.  Medication adherence data for each trial year were not reported, but by the time of study termination 40% of women had stopped taking study medication (HRT: 42%; placebo: 38%). Therefore only 60% of women remained medication compliant.  At 5.2 years follow-up 6.2% of women in the HT arm had initiated hormone use through their own physician and 10.7%  of women in the placebo arm had also initiated hormone use (drop-in)</P>
<P>
<B>Follow-up times: </B>baseline, and then every six months. At baseline participants had a clinical examination, including breast and pelvic examination with Papanicolaou test and endometrial evaluation, a screening mammogram and standardised 12-lead electrocardiogram (ECG). Fasting total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were measured in a subsample of participants.  Annual examinations included mammograms and clinical breast examinations. ECG results were collected at three- and six-year follow-up.</P>
<P>Participant attrition rates were low. Over the 5.2 year follow-up 3.5% [total n = 583; (HRT: n = 307; placebo: n = 276)] women withdrew, were considered lost to follow-up, or stopped providing outcome data for more than 18-months. Vital status at the end of the trial was therefore known for 15,576 (96.5%) of randomised participants, including 580 (2.7%) known to be deceased</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 11:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes:</B>
</P>
<P>CHD (defined as acute MI requiring overnight hospitalisation, silent MI, or CHD death)</P>
<P>Death from CVD</P>
<P>Non-fatal MI (defined as acute MI requiring overnight hospitalisation, silent MI)</P>
<P>
<B>Secondary outcomes:</B>
</P>
<P>Death from any cause</P>
<P>Stroke (fatal and non-fatal combined)</P>
<P>Angina (confirmed)</P>
<P>Revascularisation (CABG or PCI combined)</P>
<P>Pulmonary embolisms</P>
<P>Venous thrombosis (pulmonary embolism plus DVT combined)</P>
<P>HRQoL not included in the analyses; length of follow-up: 5.6 years</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 12:20:30 +0000" MODIFIED_BY="[Empty name]">
<P>The sample size calculation was adequate so the trial was powered to detect differences between the HT and placebo groups in terms of CVD events, and adverse events. All outcomes were prespecified and defined <I>a prior, </I>and reported in the trial results. All study personnel, except the study gynaecologist were &#8216;blinded&#8217;.  The gynaecologist was &#8216;unblinded&#8217; if necessary to treatment group, but separate from the rest of the trial team, and therefore &#8216;blinding&#8217; is likely to have been maintained.  Participant attrition rates were very low at 3.5%.  However, medication compliance rates were low, with only 60% of women still medication compliant at 5.2 year follow-up.  This is likely to have &#8216;diluted&#8217; the true effects, both positive and negative, of the HT combination therapy compared to placebo relative to what might be observed with full medication adherence.  Additionally the trial was stopped early which would have further decreased the power to detect differences between the two trial arms, and reduced the precision of the estimated effects for the outcomes assessed.   </P>
<P>Events for this trial were reported stratified according to the time since menopause that treatment was started. This allowed accurate allocation of events, specifically: death, coronary heart disease (death from cardiovascular causes and non-fatal myocardial infarction), stroke and venous thromboembolism, to subgroup analysis according to whether treatment was started &lt; 10 years or &gt; 10 years after the menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-06 13:15:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WHI-II-2004">
<CHAR_METHODS MODIFIED="2015-02-03 11:40:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective: </B>To assess the effects on major disease incidence rates of the most commonly used post-menopausal HT in the United States </P>
<P>
<B>Trial type:</B> Multicentre randomised placebo controlled primary prevention trial (RCT) involving 40 primary care sites in the United States. The trial recruitment was conducted from January 1993 to September 1998, with a mean follow-up of 6.8 years (range: 5.7 to 10.7).  The primary aim of the trial was to assess the effects of oestrogen therapy compared to placebo on disease incident rates of CHD, hip fractures and deaths from all causes.  The primary outcome measure was CHD events (defined as acute MI requiring overnight hospitalisation, silent MI, or CHD death), with invasive breast cancer as the primary adverse outcome.  Secondary outcomes included stroke (both fatal and non-fatal), pulmonary embolism, DVT, angina (both hospitalisation due to and confirmed), revascularisation (CABG or PCI combined), death from all causes, as well as a global index of risks and benefits defined as time to the first event among CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, hip fracture or death due to other causes to summarise overall effects. </P>
<P>The trial was stopped early after a mean follow-up of 6.8 years when the National Institutes of Health (NIH) concluded that CEE alone did not appear to affect the risk of heart disease, but was associated with a significant increase in the risk of stroke, and given the likelihood that neither cardio-protection or breast cancer risk would be demonstrated in the remaining intervention period terminated the trial on March 1, 2004</P>
<P> </P>
<P>
<B>Recruitment:</B> Letter of invitation in conjunction with media awareness programme.  Sampling method gave women from minority groups six-fold higher odds for selection than Caucasian women and resulted in sample with 84% racially/ethnically designated &#8220;white&#8221;, 16% non-&#8220;white&#8221;</P>
<P>
<B>Screening:</B> Interested women screened by phone or mail for eligibility, then attended three screening visits for history, clinical examination and tests. Three-month washout period before baseline evaluation of women using post-menopausal hormones at baseline screening. Lead-in placebo pills given for at least four weeks during screening process to establish compliance with pill taking</P>
<P>
<B>Randomisation:</B> Centrally randomised by permuted block algorithm</P>
<P>
<B>Stratification:</B> By clinical centre site and age group</P>
<P>
<B>Allocation:</B> By local access to remote study database</P>
<P>
<B>Baseline equality of treatment groups:</B> No substantive differences between study groups at baseline</P>
<P>
<B>Blinding:</B> All participants, clinic staff, and outcome assessors blinded, with the exception of 331 participants who were unblinded from the unopposed oestrogen arm and reassigned to combined HT arm due to change in protocol</P>
<P>
<B>Analysis:</B> ITT</P>
<P>
<B>Funding Source: </B>The National Heart, Lung, and Blood Institute. Wyeth-Ayerst Research provided the study medication</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-06 13:15:13 +0000" MODIFIED_BY="[Empty name]">
<P>10,739 healthy post-menopausal women who had previously undergone hysterectomy with or without an oophorectomy (including 248 in experimental arm, 183 in placebo arm who joined this study after randomisation to corresponding arms in WHI 2002 having subsequently had a hysterectomy for reasons other than cancer) were randomised to receive either daily conjugated equine oestrogen (n = 5310) or placebo (n = 5429). The mean age of the women was 63.6 years [(SD: ± 7.3; range: 50 to 79)] (Age ratio of 33%: 45%: 21% for the baseline age categories of 50 to 59, 60 to 69, 70 to 79, respectively). Included women were 75% White, 15% Black, 6% Hispanic, 1% American Indian, 1.5% Asian/Pacific Islander, and 1.5% unknown. In terms of previous hormone use: 74% were &#8216;never&#8217; HT users, 20% were past users and 6% were current users (therefore requiring a three-month washout period prior to randomisation). 53% of women had used HRT &lt; five years, 19% for five to &lt; 10 years, and 18% for &#8805; 10 years. </P>
<P>In terms of risk factors for CVD: 51% were never smokers, 38.5% were past smokers, and 10.5% were current smokers. The mean BMI among the women was 28.5 kg/m<SUP>2 </SUP>(SD: ± 5.85); mean systolic blood pressure was 127.5 (SD: ±17.55) mm Hg and mean diastolic blood pressure was 75.7 (SD: ± 9.1). The CHD manifestations within the groups were: 4.4% were being treated for diabetes, 36% for hypertension or BP &#8805; 140/90 mm Hg, 1.6% had a previous MI, 2.9% had a history of angina, 1.3% had undergone either CABG/PTCA surgery, 0.85% had suffered a previous stroke, and 0.85% had a history of DVT or PE</P>
<P>
<B>Inclusion criteria:</B> </P>
<UL>
<LI>women age 50 to 79 years of age at initial screening</LI>
<LI>who had undergone a hysterectomy (thereby considered menopausal for enrolment purposes)</LI>
</UL>
<P>
<B>Exclusion criteria: </B>
</P>
<UL>
<LI>invasive cancer in the past ten years</LI>
<LI>breast cancer at any time or suspicion of breast cancer at baseline screening</LI>
<LI>endometrial cancer or endometrial hyperplasia at baseline</LI>
<LI>malignant melanoma</LI>
<LI>acute MI, stroke, TIA or pulmonary embolism</LI>
<LI>deep vein thrombosis that was non-traumatic or that had occurred in the previous six months</LI>
<LI>known chronic active hepatitis or severe cirrhosis</LI>
<LI>blood counts indicative of disease</LI>
<LI>bleeding disorder</LI>
<LI>lipaemic serum and hypertriglyceridaemia diagnosis</LI>
<LI>current use of anticoagulants or tamoxifen</LI>
<LI>papanicolaou smear or pelvic abnormalities</LI>
<LI>severe hypertension</LI>
<LI>current use of oral corticosteroids</LI>
<LI>bleeding disorder;</LI>
<LI>for reasons of adherence or retention: severe menopausal symptoms inconsistent with assignment to placebo</LI>
<LI>inability or unwillingness to discontinue current HT use or oral testosterone use</LI>
<LI>inadequate adherence with placebo run-in</LI>
<LI>unwillingness to have baseline or follow-up endometrial aspirations</LI>
<LI>alcoholism</LI>
<LI>drug dependency</LI>
<LI>mental illness</LI>
<LI>dementia</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 11:42:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimens: </B>0.625 mg conjugated equine oestrogen daily (CEE) (continuous dosage regimen)</P>
<P>
<B>Comparator: </B>identical placebo tablet daily</P>
<P>Medication adherence was defined as participants taking &gt; 80 study pills, and was monitored by weighing medication bottles at each clinic visit.  Medication adherence data for each trial year were not reported, but by the time of study termination 53.8% of women had stopped taking study medication. Therefore only 46.2% of women remained medication compliant. Compliance rates did not differ significantly between the two trial arms.  At 6.8 years follow-up 5.7% of women in the HT arm had initiated hormone use through their own physician and 9.1%  of women in the placebo arm had also initiated hormone use (drop-in)</P>
<P>
<B>Follow-up times: </B>Baseline, and then every six-month, with an annual clinic visit. At baseline participants completed a medical, reproductive history and psychosocial questionnaire; ECG, and underwent breast examination and gynaecological examination. Mammograms and breast examinations were repeated annually and ECGs were repeated at visit years three and six. </P>
<P>Participant attrition rates were low.  Over the 6.8 year follow-up 5.2% [total n = 563; (HT: n = 262; placebo: n = 301)] women withdrew [n = 321 (HT: n = 136; placebo: n = 185)] were considered lost to follow-up [n = 142 (HT: n = 126; placebo: n = 116)], or stopped providing outcome data for more than 18-months.  Vital status at the end of the trial was therefore known for 10,176 (94.8%) of randomised participants, including 580 (5.4%) known to be deceased</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 11:42:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes:</B>
</P>
<P>CHD (defined as acute MI requiring overnight hospitalisation, silent MI, or CHD death)</P>
<P>Death from CVD</P>
<P>Non-fatal MI (defined as acute MI requiring overnight hospitalisation, silent MI)</P>
<P>
<B>Secondary outcomes: </B>
</P>
<P>Death from any cause</P>
<P>Stroke (fatal and non-fatal combined)</P>
<P>Angina (confirmed)</P>
<P>Revascularisation (CABG or PCI combined)</P>
<P>Pulmonary embolisms</P>
<P>Venous thrombosis (pulmonary embolism plus DVT combined)</P>
<P>HRQoL not included in the analyses; length of follow-up: 7.1 years</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 12:20:44 +0000" MODIFIED_BY="[Empty name]">
<P>The sample size calculation was adequate so the trial was powered to detect differences between the HT and placebo groups in terms of CVD events.  All outcomes were prespecified and defined <I>a prior, </I>and reported in the trial results. All study personnel, except the study gynaecologist were &#8216;blinded&#8217;. The gynaecologist was &#8216;unblinded&#8217; if necessary to treatment group, but separate from the rest of the trial team, and therefore &#8216;blinding&#8217; is likely to have been maintained.  Participant attrition rates were low at 5.2%.  However, medication compliance rates were low, with only 46.2% of women still medication compliant at 6.8 years follow-up.  This is likely to have &#8216;diluted&#8217; the true effects, both positive and negative, of oestrogens relative to placebo relative to what might be observed with full medication adherence.  Additionally, the trial was stopped early which would have further decreased the power to detect differences between the two trial arms, and reduced the precision of the estimated effects for the outcomes assessed. </P>
<P>Events for this trial were reported stratified according to the time since menopause that treatment was started. This allowed accurate allocation of events, specifically: death, coronary heart disease (death from cardiovascular causes and non-fatal myocardial infarction), stroke and venous thromboembolism, to subgroup analysis according to whether treatment was started &lt; 10 years or &gt; 10 years after the menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-03 11:47:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WHISP-2006">
<CHAR_METHODS MODIFIED="2015-02-03 11:43:56 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre, randomised, controlled, pilot study involving 17 centres in UK. The trial was run from October 1999 to October 2002 and was designed to test effect of oral oestradiol-17&#946; 1 mg plus norethisterone acetate 0.5 mg daily, or matching placebo, on lipids, lipoproteins and haemostasis markers in post-menopausal women who had recently had an acute coronary syndrome [ACS]</P>
<P>
<B>Recruitment: </B>Not reported</P>
<P>
<B>Screening: </B>Not reported</P>
<P>
<B>Randomisation: </B>Randomised by telephone call to the co-ordinating centre</P>
<P>
<B>Stratification: </B>By centre</P>
<P>
<B>Allocation: </B>Blinded treatment pack allocated to participant</P>
<P>
<B>Baseline equality of treatment groups: </B>No substantive differences between treatment groups</P>
<P>
<B>Blinding: </B>Staff and participants were blinded</P>
<P>
<B>Analysis: </B>Primary outcome of lipid level analysed according to last recorded level carried through for participants who were lost to follow-up. For the outcomes of this review reported as adverse events these were analysed in an ITT manner</P>
<P>
<B>Funding Source: </B>UK MRC and Novo Nordisk</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 11:46:25 +0000" MODIFIED_BY="[Empty name]">
<P>100 postmenopausal women &gt; 55 years who were enrolled 2-28 days post-ACS</P>
<P>The mean age of participants was: 69.4 years in the HT group (SD 8.6), 68.3 years in the placebo group (SD 9.0)</P>
<P>Years since menopause: 21.6 years in the HT group (interquartile range 15.8to 29.9) [HT], 23.9 years in the placebo group(interquartile range 13.8 to 30.5)</P>
<P>
<B>CVS Risk Factors</B>
</P>
<P>BMI: 26.0 (SD 3.9) [HT], 26.4 (SD 4.7) [placebo]</P>
<P>Smoking (current): 17 (34.7%) [HT], 13 (25.5%) [placebo]</P>
<P>Smoking (ex): 14 (28.6%) [HT], 19 (37.2%) [placebo]</P>
<P>Smoking (never): 18 (36.7%) [HT], 19 (37.2%) [placebo]</P>
<P>Diabetes: 37 (75.5%) [HT], 40 (78.4%) [placebo]</P>
<P>
<B>Inclusion criteria:</B>
</P>
<UL>
<LI>Post-menopausal women (amenorrhoea for &gt; 12 months or women with hysterectomy &gt; 12 months oestrogen deficiency symptoms or aged &gt; 55</LI>
</UL>
<UL>
<LI>&gt; 48 hours and &lt; 28 days after admission with ACS (MI or unstable angina), plus at least one of the following:</LI>
</UL>
<P>elevated cardiac enzymes (CK or AST twice upper limit or CKMB or troponin above the threshold considered diagnostic for myocardial damage in that centre), changes on the electrocardiogram (ECG) supportive of a diagnosis of acute myocardial ischaemia, prior history of CHD documented by history of prior MI or prior revascularisation or angiography showing &gt; 50% stenosis in at least one major epicardial coronary artery</P>
<UL>
<LI>Provision of written informed consent</LI>
</UL>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>Women for whom the diagnosis of ACS is not confirmed at the time they are considered for randomisation</LI>
<LI>Use of HT currently or within the previous 12 months (except for vaginal oestrogen use)</LI>
<LI>Patients for whom there are clear indications for, or contraindications to, long-term HT</LI>
<LI>Increased risk of thromboembolism</LI>
<LI>Prior history of deep venous thrombosis or pulmonary embolus</LI>
<LI>BMI &gt; 32 kg/m2</LI>
<LI>Prolonged immobility or bed rest</LI>
<LI>Known breast or endometrial cancer</LI>
<LI>Post-menopausal bleeding that has not been adequately investigated prior to the start of the study</LI>
<LI>Presence of non-cardiac condition influencing survival</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-03 11:47:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen: </B>continuous combined oral oestradiol-17&#946; 1 mg plus norethisterone acetate 0.5 mg daily</P>
<P>
<B>Comparator:</B> placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 11:46:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes</B>: lipid profile, markers of coagulation and fibrinolysis</P>
<P>
<B>Secondary outcomes: </B>feasibility of enrolment and safety and tolerability of HRT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 11:47:01 +0000" MODIFIED_BY="[Empty name]">
<P>Methods for verifying medication compliance: checked every three months in clinic, not specified how.</P>
<P>Follow-up duration was planned for 12 months, but was reported to be a median of seven months.</P>
<P>Events were not stratified according to time since menopause. However the median time since menopause that treatment was started was reported for each group, 23.9 years (interquartile range 13.8 to 30.5) for the control group and 21.6 years (interquartile range 15.8 to 29.9) for the hormone group. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-06 13:15:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WISDOM-2007">
<CHAR_METHODS MODIFIED="2015-03-06 13:15:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Objective:</B>  To assess the long-term benefits and risks of HT</P>
<P>Multicentre three-armed randomised controlled (RCT) trial involving 499 general practices; (n = 385 UK); (n = 91 Australia) and (n = 24) New Zealand.</P>
<P>The trial was conducted between 1999 - 2002, with an intended follow-up period of ten-years. The trial was halted early after the publication of the results from <LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>, which showed no statistically significant benefit for treatment with HT compared with placebo. The median follow-up time was 11.9 months (interquartile range: 7.1 to 19.6) for the entire trial participants and 12.8 months (range: 7.5 to 20.4 ) months for participants randomised to combination therapy.  The trial was composed of three different strata:</P>
<P>Strata 1: Women with an intact uterus or sub-total hysterectomy not taking HT randomised to combined oestrogen and progesterone therapy or placebo</P>
<P>Strata 2: Hysterectomised women taking HT and randomised to oestrogen only HT or combined HT</P>
<P>Stratum 3: Hysterectomised women not taking HT randomised to oestrogen only HT or combined HT or placebo</P>
<P>The design therefore allowed for two main comparisons to be made: (1) combined oestrogen and progestogen therapy versus placebo, and in women who had a hysterectomy, (2) oestrogen alone versus combination oestrogen and progestogen therapy</P>
<P>Only the baseline demographic data and results from strata 1 are reported within this report, as this was the only comparison of HT versus placebo within the trial</P>
<P> </P>
<P>
<B>Recruitment:</B>  Practice registries</P>
<P>
<B>Screening:</B> 14,203 screened for eligibility All women took placebo medication during run in: those who achieved 80% compliance were randomised</P>
<P>
<B>Randomisation:</B> Remote computer-generated</P>
<P>
<B>Stratification:</B> By hysterectomy status and intended use of HT: women with no uterus and unwilling to take placebo randomised to CEE or combined HT. Equal probability of any treatment within each stratum</P>
<P>
<B>Allocation:</B> Remote computer-generated</P>
<P>
<B>Baseline equality of treatment groups:</B>  No substantive differences at baseline</P>
<P>
<B>Blinding:</B> All participants, clinic staff, and outcome assessors blinded except when vaginal bleeding triggered a code break</P>
<P>
<B>Analysis:</B> ITT</P>
<P>
<B>Funding Source:</B> Non-commercial medical research funding</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-03 12:08:13 +0000" MODIFIED_BY="[Empty name]">
<P>4385 healthy women in strata one (out of a total of 5692 women randomised) were randomised to either combined HT or placebo</P>
<P> </P>
<P>The mean age of the women was 63.3 years (SD: 4.7), with a mean of 14.7 years (SD: 7.1) since menopause. Post-menopausal status was defined as the presence of no menses in the past 12 months or having undergone a hysterectomy. Women taking HT at baseline screening, who were prepared to enter the placebo controlled strata of the study, ceased therapy for three months before the run-in phase.  During run-in they took placebo so that at randomisation they had not taken HT for six months</P>
<P>At baseline, 9% of women were taking oestrogen, and therefore underwent a three-month &#8216;wash out &#8216;period prior to randomisation.</P>
<P>2% of the included women were of non-white ethnic status; 18% were using HT at screening and 86% had previously used HT. In terms of risk factors for CVD: mean BMI was 28.0 kg/m<SUP>2</SUP>; mean systolic blood pressure was 136.5 mm Hg and mean diastolic blood pressure 73 mm Hg; 24% were current smokers; 55% were former smokers; 10% had previous angina; 3% had a previous MI; 3% had a previous stroke and 7% had diabetes. Inclusion criteria: Stated above, but only women who were 80% or more medication compliant in the run-in period were eligible for participation in the trial</P>
<P>
<B>Exclusion criteria:</B>
</P>
<UL>
<LI>for the placebo-controlled group oral transdermal HT use in the last six months</LI>
<LI>ever use of HT implant in women with a uterus</LI>
<LI>HT implant inserted in last eight months in women with a hysterectomy</LI>
<LI>history of endometriosis or endometrial hyperplasia in a woman with a uterus</LI>
<LI>history of invasive breast cancer, lobular carcinoma in situ (LCIS), ductal carcinoma in-situ (DCIS), Paget's disease of the nipple or atypical hyperplasia of the breast; BRCA1 or BRCA2 mutation carrier</LI>
<LI>history of melanoma</LI>
<LI>invasive cancer at any other site apart from basal and squamous cell skin cancer within the last ten years</LI>
<LI>history of meningioma, myocardial infarction, cerebrovascular accident, subarachnoid haemorrhage or transient ischaemic attack within the last six months</LI>
<LI>history of currently active liver disease or chronic liver disease but excluding Hepatitis A unless currently active</LI>
<LI>severe renal impairment</LI>
<LI>gall bladder disease in a woman who had not had a cholecystectomy or of gallstones following a cholecystectomy</LI>
<LI>deep vein thrombosis, pulmonary embolism or retinal vein occlusion</LI>
<LI>positive thrombophilia screen (Factor V Leiden or prothrombin mutations, Protein C, Protein S or antithrombin III deficiencies, APC resistance, dysfibrinogenaemia or antiphospholipid antibodies)</LI>
<LI>otosclerosis</LI>
<LI>porphyria</LI>
<LI>currently pregnant or taking contraceptive drugs in the last 12 months</LI>
<LI>current triglyceride level (fasting) &gt; 5.5 mmol/L</LI>
<LI>active participant in any other intervention trial likely to affect trial outcomes</LI>
<LI>taking tamoxifen, toremifene, raloxifene or any other selective oestrogen receptor modulator (SERM)</LI>
</UL>
<UL>
<LI>history of hepatitis B, hepatitis C or HIV (not an exclusion criteria in New Zealand)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-06 13:15:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>HT regimen:</B> 0.625 mg conjugated equine oestrogen in combination with 2.5 mg medroxyprogesterone acetate (MPA) daily (continuous dosage regimen)</P>
<P>
<B>Comparator: </B>placebo tablet daily</P>
<P>Participants were classified as medication compliant if they took &#8805; 80% of their medication throughout the trial. Trial treatment delivered 73% of time to women in combined HT arm and 86% of time to women on placebo</P>
<P> </P>
<P>
<B>Follow-up  times:</B> four, 14, 27, 40 and 52 weeks and then at six-month intervals.  At baseline recent cervical screening and mammography were checked and then at each follow-up visit information was collected on all outcomes (none of the outcomes were defined), adverse events and patients other medical history</P>
<P>
<B>Losses to follow-up:</B> five</P>
<P>
<B>Dropouts:</B> 615 (14%) had withdrawn from randomised treatment by trial closure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-03 11:50:29 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Death from CVD</P>
<P>Angina</P>
<P>Non-fatal MI</P>
<P>Fatal MI</P>
<P>Secondary outcomes:</P>
<P>Pulmonary embolism</P>
<P>Venous thromboembolism </P>
<P>Health-related quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 11:50:38 +0000" MODIFIED_BY="[Empty name]">
<P>Powered in protocol to detect 25% reduction in CHD over ten years. This assumed an 18,000 sample size but trial stopped early with 26% of target<BR/>A further 1307 women were in comparison of combined therapy vs oestrogen only and not included in this review.</P>
<P>Events were not stratified according to time since menopause. However the mean time since menopause that treatment was started was reported for each group, 14.7 years (SD 7.1) for the control group and 14.8 years (SD 7.2) for the hormone group. For the subgroup analysis of when treatment was started, the entirety of events in this study were analysed as if all participants had started treatment more than 10 years after their menopause</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-02-05 22:30:44 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-10-28 10:15:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aitken-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 10:15:10 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 10:15:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aloia-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 10:15:25 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 10:15:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Angerer-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 10:15:33 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Angerer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:03 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-09 16:41:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bui-Minh-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-09 16:41:52 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient follow-up duration and no relevant outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CHART-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:06 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:51:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christensen-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:51:55 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:51:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christiansen-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:51:58 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christiansen-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:00 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 09:59:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christiansen-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 09:59:46 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-07 15:29:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-07 15:29:55 +0000" MODIFIED_BY="[Empty name]">
<P>Wrong intervention. Transdermal patches used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coope-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>Study population not post-menopausal and not generalisable population as majority recruited suffered from depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:15 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only; did not report relevant clinical outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:12 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-25 18:38:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Enderle-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-25 18:38:27 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review and insufficient follow-up duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallagher-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:24 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Genant-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:26 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Genant-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:21 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grady-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:32 +0000" MODIFIED_BY="[Empty name]">
<P>Letter commenting on historical studies, no new data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hart-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:24 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hassager-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:41 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heikkinen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:30 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herrington-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:44 +0000" MODIFIED_BY="[Empty name]">
<P>Review article, no new data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:52:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HERS-II">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:52:46 +0000" MODIFIED_BY="[Empty name]">
<P>This trial was the long-term open label follow-up phase of <LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>, and therefore not included as a separate trial, as done in the original review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-08 21:37:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holmberg-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-08 21:37:25 +0000" MODIFIED_BY="[Empty name]">
<P>Wrong patient population: trial is of women with breast cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HOPE-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:34 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hsia-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:42 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-09 10:51:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hsia-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-09 10:51:28 +0000" MODIFIED_BY="[Empty name]">
<P>WHI: combination trial with 5.6 year follow-up; reports peripheral arterial disease outcomes only. No relevant clinical outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-08 21:38:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-08 21:38:32 +0000" MODIFIED_BY="[Empty name]">
<P>No clinically relevant data reported. Reports number of hot flushes by year and treatment group in the HERS 1 trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-25 18:38:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Itoi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-25 18:38:46 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review and no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:53:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jensen-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:53:04 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karim-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:50 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:53 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-03 09:34:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Komulainen-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-03 09:34:43 +0100" MODIFIED_BY="[Empty name]">
<P>No clear placebo comparison</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:51:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lamon_x002d_Fava-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:51:58 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:52:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lamon_x002d_Fava-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:52:01 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:52:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leggate-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:52:03 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:53:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindsay-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:53:19 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:52:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madsen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:52:13 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-09 10:52:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marsden-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-09 10:52:01 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract for a trial to be undertaken</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:53:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Molander-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:53:26 +0000" MODIFIED_BY="[Empty name]">
<P>Length of follow-up insufficient</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-09 10:52:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moriyama-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-09 10:52:16 +0000" MODIFIED_BY="[Empty name]">
<P>Wrong comparison. HT compared with either being physically active or sedentary, and being active or sedentary compared to placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-09 10:52:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mosca-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-09 10:52:52 +0000" MODIFIED_BY="[Empty name]">
<P>Wrong intervention (Raloxifene) and outside the scope of the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-09 10:53:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nair-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-09 10:53:04 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant clinical outcomes reported. Examination of relationship between baseline brachial pulse pressure and CV outcomes in HERS I</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-08 21:39:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neuhouser-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-08 21:39:38 +0000" MODIFIED_BY="[Empty name]">
<P>Does not report results for HT or placebo users separately from all women randomised to take vitamins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-10 09:15:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nikolov-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-10 09:15:20 +0100" MODIFIED_BY="[Empty name]">
<P>Review article no new data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-10 10:17:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nordin-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-10 10:17:40 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong population (included pre-menopausal women), insufficient duration of treatment and non-relevant outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 10:17:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Obel-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 10:17:59 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:50:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-OPAL-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:50:46 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:53:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pagliaro-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:53:57 +0000" MODIFIED_BY="[Empty name]">
<P>Wrong intervention. Transdermal patches used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:50:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PEPI-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:50:54 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:52:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinkerton-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:52:26 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:50:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Post-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:50:50 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 08:55:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prentice-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 08:55:12 +0000" MODIFIED_BY="[Empty name]">
<P>WHI: outcomes for breast cancer for both the oestrogen alone and combination trials. No relevant outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 08:55:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prentice-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 08:55:13 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant clinical outcomes reported. WHI: outcomes for breast cancer for both the oestrogen alone and combination trials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:54:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riggs-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:54:12 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:52:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SMART_x002d_5-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:52:32 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:54:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soma-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:54:19 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review and not a randomised control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:52:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steiner-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:52:44 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:52:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stevenson-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:52:46 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:54:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svendsen-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:54:24 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-08 21:41:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Toh-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-08 21:41:06 +0000" MODIFIED_BY="[Empty name]">
<P>Effect of HT in WHI compared with The Nurses Health Study.  The outcome is not clear and defined, just stated as CHD risk</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:52:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tuppurainen--1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:52:53 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-10 09:10:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ulloa-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-10 09:10:22 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant clinical outcomes and insufficient follow-up duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:54:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walter-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:54:32 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:53:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WHIMS-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:53:01 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 11:54:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wimalawansa-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 11:54:38 +0000" MODIFIED_BY="[Empty name]">
<P>Percutaneous HRT, no oral HRT intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:53:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeboah-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:53:07 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 13:53:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ylikorkala-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-28 13:53:11 +0000" MODIFIED_BY="[Empty name]">
<P>No outcomes relevant to this review and no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00154180">
<CHAR_METHODS MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised placebo controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<P>Recently menopausal healthy women (within 36 months of menses)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<P>0.45 mg oral oestrogen weekly with 200 mg cyclic oral, micronised progesterone for 12 days each month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<P>Rate of change of carotid intimal medial thickness by ultrasound; Cognitive and Affective scores; health related quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]">
<P>Sponsor:  Kronos Longevity Research Institute</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-03-03 14:48:36 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-04-25 15:21:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00114517">
<CHAR_STUDY_NAME MODIFIED="2013-02-07 15:24:14 +0000" MODIFIED_BY="[Empty name]">
<P>Early versus Late Intervention Trial with Estradiol (ELITE)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-07 15:24:23 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised placebo controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-06 14:39:54 +0000" MODIFIED_BY="[Empty name]">
<P>Post-menopausal healthy women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 18:52:29 +0000" MODIFIED_BY="[Empty name]">
<P>17&#946;-oestradiol versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-07 15:24:47 +0000" MODIFIED_BY="[Empty name]">
<P>Atherosclerotic progression and cognition</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-04-25 15:21:21 +0100" MODIFIED_BY="[Empty name]">
<P>2005 to 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-02-07 15:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>Principal Investigator: Howard N. Hodis, MD; University of Southern California, Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-02-07 15:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>Additional information: USC Atherosclerosis Research Unit ELITE Trial</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-02-03 12:28:37 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-02-03 11:47:13 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 07:22:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DOPS-2012">
<DESCRIPTION>
<P>Sequence generation was undertaken using stratified (study centre) blocked (n = 10) computer generated randomisation </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 11:55:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EAGAR-2006">
<DESCRIPTION>
<P>Method of sequence generation was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 11:29:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPAT-2001">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 14:16:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPHT-2006">
<DESCRIPTION>
<P>Remotely randomised in permuted blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 15:34:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ERA-2000">
<DESCRIPTION>
<P>Computerised in random blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-26 13:00:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ERT-II-1979">
<DESCRIPTION>
<P>Pairs of participants were matched for age and diagnosis. Research nurse randomly selected which of the pair would be assigned to the treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 16:11:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2002">
<DESCRIPTION>
<P>List of random numbers generated by trial statistician in blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-18 15:48:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVTET-2000">
<DESCRIPTION>
<P>Computer-generated 1:1 block randomisation with fixed block sizes of ten</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 08:12:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenspan-2005">
<DESCRIPTION>
<P>Randomised lists were prepared by the study statistician. Randomisation was stratified by prior hysterectomy and three levels of total hip bone mineral density to ensure balance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 08:14:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HALL-1998">
<DESCRIPTION>
<P>Methods of randomisation not reported; imbalance in baseline participant characteristics between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 21:07:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERS-I-1998">
<DESCRIPTION>
<P>Computer-generated random numbers in blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-16 14:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STOP-IT-2001">
<DESCRIPTION>
<P>Used a simple randomisation strategy stratified on hysterectomy status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 22:09:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAVE-2002">
<DESCRIPTION>
<P>Computer randomised, permuted block design with random blocks of two and four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 11:22:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WELL_x002d_HART-2003">
<DESCRIPTION>
<P>Stratification according to the presence or absence of diabetes</P>
<P>Randomisation with the use of a computerised random-number generator</P>
<P>Adaptive randomisation was used for imbalances among the treatment groups in the total cholesterol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:39:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WEST-2001">
<DESCRIPTION>
<P>Computer-generated at pharmacy, in blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-28 14:29:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-I-2002">
<DESCRIPTION>
<P>Centrally randomised by permuted block algorithm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-27 15:14:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-II-2004">
<DESCRIPTION>
<P>Centrally randomised by permuted block algorithm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 11:47:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHISP-2006">
<DESCRIPTION>
<P>Telephone call to co-ordinating centre and stratified randomisation (blocks of four)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 12:13:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WISDOM-2007">
<DESCRIPTION>
<P>Remote computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-02-03 11:22:51 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 07:22:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DOPS-2012">
<DESCRIPTION>
<P>States open-label meaning that allocation was not concealed but later in the paper states used sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 11:13:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EAGAR-2006">
<DESCRIPTION>
<P>Methods of allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 11:29:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPAT-2001">
<DESCRIPTION>
<P>Blinded medication packets assigned sequentially and remotely after eligibility confirmed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 14:16:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPHT-2006">
<DESCRIPTION>
<P>Non-transparent sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 15:34:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ERA-2000">
<DESCRIPTION>
<P>Computer displayed treatment assignment<BR/>after eligible participant details entered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 08:02:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ERT-II-1979">
<DESCRIPTION>
<P>&#8220;a serious attempt was made to prevent the research physicians from knowing&#8221; however the code was broken in major medical complications 13 times (HRT) and 17 times (control). However the research nurse who did the allocating was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 16:11:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2002">
<DESCRIPTION>
<P>Women assigned consecutively to numbers kept on list accessible to statistician only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 16:29:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EVTET-2000">
<DESCRIPTION>
<P>Method of allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 20:26:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greenspan-2005">
<DESCRIPTION>
<P>Block sizes (four, eight or 12) were randomly determined to enhance blinding of study staff. Further methods of allocation concealment are not reported. Also randomisation methods were prepared by the study statistician with participants randomised by the research pharmacist. Both were involved later in the study so may introduce bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 08:14:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HALL-1998">
<DESCRIPTION>
<P>Methods of allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 21:07:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERS-I-1998">
<DESCRIPTION>
<P>Computer displayed after participant details entered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-16 16:38:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STOP-IT-2001">
<DESCRIPTION>
<P>An independent statistical group performed blinding and randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 22:10:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAVE-2002">
<DESCRIPTION>
<P>Remotely by phone call to study coordinating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 11:22:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WELL_x002d_HART-2003">
<DESCRIPTION>
<P>Data co-ordinating centre performed randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:39:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WEST-2001">
<DESCRIPTION>
<P>By remote contact with trial pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-28 14:29:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-I-2002">
<DESCRIPTION>
<P>By local access to remote study database</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-27 15:14:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-II-2004">
<DESCRIPTION>
<P>By local access to remote study database</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-16 15:41:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHISP-2006">
<DESCRIPTION>
<P>Telephone call to separate centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 12:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WISDOM-2007">
<DESCRIPTION>
<P>Remote computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-02-03 12:25:52 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-02-03 07:22:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DOPS-2012">
<DESCRIPTION>
<P>Open-label trial in which participants and study personnel knew the treatment arm to which patients were randomised </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-02 11:56:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EAGAR-2006">
<DESCRIPTION>
<P>Blinding of participants and study personnel not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-20 14:01:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPAT-2001">
<DESCRIPTION>
<P>Participants, gynaecologists, clinical staff, image analysts, the data monitor and data analyst were blinded to treatment assignment until analyses were completed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-02 14:16:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPHT-2006">
<DESCRIPTION>
<P>Participants and investigators blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-02 15:35:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ERA-2000">
<DESCRIPTION>
<P>Participants and clinicians blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-02-03 08:02:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ERT-II-1979">
<DESCRIPTION>
<P>Matched placebo used, so participants likely blinded. No prespecified outcomes but physicians unblinded if participants became ill and therefore adverse event diagnosis and reporting is likely performed by unblinded assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-02 16:11:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2002">
<DESCRIPTION>
<P>Participants and clinicians blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-02 16:32:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVTET-2000">
<DESCRIPTION>
<P>Participants and study personnel blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-02-03 12:25:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenspan-2005">
<DESCRIPTION>
<P>Double-blinded but not further specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-02-03 08:14:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HALL-1998">
<DESCRIPTION>
<P>Blinding of participants and study personnel not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-02 21:08:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERS-I-1998">
<DESCRIPTION>
<P>Participants, clinical centre staff, data analysts<BR/>and funders blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-02-03 11:15:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STOP-IT-2001">
<DESCRIPTION>
<P>States double-blind, staff and investigators blinded throughout treatment period. Also used placebo but no description is provided. An independent statistical group performed blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-02 22:10:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAVE-2002">
<DESCRIPTION>
<P>Participants, investigators and staff at clinical centres blinded except (when necessary) the study gynaecologist</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-26 11:42:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WELL_x002d_HART-2003">
<DESCRIPTION>
<P>Participants, gynaecologists and clinical staff were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:40:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WEST-2001">
<DESCRIPTION>
<P>Participants and investigators blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-01-28 14:29:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-I-2002">
<DESCRIPTION>
<P>All participants and clinic staff blinded, with the exception of 331 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-01-28 14:29:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-II-2004">
<DESCRIPTION>
<P>All participants and clinic staff blinded, with the exception of 331 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-16 15:41:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHISP-2006">
<DESCRIPTION>
<P>States double-blind and placebo-controlled. A blinded treatment pack was allocated to patients. Not stated if personnel assessing outcome were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 12:14:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WISDOM-2007">
<DESCRIPTION>
<P>All participants and clinic staff blinded except when vaginal bleeding triggered a code break</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-02-03 12:25:59 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-03 07:22:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DOPS-2012">
<DESCRIPTION>
<P>PROBE (prospectively randomised, open with blinded endpoint evaluation) design was used to assess endpoints but not say who endpoint assessors were</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-02 11:56:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EAGAR-2006">
<DESCRIPTION>
<P>Blinding of outcome assessors not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-18 14:40:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPAT-2001">
<DESCRIPTION>
<P>Adverse events and bleeding were assessed by the study gynaecologist who was blinded to treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-02 14:17:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPHT-2006">
<DESCRIPTION>
<P>Outcome assessment blinded apart from for cancer outcomes </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-02 15:35:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ERA-2000">
<DESCRIPTION>
<P>Outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-03 08:02:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ERT-II-1979">
<DESCRIPTION>
<P>No prespecified outcomes but physicians unblinded if participants became ill and therefore adverse event diagnosis and reporting is likely performed by unblinded assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-02 16:11:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2002">
<DESCRIPTION>
<P>Outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-02 16:32:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVTET-2000">
<DESCRIPTION>
<P>Blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-16 14:26:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenspan-2005">
<DESCRIPTION>
<P>Double-blinded, including those who assessed outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-03 08:14:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HALL-1998">
<DESCRIPTION>
<P>Blinding of outcome assessors not reported, but may not influence ascertainment of outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-02 21:08:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERS-I-1998">
<DESCRIPTION>
<P>Outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-03 12:25:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STOP-IT-2001">
<DESCRIPTION>
<P>&#8220;Double-blinded&#8221; but unspecified how</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-02 22:10:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAVE-2002">
<DESCRIPTION>
<P>Participants, investigators and staff at clinical centres blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-26 11:42:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WELL_x002d_HART-2003">
<DESCRIPTION>
<P>Image analysts were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 11:40:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WEST-2001">
<DESCRIPTION>
<P>Endpoint assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-28 14:29:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-I-2002">
<DESCRIPTION>
<P>Outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-27 15:18:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-II-2004">
<DESCRIPTION>
<P>Outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-16 15:41:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WHISP-2006">
<DESCRIPTION>
<P>Staff were blinded. Not stated if personnel assessing outcome were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 12:14:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WISDOM-2007">
<DESCRIPTION>
<P>All outcome assessors blinded except when vaginal bleeding triggered a code break</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="GROUP" MODIFIED="2015-02-03 11:50:52 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-05.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 07:22:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DOPS-2012">
<DESCRIPTION>
<P>Attrition rates very low, with censoring unlikely to be related to patient outcome status. Study used intention-to-treat analysis. No participants were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 07:29:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EAGAR-2006">
<DESCRIPTION>
<P>Data complete for clinical outcomes/events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 07:34:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPAT-2001">
<DESCRIPTION>
<P>33 women were not able to be evaluated for primary (physiological) study endpoints, but clinical endpoints were reported for all by intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-11-20 14:03:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EPHT-2006">
<DESCRIPTION>
<P>Analysed by intention to treat. However, stated participation rates differ across trial publications</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 07:56:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ERA-2000">
<DESCRIPTION>
<P>No losses to follow-up for clinical adverse events. Analysed by ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-04-26 13:02:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ERT-II-1979">
<DESCRIPTION>
<P>All participants included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 08:05:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2002">
<DESCRIPTION>
<P>No losses to follow-up, analysed by ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2014-05-23 18:22:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-EVTET-2000">
<DESCRIPTION>
<P>The main findings were not reported by ITT, as drop-outs from the placebo group were not included in the denominator for the rate of recurrent thromboembolism</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 08:12:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenspan-2005">
<DESCRIPTION>
<P>No prior published design paper. All outcomes specified in current paper were reported. Analyses were performed on intention-to-treat basis. No drop outs were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 08:14:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-HALL-1998">
<DESCRIPTION>
<P>Analyses do not appear to be undertaken on an ITT basis, it is unclear whether withdrawals were included in the analyses, and no statistical tests for between group differences conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-02-02 21:09:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERS-I-1998">
<DESCRIPTION>
<P>Vital status known for all women at end of trial. 59 women did not complete follow-up (32 in experimental arm, 27 in placebo<BR/>arm). Analysed by intention to treat</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 11:15:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STOP-IT-2001">
<DESCRIPTION>
<P>The number of participants stopping their study medication was modest with similar rates in both the intervention and placebo groups. The primary outcome was assessed on an intention-to-treat analysis basis. 73 participants did not complete the study (11 in placebo group, 22 in calcitriol group, 20 in HT group and 20 in HT + calcitriol group); the reasons for not completing were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2013-03-18 15:54:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAVE-2002">
<DESCRIPTION>
<P>Losses to follow-up five (three in HT group, two in placebo group), 98% of women analysed by intention to treat</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 11:22:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WELL_x002d_HART-2003">
<DESCRIPTION>
<P>44 participants dropped out between different treatment groups but in comparable numbers between groups (11 in the control group, 17 in the oestrogen group and 16 in the oestrogen-progestin group). The reasons for dropping out included: death (n = 5), medical problems (n = 7), open-label use of oestrogen therapy (n = 4), loss of follow-up (n = 5) and personal reasons (n = 23)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 11:35:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WEST-2001">
<DESCRIPTION>
<P>No losses to follow-up, analysed by ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 11:38:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-I-2002">
<DESCRIPTION>
<P>583 participants (3.5%) withdrew, were lost to follow-up, or stopped providing outcome information for more than 18 months Analysis conducted on ITT basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 11:43:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-II-2004">
<DESCRIPTION>
<P>563 participants (5.2%) withdrew, were lost to follow-up, or stopped providing outcome information for more than 18 months Analysis conducted on ITT basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 11:47:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-WHISP-2006">
<DESCRIPTION>
<P>Significant difference between numbers of participants lost to follow-up between different treatment groups, 13 in the treatment group compared to 6 in the control group, the reasons are not stated. Intention-to-treat analysis was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2015-02-03 11:50:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WISDOM-2007">
<DESCRIPTION>
<P>615 (14%) had withdrawn from randomised treatment by trial closure. Analysed by ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-02-03 11:22:32 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 07:22:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DOPS-2012">
<DESCRIPTION>
<P>The trial methods paper is available, and all clinical outcomes specified in the paper are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 11:56:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EAGAR-2006">
<DESCRIPTION>
<P>Paper reports main outcome measures of angiographic and intravascular ultrasound (IVUS) as well as all CVD events that occurred in the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 11:32:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPAT-2001">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 14:18:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPHT-2006">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 15:36:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ERA-2000">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 08:02:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ERT-II-1979">
<DESCRIPTION>
<P>No prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 16:12:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2002">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 20:25:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVTET-2000">
<DESCRIPTION>
<P>Reported all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 08:12:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenspan-2005">
<DESCRIPTION>
<P>All patients randomised were included in analysis. Limited data, on events according to alendronate status, most results reported according to HT status only. All outcomes specified were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 08:15:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HALL-1998">
<DESCRIPTION>
<P>The paper reports the results for the main outcome of interest, angina, but it is unclear whether any other outcomes were prespecified but not reported. It appears that just the events that occurred in the trial were reported, rather than these being defined a priori for consideration in the trial. Additionally, HRQoL was measured within the trial, but the results of the assessments were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 21:09:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERS-I-1998">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-16 14:43:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STOP-IT-2001">
<DESCRIPTION>
<P>All outcomes stated were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 22:11:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAVE-2002">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 11:22:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WELL_x002d_HART-2003">
<DESCRIPTION>
<P>No prior published design paper</P>
<P>All outcomes specified in current paper were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:40:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WEST-2001">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-28 14:30:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-I-2002">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-27 15:20:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-II-2004">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-25 18:35:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHISP-2006">
<DESCRIPTION>
<P>No prior published design paper. All outcomes specified in current paper were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 12:15:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WISDOM-2007">
<DESCRIPTION>
<P>All expected outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-07" LEVEL="STUDY" MODIFIED="2015-02-03 12:28:37 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 12:27:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DOPS-2012">
<DESCRIPTION>
<P>The number of women randomised to HT treatment who discontinued treatment prior to 10.1 year follow-up was high (53%), whilst in the no treatment control group 23% of women started using some form of HT during this follow-up period. This &#8216;cross-over&#8217; between treatment arms potentially confounds the interpretation of the HT treatment effect relative to no treatment, and may potentially underestimate the true HT treatment effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 11:56:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EAGAR-2006">
<DESCRIPTION>
<P>It is unlikely that the trial was powered to detect differences in clinical events between the HRT and placebo treatment groups.  Therefore the lack of significant differences in event rates between the two groups should be treated with caution</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 11:32:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EPAT-2001">
<DESCRIPTION>
<P>No obvious source of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 07:51:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EPHT-2006">
<DESCRIPTION>
<P>EQ-5D not measured at baseline, and therefore it is unclear whether there is between group baseline imbalance. Follow-up data for EQ-5D only reported at 2- and 3.6-years follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-19 08:54:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ERA-2000">
<DESCRIPTION>
<P>More in unopposed oestrogen group using nitrates at baseline, otherwise prognostic balance between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 12:28:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ERT-II-1979">
<DESCRIPTION>
<P>Death and cardiovascular outcomes were not prespecified as outcomes for this study but were reported afterwards as adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 16:12:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2002">
<DESCRIPTION>
<P>No apparent source of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 16:31:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVTET-2000">
<DESCRIPTION>
<P>No apparent source of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 12:28:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greenspan-2005">
<DESCRIPTION>
<P>Death and cardiovascular outcomes were not prespecified as outcomes for this study but were reported afterwards as adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 08:15:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-HALL-1998">
<DESCRIPTION>
<P>It is unlikely that the trial was powered to detect differences in clinical events between the HT and placebo treatment groups.  Furthermore, no statistical analyses were undertaken to assess differences in clinical event rates between the trial arms. Therefore, the lack of significant differences in event rates between the two groups should be treated with caution</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 21:08:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HERS-I-1998">
<DESCRIPTION>
<P>More women in control arm on statins at randomisation (67% versus 54%). When adjusted in analyses - made no statistically significant difference</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 12:28:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-STOP-IT-2001">
<DESCRIPTION>
<P>Death and cardiovascular outcomes were not prespecified as outcomes for this study but were reported afterwards as adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-02 22:12:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WAVE-2002">
<DESCRIPTION>
<P>Groups balanced at baseline, apart from HT group had a higher prevalence of diabetes and higher fasting blood glucose levels</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 11:22:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WELL_x002d_HART-2003">
<DESCRIPTION>
<P>Death and cardiovascular outcomes were not prespecified as outcomes for this study but were reported afterwards as adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:40:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WEST-2001">
<DESCRIPTION>
<P>No apparent source of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:40:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-I-2002">
<DESCRIPTION>
<P>No apparent source of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:41:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WHI-II-2004">
<DESCRIPTION>
<P>No apparent source of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-03 11:47:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WHISP-2006">
<DESCRIPTION>
<P>Death and cardiovascular outcomes were not prespecified as outcomes for this study but were reported afterwards as adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 12:15:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WISDOM-2007">
<DESCRIPTION>
<P>No apparent source of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-05-18 09:34:12 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-02-12 07:41:01 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-02-12 07:41:01 +0000" MODIFIED_BY="[Empty name]">Hormone therapy compared to placebo for primary prevention of cardiovascular disease in post-menopausal women</TITLE>
<TABLE COLS="7" ROWS="17">
<TR>
<TD COLSPAN="7">
<P>
<B>Hormone therapy compared to placebo for primary prevention of cardiovascular disease in post-menopausal women</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Post-menopausal women without prior cardiovascular disease<BR/>
<B>Intervention:</B> Hormone therapy<BR/>
<B>Comparison: P</B>lacebo or no treatment </P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Hormone therapy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Death (all-causes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1 </B>
<BR/>(0.89 to 1.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>34,422<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
<BR/>(29 to 36)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Death (cardiovascular causes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.81 </B>
<BR/>(0.47 to 1.40)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>28,353<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
<BR/>(4 to 11)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Stroke</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.32 </B>
<BR/>(1.12 to 1.56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>28,719<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>23 per 1000</B>
<BR/>(20 to 28)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Venous thromboembolism</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.92 </B>
<BR/>(1.24 to 2.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>33,477<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
<BR/>(13 to 31)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Pulmonary embolism</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>31,732<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>5 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 1000</B>
<BR/>(5 to 15)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded one level due to inconsistency.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-03-06 13:15:18 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-02-10 14:01:46 +0000" MODIFIED_BY="[Empty name]">Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post-menopausal women</TITLE>
<TABLE COLS="7" ROWS="17">
<TR>
<TD COLSPAN="7">
<P>Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post-menopausal women</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Post-menopausal women with pre-exisiting cardiovascular disease</P>
<P>
<B>Intervention: </B>Hormone therapy</P>
<P>
<B>Comparison: </B>Placebo or no treatment</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>Hormone therapy</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Death (all-causes)</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 1.04 </B>
</P>
<P>(0.87 to 1.24)</P>
</TD>
<TD ROWSPAN="2">
<P>5445</P>
<P>(7 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>84 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>88 per 1000</B>
</P>
<P>(73 to 105)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Death (cardiovascular causes)</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 1.00</B>
</P>
<P>(0.78 to 1.29)</P>
</TD>
<TD ROWSPAN="2">
<P>5259</P>
<P>(6 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>45 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>45 per 1000 </B>
</P>
<P>(35 to 58)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Stroke</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 1.09</B>
</P>
<P>(0.89 to 1.33)</P>
</TD>
<TD ROWSPAN="2">
<P>5172</P>
<P>(5 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>65 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>71 per 1000</B>
</P>
<P>(58 to 86)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Venous thromboembolism</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 2.02</B>
</P>
<P>(1.13 to 3.62)</P>
</TD>
<TD ROWSPAN="2">
<P>4399</P>
<P>(6 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>11 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>23 per 1000</B>
</P>
<P>(13 to 40)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Pulmonary embolism</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 2.48</B>
</P>
<P>(0.92 to 6.70)</P>
</TD>
<TD ROWSPAN="2">
<P>3920</P>
<P>(3 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>4 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>10 per 1000</B>
</P>
<P>(4 to 27)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Downgraded one level due to imprecision: Confidence interval for the absolute effect includes small decrease and large increased risk. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2015-05-18 09:34:12 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2015-02-02 04:32:09 +0000" MODIFIED_BY="[Empty name]">Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post-menopausal women</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post-menopausal women</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Post-menopausal women<BR/>
<B>Intervention:</B> Hormone therapy commenced lessthan 10 years after the menopause</P>
<P>
<B>Comparison</B>: Placebo or no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hormone therapy commenced</B>
<BR/>
<B>less than 10 years after the menopause</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Death (all-causes)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.70 </B>
<BR/>(0.52 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>9088<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 1000</B>
<BR/>(12 to 21)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Coronary heart disease (death from cardiovascular causes and non-fatal myocardial infarction)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.52 </B>
<BR/>(0.29 to 0.96)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>8311<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
<BR/>(5 to 18)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Stroke</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.37 </B>
<BR/>(0.80 to 2.34)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>8143<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 1000</B>
<BR/>(7 to 21)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Venous thromboembolism</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.74 </B>
<BR/>(1.11 to 2.73)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>9838<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>11 per 1000</B>
<BR/>(7 to 17)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded one level due to risk of bias. The results are significant due to the DOPS 2012 trial, that has high risk of bias. We downgraded our confidence in the results of that metanalysis because, had the DOPS not been there, the metanalysis would not be significant.<BR/>
<SUP>2</SUP> Composite outcome.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2015-03-06 13:45:35 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2015-02-10 12:08:58 +0000" MODIFIED_BY="[Empty name]">Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post-menopausal women</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post-menopausal women</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Post-menopausal women</P>
<P>
<B>Intervention: </B>Hormone therapy commenced less than 10 years after the menopause</P>
<P>
<B>Comparison: </B>Placebo or no treatment</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Hormone therapy commenced</B>
<BR/>more<B> than 10 years after the menopause</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Death (all-causes)</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 1.06 </B>
</P>
<P>(0.95 to 1.18)</P>
</TD>
<TD ROWSPAN="2">
<P>27,750</P>
<P>(12 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>45 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>47 per 1000</B>
</P>
<P>(42 to 53)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Coronary heart disease (death from cardiovascular causes and non-fatal myocardial infarction)</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 1.07</B>
</P>
<P>(0.96 to 1.20)</P>
</TD>
<TD ROWSPAN="2">
<P>23,491</P>
<P>(12 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>49 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>52 per 1000</B>
</P>
<P>(47 to 59)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Stroke</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 1.21 </B>
</P>
<P>(1.06 to 1.38)</P>
</TD>
<TD ROWSPAN="2">
<P>22,722</P>
<P>(8 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>32 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>39 per 1000</B>
</P>
<P>(34 to 44)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Venous thromboembolism</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR 1.96 </B>
</P>
<P>(1.37 to 2.80)</P>
</TD>
<TD ROWSPAN="2">
<P>27,475</P>
<P>(9 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>12 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>24 per 1000</B>
</P>
<P>(16 to 34)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>We did not downgrade for inconsistency. Although the I square indicated that there was a substantial amount of statistical variation (41%), the direction of effect across the results of the studies was consistent.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-02-11 22:15:57 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-02-09 15:23:01 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-05-01 16:33:18 +0100" MODIFIED_BY="[Empty name]">Studies reviewed for relevant adverse events</TITLE>
<TABLE COLS="13" ROWS="21">
<TR>
<TH ROWSPAN="2">
<P>Study</P>
</TH>
<TH ROWSPAN="2">
<P>Population size</P>
</TH>
<TH ROWSPAN="2">
<P>Duration of follow-up (years)</P>
</TH>
<TH ROWSPAN="2">
<P>Outcomes</P>
</TH>
<TH ROWSPAN="2">
<P>Included in Review</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="8">
<P>Adverse events reported</P>
</TH>
</TR>
<TR>
<TH>
<P>Death (all- causes)</P>
</TH>
<TH>
<P>Death (CV causes)</P>
</TH>
<TH>
<P>Non-fatal MI</P>
</TH>
<TH>
<P>Stroke</P>
</TH>
<TH>
<P>Angina</P>
</TH>
<TH>
<P>Revascularisation</P>
</TH>
<TH>
<P>VTE</P>
</TH>
<TH>
<P>PE</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CHART-2006" TYPE="STUDY">CHART 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1265</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Bone mineral density</P>
<P>Serum lipids (LDL, HDL, TG)</P>
<P>Endometrial hyperplasia and proliferation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-de-Maat-2007" TYPE="REFERENCE">de Maat 2007</LINK>²</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>436</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CRP</P>
<P>Fibrinogen</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>168</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not specified</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Genant-1997" TYPE="STUDY">Genant 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>406</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Bone mineral density</P>
<P>Serum lipids</P>
<P>Endometrial tissue structure</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
<P>(no events in placebo arm)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>373</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time to rise from a chair</P>
<P>Timed walking</P>
<P>Balance</P>
<P>Instrumental Activities of Daily Living<BR/>Physical Activity Scale of the Elderly<BR/>Folstein Mini-Mental State Examination<BR/>Falls</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hart-1984" TYPE="STUDY">Hart 1984</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Bone mineral density</P>
<P>Serum lipids</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Heikkinen-1997" TYPE="STUDY">Heikkinen 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>232</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serum lipids</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HOPE-2002" TYPE="STUDY">HOPE 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2673</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number and severity of hot flushes<BR/>Papanicolaou smear with vaginal maturation index</P>
<P>Bone mineral density</P>
<P>Serum lipids</P>
<P>Lipoproteins</P>
<P>Glucose tolerance</P>
<P>Coagulation/fibrinolytic factors</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kim-1996" TYPE="STUDY">Kim 1996</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>551</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serum lipids,</P>
<P>Lipoproteins</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Leggate-1984" TYPE="STUDY">Leggate 1984</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Bone mineral density</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-OPAL-2006" TYPE="STUDY">OPAL 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>571</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Change in carotid intima media thickness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
<P>(no events in one group)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-PEPI-1995" TYPE="STUDY">PEPI 1995</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>875</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>HDL</P>
<P>Systolic blood pressure</P>
<P>Serum insulin</P>
<P>Serum glucose</P>
<P>Fibrinogen</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
<P>(no events in some groups)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-SMART_x002d_5-2012" TYPE="STUDY">SMART-5 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>503</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Endometrial hyperplasia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
<P>(no events in one group)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;&#10013;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Stevenson-2005" TYPE="STUDY">Stevenson 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>579</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serum lipids</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>369</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Bone mineral density</P>
<P>Serum 25-hydroxyvitamin D</P>
<P>Serum lipids</P>
<P>Depression</P>
<P>Calcium absorption</P>
<P>Serum PTH</P>
<P>Osteocalcin</P>
<P>Urinary N -telopeptides/creatinine ratio</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Tofteng-2002" TYPE="REFERENCE">Tofteng 2002</LINK>²</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>429</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Bone mineral density</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>226</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Change in coronary stenosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.58</P>
<P>(7 months)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serum lipids</P>
<P>Antithrombin</P>
<P>Factor VII</P>
<P>Fibrinogen</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;¹</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;¹</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="13">
<P>*Part of a composite endpoint.</P>
<P>&#10013;In a non-relevant treatment group (bazedoxifene and oestrogen).</P>
<P>¹Not included in analysis as no event in one of the groups.</P>
<P>²Sub-study of <LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-02-11 22:15:57 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-02-08 16:06:46 +0000" MODIFIED_BY="[Empty name]">Summary of trial characteristics</TITLE>
<TABLE COLS="9" ROWS="20">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Trial (year)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Country</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Length of follow-up (years)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No. participants</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Mean age of participants (years)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>% hysterectomy</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Primary or secondary prevention</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>HT type</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Participant previous indication</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Denmark</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1006</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18.9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single and combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>83</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CAGB</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>222</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>62</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Estonia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>777</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>310</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single and combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CHD</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>168</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 .0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1017</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MI or TIA</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Norway</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>140</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DVT or PE</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>366</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single and combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>373</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71.2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single and combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sweden</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CHD</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2763</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CHD</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>International</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>423</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CHD</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>226</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single and combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CHD</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>664</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MI or TIA</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16,608</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10,739</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Single</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.58 (7 months)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68.9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Secondary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ACS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>International</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4385</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Combination</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Trial stopped early due to publication of WHI I 2002 results<BR/>
<SUP>2</SUP> Trial stopped early due to publication of HER I 1998 results<BR/>
<SUP>3 </SUP>Trial stopped early as the weighted log-rank test statistic for breast cancer crossed designated stopping boundary, and global index supportive of finding of overall harm.<BR/>
<SUP>4</SUP> Trial stopped early as National Institutes of Health (NIH) concluded that conjugated equine oestrogen alone did not appear to affect the risk of heart disease, but was associated with a significant increase in the risk of stroke<BR/>CABG: coronary artery bypass graft; CHD: Coronary heart disease; DVT: Deep vein thrombosis; MI: myocardial infarction; NR: not reported; PE: Pulmonary embolism; TIA: Transient ischaemic attack</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-02-09 14:00:04 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-02-08 16:35:41 +0000" MODIFIED_BY="[Empty name]">Medication adherence in the trials</TITLE>
<TABLE COLS="5" ROWS="20">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Trial</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Adherence definition</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Assessment method</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>HR arm</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Placebo arm</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>
</P>
</TD>
<TD COLSPAN="4">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>% study medication</P>
<P>taken</P>
</TD>
<TD VALIGN="TOP">
<P>Pill counts</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 80% up to 30 months of treatment</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 80% up to 30 months of treatment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>% study medication</P>
<P>taken</P>
</TD>
<TD VALIGN="TOP">
<P>Pill counts</P>
</TD>
<TD VALIGN="TOP">
<P>Level of adherence 95% (87% of participants evaluated)</P>
</TD>
<TD VALIGN="TOP">
<P>Level of adherence 92% (92% of participants evaluated)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 80% of prescribed</P>
<P>treatment taken</P>
</TD>
<TD VALIGN="TOP">
<P>Number of collected/returned</P>
<P>drugs and clinic reports</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 40% compliant at three years (estimated from graph)</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 30% compliant at three years (estimated</P>
<P>from graph)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>% study medication</P>
<P>taken</P>
</TD>
<TD VALIGN="TOP">
<P>Pill counts</P>
</TD>
<TD VALIGN="TOP">
<P>Level of adherence at 3.2 years:</P>
<P>Women on single therapy (measured in 79%</P>
<P>of participants): 74%; women on combination therapy (measured in 82% of participants): 84%</P>
</TD>
<TD VALIGN="TOP">
<P>Level of adherence at 3.2 years:</P>
<P>(measured in 80% of participants): 86%</P>
<P> </P>
<P>5 women initiated treatment outside study</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>
</P>
</TD>
<TD COLSPAN="4">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8220;Regular tablet use&#8221;</P>
</TD>
<TD VALIGN="TOP">
<P>Self report to family doctor. Self report</P>
<P>to study nurse at six weeks and whenever in contact with trial staff</P>
</TD>
<TD VALIGN="TOP">
<P>Number non-adherent:</P>
<P>51% at 12 months</P>
<P>57% at 24 months</P>
</TD>
<TD VALIGN="TOP">
<P>Number non-adherent:</P>
<P>31% at 12 months</P>
<P>37% at 24 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>
</P>
</TD>
<TD>
<P>Not defined</P>
</TD>
<TD>
<P>Pill counts</P>
</TD>
<TD>
<P>65% at 36 months in those taking HRT</P>
<P>62% at 36 months in those taking HRT + calcitriol</P>
</TD>
<TD>
<P>78% at 36 months</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>
</P>
</TD>
<TD>
<P>&#8805; 80% of the medication &#8805; 80% of the study period</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>61%</P>
</TD>
<TD>
<P>67%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Not reported </P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Taking at least 80%</P>
<P>of study medication</P>
</TD>
<TD VALIGN="TOP">
<P>Pill counts</P>
</TD>
<TD VALIGN="TOP">
<P>82% adherent at one year; 75% adherent at three years</P>
<P> </P>
<P>3% initiated treatment outside study</P>
<P> </P>
<P>About 50% continued to use open-label HT during unblinded follow-up (4.2 to 6.8 years)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>91% adherent at one year;  81% adherent</P>
<P>at three years</P>
<P> </P>
<P>Under 10% used HRT during unblinded follow-up (4.2 to 6.8 years)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>% study medication</P>
<P>taken</P>
</TD>
<TD VALIGN="TOP">
<P>Pill counts</P>
</TD>
<TD VALIGN="TOP">
<P>At 2.8 years:</P>
<P>Adherence 67% in the 78% of women analysed</P>
</TD>
<TD VALIGN="TOP">
<P>At 2.8 years:</P>
<P>Adherence 70% in the 81% of women analysed</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>
</P>
</TD>
<TD>
<P>% study medication</P>
<P>taken</P>
</TD>
<TD>
<P>Pill counts</P>
</TD>
<TD>
<P>Oestrogen group: 92.6% with oestrogen and 99.9% with progestin matched placebo</P>
<P/>
<P>Oestrogen-Progestin group: 94.1% with oestrogen and 96.1% with progestin</P>
</TD>
<TD VALIGN="TOP">
<P>93.6% with oestrogen matched placebo and 98.4% with progestin matched placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>% study medication</P>
<P>taken</P>
</TD>
<TD VALIGN="TOP">
<P>Self report to study</P>
<P>nurse three-monthly</P>
<P> </P>
<P>Computer chip in medication</P>
<P>bottle records opening date and time</P>
<P> </P>
<P>Pill counts</P>
</TD>
<TD VALIGN="TOP">
<P>At 2.8 years:</P>
<P>Mean adherence including drop-outs: 70%</P>
<P/>
<P>Mean adherence excluding dropouts: 90%</P>
<P/>
<P>35% discontinued medication by 2.8 years, of whom 1% initiated treatment outside study</P>
</TD>
<TD VALIGN="TOP">
<P>At 2.8 years: Mean adherence including dropouts: 74% over 2.8 years</P>
<P/>
<P>Mean adherence excluding dropouts: 90%</P>
<P>24% discontinued medication</P>
<P> </P>
<P>2% initiated treatment outside study</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Taking at least 80% of study medication</P>
<P/>
<P>Temporary</P>
<P>discontinuation (e.g. during surgery) permitted</P>
</TD>
<TD VALIGN="TOP">
<P>Weighing medication bottles</P>
</TD>
<TD VALIGN="TOP">
<P>42% non-adherent by 5.2 years</P>
<P> </P>
<P>Of these 6.2% initiated HRT outside study</P>
</TD>
<TD VALIGN="TOP">
<P>38% non-adherent by 5.2 years</P>
<P> </P>
<P>Of these 10.7% initiated HRT outside study</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Taking at least 80%</P>
<P>of study medication</P>
<P/>
<P>Temporary</P>
<P>discontinuation (e.g. during surgery) permitted</P>
</TD>
<TD VALIGN="TOP">
<P>Weighing medication bottles</P>
</TD>
<TD VALIGN="TOP">
<P>At 6.8 years, about 53.8% of women were non-adherent</P>
<P> </P>
<P>In addition 5.7% of women had initiated hormone use through their own physician</P>
</TD>
<TD VALIGN="TOP">
<P>At 6.8 years, about 53.8% of women were non-adherent</P>
<P> </P>
<P>In addition 9.1% of women had initiated hormone use through their own physician</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>
</P>
</TD>
<TD>
<P>Not specified</P>
</TD>
<TD>
<P>Not specified</P>
</TD>
<TD>
<P>25 out of 49 discontinued study drug (51%)</P>
</TD>
<TD>
<P>14 out of 51 discontinued study drug (27%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Supply of study</P>
<P>medication</P>
</TD>
<TD VALIGN="TOP">
<P>Time at risk minus temporary interruptions and time after withdrawal from treatment</P>
</TD>
<TD VALIGN="TOP">
<P>73% of time</P>
</TD>
<TD VALIGN="TOP">
<P>86% of time</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>HRT: hormone replacement therapy</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2015-02-09 14:00:10 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-10-04 09:40:57 +0100" MODIFIED_BY="[Empty name]">Summary of outcomes by trials - primary prevention</TITLE>
<TABLE COLS="9" ROWS="13">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome </B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Death (CV causes)</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Non-fatal MI</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Stroke</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Angina</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Venous thromboembolism</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Pulmonary embolism</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Revascularisation</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Trial</B>
</P>
</TD>
<TD COLSPAN="8" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Number of trials </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>8</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>4</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>2</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>6</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Total N</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>34,422</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>28,353</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>29,482</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>28,719</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>27,347</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>33,477</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>31,732</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>27,569</B>
</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> No events in control group.<BR/>CV: cardiovascular; MI: myocardial infarction<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2015-02-09 14:00:14 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-10-04 09:41:33 +0100" MODIFIED_BY="[Empty name]">Summary of outcomes by trials - secondary prevention</TITLE>
<TABLE COLS="9" ROWS="14">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome </B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Death (CV causes)</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Non-fatal MI</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Stroke</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Angina</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Venous thromboembolism</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Pulmonary embolism</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Revascularisation</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Trial</B>
</P>
</TD>
<TD COLSPAN="8" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#10003;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Number of trials </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>6</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>5</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>6</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Total N</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>5445</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>5259</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>5359</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>5172</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>3155</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>4399</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>3920</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>3155</B>
</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> No outcomes relevant to this review.<BR/>CV: cardiovascular; MI: myocardial infarction<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2015-02-09 14:00:36 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2013-05-15 15:06:15 +0100" MODIFIED_BY="[Empty name]">Trials according to number of years since menopause when treatment commenced</TITLE>
<TABLE COLS="4" ROWS="28">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Population</P>
</TH>
<TH>
<P>Time since menopause (years)</P>
</TH>
<TH>
<P>Mean age (years)</P>
</TH>
</TR>
<TR>
<TD COLSPAN="4">
<P>&lt; 10 years since menopause (or mean age &lt; 60)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-DOPS-2012" TYPE="STUDY">DOPS 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>1006</P>
</TD>
<TD ALIGN="LEFT">
<P>0.59</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-ERT-II-1979" TYPE="STUDY">ERT II 1979</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>168</P>
</TD>
<TD ALIGN="LEFT">
<P>4.6</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-EPHT-2006" TYPE="STUDY">EPHT 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>1178</P>
</TD>
<TD ALIGN="LEFT">
<P>8.8</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-EVTET-2000" TYPE="STUDY">EVTET 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>140</P>
</TD>
<TD ALIGN="LEFT">
<P>NK<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT">
<P>55.7</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>5494</P>
</TD>
<TD ALIGN="LEFT">
<P>&lt; 10 yrs</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>1643</P>
</TD>
<TD ALIGN="LEFT">
<P>&lt; 10 yrs</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>TOTAL</P>
</TD>
<TD ALIGN="LEFT">
<P>9629</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4">
<P>&#8805; 10 years since menopause (or mean age &#8805; 60)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WHI-I-2002" TYPE="STUDY">WHI I 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>9694</P>
</TD>
<TD ALIGN="LEFT">
<P>&#8805; 10</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WHI-II-2004" TYPE="STUDY">WHI II 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>7468</P>
</TD>
<TD ALIGN="LEFT">
<P>&#8805; 10</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-HALL-1998" TYPE="STUDY">HALL 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>373</P>
</TD>
<TD ALIGN="LEFT">
<P>12.5</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WISDOM-2007" TYPE="STUDY">WISDOM 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>4385</P>
</TD>
<TD ALIGN="LEFT">
<P>14.7</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-ESPRIT-2002" TYPE="STUDY">ESPRIT 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>1017</P>
</TD>
<TD ALIGN="LEFT">
<P>16.1</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-HERS-I-1998" TYPE="STUDY">HERS I 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>2763</P>
</TD>
<TD ALIGN="LEFT">
<P>18</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WELL_x002d_HART-2003" TYPE="STUDY">WELL-HART 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>226</P>
</TD>
<TD ALIGN="LEFT">
<P>18.2</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WHISP-2006" TYPE="STUDY">WHISP 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>100</P>
</TD>
<TD ALIGN="LEFT">
<P>22.8</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-ERA-2000" TYPE="STUDY">ERA 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>309</P>
</TD>
<TD ALIGN="LEFT">
<P>23.0</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WEST-2001" TYPE="STUDY">WEST 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>664</P>
</TD>
<TD ALIGN="LEFT">
<P>25</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-EPAT-2001" TYPE="STUDY">EPAT 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>222</P>
</TD>
<TD ALIGN="LEFT">
<P>NK<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT">
<P>62.2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-EAGAR-2006" TYPE="STUDY">EAGAR 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>83</P>
</TD>
<TD ALIGN="LEFT">
<P>NK<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT">
<P>64</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-WAVE-2002" TYPE="STUDY">WAVE 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>423</P>
</TD>
<TD ALIGN="LEFT">
<P>NK<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT">
<P>65</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-STOP-IT-2001" TYPE="STUDY">STOP IT 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>489</P>
</TD>
<TD ALIGN="LEFT">
<P>NK<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT">
<P>71</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT">
<P>489</P>
</TD>
<TD ALIGN="LEFT">
<P>NK<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT">
<P>71.2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>TOTAL</P>
</TD>
<TD ALIGN="LEFT">
<P>28705</P>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
<TD ALIGN="LEFT">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<SUP>1</SUP>Author contacted but data was not collected.<BR/>
<SUP>2</SUP>Author contacted; reported data available from National Institutes of Health (NIH) (who funded trial) but data currently pending.<BR/>
<SUP>3</SUP>Author emailed, but no reply.</P>
<P>NK: not known</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-03-04 19:06:24 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-02-11 21:54:41 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Hormone therapy versus placebo in primary prevention</NAME>
<DICH_OUTCOME CHI2="5.8093730403125" CI_END="1.120983139136924" CI_START="0.888943496319344" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9982437933788574" ESTIMABLE="YES" EVENTS_1="553" EVENTS_2="549" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.04959908036048278" LOG_CI_START="-0.051125843097941666" LOG_EFFECT_SIZE="-7.633813687294446E-4" METHOD="MH" MODIFIED="2015-02-11 21:53:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5621762525312184" P_Q="1.0" P_Z="0.9762994252904531" Q="0.0" RANDOM="YES" SCALE="65.97" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17432" TOTAL_2="16990" WEIGHT="100.0" Z="0.02970863491985993">
<NAME>Death (all-causes)</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0803496976754556" CI_START="0.3105454039025519" EFFECT_SIZE="0.5792215752375115" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="0.033564354735557134" LOG_CI_START="-0.5078748939648187" LOG_EFFECT_SIZE="-0.23715526961463076" MODIFIED="2014-02-20 08:41:09 +0000" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.31804409485410695" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.10115204627156818" WEIGHT="3.4607834344007107"/>
<DICH_DATA CI_END="14.708063445162583" CI_START="0.05795613812724304" EFFECT_SIZE="0.9232673267326733" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1675554945871283" LOG_CI_START="-1.2369005611909631" LOG_EFFECT_SIZE="-0.03467253330191734" MODIFIED="2014-02-20 08:41:08 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="1.412389389413484" STUDY_ID="STD-EPHT-2006" TOTAL_1="404" TOTAL_2="373" VAR="1.9948437873277944" WEIGHT="0.17548508224862536"/>
<DICH_DATA CI_END="1.6015303258325488" CI_START="0.11468622630812386" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20453516667579472" LOG_CI_START="-0.9404887372649836" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2014-02-20 08:41:19 +0000" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.6725927091345493" STUDY_ID="STD-ERT-II-1979" TOTAL_1="84" TOTAL_2="84" VAR="0.45238095238095233" WEIGHT="0.7738286155726236"/>
<DICH_DATA CI_END="5.437669363215036" CI_START="0.045485176805895686" EFFECT_SIZE="0.49732620320855614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7354127968342812" LOG_CI_START="-1.3421301127994087" LOG_EFFECT_SIZE="-0.30335865798256384" MODIFIED="2014-02-20 08:41:19 +0000" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="1.2203589891220905" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.4892760623310908" WEIGHT="0.23505737784063838"/>
<DICH_DATA CI_END="14.447049921493582" CI_START="0.15961033592422763" EFFECT_SIZE="1.5185185185185186" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1597791734857832" LOG_CI_START="-0.7969389883642868" LOG_EFFECT_SIZE="0.1814200925607482" MODIFIED="2014-02-20 08:41:20 +0000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="1.1493859341818446" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="1.3210880256950717" WEIGHT="0.26498258956529064"/>
<DICH_DATA CI_END="1.211445169372503" CI_START="0.8408933751797771" EFFECT_SIZE="1.0093048188326859" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="218" LOG_CI_END="0.08330376252813565" LOG_CI_START="-0.0752590690139268" LOG_EFFECT_SIZE="0.0040223467571044195" MODIFIED="2014-02-20 08:41:06 +0000" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.09314059214648232" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.008675169905397363" WEIGHT="40.35256138033446"/>
<DICH_DATA CI_END="1.2060733092036264" CI_START="0.8787538223854828" EFFECT_SIZE="1.0294860516489746" ESTIMABLE="YES" EVENTS_1="291" EVENTS_2="289" LOG_CI_END="0.08137370648985735" LOG_CI_START="-0.05613277288271708" LOG_EFFECT_SIZE="0.012620466803570148" MODIFIED="2014-02-20 08:41:06 +0000" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.08077198665150079" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.006524113827630221" WEIGHT="53.657145681581845"/>
<DICH_DATA CI_END="4.8675616702834485" CI_START="0.5225830921689938" EFFECT_SIZE="1.5948998178506375" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6873114625842897" LOG_CI_START="-0.28184464569268525" LOG_EFFECT_SIZE="0.20273340844580218" MODIFIED="2014-02-20 08:41:06 +0000" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.5692870954020025" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.3240877969912487" WEIGHT="1.0801558384558063"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.4587407974071676" CI_END="1.40352344874004" CI_START="0.46501430889646667" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8078728158168433" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="115" I2="69.03421173361082" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.14721967281180962" LOG_CI_START="-0.3325336832838799" LOG_EFFECT_SIZE="-0.09265700523603511" METHOD="MH" MODIFIED="2015-02-11 21:53:27 +0000" MODIFIED_BY="[Empty name]" NO="2" NOTES="&lt;p&gt;WHI I: data from Mason, J (2003) N Engl J Med 349:6 (5.6 year follow-up)&lt;/p&gt;" NOTES_MODIFIED="2015-02-11 21:53:27 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.03958247321480313" P_Q="1.0" P_Z="0.4490055434244148" Q="0.0" RANDOM="YES" SCALE="65.44" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.15486267996410652" TOTALS="YES" TOTAL_1="14318" TOTAL_2="14035" WEIGHT="100.0" Z="0.7570739875835117">
<NAME>Death (cardiovascular causes)</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7453621898257934" CI_START="0.10434731502499545" EFFECT_SIZE="0.2788844621513944" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.12763264158821677" LOG_CI_START="-0.981518721345346" LOG_EFFECT_SIZE="-0.5545756814667814" MODIFIED="2013-04-05 12:44:18 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.5015769100536015" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.2515793966989186" WEIGHT="19.539461266848473"/>
<DICH_DATA CI_END="1.7287618699642935" CI_START="0.6905099259207638" EFFECT_SIZE="1.0925782492634957" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" LOG_CI_END="0.23773517506518782" LOG_CI_START="-0.16083007415756978" LOG_EFFECT_SIZE="0.03845255045380901" MODIFIED="2013-02-04 15:05:19 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.23411920032325045" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.05481179995999828" WEIGHT="37.87613646185866"/>
<DICH_DATA CI_END="1.4258046817841077" CI_START="0.7100564630621944" EFFECT_SIZE="1.0061818073117508" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="63" LOG_CI_END="0.15406003643228386" LOG_CI_START="-0.1487071151945181" LOG_EFFECT_SIZE="0.0026764606188829066" MODIFIED="2013-07-22 09:44:47 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.1778469235871551" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.03162952822941538" WEIGHT="42.584402271292866"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.74194870508958" CI_END="1.3120386659498173" CI_START="0.7959660056241797" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0219286551225353" ESTIMABLE="YES" EVENTS_1="312" EVENTS_2="296" I2="22.500132349681135" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.11794663394299784" LOG_CI_START="-0.09910547985666975" LOG_EFFECT_SIZE="0.009420577043164059" METHOD="MH" MODIFIED="2015-02-11 21:53:39 +0000" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;WHI I: data from Mason, J (2003) N Engl J Med 349:6 (5.6 year follow-up)&lt;/p&gt;" NOTES_MODIFIED="2015-02-11 21:53:39 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.257625115837" P_Q="1.0" P_Z="0.8649046135302463" Q="0.0" RANDOM="YES" SCALE="60.8" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.021673451681364156" TOTALS="YES" TOTAL_1="14943" TOTAL_2="14539" WEIGHT="100.0" Z="0.17013418017414947">
<NAME>Non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.237815506875535" CI_START="0.028152007983818443" EFFECT_SIZE="0.250996015936255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3498242789534236" LOG_CI_START="-1.5504906230083364" LOG_EFFECT_SIZE="-0.6003331720274564" MODIFIED="2014-02-20 08:42:34 +0000" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="1.116254380122812" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="1.246023841143363" WEIGHT="1.2822942074963846"/>
<DICH_DATA CI_END="15.788688730301793" CI_START="0.06333648202721173" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1983460628239087" LOG_CI_START="-1.1983460628239087" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-02-20 08:42:48 +0000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="1.407828818422887" STUDY_ID="STD-EPAT-2001" TOTAL_1="111" TOTAL_2="111" VAR="1.9819819819819822" WEIGHT="0.8112976253985604"/>
<DICH_DATA CI_END="3.1401207905561583" CI_START="0.03538434299893023" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49694635433532724" LOG_CI_START="-1.4511888637746524" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-02-20 08:42:48 +0000" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="1.1443442705426587" STUDY_ID="STD-ERT-II-1979" TOTAL_1="84" TOTAL_2="84" VAR="1.3095238095238095" WEIGHT="1.2211269830711082"/>
<DICH_DATA CI_END="3.1584379030652805" CI_START="0.03480389286499995" EFFECT_SIZE="0.3315508021390374" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4994723428035393" LOG_CI_START="-1.4583721768800295" LOG_EFFECT_SIZE="-0.4794499170382451" MODIFIED="2014-02-20 08:42:48 +0000" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="1.1500475623488031" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.322609395664424" WEIGHT="1.2092402269787013"/>
<DICH_DATA CI_END="4.9978539581179335" CI_START="0.36454536327993514" EFFECT_SIZE="1.3497942386831276" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6987835614922779" LOG_CI_START="-0.43824842126554414" LOG_EFFECT_SIZE="0.13026757011336693" MODIFIED="2014-02-20 08:42:47 +0000" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.667898215071033" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="0.4460880256950718" WEIGHT="3.475191896017997"/>
<DICH_DATA CI_END="1.6059104861712061" CI_START="0.9911892401499814" EFFECT_SIZE="1.261650187071252" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="114" LOG_CI_END="0.20572133394058245" LOG_CI_START="-0.003843421088058969" LOG_EFFECT_SIZE="0.10093895642626174" MODIFIED="2014-02-20 08:42:31 +0000" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.12309937446609172" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.015153455993943075" WEIGHT="44.14057541241641"/>
<DICH_DATA CI_END="1.1268642977624101" CI_START="0.7296809280619876" EFFECT_SIZE="0.9067807819926464" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="168" LOG_CI_END="0.05187161943437449" LOG_CI_START="-0.13686700491313059" LOG_EFFECT_SIZE="-0.04249769273937804" MODIFIED="2014-02-20 08:42:31 +0000" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.11086600221298273" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.012291270446689094" WEIGHT="47.860273648620826"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8810209808223044" CI_END="1.5550503143278924" CI_START="1.124971987964447" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3226443374899344" ESTIMABLE="YES" EVENTS_1="340" EVENTS_2="251" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.1917444453766553" LOG_CI_START="0.0511417085594456" LOG_EFFECT_SIZE="0.12144307696805046" METHOD="MH" MODIFIED="2015-02-11 21:53:51 +0000" MODIFIED_BY="[Empty name]" NO="4" NOTES="&lt;p&gt;WHI I: data from Wassertheil-Smoller, S (2003) JAMA; 289: 20 (5.6 year follow-up)&lt;/p&gt;" NOTES_MODIFIED="2015-02-11 21:53:51 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.5974647170173703" P_Q="1.0" P_Z="7.097960822140413E-4" Q="0.0" RANDOM="YES" SCALE="56.49" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14561" TOTAL_2="14158" WEIGHT="100.0" Z="3.3857670542863954">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7207755883404043" CI_START="0.3616252119729508" EFFECT_SIZE="0.7888446215139442" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.235724236335556" LOG_CI_START="-0.44174129877457013" LOG_EFFECT_SIZE="-0.10300853121950705" MODIFIED="2014-02-20 08:43:27 +0000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.3979466088321716" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.1583615034810254" WEIGHT="4.307379494800416"/>
<DICH_DATA CI_END="6.0191240439104305" CI_START="0.4729572342801669" EFFECT_SIZE="1.6872427983539096" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.7795332934877255" LOG_CI_START="-0.3251781272448788" LOG_EFFECT_SIZE="0.22717758312142333" MODIFIED="2014-02-20 08:43:35 +0000" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.6489129569480577" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="0.4210880256950718" WEIGHT="1.6199061745676155"/>
<DICH_DATA CI_END="1.7187314984683026" CI_START="1.0512645603883475" EFFECT_SIZE="1.344188049776848" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="107" LOG_CI_END="0.23520803617426786" LOG_CI_START="0.021712023980781564" LOG_EFFECT_SIZE="0.12846003007752468" MODIFIED="2014-02-20 08:43:26 +0000" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.12540861438475842" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.015727320561905036" WEIGHT="43.37185664748151"/>
<DICH_DATA CI_END="1.6977059474243292" CI_START="1.0774553764550976" EFFECT_SIZE="1.3524800925308065" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="127" LOG_CI_END="0.22986247008341917" LOG_CI_START="0.032399292604814244" LOG_EFFECT_SIZE="0.13113088134411674" MODIFIED="2014-02-20 08:43:25 +0000" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.11599084790942531" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.013453876798747435" WEIGHT="50.70085768315046"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3334617003006541" CI_END="1.0836271482569932" CI_START="0.741280044955194" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8962539713577913" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="297" I2="25.00721994680979" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.03487987693561545" LOG_CI_START="-0.13001769080297473" LOG_EFFECT_SIZE="-0.04756890693367964" METHOD="MH" MODIFIED="2015-02-11 21:54:02 +0000" MODIFIED_BY="[Empty name]" NO="5" NOTES="&lt;p&gt;WHI I: data from Mason, J (2003) N Engl J Med 349:6 (5.6 year follow-up)&lt;/p&gt;" NOTES_MODIFIED="2015-02-11 21:54:02 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.24819045769737458" P_Q="1.0" P_Z="0.25813797320707677" Q="0.0" RANDOM="YES" SCALE="60.8" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004791825034711161" TOTALS="YES" TOTAL_1="13816" TOTAL_2="13531" WEIGHT="100.00000000000001" Z="1.1308031483126706">
<NAME>Angina</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0356359818040024" CI_START="0.6200079100008957" EFFECT_SIZE="0.8013129854183229" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="126" LOG_CI_END="0.015207131012988456" LOG_CI_START="-0.20760276977944395" LOG_EFFECT_SIZE="-0.09619781938322772" MODIFIED="2013-02-04 15:22:18 +0000" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.13087963865227148" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.017129479813749158" WEIGHT="42.799362675440584"/>
<DICH_DATA CI_END="1.2037467411083038" CI_START="0.7890390637571149" EFFECT_SIZE="0.9745784738053546" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="171" LOG_CI_END="0.08053512437300911" LOG_CI_START="-0.10290149520097967" LOG_EFFECT_SIZE="-0.011183185413985277" MODIFIED="2013-07-22 09:48:25 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.10775157836367237" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.011610402639862629" WEIGHT="57.20063732455943"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.455508011933128" CI_END="2.9865527777876197" CI_START="1.235500664798819" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9209081035836575" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="169" I2="56.35287413887248" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.4751701939196555" LOG_CI_START="0.09184298342355426" LOG_EFFECT_SIZE="0.2835065886716049" METHOD="MH" MODIFIED="2015-02-11 21:54:15 +0000" MODIFIED_BY="[Empty name]" NO="6" NOTES="&lt;p&gt;WHI I: data from Cushman, M (2004) JAMA; 292: 13 (5.6 year follow-up)&lt;/p&gt;" NOTES_MODIFIED="2015-02-11 21:54:15 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.04306037633950521" P_Q="1.0" P_Z="0.003741686031196629" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11025538339556068" TOTALS="YES" TOTAL_1="16944" TOTAL_2="16533" WEIGHT="100.0" Z="2.899156062816513">
<NAME>Venous thromboembolism</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.099608827297346" CI_START="0.14197739970945414" EFFECT_SIZE="1.00398406374502" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8512344207153756" LOG_CI_START="-0.8477807821143637" LOG_EFFECT_SIZE="0.0017268193005059549" MODIFIED="2014-02-20 08:44:29 +0000" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.9980099404030819" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.9960238411433631" WEIGHT="4.582998814960698"/>
<DICH_DATA CI_END="21.750677452860142" CI_START="0.1819407072235827" EFFECT_SIZE="1.9893048128342246" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3374727881622435" LOG_CI_START="-0.7400701214714465" LOG_EFFECT_SIZE="0.29870133334539856" MODIFIED="2014-02-20 08:44:40 +0000" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="1.2203589891220905" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.4892760623310908" WEIGHT="3.1697259773309687"/>
<DICH_DATA CI_END="17.920833529726732" CI_START="0.2287491309184868" EFFECT_SIZE="2.0246913580246915" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2533582056018944" LOG_CI_START="-0.6406405472637983" LOG_EFFECT_SIZE="0.30635882916904816" MODIFIED="2014-02-20 08:44:40 +0000" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.1125442428783399" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="1.2377546923617384" WEIGHT="3.7611561413806256"/>
<DICH_DATA CI_END="2.740348899453019" CI_START="1.5985772138600978" EFFECT_SIZE="2.093002462657938" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="76" LOG_CI_END="0.43780586043379544" LOG_CI_START="0.2037336182389182" LOG_EFFECT_SIZE="0.32076973933635683" MODIFIED="2014-02-20 08:44:28 +0000" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.13749519374155664" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.018904928302028192" WEIGHT="39.254135488217266"/>
<DICH_DATA CI_END="1.7442992723607342" CI_START="0.9983405160360681" EFFECT_SIZE="1.319622914203127" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="86" LOG_CI_END="0.2416209996243175" LOG_CI_START="-7.213033897165705E-4" LOG_EFFECT_SIZE="0.12044984811730046" MODIFIED="2014-02-20 08:44:27 +0000" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.14235306840419062" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.020264396084088178" WEIGHT="38.84527230501545"/>
<DICH_DATA CI_END="24.387203426488465" CI_START="2.1911277687368984" EFFECT_SIZE="7.309957498482088" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="1.387162000966482" LOG_CI_START="0.34066770281836045" LOG_EFFECT_SIZE="0.8639148518924211" MODIFIED="2014-02-20 08:44:27 +0000" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.614715930962528" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.37787567577912745" WEIGHT="10.386711273094983"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.346288749349162" CI_END="3.0384579882678535" CI_START="1.1741212680266977" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.888787480377531" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="79" I2="53.98372921496549" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.4826532358817611" LOG_CI_START="0.06971295493114522" LOG_EFFECT_SIZE="0.27618309540645325" METHOD="MH" MODIFIED="2015-02-11 21:54:29 +0000" MODIFIED_BY="[Empty name]" NO="7" NOTES="&lt;p&gt;WHI I: data from Cushman, M (2004) JAMA; 292: 13 (5.6 year follow-up)&lt;/p&gt;" NOTES_MODIFIED="2015-02-11 21:54:29 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.11381924340429428" P_Q="1.0" P_Z="0.00874847602986825" Q="0.0" RANDOM="YES" SCALE="4.26" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08768829896373387" TOTALS="YES" TOTAL_1="16012" TOTAL_2="15720" WEIGHT="100.0" Z="2.621729800199239">
<NAME>Pulmonary embolism</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.153995654871901" CI_START="1.4733378279605502" EFFECT_SIZE="2.1556672070488943" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="38" LOG_CI_END="0.4988610906839251" LOG_CI_START="0.16830233950871978" LOG_EFFECT_SIZE="0.3335817150963225" MODIFIED="2013-02-04 15:45:03 +0000" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.19417184673252372" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.03770270606351868" WEIGHT="46.92273505516029"/>
<DICH_DATA CI_END="2.0612171944924533" CI_START="0.9015801840238" EFFECT_SIZE="1.3632140615191464" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="39" LOG_CI_END="0.3141237566504989" LOG_CI_START="-0.044995642285477463" LOG_EFFECT_SIZE="0.13456405718251074" MODIFIED="2013-07-22 09:50:14 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.21094851260468717" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.044499274970129864" WEIGHT="44.51015123507583"/>
<DICH_DATA CI_END="22.720606039534655" CI_START="1.0933191344746165" EFFECT_SIZE="4.984061930783242" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3564199113750486" LOG_CI_START="0.03874694887674371" LOG_EFFECT_SIZE="0.6975834301258962" MODIFIED="2013-02-04 15:45:03 +0000" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.7740076207578636" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.5990877969912487" WEIGHT="8.567113709763877"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.49981697468168945" CI_END="1.08751908619887" CI_START="0.8474157280968673" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9599899886199101" ESTIMABLE="YES" EVENTS_1="468" EVENTS_2="483" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.036436887657122885" LOG_CI_START="-0.07190347972340366" LOG_EFFECT_SIZE="-0.017733296033140375" METHOD="MH" MODIFIED="2015-02-11 21:54:41 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7788720661735558" P_Q="1.0" P_Z="0.5211205676628577" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13927" TOTAL_2="13642" WEIGHT="100.0" Z="0.6416190454674325">
<NAME>Revascularisation</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.434937107167446" CI_START="0.04599869236210789" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7351945228163949" LOG_CI_START="-1.3372545141443573" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-05-26 09:17:26 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="1.2173668230989303" STUDY_ID="STD-EPAT-2001" TOTAL_1="111" TOTAL_2="111" VAR="1.4819819819819822" WEIGHT="0.27328317106419375"/>
<DICH_DATA CI_END="1.2013169418641771" CI_START="0.822992625444723" EFFECT_SIZE="0.9943213685604996" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="205" LOG_CI_END="0.07965760186052834" LOG_CI_START="-0.08460405633452547" LOG_EFFECT_SIZE="-0.0024732272369985524" MODIFIED="2014-02-20 08:45:33 +0000" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.09648811113209632" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.009309955589839769" WEIGHT="43.501897682307344"/>
<DICH_DATA CI_END="1.106827250868629" CI_START="0.7935854125210353" EFFECT_SIZE="0.937209667294413" ESTIMABLE="YES" EVENTS_1="253" EVENTS_2="276" LOG_CI_END="0.04407984323741782" LOG_CI_START="-0.10040632386779591" LOG_EFFECT_SIZE="-0.02816324031518905" MODIFIED="2014-02-20 08:45:32 +0000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.08487188977566461" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.007203237674092562" WEIGHT="56.224819146628455"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-02-11 21:56:37 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Hormone therapy versus placebo in secondary prevention</NAME>
<DICH_OUTCOME CHI2="3.696454126907372" CI_END="1.2359321056486523" CI_START="0.8721894962342112" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0382518965094096" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="223" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.09199461399549957" LOG_CI_START="-0.05938914783341281" LOG_EFFECT_SIZE="0.016302733081043377" METHOD="MH" MODIFIED="2015-02-11 21:54:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.717675123625954" P_Q="1.0" P_Z="0.6729209144929513" Q="0.0" RANDOM="YES" SCALE="75.17" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2801" TOTAL_2="2644" WEIGHT="100.0" Z="0.42214263012602865">
<NAME>Death (all-causes)</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.480447841704783" CI_START="0.3589806450563251" EFFECT_SIZE="0.9436274509803921" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.3945300992222517" LOG_CI_START="-0.4449289663850102" LOG_EFFECT_SIZE="-0.025199433581379285" MODIFIED="2013-07-22 09:55:47 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.49310241052709763" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.24314998726763434" WEIGHT="3.2520674086488652"/>
<DICH_DATA CI_END="1.2655561496570695" CI_START="0.5134707001114593" EFFECT_SIZE="0.8061178587494376" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="39" LOG_CI_END="0.10228141851462516" LOG_CI_START="-0.28948433326039363" LOG_EFFECT_SIZE="-0.09360145737288424" MODIFIED="2013-07-22 09:56:44 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.2301251418643935" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.05295758091810723" WEIGHT="14.931576089724496"/>
<DICH_DATA CI_END="1.3397868104508874" CI_START="0.8373884590019809" EFFECT_SIZE="1.05920820077766" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="123" LOG_CI_END="0.12703569805831066" LOG_CI_START="-0.07707302890728479" LOG_EFFECT_SIZE="0.02498133457551292" MODIFIED="2013-02-04 17:22:08 +0000" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.11989447657408399" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.014374685512973575" WEIGHT="55.00921382195068"/>
<DICH_DATA CI_END="4.142475448090552" CI_START="0.7605657630275782" EFFECT_SIZE="1.775" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6172599430924868" LOG_CI_START="-0.11886322831026105" LOG_EFFECT_SIZE="0.24919835739111287" MODIFIED="2013-02-04 17:22:08 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.4324023947504401" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.18697183098591547" WEIGHT="4.229194017285023"/>
<DICH_DATA CI_END="2.5310768550853693" CI_START="0.19693678897564382" EFFECT_SIZE="0.7060185185185185" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.40330533252796047" LOG_CI_START="-0.7056731474642131" LOG_EFFECT_SIZE="-0.15118390746812627" MODIFIED="2013-09-10 10:47:27 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.6514194486794126" STUDY_ID="STD-WELL_x002d_HART-2003" TOTAL_1="108" TOTAL_2="61" VAR="0.42434729811778993" WEIGHT="1.863426849926513"/>
<DICH_DATA CI_END="1.6745591246049474" CI_START="0.7706372169075482" EFFECT_SIZE="1.1359918940435696" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" LOG_CI_END="0.22390048602719245" LOG_CI_START="-0.113150021137594" LOG_EFFECT_SIZE="0.0553752324447992" MODIFIED="2013-07-22 09:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.19798513633551407" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.03919811420979209" WEIGHT="20.17291303286537"/>
<DICH_DATA CI_END="5.5571126475582515" CI_START="0.048734778934554725" EFFECT_SIZE="0.5204081632653061" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7448492004055154" LOG_CI_START="-1.3121609995946324" LOG_EFFECT_SIZE="-0.28365589959455845" MODIFIED="2013-04-05 14:32:23 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="1.2082979738447959" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="1.459983993597439" WEIGHT="0.5416087795990527"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9403324147441197" CI_END="1.2880809926782315" CI_START="0.7757634913327309" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.999623032947618" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="115" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.10994317169408904" LOG_CI_START="-0.11027066284607268" LOG_EFFECT_SIZE="-1.637455759918378E-4" METHOD="MH" MODIFIED="2015-02-11 21:55:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5580383445256138" P_Q="1.0" P_Z="0.997674359888961" Q="0.0" RANDOM="YES" SCALE="75.17" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2684" TOTAL_2="2575" WEIGHT="99.99999999999999" Z="0.0029147617563803924">
<NAME>Death (cardiovascular causes)</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7760767745511554" CI_START="0.1040699784128669" EFFECT_SIZE="0.5375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4434314726988307" LOG_CI_START="-0.9826745355235449" LOG_EFFECT_SIZE="-0.26962153141235706" MODIFIED="2014-02-20 09:10:31 +0000" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.8377017285684156" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="0.7017441860465116" WEIGHT="2.384435501629527"/>
<DICH_DATA CI_END="4.0339752620800375" CI_START="0.2626908973081981" EFFECT_SIZE="1.0294117647058822" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6057332306206547" LOG_CI_START="-0.5805549760046137" LOG_EFFECT_SIZE="0.012589127308020467" MODIFIED="2014-02-20 09:10:51 +0000" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.6968315647930113" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.48557422969187675" WEIGHT="3.4459484213838834"/>
<DICH_DATA CI_END="1.1847837681751165" CI_START="0.3991933767863154" EFFECT_SIZE="0.6877192982456141" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="0.07363909561420956" LOG_CI_START="-0.3988166729182779" LOG_EFFECT_SIZE="-0.16258878865203413" MODIFIED="2014-02-20 09:10:52 +0000" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.2775228571297553" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.07701893622946254" WEIGHT="21.72535524622494"/>
<DICH_DATA CI_END="1.667622090523034" CI_START="0.8477749983613915" EFFECT_SIZE="1.1890198968312453" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="59" LOG_CI_END="0.2220976394697986" LOG_CI_START="-0.07171939530942523" LOG_EFFECT_SIZE="0.07518912208018669" MODIFIED="2014-02-20 09:10:52 +0000" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.1725895806470948" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.02978716334794004" WEIGHT="56.173987792198886"/>
<DICH_DATA CI_END="3.8307740527034375" CI_START="0.47743203206466955" EFFECT_SIZE="1.3523809523809525" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.583286537115437" LOG_CI_START="-0.3210884464892002" LOG_EFFECT_SIZE="0.13109904531311845" MODIFIED="2014-02-20 09:10:52 +0000" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.5312343420977325" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.2822099262240107" WEIGHT="5.929145628078389"/>
<DICH_DATA CI_END="1.8061954463740633" CI_START="0.37322405427999605" EFFECT_SIZE="0.8210454234193106" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.25676474303681374" LOG_CI_START="-0.42803037375614233" LOG_EFFECT_SIZE="-0.0856328153596643" MODIFIED="2014-02-20 09:10:53 +0000" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="0.4022520413946803" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.16180670480618758" WEIGHT="10.341127410484361"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9414914253397484" CI_END="1.1808743310744654" CI_START="0.8070221072068966" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9762129332324221" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="196" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.07220368235113624" LOG_CI_START="-0.09311456824390109" LOG_EFFECT_SIZE="-0.010455442946382457" METHOD="MH" MODIFIED="2015-02-11 21:55:29 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8161537171588255" P_Q="1.0" P_Z="0.8042015353662001" Q="0.0" RANDOM="YES" SCALE="60.8" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2733" TOTAL_2="2626" WEIGHT="99.99999999999999" Z="0.24791324059580985">
<NAME>Non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.2747548900469" CI_START="0.15885414937912085" EFFECT_SIZE="1.075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8618183651227709" LOG_CI_START="-0.7990014366195226" LOG_EFFECT_SIZE="0.03140846425162412" MODIFIED="2014-02-20 09:11:22 +0000" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.9755737727340315" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="0.9517441860465116" WEIGHT="0.9908241271028415"/>
<DICH_DATA CI_END="2.1744398918162573" CI_START="0.35804471566811946" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.3373474069365952" LOG_CI_START="-0.4460627315817805" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2014-02-20 09:11:39 +0000" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.4601789933084222" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.2117647058823529" WEIGHT="4.453107983389047"/>
<DICH_DATA CI_END="2.037834008054848" CI_START="0.8285178372366147" EFFECT_SIZE="1.2993774759479344" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="31" LOG_CI_END="0.309168805616549" LOG_CI_START="-0.08169813717820539" LOG_EFFECT_SIZE="0.11373533421917185" MODIFIED="2014-02-20 09:11:39 +0000" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.22959717702021" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.05271486369564965" WEIGHT="17.888903361473783"/>
<DICH_DATA CI_END="1.1525832151445718" CI_START="0.7223105551950677" EFFECT_SIZE="0.9124269954574952" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="134" LOG_CI_END="0.061672290741459045" LOG_CI_START="-0.14127603870542968" LOG_EFFECT_SIZE="-0.039801873981985314" MODIFIED="2014-02-20 09:11:40 +0000" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.11921285332753537" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.01421170439849246" WEIGHT="66.35453960502944"/>
<DICH_DATA CI_END="4.00250238948859" CI_START="0.2570330783326605" EFFECT_SIZE="1.0142857142857142" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6023315998646414" LOG_CI_START="-0.5900109824550045" LOG_EFFECT_SIZE="0.006160308704818433" MODIFIED="2014-02-20 09:11:40 +0000" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.7003879350455318" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.49054325955734407" WEIGHT="1.9223811233604404"/>
<DICH_DATA CI_END="2.4106942128632998" CI_START="0.5316026748768943" EFFECT_SIZE="1.132047477744807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.38214212531381375" LOG_CI_START="-0.27441284247469255" LOG_EFFECT_SIZE="0.05386464141956063" MODIFIED="2014-02-20 09:11:41 +0000" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.3856636380784744" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.1487364417359245" WEIGHT="6.340148327865856"/>
<DICH_DATA CI_END="1.9662875568276528" CI_START="0.13773400307232253" EFFECT_SIZE="0.5204081632653061" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.293647030897579" LOG_CI_START="-0.8609588300866959" LOG_EFFECT_SIZE="-0.28365589959455845" MODIFIED="2014-02-20 09:11:41 +0000" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.6782211981333516" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="0.45998399359743897" WEIGHT="2.050095471778585"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8281551695995706" CI_END="1.3294872792581813" CI_START="0.8903302388288521" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0879718410243242" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="164" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.12368418629006998" LOG_CI_START="-0.05044887616503159" LOG_EFFECT_SIZE="0.0366176550625192" METHOD="MH" MODIFIED="2015-02-11 21:55:45 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5869825064860632" P_Q="1.0" P_Z="0.40976688577435527" Q="0.0" RANDOM="YES" SCALE="80.9" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2640" TOTAL_2="2532" WEIGHT="99.99999999999999" Z="0.8243039444545854">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5295638375635807" CI_START="0.36623161520694963" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.40304564399434495" LOG_CI_START="-0.43624416763326834" LOG_EFFECT_SIZE="-0.016599261819461704" MODIFIED="2013-07-22 10:03:51 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.4930029899016314" STUDY_ID="STD-ERA-2000" TOTAL_1="200" TOTAL_2="105" VAR="0.24305194805194805" WEIGHT="4.304657214102718"/>
<DICH_DATA CI_END="4.4716378934767445" CI_START="0.5995939113652367" EFFECT_SIZE="1.6374269005847952" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6504666277871072" LOG_CI_START="-0.22214278588697645" LOG_EFFECT_SIZE="0.21416192095006537" MODIFIED="2013-07-22 10:03:59 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.5125750890784181" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.26273322194374826" WEIGHT="3.9821965179856194"/>
<DICH_DATA CI_END="1.443608728726371" CI_START="0.8482150081747728" EFFECT_SIZE="1.1065670289855072" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="96" LOG_CI_END="0.15944949934080593" LOG_CI_START="-0.07149404747425424" LOG_EFFECT_SIZE="0.043977725933275875" MODIFIED="2013-02-04 17:26:36 +0000" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.13565738258816024" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.01840292545067048" WEIGHT="56.852663147935466"/>
<DICH_DATA CI_END="7.296409439022344" CI_START="0.7137998578525512" EFFECT_SIZE="2.282142857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.863109196498933" LOG_CI_START="-0.1464235428665713" LOG_EFFECT_SIZE="0.3583428268161809" MODIFIED="2013-02-04 17:26:36 +0000" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.593004528370952" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.3516543706684552" WEIGHT="2.9752376448349676"/>
<DICH_DATA CI_END="1.357296527569838" CI_START="0.6672592922489862" EFFECT_SIZE="0.9516662862360191" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="52" LOG_CI_END="0.13267473802010643" LOG_CI_START="-0.17570536951593715" LOG_EFFECT_SIZE="-0.021515315747915372" MODIFIED="2013-07-22 10:04:13 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.18114400167282346" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.032813149342043865" WEIGHT="31.885245475141218"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3421312214682053" CI_END="1.1232058942773944" CI_START="0.7359654924232122" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9091978767432956" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="152" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.05045937385039394" LOG_CI_START="-0.13314254816456073" LOG_EFFECT_SIZE="-0.04134158715708342" METHOD="MH" MODIFIED="2015-02-11 21:56:00 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5111636277127956" P_Q="1.0" P_Z="0.37742598146541717" Q="0.0" RANDOM="YES" SCALE="65.44" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1624" TOTAL_2="1531" WEIGHT="100.00000000000001" Z="0.882648950537754">
<NAME>Angina</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6511292936325925" CI_START="0.6276947729395124" EFFECT_SIZE="1.29" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4234309084731628" LOG_CI_START="-0.20225148787466488" LOG_EFFECT_SIZE="0.11058971029924898" MODIFIED="2014-02-20 09:12:29 +0000" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.3675289367925265" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="0.13507751937984497" WEIGHT="8.610860907367393"/>
<DICH_DATA CI_END="1.2544479834030453" CI_START="0.4751690264371088" EFFECT_SIZE="0.7720588235294118" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="0.09845265768778795" LOG_CI_START="-0.3231518762883468" LOG_EFFECT_SIZE="-0.11234960930027943" MODIFIED="2014-02-20 09:12:42 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.24765259023368302" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.06133180544945251" WEIGHT="18.96460935021197"/>
<DICH_DATA CI_END="1.1669688574562547" CI_START="0.7100965863809147" EFFECT_SIZE="0.9103079710144928" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="120" LOG_CI_END="0.06705926631497713" LOG_CI_START="-0.14868257511283134" LOG_EFFECT_SIZE="-0.0408116543989271" MODIFIED="2014-02-20 09:12:43 +0000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.12672782559403326" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.016059941779791708" WEIGHT="72.42452974242065"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.622755987268309" CI_END="3.6185925351357806" CI_START="1.129115817821105" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.021338682574294" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="24" I2="11.075636016900333" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.5585396829410711" LOG_CI_START="0.052738491491698736" LOG_EFFECT_SIZE="0.30563908721638494" METHOD="MH" MODIFIED="2015-02-11 21:56:17 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.34467302670407096" P_Q="1.0" P_Z="0.01785149672459885" Q="0.0" RANDOM="YES" SCALE="60.8" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06759692472240329" TOTALS="YES" TOTAL_1="2251" TOTAL_2="2148" WEIGHT="100.0" Z="2.3686840337218595">
<NAME>Venous thromboembolism</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.898052239974323" CI_START="0.44920623069365717" EFFECT_SIZE="3.6029411764705883" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4608685718244399" LOG_CI_START="-0.3475542285078478" LOG_EFFECT_SIZE="0.5566571716582962" MODIFIED="2014-02-20 09:13:37 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.0622765047524207" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="1.1284313725490196" WEIGHT="7.380630187019663"/>
<DICH_DATA CI_END="60.53069000772904" CI_START="0.9985868286674504" EFFECT_SIZE="7.774647887323944" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.781975624595539" LOG_CI_START="-6.14166575291521E-4" LOG_EFFECT_SIZE="0.8906807290101236" MODIFIED="2014-02-20 09:13:18 +0000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="1.0471020672955231" STUDY_ID="STD-EVTET-2000" TOTAL_1="71" TOTAL_2="69" VAR="1.096422739334558" WEIGHT="7.5835854220923355"/>
<DICH_DATA CI_END="4.944828188696005" CI_START="1.3893322295528723" EFFECT_SIZE="2.6210702341137124" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="13" LOG_CI_END="0.6941512063482554" LOG_CI_START="0.1428061105387294" LOG_EFFECT_SIZE="0.4184786584434924" MODIFIED="2014-02-20 09:13:36 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.32386283848075587" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.10488713814881216" WEIGHT="51.17830835166588"/>
<DICH_DATA CI_END="4.00250238948859" CI_START="0.2570330783326605" EFFECT_SIZE="1.0142857142857142" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6023315998646414" LOG_CI_START="-0.5900109824550045" LOG_EFFECT_SIZE="0.006160308704818433" MODIFIED="2014-02-20 09:13:36 +0000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.7003879350455318" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.49054325955734407" WEIGHT="15.815816176652062"/>
<DICH_DATA CI_END="3.226477749099707" CI_START="0.16414571724237792" EFFECT_SIZE="0.7277448071216617" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.50872867440935" LOG_CI_START="-0.7847704440480551" LOG_EFFECT_SIZE="-0.13802088481935254" MODIFIED="2014-02-20 09:13:35 +0000" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.7598077851057812" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.577307870307353" WEIGHT="13.68797785875338"/>
<DICH_DATA CI_END="16.182715183911206" CI_START="0.06694170992082278" EFFECT_SIZE="1.0408163265306123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2090513906050862" LOG_CI_START="-1.1743031984662406" LOG_EFFECT_SIZE="0.017374096069422723" MODIFIED="2014-02-20 09:13:35 +0000" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="1.3999942834159855" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="1.959983993597439" WEIGHT="4.353682003816678"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.571821717501447" CI_END="6.6959385051684395" CI_START="0.9183408898642521" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4797488028654624" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" I2="22.234111859704573" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.8258114564863015" LOG_CI_START="-0.03699607794255361" LOG_EFFECT_SIZE="0.3944076892718739" METHOD="MH" MODIFIED="2015-02-11 21:56:27 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.2763988319132381" P_Q="1.0" P_Z="0.07315178781242594" Q="0.0" RANDOM="YES" SCALE="70.42" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1803516806679238" TOTALS="YES" TOTAL_1="1964" TOTAL_2="1956" WEIGHT="100.0" Z="1.791882512269089">
<NAME>Pulmonary embolism</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.844656284468638" CI_START="0.19923396233650614" EFFECT_SIZE="0.9824561403508771" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6852629704365718" LOG_CI_START="-0.7006366277691538" LOG_EFFECT_SIZE="-0.0076868286662910065" MODIFIED="2014-02-20 09:14:44 +0000" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.814084284299696" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.6627332219437483" WEIGHT="30.46714430116173"/>
<DICH_DATA CI_END="60.53069000772904" CI_START="0.9985868286674504" EFFECT_SIZE="7.774647887323944" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.781975624595539" LOG_CI_START="-6.14166575291521E-4" LOG_EFFECT_SIZE="0.8906807290101236" MODIFIED="2014-02-20 09:14:44 +0000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="1.0471020672955231" STUDY_ID="STD-EVTET-2000" TOTAL_1="71" TOTAL_2="69" VAR="1.096422739334558" WEIGHT="20.118189230287655"/>
<DICH_DATA CI_END="8.634039355361953" CI_START="0.8797059941206652" EFFECT_SIZE="2.7559782608695653" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9362140239099611" LOG_CI_START="-0.055662448833287616" LOG_EFFECT_SIZE="0.44027578753833674" MODIFIED="2014-02-20 09:14:42 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.5826331499571096" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.3394613874289438" WEIGHT="49.414666468550614"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.962679632783499" CI_END="1.528366090527213" CI_START="0.6265006280954765" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9785306922499297" ESTIMABLE="YES" EVENTS_1="313" EVENTS_2="312" I2="59.69919180782928" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.1842273935411794" LOG_CI_START="-0.20307848926957134" LOG_EFFECT_SIZE="-0.009425547864195995" METHOD="MH" MODIFIED="2015-02-11 21:56:37 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.08363116305801555" P_Q="1.0" P_Z="0.9240002178722844" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0837132998652488" TOTALS="YES" TOTAL_1="1624" TOTAL_2="1531" WEIGHT="100.0" Z="0.0953960947575351">
<NAME>Revascularisation</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.72924878206047" CI_START="1.1252220490946176" EFFECT_SIZE="8.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8177586687679657" LOG_CI_START="0.05123823371916966" LOG_EFFECT_SIZE="0.9344984512435677" MODIFIED="2014-02-20 09:15:18 +0000" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="1.0376628479648444" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="1.0767441860465117" WEIGHT="4.46019818583355"/>
<DICH_DATA CI_END="1.2826827377375105" CI_START="0.5177781542562936" EFFECT_SIZE="0.8149509803921569" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="24" LOG_CI_END="0.10811925007048487" LOG_CI_START="-0.28585627697199795" LOG_EFFECT_SIZE="-0.08886851345075655" MODIFIED="2014-02-20 09:15:33 +0000" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.23142317479506588" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.05355668583222762" WEIGHT="37.705769014994154"/>
<DICH_DATA CI_END="1.0821737759007206" CI_START="0.8032447785490178" EFFECT_SIZE="0.9323360096955007" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="287" LOG_CI_END="0.03429700555331561" LOG_CI_START="-0.09515208887600168" LOG_EFFECT_SIZE="-0.030427541661343035" MODIFIED="2014-02-20 09:15:33 +0000" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.07603903885113282" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.005781935429404085" WEIGHT="57.8340327991723"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-03-04 19:06:24 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Hormone therapy versus placebo in both primary and secondary prevention</NAME>
<DICH_OUTCOME CHI2="9.636653830859922" CI_END="1.1128691072729822" CI_START="0.9174560063064865" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0104496260084097" ESTIMABLE="YES" EVENTS_1="794" EVENTS_2="772" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.04644408676779757" LOG_CI_START="-0.03741475179130978" LOG_EFFECT_SIZE="0.0045146674882438845" METHOD="MH" MODIFIED="2015-03-04 19:06:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7882367186924379" P_Q="1.0" P_Z="0.8328597616283606" Q="0.0" RANDOM="YES" SCALE="61.8" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20233" TOTAL_2="19635" WEIGHT="100.00000000000003" Z="0.21103525474884993">
<NAME>Death (all-causes)</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0803496976754556" CI_START="0.3105454039025519" EFFECT_SIZE="0.5792215752375115" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="0.033564354735557134" LOG_CI_START="-0.5078748939648187" LOG_EFFECT_SIZE="-0.23715526961463076" MODIFIED="2014-02-20 08:27:18 +0000" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.31804409485410695" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.10115204627156818" WEIGHT="2.3988230734145746"/>
<DICH_DATA CI_END="14.708063445162583" CI_START="0.05795613812724304" EFFECT_SIZE="0.9232673267326733" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1675554945871283" LOG_CI_START="-1.2369005611909631" LOG_EFFECT_SIZE="-0.03467253330191734" MODIFIED="2014-02-20 08:27:17 +0000" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="1.412389389413484" STUDY_ID="STD-EPHT-2006" TOTAL_1="404" TOTAL_2="373" VAR="1.9948437873277944" WEIGHT="0.12163652315070456"/>
<DICH_DATA CI_END="2.5045182817219462" CI_START="0.3623348097964439" EFFECT_SIZE="0.9526143790849673" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.3987242061680698" LOG_CI_START="-0.440889940941164" LOG_EFFECT_SIZE="-0.021082867386547133" MODIFIED="2014-02-20 08:27:30 +0000" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.4931935061690218" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="106" VAR="0.24323983452729292" WEIGHT="0.9975580808582986"/>
<DICH_DATA CI_END="1.6015303258325488" CI_START="0.11468622630812386" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20453516667579472" LOG_CI_START="-0.9404887372649836" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2014-02-20 08:27:31 +0000" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.6725927091345493" STUDY_ID="STD-ERT-II-1979" TOTAL_1="84" TOTAL_2="84" VAR="0.45238095238095233" WEIGHT="0.536375064516428"/>
<DICH_DATA CI_END="1.2655561496570695" CI_START="0.5134707001114593" EFFECT_SIZE="0.8061178587494376" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="39" LOG_CI_END="0.10228141851462516" LOG_CI_START="-0.28948433326039363" LOG_EFFECT_SIZE="-0.09360145737288424" MODIFIED="2014-02-20 08:27:31 +0000" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.2301251418643935" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.05295758091810723" WEIGHT="4.581890983550782"/>
<DICH_DATA CI_END="5.437669363215036" CI_START="0.045485176805895686" EFFECT_SIZE="0.49732620320855614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7354127968342812" LOG_CI_START="-1.3421301127994087" LOG_EFFECT_SIZE="-0.30335865798256384" MODIFIED="2014-02-20 08:27:32 +0000" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="1.2203589891220905" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.4892760623310908" WEIGHT="0.16292873340053204"/>
<DICH_DATA CI_END="1.3397868104508874" CI_START="0.8373884590019809" EFFECT_SIZE="1.05920820077766" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="123" LOG_CI_END="0.12703569805831066" LOG_CI_START="-0.07707302890728479" LOG_EFFECT_SIZE="0.02498133457551292" MODIFIED="2014-02-20 08:27:32 +0000" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.11989447657408399" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.014374685512973575" WEIGHT="16.880081466849585"/>
<DICH_DATA CI_END="14.447049921493582" CI_START="0.15961033592422763" EFFECT_SIZE="1.5185185185185186" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1597791734857832" LOG_CI_START="-0.7969389883642868" LOG_EFFECT_SIZE="0.1814200925607482" MODIFIED="2014-02-20 08:27:33 +0000" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="1.1493859341818446" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="1.3210880256950717" WEIGHT="0.18367122992555457"/>
<DICH_DATA CI_END="4.142475448090552" CI_START="0.7605657630275782" EFFECT_SIZE="1.775" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6172599430924868" LOG_CI_START="-0.11886322831026105" LOG_EFFECT_SIZE="0.24919835739111287" MODIFIED="2014-02-20 08:27:33 +0000" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.4324023947504401" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.18697183098591547" WEIGHT="1.2977669483143421"/>
<DICH_DATA CI_END="2.5310768550853693" CI_START="0.19693678897564382" EFFECT_SIZE="0.7060185185185185" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.40330533252796047" LOG_CI_START="-0.7056731474642131" LOG_EFFECT_SIZE="-0.15118390746812627" MODIFIED="2014-02-20 08:27:34 +0000" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.6514194486794126" STUDY_ID="STD-WELL_x002d_HART-2003" TOTAL_1="108" TOTAL_2="61" VAR="0.42434729811778993" WEIGHT="0.5718096087699917"/>
<DICH_DATA CI_END="1.6745591246049474" CI_START="0.7706372169075482" EFFECT_SIZE="1.1359918940435696" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" LOG_CI_END="0.22390048602719245" LOG_CI_START="-0.113150021137594" LOG_EFFECT_SIZE="0.0553752324447992" MODIFIED="2014-02-20 08:27:34 +0000" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.19798513633551407" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.03919811420979209" WEIGHT="6.190243265802849"/>
<DICH_DATA CI_END="1.211445169372503" CI_START="0.8408933751797771" EFFECT_SIZE="1.0093048188326859" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="218" LOG_CI_END="0.08330376252813565" LOG_CI_START="-0.0752590690139268" LOG_EFFECT_SIZE="0.0040223467571044195" MODIFIED="2014-02-20 08:27:12 +0000" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.09314059214648232" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.008675169905397363" WEIGHT="27.970156799853726"/>
<DICH_DATA CI_END="1.2060733092036264" CI_START="0.8787538223854828" EFFECT_SIZE="1.0294860516489746" ESTIMABLE="YES" EVENTS_1="291" EVENTS_2="289" LOG_CI_END="0.08137370648985735" LOG_CI_START="-0.05613277288271708" LOG_EFFECT_SIZE="0.012620466803570148" MODIFIED="2014-02-20 08:27:12 +0000" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.08077198665150079" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.006524113827630221" WEIGHT="37.19215650280486"/>
<DICH_DATA CI_END="5.5571126475582515" CI_START="0.048734778934554725" EFFECT_SIZE="0.5204081632653061" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7448492004055154" LOG_CI_START="-1.3121609995946324" LOG_EFFECT_SIZE="-0.28365589959455845" MODIFIED="2014-02-20 08:27:35 +0000" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="1.2082979738447959" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="1.459983993597439" WEIGHT="0.1661976183187123"/>
<DICH_DATA CI_END="4.8675616702834485" CI_START="0.5225830921689938" EFFECT_SIZE="1.5948998178506375" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6873114625842897" LOG_CI_START="-0.28184464569268525" LOG_EFFECT_SIZE="0.20273340844580218" MODIFIED="2015-02-11 21:35:52 +0000" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.5692870954020025" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.3240877969912487" WEIGHT="0.7487041004690732"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.590267092433372" CI_END="1.1835288434784417" CI_START="0.7767209156775396" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9587865283979301" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="239" I2="16.582093878157757" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.07317884647370657" LOG_CI_START="-0.10973499992974808" LOG_EFFECT_SIZE="-0.01827807672802073" METHOD="MH" MODIFIED="2015-02-11 21:57:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2949689671418273" P_Q="1.0" P_Z="0.6952742731894618" Q="0.0" RANDOM="YES" SCALE="65.44" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.016683046641602663" TOTALS="YES" TOTAL_1="17002" TOTAL_2="16611" WEIGHT="100.0" Z="0.39170760221795575">
<NAME>Death (cardiovascular causes)</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7453621898257934" CI_START="0.10434731502499545" EFFECT_SIZE="0.2788844621513944" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.12763264158821677" LOG_CI_START="-0.981518721345346" LOG_EFFECT_SIZE="-0.5545756814667814" MODIFIED="2014-02-20 08:29:30 +0000" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.5015769100536015" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.2515793966989186" WEIGHT="4.303368068211809"/>
<DICH_DATA CI_END="2.7760767745511554" CI_START="0.1040699784128669" EFFECT_SIZE="0.5375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4434314726988307" LOG_CI_START="-0.9826745355235449" LOG_EFFECT_SIZE="-0.26962153141235706" MODIFIED="2014-02-20 08:29:29 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.8377017285684156" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="0.7017441860465116" WEIGHT="1.606887907426032"/>
<DICH_DATA CI_END="4.072908653340096" CI_START="0.2651592104117885" EFFECT_SIZE="1.0392156862745099" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6099046698956698" LOG_CI_START="-0.5764932828899644" LOG_EFFECT_SIZE="0.016705693502852715" MODIFIED="2014-02-20 08:29:46 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6968960302308626" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="106" VAR="0.48566407695153535" WEIGHT="2.2980763268131676"/>
<DICH_DATA CI_END="1.2655561496570695" CI_START="0.5134707001114593" EFFECT_SIZE="0.8061178587494376" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="39" LOG_CI_END="0.10228141851462516" LOG_CI_START="-0.28948433326039363" LOG_EFFECT_SIZE="-0.09360145737288424" MODIFIED="2014-02-20 08:29:45 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.2301251418643935" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.05295758091810723" WEIGHT="16.5769906594002"/>
<DICH_DATA CI_END="1.667622090523034" CI_START="0.8477749983613915" EFFECT_SIZE="1.1890198968312453" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="59" LOG_CI_END="0.2220976394697986" LOG_CI_START="-0.07171939530942523" LOG_EFFECT_SIZE="0.07518912208018669" MODIFIED="2014-02-20 08:29:45 +0000" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.1725895806470948" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.02978716334794004" WEIGHT="24.842410499798977"/>
<DICH_DATA CI_END="3.8307740527034375" CI_START="0.47743203206466955" EFFECT_SIZE="1.3523809523809525" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.583286537115437" LOG_CI_START="-0.3210884464892002" LOG_EFFECT_SIZE="0.13109904531311845" MODIFIED="2014-02-20 08:29:44 +0000" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.5312343420977325" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.2822099262240107" WEIGHT="3.8623592301419833"/>
<DICH_DATA CI_END="1.8061954463740633" CI_START="0.37322405427999605" EFFECT_SIZE="0.8210454234193106" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.25676474303681374" LOG_CI_START="-0.42803037375614233" LOG_EFFECT_SIZE="-0.0856328153596643" MODIFIED="2014-02-20 08:29:44 +0000" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.4022520413946803" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.16180670480618758" WEIGHT="6.467777691481407"/>
<DICH_DATA CI_END="1.7287618699642935" CI_START="0.6905099259207638" EFFECT_SIZE="1.0925782492634957" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" LOG_CI_END="0.23773517506518782" LOG_CI_START="-0.16083007415756978" LOG_EFFECT_SIZE="0.03845255045380901" MODIFIED="2014-02-20 08:29:26 +0000" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.23411920032325045" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.05481179995999828" WEIGHT="16.147066361370843">
<FOOTNOTE>WHI I: data from Mason, J (2003) (5.6 year follow-up)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4258046817841077" CI_START="0.7100564630621944" EFFECT_SIZE="1.0061818073117508" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="63" LOG_CI_END="0.15406003643228386" LOG_CI_START="-0.1487071151945181" LOG_EFFECT_SIZE="0.0026764606188829066" MODIFIED="2014-02-20 08:29:26 +0000" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.1778469235871551" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.03162952822941538" WEIGHT="23.895063255355584">
<FOOTNOTE>WHI II: data from: Hsia, J (2006) (7.1 year follow-up) </FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.896569102744628" CI_END="1.1415755608485294" CI_START="0.8945660811306456" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0105517185096407" ESTIMABLE="YES" EVENTS_1="510" EVENTS_2="492" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.05750466271500271" LOG_CI_START="-0.04838757280438539" LOG_EFFECT_SIZE="0.004558544955308695" METHOD="MH" MODIFIED="2015-02-11 21:57:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.619482222807001" P_Q="1.0" P_Z="0.865994379494009" Q="0.0" RANDOM="YES" SCALE="60.8" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17676" TOTAL_2="17165" WEIGHT="99.99999999999999" Z="0.1687486129741">
<NAME>Non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.237815506875535" CI_START="0.028152007983818443" EFFECT_SIZE="0.250996015936255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3498242789534236" LOG_CI_START="-1.5504906230083364" LOG_EFFECT_SIZE="-0.6003331720274564" MODIFIED="2014-02-20 08:31:53 +0000" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="1.116254380122812" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="1.246023841143363" WEIGHT="0.31051106855081956"/>
<DICH_DATA CI_END="7.2747548900469" CI_START="0.15885414937912085" EFFECT_SIZE="1.075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8618183651227709" LOG_CI_START="-0.7990014366195226" LOG_EFFECT_SIZE="0.03140846425162412" MODIFIED="2014-02-20 08:31:53 +0000" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.9755737727340315" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="0.9517441860465116" WEIGHT="0.4065212060400381"/>
<DICH_DATA CI_END="15.788688730301793" CI_START="0.06333648202721173" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1983460628239087" LOG_CI_START="-1.1983460628239087" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-02-20 08:32:03 +0000" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="1.407828818422887" STUDY_ID="STD-EPAT-2001" TOTAL_1="111" TOTAL_2="111" VAR="1.9819819819819822" WEIGHT="0.19521075260548942"/>
<DICH_DATA CI_END="2.1744398918162573" CI_START="0.35804471566811946" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.3373474069365952" LOG_CI_START="-0.4460627315817805" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2014-02-20 08:32:04 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.4601789933084222" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.2117647058823529" WEIGHT="1.8270475844457725"/>
<DICH_DATA CI_END="3.1401207905561583" CI_START="0.03538434299893023" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49694635433532724" LOG_CI_START="-1.4511888637746524" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-02-20 08:32:04 +0000" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="1.1443442705426587" STUDY_ID="STD-ERT-II-1979" TOTAL_1="84" TOTAL_2="84" VAR="1.3095238095238095" WEIGHT="0.2954541120515516"/>
<DICH_DATA CI_END="2.037834008054848" CI_START="0.8285178372366147" EFFECT_SIZE="1.2993774759479344" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="31" LOG_CI_END="0.309168805616549" LOG_CI_START="-0.08169813717820539" LOG_EFFECT_SIZE="0.11373533421917185" MODIFIED="2014-02-20 08:32:05 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.22959717702021" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.05271486369564965" WEIGHT="7.339565489290111"/>
<DICH_DATA CI_END="3.1584379030652805" CI_START="0.03480389286499995" EFFECT_SIZE="0.3315508021390374" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4994723428035393" LOG_CI_START="-1.4583721768800295" LOG_EFFECT_SIZE="-0.4794499170382451" MODIFIED="2014-02-20 08:32:05 +0000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="1.1500475623488031" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.322609395664424" WEIGHT="0.292530958589522"/>
<DICH_DATA CI_END="1.1525832151445718" CI_START="0.7223105551950677" EFFECT_SIZE="0.9124269954574952" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="134" LOG_CI_END="0.061672290741459045" LOG_CI_START="-0.14127603870542968" LOG_EFFECT_SIZE="-0.039801873981985314" MODIFIED="2014-02-20 08:32:06 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.11921285332753537" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.01421170439849246" WEIGHT="27.224334499545606"/>
<DICH_DATA CI_END="4.9978539581179335" CI_START="0.36454536327993514" EFFECT_SIZE="1.3497942386831276" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6987835614922779" LOG_CI_START="-0.43824842126554414" LOG_EFFECT_SIZE="0.13026757011336693" MODIFIED="2014-02-20 08:32:06 +0000" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.667898215071033" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="0.4460880256950718" WEIGHT="0.86732701186132"/>
<DICH_DATA CI_END="4.00250238948859" CI_START="0.2570330783326605" EFFECT_SIZE="1.0142857142857142" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6023315998646414" LOG_CI_START="-0.5900109824550045" LOG_EFFECT_SIZE="0.006160308704818433" MODIFIED="2014-02-20 08:32:07 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.7003879350455318" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.49054325955734407" WEIGHT="0.7887259417290874"/>
<DICH_DATA CI_END="2.4106942128632998" CI_START="0.5316026748768943" EFFECT_SIZE="1.132047477744807" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.38214212531381375" LOG_CI_START="-0.27441284247469255" LOG_EFFECT_SIZE="0.05386464141956063" MODIFIED="2014-02-20 08:32:06 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.3856636380784744" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.1487364417359245" WEIGHT="2.601273701573115"/>
<DICH_DATA CI_END="1.6059104861712061" CI_START="0.9911892401499814" EFFECT_SIZE="1.261650187071252" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="114" LOG_CI_END="0.20572133394058245" LOG_CI_START="-0.003843421088058969" LOG_EFFECT_SIZE="0.10093895642626174" MODIFIED="2014-02-20 08:31:48 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.12309937446609172" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.015153455993943075" WEIGHT="25.53240623840992">
<FOOTNOTE>WHI I: data from Mason, J (2003) (5.6 year follow-up)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1268642977624101" CI_START="0.7296809280619876" EFFECT_SIZE="0.9067807819926464" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="168" LOG_CI_END="0.05187161943437449" LOG_CI_START="-0.13686700491313059" LOG_EFFECT_SIZE="-0.04249769273937804" MODIFIED="2014-02-20 08:31:47 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.11086600221298273" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.012291270446689094" WEIGHT="31.477966092385746">
<FOOTNOTE>WHI II: data from: Hsia, J (2006) (7.1 year follow-up) </FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.9662875568276528" CI_START="0.13773400307232253" EFFECT_SIZE="0.5204081632653061" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.293647030897579" LOG_CI_START="-0.8609588300866959" LOG_EFFECT_SIZE="-0.28365589959455845" MODIFIED="2014-02-20 08:32:08 +0000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.6782211981333516" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="0.45998399359743897" WEIGHT="0.8411253429218815"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.493943554580366" CI_END="1.405333644578358" CI_START="1.0958266675918449" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2409682045052581" ESTIMABLE="YES" EVENTS_1="540" EVENTS_2="420" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.14777944366982426" LOG_CI_START="0.039741865041071266" LOG_EFFECT_SIZE="0.09376065435544777" METHOD="MH" MODIFIED="2015-02-11 21:57:28 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7893018438178414" P_Q="1.0" P_Z="6.691464858552176E-4" Q="0.0" RANDOM="YES" SCALE="56.49" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17609" TOTAL_2="17063" WEIGHT="100.00000000000001" Z="3.401918259109862">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7207755883404043" CI_START="0.3616252119729508" EFFECT_SIZE="0.7888446215139442" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.235724236335556" LOG_CI_START="-0.44174129877457013" LOG_EFFECT_SIZE="-0.10300853121950705" MODIFIED="2014-02-20 08:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.3979466088321716" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.1583615034810254" WEIGHT="2.543169297570546"/>
<DICH_DATA CI_END="14.708063445162583" CI_START="0.05795613812724304" EFFECT_SIZE="0.9232673267326733" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1675554945871283" LOG_CI_START="-1.2369005611909631" LOG_EFFECT_SIZE="-0.03467253330191734" MODIFIED="2014-02-20 08:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="1.412389389413484" STUDY_ID="STD-EPHT-2006" TOTAL_1="404" TOTAL_2="373" VAR="1.9948437873277944" WEIGHT="0.20189055209658696"/>
<DICH_DATA CI_END="2.480447841704783" CI_START="0.3589806450563251" EFFECT_SIZE="0.9436274509803921" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.3945300992222517" LOG_CI_START="-0.4449289663850102" LOG_EFFECT_SIZE="-0.025199433581379285" MODIFIED="2014-02-20 08:34:32 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.49310241052709763" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.24314998726763434" WEIGHT="1.6563443744981996"/>
<DICH_DATA CI_END="4.4716378934767445" CI_START="0.5995939113652367" EFFECT_SIZE="1.6374269005847952" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6504666277871072" LOG_CI_START="-0.22214278588697645" LOG_EFFECT_SIZE="0.21416192095006537" MODIFIED="2014-02-20 08:34:32 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.5125750890784181" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.26273322194374826" WEIGHT="1.5328861367074562"/>
<DICH_DATA CI_END="1.443608728726371" CI_START="0.8482150081747728" EFFECT_SIZE="1.1065670289855072" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="96" LOG_CI_END="0.15944949934080593" LOG_CI_START="-0.07149404747425424" LOG_EFFECT_SIZE="0.043977725933275875" MODIFIED="2014-02-20 08:34:31 +0000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.13565738258816024" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.01840292545067048" WEIGHT="21.884570181496976"/>
<DICH_DATA CI_END="6.0191240439104305" CI_START="0.4729572342801669" EFFECT_SIZE="1.6872427983539096" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.7795332934877255" LOG_CI_START="-0.3251781272448788" LOG_EFFECT_SIZE="0.22717758312142333" MODIFIED="2014-02-20 08:34:31 +0000" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.6489129569480577" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="0.4210880256950718" WEIGHT="0.9564273714629364"/>
<DICH_DATA CI_END="7.296409439022344" CI_START="0.7137998578525512" EFFECT_SIZE="2.282142857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.863109196498933" LOG_CI_START="-0.1464235428665713" LOG_EFFECT_SIZE="0.3583428268161809" MODIFIED="2014-02-20 08:34:30 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.593004528370952" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.3516543706684552" WEIGHT="1.1452725948052105"/>
<DICH_DATA CI_END="1.5126921475891875" CI_START="0.7877532362135619" EFFECT_SIZE="1.0916172106824926" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="56" LOG_CI_END="0.17975055247326543" LOG_CI_START="-0.10360980400060796" LOG_EFFECT_SIZE="0.03807037423632875" MODIFIED="2014-02-20 08:34:30 +0000" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.16644727604913953" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.027704695704178457" WEIGHT="14.53688998682318"/>
<DICH_DATA CI_END="1.7187314984683026" CI_START="1.0512645603883475" EFFECT_SIZE="1.344188049776848" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="107" LOG_CI_END="0.23520803617426786" LOG_CI_START="0.021712023980781564" LOG_EFFECT_SIZE="0.12846003007752468" MODIFIED="2014-02-20 08:34:05 +0000" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.12540861438475842" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.015727320561905036" WEIGHT="25.60767499999831">
<FOOTNOTE>WHI I: data from Wassertheil-Smoller, S (2003) (5.6 year follow-up)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6977059474243292" CI_START="1.0774553764550976" EFFECT_SIZE="1.3524800925308065" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="127" LOG_CI_END="0.22986247008341917" LOG_CI_START="0.032399292604814244" LOG_EFFECT_SIZE="0.13113088134411674" MODIFIED="2014-02-20 08:34:05 +0000" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.11599084790942531" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.013453876798747435" WEIGHT="29.934874504540605">
<FOOTNOTE>WHI II: data from Hendrix, S (2006) (7.1 year follow-up)</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.680726915044771" CI_END="1.0282567633144803" CI_START="0.7942663515803884" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9037199499212415" ESTIMABLE="YES" EVENTS_1="423" EVENTS_2="449" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.01210157474381741" LOG_CI_START="-0.10003383557788866" LOG_EFFECT_SIZE="-0.04396613041703563" METHOD="MH" MODIFIED="2015-02-11 21:57:40 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6125915278309819" P_Q="1.0" P_Z="0.12431091481926393" Q="0.0" RANDOM="YES" SCALE="52.92" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15440" TOTAL_2="15062" WEIGHT="100.0" Z="1.5369281105720538">
<NAME>Angina</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6511292936325925" CI_START="0.6276947729395124" EFFECT_SIZE="1.29" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4234309084731628" LOG_CI_START="-0.20225148787466488" LOG_EFFECT_SIZE="0.11058971029924898" MODIFIED="2014-02-20 08:35:16 +0000" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.3675289367925265" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="0.13507751937984497" WEIGHT="3.212015857194118"/>
<DICH_DATA CI_END="1.2544479834030453" CI_START="0.4751690264371088" EFFECT_SIZE="0.7720588235294118" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="0.09845265768778795" LOG_CI_START="-0.3231518762883468" LOG_EFFECT_SIZE="-0.11234960930027943" MODIFIED="2014-02-20 08:35:24 +0000" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.24765259023368302" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.06133180544945251" WEIGHT="7.074162109186382"/>
<DICH_DATA CI_END="1.1669688574562547" CI_START="0.7100965863809147" EFFECT_SIZE="0.9103079710144928" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="120" LOG_CI_END="0.06705926631497713" LOG_CI_START="-0.14868257511283134" LOG_EFFECT_SIZE="-0.0408116543989271" MODIFIED="2014-02-20 08:35:24 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.12672782559403326" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.016059941779791708" WEIGHT="27.015735184323624"/>
<DICH_DATA CI_END="1.0356359818040024" CI_START="0.6200079100008957" EFFECT_SIZE="0.8013129854183229" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="126" LOG_CI_END="0.015207131012988456" LOG_CI_START="-0.20760276977944395" LOG_EFFECT_SIZE="-0.09619781938322772" MODIFIED="2014-02-20 08:35:14 +0000" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.13087963865227148" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.017129479813749158" WEIGHT="25.328914766591836">
<FOOTNOTE>WHI I: data from Mason, J (2003) (5.6 year follow-up)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2037467411083038" CI_START="0.7890390637571149" EFFECT_SIZE="0.9745784738053546" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="171" LOG_CI_END="0.08053512437300911" LOG_CI_START="-0.10290149520097967" LOG_EFFECT_SIZE="-0.011183185413985277" MODIFIED="2014-02-20 08:35:13 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.10775157836367237" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.011610402639862629" WEIGHT="37.36917208270404">
<FOOTNOTE>WHI II: data from: Hsia, J (2006) (7.1 year follow-up) </FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.94578772787114" CI_END="2.6919134568907035" CI_START="1.3628409835874438" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.915372022172508" ESTIMABLE="YES" EVENTS_1="353" EVENTS_2="188" I2="39.78236434325467" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.4300610935166582" LOG_CI_START="0.13444518527025004" LOG_EFFECT_SIZE="0.28225313939345414" METHOD="MH" MODIFIED="2015-02-11 21:57:54 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.09243595142676775" P_Q="1.0" P_Z="1.8202824127316457E-4" Q="0.0" RANDOM="YES" SCALE="75.17" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07867658207216284" TOTALS="YES" TOTAL_1="18914" TOTAL_2="18399" WEIGHT="100.0" Z="3.7427348955348743">
<NAME>Venous thromboembolism</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.099608827297346" CI_START="0.14197739970945414" EFFECT_SIZE="1.00398406374502" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8512344207153756" LOG_CI_START="-0.8477807821143637" LOG_EFFECT_SIZE="0.0017268193005059549" MODIFIED="2014-02-20 08:36:09 +0000" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.9980099404030819" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.9960238411433631" WEIGHT="2.805713921087844"/>
<DICH_DATA CI_END="28.898052239974323" CI_START="0.44920623069365717" EFFECT_SIZE="3.6029411764705883" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4608685718244399" LOG_CI_START="-0.3475542285078478" LOG_EFFECT_SIZE="0.5566571716582962" MODIFIED="2014-05-26 09:23:23 +0100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="1.0622765047524207" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="1.1284313725490196" WEIGHT="2.4979554868073652"/>
<DICH_DATA CI_END="21.750677452860142" CI_START="0.1819407072235827" EFFECT_SIZE="1.9893048128342246" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3374727881622435" LOG_CI_START="-0.7400701214714465" LOG_EFFECT_SIZE="0.29870133334539856" MODIFIED="2014-05-26 09:23:24 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="1.2203589891220905" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.4892760623310908" WEIGHT="1.9230822749512253"/>
<DICH_DATA CI_END="4.944828188696005" CI_START="1.3893322295528723" EFFECT_SIZE="2.6210702341137124" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="13" LOG_CI_END="0.6941512063482554" LOG_CI_START="0.1428061105387294" LOG_EFFECT_SIZE="0.4184786584434924" MODIFIED="2014-05-26 09:23:25 +0100" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.32386283848075587" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.10488713814881216" WEIGHT="16.426459077997343"/>
<DICH_DATA CI_END="17.920833529726732" CI_START="0.2287491309184868" EFFECT_SIZE="2.0246913580246915" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2533582056018944" LOG_CI_START="-0.6406405472637983" LOG_EFFECT_SIZE="0.30635882916904816" MODIFIED="2014-05-26 09:23:26 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="1.1125442428783399" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="1.2377546923617384" WEIGHT="2.2905122333191716"/>
<DICH_DATA CI_END="3.226477749099707" CI_START="0.16414571724237792" EFFECT_SIZE="0.7277448071216617" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.50872867440935" LOG_CI_START="-0.7847704440480551" LOG_EFFECT_SIZE="-0.13802088481935254" MODIFIED="2014-05-26 09:23:27 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.7598077851057812" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.577307870307353" WEIGHT="4.59660579984343"/>
<DICH_DATA CI_END="2.740348899453019" CI_START="1.5985772138600978" EFFECT_SIZE="2.093002462657938" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="76" LOG_CI_END="0.43780586043379544" LOG_CI_START="0.2037336182389182" LOG_EFFECT_SIZE="0.32076973933635683" MODIFIED="2014-02-20 08:36:07 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.13749519374155664" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.018904928302028192" WEIGHT="30.900340923727953">
<FOOTNOTE>WHI I: data from Cushman, M (2004) (5.6 year follow-up)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7442992723607342" CI_START="0.9983405160360681" EFFECT_SIZE="1.319622914203127" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="86" LOG_CI_END="0.2416209996243175" LOG_CI_START="-7.213033897165705E-4" LOG_EFFECT_SIZE="0.12044984811730046" MODIFIED="2014-02-20 08:36:06 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.14235306840419062" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.020264396084088178" WEIGHT="30.475764386045682">
<FOOTNOTE>WHI II: data from Curb, J (2006) (7.1 year follow-up)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="16.182715183911206" CI_START="0.06694170992082278" EFFECT_SIZE="1.0408163265306123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2090513906050862" LOG_CI_START="-1.1743031984662406" LOG_EFFECT_SIZE="0.017374096069422723" MODIFIED="2014-05-26 09:23:30 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="1.3999942834159855" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="1.959983993597439" WEIGHT="1.4790603077338744"/>
<DICH_DATA CI_END="24.387203426488465" CI_START="2.1911277687368984" EFFECT_SIZE="7.309957498482088" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="1.387162000966482" LOG_CI_START="0.34066770281836045" LOG_EFFECT_SIZE="0.8639148518924211" MODIFIED="2014-02-20 08:36:05 +0000" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.614715930962528" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.37787567577912745" WEIGHT="6.604505588486112"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.765193824092775" CI_END="2.4800116435588024" CI_START="1.32479333815419" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8125956261481835" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="89" I2="11.31074502799466" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.3944537198268078" LOG_CI_START="0.12214813555633264" LOG_EFFECT_SIZE="0.2583009276915702" METHOD="MH" MODIFIED="2015-02-11 21:58:04 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.34310904424410227" P_Q="1.0" P_Z="2.0054707435354942E-4" Q="0.0" RANDOM="YES" SCALE="56.49" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02190914671155624" TOTALS="YES" TOTAL_1="18313" TOTAL_2="18003" WEIGHT="100.0" Z="3.718326356068445">
<NAME>Pulmonary embolism</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.844656284468638" CI_START="0.19923396233650614" EFFECT_SIZE="0.9824561403508771" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6852629704365718" LOG_CI_START="-0.7006366277691538" LOG_EFFECT_SIZE="-0.0076868286662910065" MODIFIED="2014-02-20 08:37:26 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.814084284299696" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.6627332219437483" WEIGHT="3.737012303504024"/>
<DICH_DATA CI_END="27.352988809612235" CI_START="0.31075577319295566" EFFECT_SIZE="2.915492957746479" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.437004787803021" LOG_CI_START="-0.5075807943273358" LOG_EFFECT_SIZE="0.46471199673784247" MODIFIED="2014-02-20 08:37:15 +0000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="1.1422591967972469" STUDY_ID="STD-EVTET-2000" TOTAL_1="71" TOTAL_2="69" VAR="1.3047560726678913" WEIGHT="1.9285324720895045"/>
<DICH_DATA CI_END="8.634039355361953" CI_START="0.8797059941206652" EFFECT_SIZE="2.7559782608695653" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9362140239099611" LOG_CI_START="-0.055662448833287616" LOG_EFFECT_SIZE="0.44027578753833674" MODIFIED="2014-02-20 08:37:27 +0000" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.5826331499571096" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.3394613874289438" WEIGHT="7.080037561032204"/>
<DICH_DATA CI_END="5.324718043950029" CI_START="0.044205783911614754" EFFECT_SIZE="0.48516320474777447" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7262966158293405" LOG_CI_START="-1.354520903579408" LOG_EFFECT_SIZE="-0.3141121438750338" MODIFIED="2014-02-20 08:37:28 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="1.2222825111135396" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="1.4939745369740198" WEIGHT="1.687805590033448"/>
<DICH_DATA CI_END="3.153995654871901" CI_START="1.4733378279605502" EFFECT_SIZE="2.1556672070488943" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="38" LOG_CI_END="0.4988610906839251" LOG_CI_START="0.16830233950871978" LOG_EFFECT_SIZE="0.3335817150963225" MODIFIED="2014-02-20 08:37:14 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.19417184673252372" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.03770270606351868" WEIGHT="42.919601321883185">
<FOOTNOTE>WHI I: data from Cushman, M (2004) (5.6 year follow-up)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.0612171944924533" CI_START="0.9015801840238" EFFECT_SIZE="1.3632140615191464" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="39" LOG_CI_END="0.3141237566504989" LOG_CI_START="-0.044995642285477463" LOG_EFFECT_SIZE="0.13456405718251074" MODIFIED="2014-02-20 08:37:13 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.21094851260468717" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.044499274970129864" WEIGHT="38.52699537761473">
<FOOTNOTE>WHI II: data from Curb, J (2006) (7.1 year follow-up)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="22.720606039534655" CI_START="1.0933191344746165" EFFECT_SIZE="4.984061930783242" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3564199113750486" LOG_CI_START="0.03874694887674371" LOG_EFFECT_SIZE="0.6975834301258962" MODIFIED="2014-02-20 08:37:13 +0000" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.7740076207578636" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.5990877969912487" WEIGHT="4.120015373842901"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.552179806714609" CI_END="1.0516466230541057" CI_START="0.8531583569276207" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9472175594832064" ESTIMABLE="YES" EVENTS_1="781" EVENTS_2="795" I2="9.945279618769227" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.021869831605385196" LOG_CI_START="-0.06897035082916557" LOG_EFFECT_SIZE="-0.023550259611890185" METHOD="MH" MODIFIED="2015-02-11 21:58:16 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.35225820332584523" P_Q="1.0" P_Z="0.30951568049234424" Q="0.0" RANDOM="YES" SCALE="65.44" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.001837560519368683" TOTALS="YES" TOTAL_1="15551" TOTAL_2="15173" WEIGHT="100.0" Z="1.0162388367973407">
<NAME>Revascularisation</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.72924878206047" CI_START="1.1252220490946176" EFFECT_SIZE="8.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8177586687679657" LOG_CI_START="0.05123823371916966" LOG_EFFECT_SIZE="0.9344984512435677" MODIFIED="2014-02-20 08:38:04 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.0376628479648444" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="1.0767441860465117" WEIGHT="0.26398432101163144"/>
<DICH_DATA CI_END="5.434937107167446" CI_START="0.04599869236210789" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7351945228163949" LOG_CI_START="-1.3372545141443573" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-02-20 08:38:14 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="1.2173668230989303" STUDY_ID="STD-EPAT-2001" TOTAL_1="111" TOTAL_2="111" VAR="1.4819819819819822" WEIGHT="0.19188901471317174"/>
<DICH_DATA CI_END="1.2826827377375105" CI_START="0.5177781542562936" EFFECT_SIZE="0.8149509803921569" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="24" LOG_CI_END="0.10811925007048487" LOG_CI_START="-0.28585627697199795" LOG_EFFECT_SIZE="-0.08886851345075655" MODIFIED="2014-02-20 08:38:14 +0000" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.23142317479506588" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.05355668583222762" WEIGHT="5.140040505570096"/>
<DICH_DATA CI_END="1.0821737759007206" CI_START="0.8032447785490178" EFFECT_SIZE="0.9323360096955007" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="287" LOG_CI_END="0.03429700555331561" LOG_CI_START="-0.09515208887600168" LOG_EFFECT_SIZE="-0.030427541661343035" MODIFIED="2014-02-20 08:38:15 +0000" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.07603903885113282" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.005781935429404085" WEIGHT="37.36843905909461"/>
<DICH_DATA CI_END="1.2013169418641771" CI_START="0.822992625444723" EFFECT_SIZE="0.9943213685604996" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="205" LOG_CI_END="0.07965760186052834" LOG_CI_START="-0.08460405633452547" LOG_EFFECT_SIZE="-0.0024732272369985524" MODIFIED="2014-02-20 08:38:03 +0000" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.09648811113209632" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.009309955589839769" WEIGHT="25.541893569234873"/>
<DICH_DATA CI_END="1.106827250868629" CI_START="0.7935854125210353" EFFECT_SIZE="0.937209667294413" ESTIMABLE="YES" EVENTS_1="253" EVENTS_2="276" LOG_CI_END="0.04407984323741782" LOG_CI_START="-0.10040632386779591" LOG_EFFECT_SIZE="-0.02816324031518905" MODIFIED="2014-02-20 08:38:02 +0000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.08487188977566461" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.007203237674092562" WEIGHT="31.49375353037561"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.675032678132622" CI_END="1.186986739366556" CI_START="0.9154904445076123" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0424370569235006" ESTIMABLE="YES" EVENTS_1="467" EVENTS_2="446" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.07444586718365602" LOG_CI_START="-0.03834618431616041" LOG_EFFECT_SIZE="0.0180498414337478" METHOD="MH" MODIFIED="2015-02-11 21:58:35 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8783207246117007" P_Q="0.6039243199955594" P_Z="0.530464789642626" Q="5.4607339249368705" RANDOM="YES" SCALE="5.24" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="83776" TOTAL_2="82844" WEIGHT="800.0" Z="0.6272966696924053">
<NAME>Death (all-causes): by year on treatment</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5716948236130646" CI_END="2.302510672750743" CI_START="0.9251710387554472" DF="1" EFFECT_SIZE="1.459526015819625" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="31" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.3622016519442446" LOG_CI_START="-0.033777970697743846" LOG_EFFECT_SIZE="0.16421184062325037" MODIFIED="2013-05-09 14:34:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4495863452924197" P_Z="0.10403794031263389" STUDIES="2" TAU2="0.0" TOTAL_1="13816" TOTAL_2="13531" WEIGHT="100.00000000000001" Z="1.6255851314227412">
<NAME>1-year follow-up</NAME>
<DICH_DATA CI_END="2.3194969544138413" CI_START="0.6550695815134098" EFFECT_SIZE="1.2326523837844567" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.3653938066102726" LOG_CI_START="-0.18371256678327808" LOG_EFFECT_SIZE="0.09084061991349728" MODIFIED="2013-05-09 14:34:07 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.32254780185175724" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.10403708447940044" WEIGHT="52.00351578269258"/>
<DICH_DATA CI_END="3.384485596207079" CI_START="0.90766247927824" EFFECT_SIZE="1.7527037933817595" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" LOG_CI_END="0.5294926701540351" LOG_CI_START="-0.04207561693887762" LOG_EFFECT_SIZE="0.24370852660757877" MODIFIED="2013-05-09 13:58:06 +0100" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.3357420411470286" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.11272271819357306" WEIGHT="47.99648421730743"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24301782803572097" CI_END="1.5023761066697496" CI_START="0.7193175202899379" DF="1" EFFECT_SIZE="1.0395602222057823" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="55" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="0.17677866809030257" LOG_CI_START="-0.14307936153631162" LOG_EFFECT_SIZE="0.016849653276995443" MODIFIED="2013-05-17 09:22:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6220349554618567" P_Z="0.8364034317864399" STUDIES="2" TAU2="0.0" TOTAL_1="13770" TOTAL_2="13500" WEIGHT="100.0" Z="0.20649607335760653">
<NAME>2-year follow-up</NAME>
<DICH_DATA CI_END="1.579283619915902" CI_START="0.5750407181892003" EFFECT_SIZE="0.9529702970297029" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.19846013096044968" LOG_CI_START="-0.24030140216465823" LOG_EFFECT_SIZE="-0.020920635602104307" MODIFIED="2013-05-17 09:20:45 +0100" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="0.2577306964623054" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8484" TOTAL_2="8085" VAR="0.066425111898945" WEIGHT="53.144389757911654"/>
<DICH_DATA CI_END="1.9648478659348407" CI_START="0.6699613054985298" EFFECT_SIZE="1.1473325766174802" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="25" LOG_CI_END="0.2933289294988189" LOG_CI_START="-0.1739502798271603" LOG_EFFECT_SIZE="0.05968932483582927" MODIFIED="2013-05-17 09:22:35 +0100" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.274482120627471" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5286" TOTAL_2="5415" VAR="0.07534043454415355" WEIGHT="46.85561024208835"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09600176057889555" CI_END="1.542817828521998" CI_START="0.8086311012995785" DF="1" EFFECT_SIZE="1.1169469458225703" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="69" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="0.18831464885098295" LOG_CI_START="-0.09224955899167127" LOG_EFFECT_SIZE="0.048032544929655877" MODIFIED="2013-05-17 09:22:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7566815057404327" P_Z="0.5021625610054382" STUDIES="2" TAU2="0.0" TOTAL_1="13712" TOTAL_2="13445" WEIGHT="100.00000000000001" Z="0.6710910053125815">
<NAME>3-year follow-up</NAME>
<DICH_DATA CI_END="1.6739647679943366" CI_START="0.6733694588085768" EFFECT_SIZE="1.0616952245767008" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="35" LOG_CI_END="0.2237463131395196" LOG_CI_START="-0.17174658526259884" LOG_EFFECT_SIZE="0.02599986393846038" MODIFIED="2013-05-17 09:20:56 +0100" MODIFIED_BY="[Empty name]" ORDER="465" O_E="0.0" SE="0.2323144862428252" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8454" TOTAL_2="8055" VAR="0.05397002051826782" WEIGHT="50.32539051518406"/>
<DICH_DATA CI_END="1.8594796669932752" CI_START="0.743560503789481" EFFECT_SIZE="1.1758552793502337" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" LOG_CI_END="0.26939143380502056" LOG_CI_START="-0.1286836870037429" LOG_EFFECT_SIZE="0.07035387340063882" MODIFIED="2013-05-17 09:22:46 +0100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="0.23383129646669554" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5258" TOTAL_2="5390" VAR="0.054677075207295665" WEIGHT="49.67460948481595"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29731031029094235" CI_END="1.358408550149739" CI_START="0.7616131529286644" DF="1" EFFECT_SIZE="1.0171439518793781" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="90" I2="0.0" ID="CMP-003.09.04" LOG_CI_END="0.13303040646227798" LOG_CI_START="-0.11826556436752274" LOG_EFFECT_SIZE="0.007382421047377686" MODIFIED="2013-05-17 09:23:02 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5855736343977477" P_Z="0.9083204644429981" STUDIES="2" TAU2="0.0" TOTAL_1="13634" TOTAL_2="13376" WEIGHT="100.0" Z="0.11515727310542914">
<NAME>4-year follow-up</NAME>
<DICH_DATA CI_END="1.6063776218542656" CI_START="0.7423962247801201" EFFECT_SIZE="1.0920479302832244" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="48" LOG_CI_END="0.20584764543199321" LOG_CI_START="-0.12936424525003826" LOG_EFFECT_SIZE="0.0382417000909775" MODIFIED="2013-05-17 09:21:46 +0100" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="0.1969051239122454" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8415" TOTAL_2="8020" VAR="0.03877162782289671" WEIGHT="56.19946995599793"/>
<DICH_DATA CI_END="1.4376059799707583" CI_START="0.5997017066647656" EFFECT_SIZE="0.9285121214609622" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="42" LOG_CI_END="0.1576398706276987" LOG_CI_START="-0.22206471522085744" LOG_EFFECT_SIZE="-0.032212422296579384" MODIFIED="2013-05-17 09:23:02 +0100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="0.22304035329545513" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5219" TOTAL_2="5356" VAR="0.04974699919816144" WEIGHT="43.80053004400207"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.006261541352962652" CI_END="1.2332141449304304" CI_START="0.6550334881934053" DF="1" EFFECT_SIZE="0.8987750347240557" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="80" I2="0.0" ID="CMP-003.09.05" LOG_CI_END="0.09103849742813451" LOG_CI_START="-0.18373649639626488" LOG_EFFECT_SIZE="-0.046348999484065165" MODIFIED="2013-05-17 09:23:19 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9369293000567857" P_Z="0.5084758663325551" STUDIES="2" TAU2="0.0" TOTAL_1="13541" TOTAL_2="13286" WEIGHT="100.00000000000001" Z="0.6612127868250485">
<NAME>5 year follow-up</NAME>
<DICH_DATA CI_END="1.3582438287629104" CI_START="0.5813084622993743" EFFECT_SIZE="0.888571117877338" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="44" LOG_CI_END="0.13297774047527572" LOG_CI_START="-0.23559335482931237" LOG_EFFECT_SIZE="-0.05130780717701832" MODIFIED="2013-05-17 09:21:46 +0100" MODIFIED_BY="[Empty name]" ORDER="467" O_E="0.0" SE="0.2165004858382613" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8360" TOTAL_2="7972" VAR="0.046872460368203174" WEIGHT="55.57914570518597"/>
<DICH_DATA CI_END="1.4655188006307842" CI_START="0.5671781300734677" EFFECT_SIZE="0.9117073066117652" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" LOG_CI_END="0.16599139422299244" LOG_CI_START="-0.24628052354347998" LOG_EFFECT_SIZE="-0.04014456466024378" MODIFIED="2013-05-17 09:23:19 +0100" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="0.24217056527493208" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5181" TOTAL_2="5314" VAR="0.05864658268558014" WEIGHT="44.42085429481404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8209019894603817" CI_START="0.8117267511392496" DF="0" EFFECT_SIZE="1.2157610192992996" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="43" I2="0.0" ID="CMP-003.09.06" LOG_CI_END="0.2602865704066432" LOG_CI_START="-0.09059014125635109" LOG_EFFECT_SIZE="0.08484821457514606" MODIFIED="2013-05-17 09:23:39 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.3431762346566275" STUDIES="1" TAU2="0.0" TOTAL_1="5149" TOTAL_2="5278" WEIGHT="100.00000000000001" Z="0.9479081352058386">
<NAME>6 year follow-up</NAME>
<DICH_DATA CI_END="1.8209019894603815" CI_START="0.8117267511392496" EFFECT_SIZE="1.2157610192992996" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="43" LOG_CI_END="0.26028657040664316" LOG_CI_START="-0.09059014125635109" LOG_EFFECT_SIZE="0.08484821457514606" MODIFIED="2013-05-17 09:23:39 +0100" MODIFIED_BY="[Empty name]" ORDER="423" O_E="0.0" SE="0.2061067172985774" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5149" TOTAL_2="5278" VAR="0.04247997891559571" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5721992623495484" CI_START="0.6706966259983375" DF="0" EFFECT_SIZE="1.0268732836406433" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" I2="0.0" ID="CMP-003.09.07" LOG_CI_END="0.19650758817580072" LOG_CI_START="-0.17347387841257594" LOG_EFFECT_SIZE="0.011516854881612406" MODIFIED="2013-05-17 09:23:57 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.9028829584301953" STUDIES="1" TAU2="0.0" TOTAL_1="5098" TOTAL_2="5235" WEIGHT="100.0" Z="0.12202027842788041">
<NAME>7-year follow-up</NAME>
<DICH_DATA CI_END="1.5721992623495484" CI_START="0.6706966259983375" EFFECT_SIZE="1.0268732836406433" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.19650758817580072" LOG_CI_START="-0.17347387841257594" LOG_EFFECT_SIZE="0.011516854881612406" MODIFIED="2013-05-17 09:23:57 +0100" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.2173289449118091" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5098" TOTAL_2="5235" VAR="0.047231870296480155" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2266181437251893" CI_START="0.448595409085837" DF="0" EFFECT_SIZE="0.7417919303797469" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" I2="0.0" ID="CMP-003.09.08" LOG_CI_END="0.08870938433765833" LOG_CI_START="-0.34814517528914146" LOG_EFFECT_SIZE="-0.12971789547574156" MODIFIED="2013-05-17 10:48:04 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.2444369274807825" STUDIES="1" TAU2="0.0" TOTAL_1="5056" TOTAL_2="5193" WEIGHT="100.0" Z="1.163968179707138">
<NAME>8-year follow-up</NAME>
<DICH_DATA CI_END="1.2266181437251893" CI_START="0.448595409085837" EFFECT_SIZE="0.7417919303797469" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" LOG_CI_END="0.08870938433765833" LOG_CI_START="-0.34814517528914146" LOG_EFFECT_SIZE="-0.12971789547574156" MODIFIED="2013-05-17 10:48:04 +0100" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="0.2566105307897281" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5056" TOTAL_2="5193" VAR="0.065848964512186" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.253744385960488" CI_END="1.159054434658727" CI_START="1.021193565798664" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="1.087942521957801" ESTIMABLE="YES" EVENTS_1="1973" EVENTS_2="1809" I2="0.0" I2_Q="2.023135870211674" ID="CMP-003.10" LOG_CI_END="0.06410383295821383" LOG_CI_START="0.009108069795609897" LOG_EFFECT_SIZE="0.036605951376911895" METHOD="MH" MODIFIED="2015-02-11 21:50:50 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9070624158142055" P_Q="0.41750239554763713" P_Z="0.009076504726240974" Q="8.165192947390654" RANDOM="YES" SCALE="6.15" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90235" TOTAL_2="88963" WEIGHT="900.0" Z="2.6091590403588674">
<NAME>Death (all-causes): cumulatively by year on treatment</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3158797080848696" CI_END="2.168738802735189" CI_START="0.9447771500737931" DF="3" EFFECT_SIZE="1.4314240689965367" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="0.3362072498650361" LOG_CI_START="-0.024670618905195972" LOG_EFFECT_SIZE="0.15576831547992004" MODIFIED="2015-02-10 12:00:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7253659137460245" P_Z="0.09064849776922018" STUDIES="4" TAU2="0.0" TOTAL_1="16061" TOTAL_2="15771" WEIGHT="100.00000000000001" Z="1.6919867616902742">
<NAME>1-year follow-up</NAME>
<DICH_DATA CI_END="2.3194969544138413" CI_START="0.6550695815134098" EFFECT_SIZE="1.2326523837844567" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.3653938066102726" LOG_CI_START="-0.18371256678327808" LOG_EFFECT_SIZE="0.09084061991349728" MODIFIED="2015-02-10 12:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.32254780185175724" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8506" TOTAL_2="8102" VAR="0.10403708447940044" WEIGHT="43.19241920398649"/>
<DICH_DATA CI_END="3.384485596207079" CI_START="0.90766247927824" EFFECT_SIZE="1.7527037933817595" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" LOG_CI_END="0.5294926701540351" LOG_CI_START="-0.04207561693887762" LOG_EFFECT_SIZE="0.24370852660757877" MODIFIED="2015-02-10 12:00:28 +0000" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.3357420411470286" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5310" TOTAL_2="5429" VAR="0.11272271819357306" WEIGHT="39.86430985347749"/>
<DICH_DATA CI_END="5.5571126475582515" CI_START="0.048734778934554725" EFFECT_SIZE="0.5204081632653061" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7448492004055154" LOG_CI_START="-1.3121609995946324" LOG_EFFECT_SIZE="-0.28365589959455845" MODIFIED="2015-02-10 12:00:19 +0000" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="1.2082979738447959" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="1.459983993597439" WEIGHT="3.0778511170676865"/>
<DICH_DATA CI_END="4.8675616702834485" CI_START="0.5225830921689938" EFFECT_SIZE="1.5948998178506375" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6873114625842897" LOG_CI_START="-0.28184464569268525" LOG_EFFECT_SIZE="0.20273340844580218" MODIFIED="2015-02-10 11:59:46 +0000" MODIFIED_BY="[Empty name]" ORDER="352" O_E="0.0" SE="0.5692870954020025" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.3240877969912487" WEIGHT="13.865419825468345"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8602485409275116" CI_END="1.4176709684191644" CI_START="0.795752363201108" DF="2" EFFECT_SIZE="1.062127592787775" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="125" I2="30.07600663432392" ID="CMP-003.10.02" LOG_CI_END="0.15157544581087" LOG_CI_START="-0.09922206295053221" LOG_EFFECT_SIZE="0.02617669143016891" MODIFIED="2015-02-10 12:04:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23927953290482362" P_Z="0.6824385272104037" STUDIES="3" TAU2="0.01961534150367518" TOTAL_1="14283" TOTAL_2="14004" WEIGHT="100.0" Z="0.4091378155303688">
<NAME>2-year follow-up</NAME>
<DICH_DATA CI_END="1.2655561496570695" CI_START="0.5134707001114593" EFFECT_SIZE="0.8061178587494376" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="39" LOG_CI_END="0.10228141851462516" LOG_CI_START="-0.28948433326039363" LOG_EFFECT_SIZE="-0.09360145737288424" MODIFIED="2013-05-15 15:55:56 +0100" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="0.2301251418643935" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.05295758091810723" WEIGHT="29.90522184886787"/>
<DICH_DATA CI_END="1.5623914990022156" CI_START="0.7115080743395719" EFFECT_SIZE="1.05435011586265" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="47" LOG_CI_END="0.19378986728282385" LOG_CI_START="-0.1478201670888691" LOG_EFFECT_SIZE="0.022984850096977386" MODIFIED="2015-02-10 12:04:16 +0000" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="0.2006634251868746" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8484" TOTAL_2="8085" VAR="0.04026581020772842" WEIGHT="36.24361394556766"/>
<DICH_DATA CI_END="2.0652234719829723" CI_START="0.9033437106930199" EFFECT_SIZE="1.3658721150208097" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="39" LOG_CI_END="0.3149670523110539" LOG_CI_START="-0.04414697476315867" LOG_EFFECT_SIZE="0.13541003877394758" MODIFIED="2015-02-10 12:00:40 +0000" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.21094535714649593" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5286" TOTAL_2="5415" VAR="0.04449794370166272" WEIGHT="33.851164205564466"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.303623996085493" CI_END="1.3720554047454745" CI_START="0.9648463194142507" DF="8" EFFECT_SIZE="1.150574902951173" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="218" I2="0.0" ID="CMP-003.10.03" LOG_CI_END="0.13737164889945222" LOG_CI_START="-0.01554185551160927" LOG_EFFECT_SIZE="0.06091489669392146" MODIFIED="2015-02-10 12:07:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9138848538061265" P_Z="0.11839415264312107" STUDIES="9" TAU2="0.0" TOTAL_1="15447" TOTAL_2="14849" WEIGHT="99.99999999999999" Z="1.5615495060673998">
<NAME>3-year follow-up</NAME>
<DICH_DATA CI_END="14.708063445162583" CI_START="0.05795613812724304" EFFECT_SIZE="0.9232673267326733" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1675554945871283" LOG_CI_START="-1.2369005611909631" LOG_EFFECT_SIZE="-0.03467253330191734" MODIFIED="2015-02-10 12:07:15 +0000" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="1.412389389413484" STUDY_ID="STD-EPHT-2006" TOTAL_1="404" TOTAL_2="373" VAR="1.9948437873277944" WEIGHT="0.4044436250396687"/>
<DICH_DATA CI_END="2.5045182817219462" CI_START="0.3623348097964439" EFFECT_SIZE="0.9526143790849673" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.3987242061680698" LOG_CI_START="-0.440889940941164" LOG_EFFECT_SIZE="-0.021082867386547133" MODIFIED="2015-02-10 12:07:03 +0000" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="0.4931935061690218" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="106" VAR="0.24323983452729292" WEIGHT="3.316898542965368"/>
<DICH_DATA CI_END="5.437669363215036" CI_START="0.045485176805895686" EFFECT_SIZE="0.49732620320855614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7354127968342812" LOG_CI_START="-1.3421301127994087" LOG_EFFECT_SIZE="-0.30335865798256384" MODIFIED="2015-02-10 12:06:46 +0000" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="1.2203589891220905" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.4892760623310908" WEIGHT="0.5417409660582791"/>
<DICH_DATA CI_END="14.447049921493582" CI_START="0.15961033592422763" EFFECT_SIZE="1.5185185185185186" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1597791734857832" LOG_CI_START="-0.7969389883642868" LOG_EFFECT_SIZE="0.1814200925607482" MODIFIED="2015-02-10 12:06:11 +0000" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="1.1493859341818446" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="1.3210880256950717" WEIGHT="0.6107101397049056"/>
<DICH_DATA CI_END="4.142475448090552" CI_START="0.7605657630275782" EFFECT_SIZE="1.775" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6172599430924868" LOG_CI_START="-0.11886322831026105" LOG_EFFECT_SIZE="0.24919835739111287" MODIFIED="2015-02-10 12:05:34 +0000" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.4324023947504401" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.18697183098591547" WEIGHT="4.31509842140601"/>
<DICH_DATA CI_END="2.290426604338318" CI_START="0.1751250663746932" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.35991637956917566" LOG_CI_START="-0.7566516871028426" LOG_EFFECT_SIZE="-0.1983676537668335" MODIFIED="2015-02-10 12:05:15 +0000" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.6558776094642135" STUDY_ID="STD-WELL_x002d_HART-2003" TOTAL_1="150" TOTAL_2="76" VAR="0.43017543859649127" WEIGHT="1.875518173159819"/>
<DICH_DATA CI_END="1.6745591246049474" CI_START="0.7706372169075482" EFFECT_SIZE="1.1359918940435696" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" LOG_CI_END="0.22390048602719245" LOG_CI_START="-0.113150021137594" LOG_EFFECT_SIZE="0.0553752324447992" MODIFIED="2015-02-10 12:05:03 +0000" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="0.19798513633551407" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.03919811420979209" WEIGHT="20.582670085010562"/>
<DICH_DATA CI_END="1.4228470963277817" CI_START="0.7857844865981557" EFFECT_SIZE="1.057379390330454" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="82" LOG_CI_END="0.1531582319261414" LOG_CI_START="-0.10469654952691404" LOG_EFFECT_SIZE="0.02423084119961369" MODIFIED="2015-02-10 12:04:13 +0000" MODIFIED_BY="[Empty name]" ORDER="465" O_E="0.0" SE="0.1514651750272785" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8454" TOTAL_2="8055" VAR="0.022941699246044108" WEIGHT="35.16748450417568"/>
<DICH_DATA CI_END="1.7346364225994508" CI_START="0.9413800060408355" EFFECT_SIZE="1.277870120937697" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="73" LOG_CI_END="0.2392084611410582" LOG_CI_START="-0.02623502990699329" LOG_EFFECT_SIZE="0.10648671561703248" MODIFIED="2015-02-10 12:00:48 +0000" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="0.15592282060809753" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5258" TOTAL_2="5390" VAR="0.02431192598638496" WEIGHT="33.18543554247969"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2658745634649245" CI_END="1.2521121170367258" CI_START="0.9501330014898274" DF="2" EFFECT_SIZE="1.0907213411141665" ESTIMABLE="YES" EVENTS_1="405" EVENTS_2="368" I2="0.0" ID="CMP-003.10.04" LOG_CI_END="0.09764321835549969" LOG_CI_START="-0.022215597058392152" LOG_EFFECT_SIZE="0.03771381064855372" MODIFIED="2015-02-10 12:06:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8755200083255558" P_Z="0.21742174044922968" STUDIES="3" TAU2="0.0" TOTAL_1="15014" TOTAL_2="14759" WEIGHT="100.0" Z="1.2334130007155297">
<NAME>4-year follow-up</NAME>
<DICH_DATA CI_END="1.3397868104508874" CI_START="0.8373884590019809" EFFECT_SIZE="1.05920820077766" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="123" LOG_CI_END="0.12703569805831066" LOG_CI_START="-0.07707302890728479" LOG_EFFECT_SIZE="0.02498133457551292" MODIFIED="2015-02-10 12:06:29 +0000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.11989447657408399" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.014374685512973575" WEIGHT="34.48393472429009"/>
<DICH_DATA CI_END="1.3530438938596132" CI_START="0.8467352054775317" EFFECT_SIZE="1.0703597056538232" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="130" LOG_CI_END="0.13131188569725982" LOG_CI_START="-0.0722523827974175" LOG_EFFECT_SIZE="0.029529751449921145" MODIFIED="2015-02-10 12:00:54 +0000" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="0.11957465897315382" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8415" TOTAL_2="8020" VAR="0.014298099068546037" WEIGHT="34.6686447292875"/>
<DICH_DATA CI_END="1.4758676239136341" CI_START="0.8979308176480109" EFFECT_SIZE="1.1511850512758566" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="115" LOG_CI_END="0.1690474057376845" LOG_CI_START="-0.04675712287738809" LOG_EFFECT_SIZE="0.061145141430148216" MODIFIED="2015-02-10 12:04:42 +0000" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="0.1267646483581388" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5219" TOTAL_2="5356" VAR="0.016069276073362584" WEIGHT="30.847420546422416"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18098728304075956" CI_END="1.226307602982974" CI_START="0.9098522211807958" DF="1" EFFECT_SIZE="1.0562947961743239" ESTIMABLE="YES" EVENTS_1="348" EVENTS_2="325" I2="0.0" ID="CMP-003.10.05" LOG_CI_END="0.08859942085290815" LOG_CI_START="-0.041029140357457625" LOG_EFFECT_SIZE="0.023785140247725264" MODIFIED="2015-02-10 12:04:45 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6705261603212538" P_Z="0.4719836050325341" STUDIES="2" TAU2="0.0" TOTAL_1="13541" TOTAL_2="13286" WEIGHT="100.0" Z="0.7192553526397978">
<NAME>5 year follow-up</NAME>
<DICH_DATA CI_END="1.256944167303024" CI_START="0.8355852299697795" EFFECT_SIZE="1.024833635813672" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="174" LOG_CI_END="0.09931598701711487" LOG_CI_START="-0.07800924533044921" LOG_EFFECT_SIZE="0.01065337084333282" MODIFIED="2015-02-10 12:01:02 +0000" MODIFIED_BY="[Empty name]" ORDER="467" O_E="0.0" SE="0.1041617192550158" STUDY_ID="STD-WHI-I-2002" TOTAL_1="8360" TOTAL_2="7972" VAR="0.01084966375816073" WEIGHT="53.43924653851725"/>
<DICH_DATA CI_END="1.360953003585481" CI_START="0.8787607374503446" EFFECT_SIZE="1.0935959331791787" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="151" LOG_CI_END="0.13384312840987797" LOG_CI_START="-0.05612935535824235" LOG_EFFECT_SIZE="0.03885688652581779" MODIFIED="2015-02-10 12:04:45 +0000" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="0.11159077734435476" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5181" TOTAL_2="5314" VAR="0.012452501588317358" WEIGHT="46.56075346148275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.355791231065612" CI_START="0.9254829653538965" DF="0" EFFECT_SIZE="1.1201614566335572" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="194" I2="0.0" ID="CMP-003.10.06" LOG_CI_END="0.13219282066935784" LOG_CI_START="-0.033631570558714685" LOG_EFFECT_SIZE="0.049280625055321596" MODIFIED="2015-02-10 12:01:06 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.2440407762492508" STUDIES="1" TAU2="0.0" TOTAL_1="5149" TOTAL_2="5278" WEIGHT="100.0" Z="1.1649462365425651">
<NAME>6 year follow-up</NAME>
<DICH_DATA CI_END="1.355791231065612" CI_START="0.9254829653538965" EFFECT_SIZE="1.1201614566335572" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="194" LOG_CI_END="0.13219282066935784" LOG_CI_START="-0.033631570558714685" LOG_EFFECT_SIZE="0.049280625055321596" MODIFIED="2015-02-10 12:01:06 +0000" MODIFIED_BY="[Empty name]" ORDER="423" O_E="0.0" SE="0.0974060682513448" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5149" TOTAL_2="5278" VAR="0.009487942132185644" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3138704735004432" CI_START="0.9296609396984149" DF="0" EFFECT_SIZE="1.10519412730815" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="236" I2="0.0" ID="CMP-003.10.07" LOG_CI_END="0.11855255288226296" LOG_CI_START="-0.0316754158193752" LOG_EFFECT_SIZE="0.043438568531443886" MODIFIED="2015-02-10 12:01:08 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.2570248747737782" STUDIES="1" TAU2="0.0" TOTAL_1="5098" TOTAL_2="5235" WEIGHT="100.0" Z="1.1334511222832846">
<NAME>7-year follow-up</NAME>
<DICH_DATA CI_END="1.3138704735004432" CI_START="0.9296609396984149" EFFECT_SIZE="1.10519412730815" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="236" LOG_CI_END="0.11855255288226296" LOG_CI_START="-0.0316754158193752" LOG_EFFECT_SIZE="0.043438568531443886" MODIFIED="2015-02-10 12:01:08 +0000" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.08824465245578063" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5098" TOTAL_2="5235" VAR="0.00778711868704151" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2436227216768072" CI_START="0.8989015328600549" DF="0" EFFECT_SIZE="1.0573052401340284" ESTIMABLE="YES" EVENTS_1="280" EVENTS_2="272" I2="0.0" ID="CMP-003.10.08" LOG_CI_END="0.09468864824467496" LOG_CI_START="-0.046287878987178455" LOG_EFFECT_SIZE="0.02420038462874825" MODIFIED="2013-05-17 10:51:03 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.5010079407288781" STUDIES="1" TAU2="0.0" TOTAL_1="5056" TOTAL_2="5193" WEIGHT="100.0" Z="0.672904677334769">
<NAME>8-year follow-up</NAME>
<DICH_DATA CI_END="1.2436227216768072" CI_START="0.8989015328600549" EFFECT_SIZE="1.0573052401340284" ESTIMABLE="YES" EVENTS_1="280" EVENTS_2="272" LOG_CI_END="0.09468864824467496" LOG_CI_START="-0.046287878987178455" LOG_EFFECT_SIZE="0.02420038462874825" MODIFIED="2013-05-17 10:51:03 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.08281030994105519" STUDY_ID="STD-WHI-II-2004" TOTAL_1="5056" TOTAL_2="5193" VAR="0.006857547432533625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.16396443256864815" CI_END="0.9631098535086248" CI_START="0.3120335257784298" DF="1" EFFECT_SIZE="0.5481993827999474" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="33" I2="0.0" ID="CMP-003.10.09" LOG_CI_END="-0.016324173881022076" LOG_CI_START="-0.5057987416278451" LOG_EFFECT_SIZE="-0.2610614577544335" MODIFIED="2013-05-17 10:49:05 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6855327117280297" P_Z="0.03655539911347469" STUDIES="2" TAU2="0.0" TOTAL_1="586" TOTAL_2="588" WEIGHT="100.0" Z="2.09069516034538">
<NAME>10-year follow-up</NAME>
<DICH_DATA CI_END="1.0803496976754556" CI_START="0.3105454039025519" EFFECT_SIZE="0.5792215752375115" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="0.033564354735557134" LOG_CI_START="-0.5078748939648187" LOG_EFFECT_SIZE="-0.23715526961463076" MODIFIED="2013-05-15 16:00:34 +0100" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.31804409485410695" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.10115204627156818" WEIGHT="81.72610367985193"/>
<DICH_DATA CI_END="1.6015303258325488" CI_START="0.11468622630812386" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20453516667579472" LOG_CI_START="-0.9404887372649836" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2013-05-15 16:10:09 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="0.6725927091345493" STUDY_ID="STD-ERT-II-1979" TOTAL_1="84" TOTAL_2="84" VAR="0.45238095238095233" WEIGHT="18.273896320148065"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-02-11 21:52:28 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause)</NAME>
<DICH_OUTCOME CHI2="12.743824653694166" CI_END="1.1188324220431964" CI_START="0.9158539227793399" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.012268276032086" ESTIMABLE="YES" EVENTS_1="734" EVENTS_2="721" I2="0.0" I2_Q="84.20878374584261" ID="CMP-004.01" LOG_CI_END="0.04876504306812705" LOG_CI_START="-0.038173790076610946" LOG_EFFECT_SIZE="0.005295626495758072" METHOD="MH" MODIFIED="2015-02-11 21:51:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6913881692545817" P_Q="0.011853630469577547" P_Z="0.8112831383480434" Q="6.33263444629686" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18589" TOTAL_2="18249" WEIGHT="200.0" Z="0.23877102629114536">
<NAME>Death (all-causes)</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5461609671279128" CI_END="0.9502675580426833" CI_START="0.5212454324919643" DF="4" EFFECT_SIZE="0.7037916057151017" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="101" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-0.02215409721488415" LOG_CI_START="-0.28295773758600756" LOG_EFFECT_SIZE="-0.15255591740044588" MODIFIED="2015-02-11 21:41:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.818434510102684" P_Z="0.02185121482906473" STUDIES="5" TAU2="0.0" TOTAL_1="4598" TOTAL_2="4490" WEIGHT="100.00000000000003" Z="2.2929442496113834">
<NAME>Hormone therapy commenced &lt;10 years after menopause</NAME>
<DICH_DATA CI_END="1.0803496976754556" CI_START="0.3105454039025519" EFFECT_SIZE="0.5792215752375115" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="0.033564354735557134" LOG_CI_START="-0.5078748939648187" LOG_EFFECT_SIZE="-0.23715526961463076" MODIFIED="2015-02-10 12:07:34 +0000" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.31804409485410695" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.10115204627156818" WEIGHT="23.20212859137431"/>
<DICH_DATA CI_END="14.708063445162583" CI_START="0.05795613812724304" EFFECT_SIZE="0.9232673267326733" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1675554945871283" LOG_CI_START="-1.2369005611909631" LOG_EFFECT_SIZE="-0.03467253330191734" MODIFIED="2015-02-10 12:07:16 +0000" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="1.412389389413484" STUDY_ID="STD-EPHT-2006" TOTAL_1="404" TOTAL_2="373" VAR="1.9948437873277944" WEIGHT="1.1765045462619563"/>
<DICH_DATA CI_END="1.6015303258325488" CI_START="0.11468622630812386" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20453516667579472" LOG_CI_START="-0.9404887372649836" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-02-10 11:37:13 +0000" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.6725927091345493" STUDY_ID="STD-ERT-II-1979" TOTAL_1="84" TOTAL_2="84" VAR="0.45238095238095233" WEIGHT="5.187978787615259"/>
<DICH_DATA CI_END="1.2620917538174898" CI_START="0.541237327071364" EFFECT_SIZE="0.8264932954083706" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="46" LOG_CI_END="0.1010909291776219" LOG_CI_START="-0.26661225940977534" LOG_EFFECT_SIZE="-0.08276066511607673" MODIFIED="2013-05-07 15:43:58 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.21599067313637585" STUDY_ID="STD-WHI-I-2002" TOTAL_1="2782" TOTAL_2="2712" VAR="0.04665197088190475" WEIGHT="50.30747341445966"/>
<DICH_DATA CI_END="1.2877291235494965" CI_START="0.3376579523122576" EFFECT_SIZE="0.6594027441485069" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.10982451789973556" LOG_CI_START="-0.4715230175870315" LOG_EFFECT_SIZE="-0.18084924984364797" MODIFIED="2013-05-07 15:44:27 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.3414864200616389" STUDY_ID="STD-WHI-II-2004" TOTAL_1="826" TOTAL_2="817" VAR="0.11661297508651407" WEIGHT="20.12591466028883"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.861855430712432" CI_END="1.1779743163774226" CI_START="0.9526265812182906" DF="11" EFFECT_SIZE="1.0593250897498732" ESTIMABLE="YES" EVENTS_1="662" EVENTS_2="620" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.07113582154008193" LOG_CI_START="-0.02107730450050778" LOG_EFFECT_SIZE="0.025029258519787025" MODIFIED="2015-02-11 21:41:48 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9376716468592207" P_Z="0.2873379296102295" STUDIES="12" TAU2="0.0" TOTAL_1="13991" TOTAL_2="13759" WEIGHT="99.99999999999999" Z="1.063979660269442">
<NAME>Hormone therapy commenced &gt;10 years after menopause</NAME>
<DICH_DATA CI_END="2.5045182817219462" CI_START="0.3623348097964439" EFFECT_SIZE="0.9526143790849673" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.3987242061680698" LOG_CI_START="-0.440889940941164" LOG_EFFECT_SIZE="-0.021082867386547133" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="0.4931935061690218" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="106" VAR="0.24323983452729292" WEIGHT="1.206218526522095"/>
<DICH_DATA CI_END="1.2655561496570695" CI_START="0.5134707001114593" EFFECT_SIZE="0.8061178587494376" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="39" LOG_CI_END="0.10228141851462516" LOG_CI_START="-0.28948433326039363" LOG_EFFECT_SIZE="-0.09360145737288424" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="315" O_E="0.0" SE="0.2301251418643935" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.05295758091810723" WEIGHT="5.540290732854646"/>
<DICH_DATA CI_END="5.437669363215036" CI_START="0.045485176805895686" EFFECT_SIZE="0.49732620320855614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7354127968342812" LOG_CI_START="-1.3421301127994087" LOG_EFFECT_SIZE="-0.30335865798256384" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="327" O_E="0.0" SE="1.2203589891220905" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.4892760623310908" WEIGHT="0.1970087361343499"/>
<DICH_DATA CI_END="1.3397868104508874" CI_START="0.8373884590019809" EFFECT_SIZE="1.05920820077766" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="123" LOG_CI_END="0.12703569805831066" LOG_CI_START="-0.07707302890728479" LOG_EFFECT_SIZE="0.02498133457551292" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="318" O_E="0.0" SE="0.11989447657408399" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.014374685512973575" WEIGHT="20.410908783373873"/>
<DICH_DATA CI_END="14.447049921493582" CI_START="0.15961033592422763" EFFECT_SIZE="1.5185185185185186" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1597791734857832" LOG_CI_START="-0.7969389883642868" LOG_EFFECT_SIZE="0.1814200925607482" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="1.1493859341818446" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="1.3210880256950717" WEIGHT="0.2220899660646164"/>
<DICH_DATA CI_END="4.142475448090552" CI_START="0.7605657630275782" EFFECT_SIZE="1.775" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6172599430924868" LOG_CI_START="-0.11886322831026105" LOG_EFFECT_SIZE="0.24919835739111287" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.0" SE="0.4324023947504401" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.18697183098591547" WEIGHT="1.5692224505042756"/>
<DICH_DATA CI_END="2.5310768550853693" CI_START="0.19693678897564382" EFFECT_SIZE="0.7060185185185185" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.40330533252796047" LOG_CI_START="-0.7056731474642131" LOG_EFFECT_SIZE="-0.15118390746812627" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.6514194486794126" STUDY_ID="STD-WELL_x002d_HART-2003" TOTAL_1="108" TOTAL_2="61" VAR="0.42434729811778993" WEIGHT="0.6914157250355526"/>
<DICH_DATA CI_END="1.6745591246049474" CI_START="0.7706372169075482" EFFECT_SIZE="1.1359918940435696" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" LOG_CI_END="0.22390048602719245" LOG_CI_START="-0.113150021137594" LOG_EFFECT_SIZE="0.0553752324447992" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="0.19798513633551407" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.03919811420979209" WEIGHT="7.485064032026702"/>
<DICH_DATA CI_END="1.2778500146190466" CI_START="0.8435540931073878" EFFECT_SIZE="1.038236779453142" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="167" LOG_CI_END="0.10647988226848232" LOG_CI_START="-0.0738870629446775" LOG_EFFECT_SIZE="0.016296409661902416" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.10594843644898828" STUDY_ID="STD-WHI-I-2002" TOTAL_1="4897" TOTAL_2="4797" VAR="0.01122507118598531" WEIGHT="26.13795404356142"/>
<DICH_DATA CI_END="1.3008577748216466" CI_START="0.9105791477851469" EFFECT_SIZE="1.0883629743733372" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="222" LOG_CI_END="0.11422981694082769" LOG_CI_START="-0.04068229923487526" LOG_EFFECT_SIZE="0.0367737588529762" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.0909961438689502" STUDY_ID="STD-WHI-II-2004" TOTAL_1="3667" TOTAL_2="3819" VAR="0.008280298199018684" WEIGHT="35.43355417196944"/>
<DICH_DATA CI_END="5.5571126475582515" CI_START="0.048734778934554725" EFFECT_SIZE="0.5204081632653061" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7448492004055154" LOG_CI_START="-1.3121609995946324" LOG_EFFECT_SIZE="-0.28365589959455845" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="322" O_E="0.0" SE="1.2082979738447959" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="1.459983993597439" WEIGHT="0.2009613777148633"/>
<DICH_DATA CI_END="4.8675616702834485" CI_START="0.5225830921689938" EFFECT_SIZE="1.5948998178506375" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6873114625842897" LOG_CI_START="-0.28184464569268525" LOG_EFFECT_SIZE="0.20273340844580218" MODIFIED="2015-02-09 15:33:45 +0000" MODIFIED_BY="[Empty name]" ORDER="314" O_E="0.0" SE="0.5692870954020025" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.3240877969912487" WEIGHT="0.9053114542381618"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.87307030590034" CI_END="1.1670123042007048" CI_START="0.9427905352763949" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0489271447300434" ESTIMABLE="YES" EVENTS_1="679" EVENTS_2="656" I2="31.422521894634542" I2_Q="80.95286586556298" ID="CMP-004.02" LOG_CI_END="0.06707543498136015" LOG_CI_START="-0.025584786030899056" LOG_EFFECT_SIZE="0.020745324475230555" METHOD="MH" MODIFIED="2015-02-11 21:51:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11117570033549062" P_Q="0.021945137272414428" P_Z="0.380151654102856" Q="5.250133657598445" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.024237835453479063" TOTALS="SUB" TOTAL_1="16022" TOTAL_2="15780" WEIGHT="199.99999999999997" Z="0.8776169185624907">
<NAME>Coronary heart disease (death from cardiovascular causes and non-fatal myocardial infarction)</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.63913966402812" CI_END="0.957712472308852" CI_START="0.28626975086964435" DF="3" EFFECT_SIZE="0.5236068285007427" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="76" I2="46.80039547278997" ID="CMP-004.02.01" LOG_CI_END="-0.018764856717369726" LOG_CI_START="-0.5432245399436252" LOG_EFFECT_SIZE="-0.2809946983304975" MODIFIED="2015-02-11 21:42:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13054949562661478" P_Z="0.0357097843207862" STUDIES="4" TAU2="0.16843524324642742" TOTAL_1="4194" TOTAL_2="4117" WEIGHT="100.0" Z="2.1002166846708006">
<NAME>Hormone therapy commenced &lt;10 years after menopause</NAME>
<DICH_DATA CI_END="0.669573659140225" CI_START="0.1119727688273862" EFFECT_SIZE="0.2738138355668236" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.17420163971471156" LOG_CI_START="-0.9508875825614018" LOG_EFFECT_SIZE="-0.5625446111380566" MODIFIED="2015-02-10 13:21:57 +0000" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.4562291674855688" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.20814505326457516" WEIGHT="25.202395786682388"/>
<DICH_DATA CI_END="3.1401207905561583" CI_START="0.03538434299893023" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49694635433532724" LOG_CI_START="-1.4511888637746524" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-02-10 14:25:54 +0000" MODIFIED_BY="[Empty name]" ORDER="307" O_E="0.0" SE="1.1443442705426587" STUDY_ID="STD-ERT-II-1979" TOTAL_1="84" TOTAL_2="84" VAR="1.3095238095238095" WEIGHT="6.421507862716086"/>
<DICH_DATA CI_END="1.3960568469282906" CI_START="0.5340099081205729" EFFECT_SIZE="0.8634281606244223" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="35" LOG_CI_END="0.14490310296093417" LOG_CI_START="-0.27245068491494384" LOG_EFFECT_SIZE="-0.06377379097700482" MODIFIED="2013-05-07 15:49:49 +0100" MODIFIED_BY="[Empty name]" ORDER="308" O_E="0.0" SE="0.2451556809328597" STUDY_ID="STD-WHI-I-2002" TOTAL_1="2782" TOTAL_2="2712" VAR="0.0601013078936541" WEIGHT="41.52826158787682"/>
<DICH_DATA CI_END="1.1491912348733015" CI_START="0.2128294497557381" EFFECT_SIZE="0.49455205811138014" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.06039230487588329" LOG_CI_START="-0.6719682777797791" LOG_EFFECT_SIZE="-0.30578798645194794" MODIFIED="2013-05-07 15:50:27 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.43019223149528746" STUDY_ID="STD-WHI-II-2004" TOTAL_1="826" TOTAL_2="817" VAR="0.185065356038895" WEIGHT="26.84783476272471"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.499819997590905" CI_END="1.1954686389363332" CI_START="0.9624917433878973" DF="11" EFFECT_SIZE="1.0726736197256779" ESTIMABLE="YES" EVENTS_1="633" EVENTS_2="580" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.07753818763243485" LOG_CI_START="-0.01660298734305187" LOG_EFFECT_SIZE="0.03046760014469151" MODIFIED="2015-02-11 21:42:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6679537497735538" P_Z="0.20457126838776307" STUDIES="12" TAU2="0.0" TOTAL_1="11828" TOTAL_2="11663" WEIGHT="99.99999999999997" Z="1.2686350896833793">
<NAME>Hormone therapy commenced &gt;10 years after menopause</NAME>
<DICH_DATA CI_END="2.354885491983085" CI_START="0.21810449504217355" EFFECT_SIZE="0.7166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37196979409381353" LOG_CI_START="-0.6613353837019277" LOG_EFFECT_SIZE="-0.1446827948040571" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="0.6069685763803413" STUDY_ID="STD-EAGAR-2006" TOTAL_1="40" TOTAL_2="43" VAR="0.36841085271317825" WEIGHT="0.8300457259523762"/>
<DICH_DATA CI_END="5.434937107167446" CI_START="0.04599869236210789" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7351945228163949" LOG_CI_START="-1.3372545141443573" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="1.2173668230989303" STUDY_ID="STD-EPAT-2001" TOTAL_1="111" TOTAL_2="111" VAR="1.4819819819819822" WEIGHT="0.2063438404831847"/>
<DICH_DATA CI_END="1.9535428387869749" CI_START="0.4477890472309119" EFFECT_SIZE="0.9352941176470588" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.29082293920800295" LOG_CI_START="-0.3489265333236478" LOG_EFFECT_SIZE="-0.029051797057822442" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="325" O_E="0.0" SE="0.37579200697605436" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="106" VAR="0.14121963250709088" WEIGHT="2.1654061001305136"/>
<DICH_DATA CI_END="1.4182423779111497" CI_START="0.7313046814124841" EFFECT_SIZE="1.0184141055307498" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="61" LOG_CI_END="0.15175045820534658" LOG_CI_START="-0.13590164645117725" LOG_EFFECT_SIZE="0.0079244058770847" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="0.16896827017612454" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="503" TOTAL_2="504" VAR="0.028550276326311814" WEIGHT="10.710854430758065"/>
<DICH_DATA CI_END="3.1584379030652805" CI_START="0.03480389286499995" EFFECT_SIZE="0.3315508021390374" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4994723428035393" LOG_CI_START="-1.4583721768800295" LOG_EFFECT_SIZE="-0.4794499170382451" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="1.1500475623488031" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.322609395664424" WEIGHT="0.23120798528383646"/>
<DICH_DATA CI_END="1.199992017167928" CI_START="0.8283152741907589" EFFECT_SIZE="0.9969813020950664" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="193" LOG_CI_END="0.07917835695474945" LOG_CI_START="-0.08180433014704966" LOG_EFFECT_SIZE="-0.0013129865961501" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="0.09456202728074982" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.008941977003445272" WEIGHT="34.19801388118338"/>
<DICH_DATA CI_END="4.9978539581179335" CI_START="0.36454536327993514" EFFECT_SIZE="1.3497942386831276" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6987835614922779" LOG_CI_START="-0.43824842126554414" LOG_EFFECT_SIZE="0.13026757011336693" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.667898215071033" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="0.4460880256950718" WEIGHT="0.685510114763931"/>
<DICH_DATA CI_END="2.7560045805000466" CI_START="0.5375305778429029" EFFECT_SIZE="1.217142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.44027993503683693" LOG_CI_START="-0.2695968255319504" LOG_EFFECT_SIZE="0.08534155475244326" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="368" O_E="0.0" SE="0.41698512310474267" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.1738765928906774" WEIGHT="1.7587062675038172"/>
<DICH_DATA CI_END="1.6535977176443544" CI_START="0.5693847608267097" EFFECT_SIZE="0.9703264094955489" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.21842986419062355" LOG_CI_START="-0.24459416061272862" LOG_EFFECT_SIZE="-0.013082148211052564" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.27198260417537684" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.07397453697401972" WEIGHT="4.1338258568139725"/>
<DICH_DATA CI_END="1.8029360643835892" CI_START="1.0883560048328538" EFFECT_SIZE="1.4007984480294058" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="100" LOG_CI_END="0.2559803260691949" LOG_CI_START="0.03677097775628685" LOG_EFFECT_SIZE="0.14637565191274085" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.12876465630277664" STUDY_ID="STD-WHI-I-2002" TOTAL_1="4897" TOTAL_2="4797" VAR="0.0165803367127722" WEIGHT="18.443404315998066"/>
<DICH_DATA CI_END="1.312259414643965" CI_START="0.8576177157121843" EFFECT_SIZE="1.0608566923052167" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="161" LOG_CI_END="0.11801969724376442" LOG_CI_START="-0.06670625638663785" LOG_EFFECT_SIZE="0.02565672042856328" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.10850893957071615" STUDY_ID="STD-WHI-II-2004" TOTAL_1="3667" TOTAL_2="3819" VAR="0.01177418996676133" WEIGHT="25.971880405557812"/>
<DICH_DATA CI_END="1.9662875568276528" CI_START="0.13773400307232253" EFFECT_SIZE="0.5204081632653061" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.293647030897579" LOG_CI_START="-0.8609588300866959" LOG_EFFECT_SIZE="-0.28365589959455845" MODIFIED="2015-02-09 15:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="0.6782211981333516" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="0.45998399359743897" WEIGHT="0.6648010755710492"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.680157192536482" CI_END="1.388183786770746" CI_START="1.0700819583727617" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.218798763179942" ESTIMABLE="YES" EVENTS_1="503" EVENTS_2="400" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.14244696777335825" LOG_CI_START="0.029417041896343518" LOG_EFFECT_SIZE="0.0859320048348509" METHOD="MH" MODIFIED="2015-02-11 21:52:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7552556429498898" P_Q="0.6566617821076672" P_Z="0.00288097816697684" Q="0.19760405683065949" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15561" TOTAL_2="15304" WEIGHT="200.0" Z="2.980160046798357">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.091730923512092" CI_END="2.3437957011426906" CI_START="0.8023663196025819" DF="2" EFFECT_SIZE="1.3713434036105667" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="37" I2="35.31131752797964" ID="CMP-004.03.01" LOG_CI_END="0.36991975336430927" LOG_CI_START="-0.09562730969569046" LOG_EFFECT_SIZE="0.13714622183430944" MODIFIED="2015-02-11 21:42:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2131274317499987" P_Z="0.24818154023635508" STUDIES="3" TAU2="0.07965975020947602" TOTAL_1="4110" TOTAL_2="4033" WEIGHT="100.0" Z="1.1547775799257658">
<NAME>Hormone therapy commenced &lt;10 years after menopause</NAME>
<DICH_DATA CI_END="1.7207755883404043" CI_START="0.3616252119729508" EFFECT_SIZE="0.7888446215139442" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.235724236335556" LOG_CI_START="-0.44174129877457013" LOG_EFFECT_SIZE="-0.10300853121950705" MODIFIED="2013-05-07 15:51:54 +0100" MODIFIED_BY="[Empty name]" ORDER="310" O_E="0.0" SE="0.3979466088321716" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.1583615034810254" WEIGHT="31.418586902333775"/>
<DICH_DATA CI_END="2.9667031181163814" CI_START="0.820032370441562" EFFECT_SIZE="1.5597411933860532" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" LOG_CI_END="0.47227408807116505" LOG_CI_START="-0.08616900368131918" LOG_EFFECT_SIZE="0.19305254219492293" MODIFIED="2013-05-07 15:53:35 +0100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="0.32803223643329604" STUDY_ID="STD-WHI-I-2002" TOTAL_1="2782" TOTAL_2="2712" VAR="0.10760514813942984" WEIGHT="39.93429366428376"/>
<DICH_DATA CI_END="4.843125885604253" CI_START="0.9121707240869787" EFFECT_SIZE="2.1018462469733654" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.685125757651277" LOG_CI_START="-0.03992387045454992" LOG_EFFECT_SIZE="0.32260094359836355" MODIFIED="2013-05-07 15:54:00 +0100" MODIFIED_BY="[Empty name]" ORDER="312" O_E="0.0" SE="0.4258977406029054" STUDY_ID="STD-WHI-II-2004" TOTAL_1="826" TOTAL_2="817" VAR="0.18138888545065973" WEIGHT="28.647119433382464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2700150754036628" CI_END="1.3835093418423996" CI_START="1.0579518175324927" DF="7" EFFECT_SIZE="1.2098290055934968" ESTIMABLE="YES" EVENTS_1="451" EVENTS_2="363" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.140982095964797" LOG_CI_START="0.024465889007050105" LOG_EFFECT_SIZE="0.08272399248592355" MODIFIED="2015-02-11 21:42:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8589511804794926" P_Z="0.005384813894943609" STUDIES="8" TAU2="0.0" TOTAL_1="11451" TOTAL_2="11271" WEIGHT="99.99999999999999" Z="2.7830642648463275">
<NAME>Hormone therapy commenced &gt;10 years after menopause</NAME>
<DICH_DATA CI_END="2.480447841704783" CI_START="0.3589806450563251" EFFECT_SIZE="0.9436274509803921" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.3945300992222517" LOG_CI_START="-0.4449289663850102" LOG_EFFECT_SIZE="-0.025199433581379285" MODIFIED="2015-02-09 15:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="326" O_E="0.0" SE="0.49310241052709763" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="0.24314998726763434" WEIGHT="1.9265204765477788"/>
<DICH_DATA CI_END="4.4716378934767445" CI_START="0.5995939113652367" EFFECT_SIZE="1.6374269005847952" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6504666277871072" LOG_CI_START="-0.22214278588697645" LOG_EFFECT_SIZE="0.21416192095006537" MODIFIED="2015-02-09 15:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="317" O_E="0.0" SE="0.5125750890784181" STUDY_ID="STD-ESPRIT-2002" TOTAL_1="513" TOTAL_2="504" VAR="0.26273322194374826" WEIGHT="1.7829242372847764"/>
<DICH_DATA CI_END="1.443608728726371" CI_START="0.8482150081747728" EFFECT_SIZE="1.1065670289855072" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="96" LOG_CI_END="0.15944949934080593" LOG_CI_START="-0.07149404747425424" LOG_EFFECT_SIZE="0.043977725933275875" MODIFIED="2015-02-09 15:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.13565738258816024" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.01840292545067048" WEIGHT="25.454291525501052"/>
<DICH_DATA CI_END="6.0191240439104305" CI_START="0.4729572342801669" EFFECT_SIZE="1.6872427983539096" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.7795332934877255" LOG_CI_START="-0.3251781272448788" LOG_EFFECT_SIZE="0.22717758312142333" MODIFIED="2015-02-09 15:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="0.6489129569480577" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="0.4210880256950718" WEIGHT="1.112435882189256"/>
<DICH_DATA CI_END="7.296409439022344" CI_START="0.7137998578525512" EFFECT_SIZE="2.282142857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.863109196498933" LOG_CI_START="-0.1464235428665713" LOG_EFFECT_SIZE="0.3583428268161809" MODIFIED="2015-02-09 15:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.593004528370952" STUDY_ID="STD-WAVE-2002" TOTAL_1="210" TOTAL_2="213" VAR="0.3516543706684552" WEIGHT="1.3320847639487325"/>
<DICH_DATA CI_END="1.5126921475891875" CI_START="0.7877532362135619" EFFECT_SIZE="1.0916172106824926" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="56" LOG_CI_END="0.17975055247326543" LOG_CI_START="-0.10360980400060796" LOG_EFFECT_SIZE="0.03807037423632875" MODIFIED="2015-02-09 15:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.16644727604913953" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.027704695704178457" WEIGHT="16.908087868757192"/>
<DICH_DATA CI_END="1.6176537701326548" CI_START="0.935116074962935" EFFECT_SIZE="1.229916275270574" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="90" LOG_CI_END="0.20888557425322674" LOG_CI_START="-0.029134477269678917" LOG_EFFECT_SIZE="0.08987554849177393" MODIFIED="2015-02-09 15:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.1398141564828119" STUDY_ID="STD-WHI-I-2002" TOTAL_1="4897" TOTAL_2="4797" VAR="0.019547998353000213" WEIGHT="23.963242726155357"/>
<DICH_DATA CI_END="1.7009083895349675" CI_START="1.0199424104184298" EFFECT_SIZE="1.3171289241085036" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="102" LOG_CI_END="0.23068092325933068" LOG_CI_START="0.008575650640762416" LOG_EFFECT_SIZE="0.11962828695004654" MODIFIED="2015-02-09 15:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.13046573657497798" STUDY_ID="STD-WHI-II-2004" TOTAL_1="3667" TOTAL_2="3819" VAR="0.017021308420051548" WEIGHT="27.520412519615846"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.206426157916743" CI_END="2.4755817560278257" CI_START="1.4123961407073047" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.869893611470747" ESTIMABLE="YES" EVENTS_1="354" EVENTS_2="188" I2="27.662161471956384" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.3936772734691369" LOG_CI_START="0.14995652220753394" LOG_EFFECT_SIZE="0.2718168978383354" METHOD="MH" MODIFIED="2015-02-11 21:52:28 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.17324042869246903" P_Q="0.6955215914472184" P_Z="1.2321646821714589E-5" Q="0.15317295880555293" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04762512245976314" TOTALS="SUB" TOTAL_1="18914" TOTAL_2="18399" WEIGHT="200.0" Z="4.371817560833796">
<NAME>Venous thromboembolism</NAME>
<GROUP_LABEL_1>HT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6089851303668838" CI_END="2.733590142028077" CI_START="1.111442139349937" DF="2" EFFECT_SIZE="1.7430511396862642" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="30" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.43673339962501695" LOG_CI_START="0.045886858654338974" LOG_EFFECT_SIZE="0.24131012913967803" MODIFIED="2015-02-11 21:42:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44731504120424204" P_Z="0.015512897841067965" STUDIES="3" TAU2="0.0" TOTAL_1="4978" TOTAL_2="4860" WEIGHT="100.00000000000001" Z="2.4201783188044668">
<NAME>Hormone therapy commenced &lt;10 years after menopause</NAME>
<DICH_DATA CI_END="7.099608827297346" CI_START="0.14197739970945414" EFFECT_SIZE="1.00398406374502" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8512344207153756" LOG_CI_START="-0.8477807821143637" LOG_EFFECT_SIZE="0.0017268193005059549" MODIFIED="2013-05-17 16:19:29 +0100" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="0.9980099404030819" STUDY_ID="STD-DOPS-2012" TOTAL_1="502" TOTAL_2="504" VAR="0.9960238411433631" WEIGHT="5.291977823824178"/>
<DICH_DATA CI_END="4.422620226133205" CI_START="1.2236132314681143" EFFECT_SIZE="2.326279567561709" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" LOG_CI_END="0.6456796477629996" LOG_CI_START="0.08764416455530245" LOG_EFFECT_SIZE="0.366661906159151" MODIFIED="2013-05-17 16:18:51 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.3277928051563933" STUDY_ID="STD-WHI-I-2002" TOTAL_1="2839" TOTAL_2="2683" VAR="0.10744812311229722" WEIGHT="49.05563658680237"/>
<DICH_DATA CI_END="2.6522642905568734" CI_START="0.7000921342127702" EFFECT_SIZE="1.3626552636937488" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.4236167980930422" LOG_CI_START="-0.15484480177553603" LOG_EFFECT_SIZE="0.13438599815875304" MODIFIED="2013-05-17 16:19:09 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="0.339791207193903" STUDY_ID="STD-WHI-II-2004" TOTAL_1="1637" TOTAL_2="1673" VAR="0.11545806448628992" WEIGHT="45.65238558937345"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.593767020826572" CI_END="2.799655999777065" CI_START="1.3656775130093501" DF="8" EFFECT_SIZE="1.9553585970499754" ESTIMABLE="YES" EVENTS_1="300" EVENTS_2="158" I2="41.1494989744678" ID="CMP-004.04.02" LOG_CI_END="0.447104671850569" LOG_CI_START="0.13534815845588938" LOG_EFFECT_SIZE="0.29122641515322917" MODIFIED="2015-02-11 21:42:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0929878087991951" P_Z="2.5046011336368236E-4" STUDIES="9" TAU2="0.086089095146933" TOTAL_1="13936" TOTAL_2="13539" WEIGHT="100.0" Z="3.6617889957245087">
<NAME>Hormone therapy commenced &gt;10 years after menopause</NAME>
<DICH_DATA CI_END="28.898052239974323" CI_START="0.44920623069365717" EFFECT_SIZE="3.6029411764705883" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4608685718244399" LOG_CI_START="-0.3475542285078478" LOG_EFFECT_SIZE="0.5566571716582962" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="1.0622765047524207" STUDY_ID="STD-ERA-2000" TOTAL_1="204" TOTAL_2="105" VAR="1.1284313725490196" WEIGHT="2.7612227150424866"/>
<DICH_DATA CI_END="21.750677452860142" CI_START="0.1819407072235827" EFFECT_SIZE="1.9893048128342246" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3374727881622435" LOG_CI_START="-0.7400701214714465" LOG_EFFECT_SIZE="0.29870133334539856" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="380" O_E="0.0" SE="1.2203589891220905" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" VAR="1.4892760623310908" WEIGHT="2.1287518562710566"/>
<DICH_DATA CI_END="4.944828188696005" CI_START="1.3893322295528723" EFFECT_SIZE="2.6210702341137124" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="13" LOG_CI_END="0.6941512063482554" LOG_CI_START="0.1428061105387294" LOG_EFFECT_SIZE="0.4184786584434924" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="381" O_E="0.0" SE="0.32386283848075587" STUDY_ID="STD-HERS-I-1998" TOTAL_1="1380" TOTAL_2="1383" VAR="0.10488713814881216" WEIGHT="17.560098685645215"/>
<DICH_DATA CI_END="17.920833529726732" CI_START="0.2287491309184868" EFFECT_SIZE="2.0246913580246915" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2533582056018944" LOG_CI_START="-0.6406405472637983" LOG_EFFECT_SIZE="0.30635882916904816" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="382" O_E="0.0" SE="1.1125442428783399" STUDY_ID="STD-STOP-IT-2001" TOTAL_1="243" TOTAL_2="123" VAR="1.2377546923617384" WEIGHT="2.5332003178389524"/>
<DICH_DATA CI_END="3.226477749099707" CI_START="0.16414571724237792" EFFECT_SIZE="0.7277448071216617" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.50872867440935" LOG_CI_START="-0.7847704440480551" LOG_EFFECT_SIZE="-0.13802088481935254" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="383" O_E="0.0" SE="0.7598077851057812" STUDY_ID="STD-WEST-2001" TOTAL_1="337" TOTAL_2="327" VAR="0.577307870307353" WEIGHT="5.055135428588541"/>
<DICH_DATA CI_END="2.776360654215779" CI_START="1.5348032617909424" EFFECT_SIZE="2.0642595253500495" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="63" LOG_CI_END="0.4434758810775147" LOG_CI_START="0.18605271349754676" LOG_EFFECT_SIZE="0.3147642972875307" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.15121164290170375" STUDY_ID="STD-WHI-I-2002" TOTAL_1="5667" TOTAL_2="5419" VAR="0.022864960949032377" WEIGHT="30.779593008747774"/>
<DICH_DATA CI_END="1.7816278927775397" CI_START="0.9641806121705514" EFFECT_SIZE="1.3106529183267315" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="71" LOG_CI_END="0.25081700329885187" LOG_CI_START="-0.01584160559725615" LOG_EFFECT_SIZE="0.11748769885079788" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="0.1566365868469763" STUDY_ID="STD-WHI-II-2004" TOTAL_1="3673" TOTAL_2="3756" VAR="0.024535020339070346" WEIGHT="30.314922641893542"/>
<DICH_DATA CI_END="16.182715183911206" CI_START="0.06694170992082278" EFFECT_SIZE="1.0408163265306123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2090513906050862" LOG_CI_START="-1.1743031984662406" LOG_EFFECT_SIZE="0.017374096069422723" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="1.3999942834159855" STUDY_ID="STD-WHISP-2006" TOTAL_1="49" TOTAL_2="51" VAR="1.959983993597439" WEIGHT="1.6390233182452403"/>
<DICH_DATA CI_END="24.387203426488465" CI_START="2.1911277687368984" EFFECT_SIZE="7.309957498482088" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="1.387162000966482" LOG_CI_START="0.34066770281836045" LOG_EFFECT_SIZE="0.8639148518924211" MODIFIED="2015-02-09 15:43:01 +0000" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.614715930962528" STUDY_ID="STD-WISDOM-2007" TOTAL_1="2196" TOTAL_2="2189" VAR="0.37787567577912745" WEIGHT="7.228052027727182"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-03-06 13:42:06 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-03-03 16:23:03 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>: Process of study selection for the review</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAQeCAYAAADyyLz+AABtIklEQVR42uy9D4RVz//H/yFJkkSS
lSSSJEkkSZIlSd6SWEny9hXJSpJIkiSRrJUkkiRJrCTJiiRZeYskWUlkJSsrkiTJ/Dzn95v7mzt7
zsw598/u/fN4cO3de/6fM/N63Dlz7rz+Zzz+97//8eqiV6vBNaH8QXvyP78SQ5dd/Ba65pQ/yh+0
uUi4oFRmAgpw7aGO68iFpBD8ryu3DZQ/QCSASIDyB4gEEAnlj/JHGUAkQEUmiABlAJEAFZkgApQB
QCSASIDyB+0tkrdv33I2qcgEEaAMIJLqi5v6Rar/ftasWW1bOLq9ILeiSPLK3p49e6i0HVZeEUmX
tEhqmQeRUJEbue2vX7+a1atX279UWkQCHSQS93lWiyVc5uzZs2bevHlmzpw55ujRo1XTHj16ZGbO
nGlmzJhhg8WzZ89y9+Xjx49m586dZvbs2XaZFStWmPv371ft040bN8ySJUvs+jTP48ePK9P//v1r
Dh8+bObOnWt6enrMnTt3EEkbiGT79u3myZMnhcuU1vvy5UuzcOFCs27dusrnJ06csPOr/GzZssV8
/vw5um9Z64ht9/fv32b//v12/SqbIyMjVdNj28/aXqq8lqk7lD9oaZGkWiRXr161wV2V4s+fP7Yy
XLhwoTLdD/bDw8Nm2bJlufuyZs0ac/v2bbsuvS5fvmwrnr9dicZVUK1X63cMDAyY8+fP22X17XbT
pk2IpMVFMjg4aI4dO1b1WapMab39/f12+pcvX+xnly5dsuXFlR2tQ0E/tm/hOlLbPX36tLl37559
//DhQ7Ny5crKtNT2s7aXKq9l6g7lD9paJGvXrrUVwccv8BKBq3y1oG9j/nbDb5n+vuibnr41Ol69
eoVIWlgkeohj48aNNmj7pMpUVjlYtWpV1bXX+wULFkT3LVxHarsSRzi96Paztpcqr/XWHUQCbSMS
fWsKb3/5wV/fpPSZKumZM2eS+6Pmv7757d2711bO2H5k7YuPKj0iaU2R/Pr1ywbS9+/fT5qWKlNZ
6/Wn55WH1L6lthtbX2r7eduLldeydYfyB20rkqwKlCUH3QrYtm2bOX78eO58N2/etN/6rl+/bu+Z
6xZAPSKhILeuSA4dOmSvd9GgXEQCZbZfVEZFxZTafq37XLTuUP6grUWiTsDv378X2qE3b95EC5Y6
Hf11ffr0qZRINmzYUHWr4N27d4ikBUXy4MED09fXl7tcqkxlrVfLhLeWwsfWi6wjtt3ly5fn3tpK
bT9re2XKa6ruUP6g5UWip1B0f9cVen+aOhldh6Fe+l9PrDjUwtDTJyLsHA/R01juKS1VqvXr15cS
iTrqz507V+m83Lp1KyJpMZGMj4/bWzWxgJ0qU1nr1TzquHfLXLlyxQb+MvuW2q5uuep2k3j69Omk
zvbY9rO2lyqvZeoO5Q9aXiR6ckXfrtw3rHCZU6dO2daEpuupKvdUimuaq6/DPa7rKkYWz58/t52b
mk+VSB2NZUQiLl68aDs59QinnpxBJK0lkn/++afQD2JjZSrvmNzjt3rpiakPHz6UPi+x7apfRz+a
VPlUmVbneNHt520vVl7L1B3KH0yrSACREESAMgCIBBAJUP4AkQAiAcofIBKgIhNEgDKASICKTBAB
ygAgEkAkQPkDRAKIBCh/gEgAkVD+KH+UAURSC81Oy0va3+4USTtf924us4iki0VSz8WPjW/UCJq9
fipya267yHVv1WNth1TVzdonRIJIWrLgUDC7UyStft3LjDSMSKAjRFIkpa0GaXRpRZUK1R9XKC8F
aF5a3jDFaGr7eSlNs9bfCelIu00kZdPcFi1XRVJA//jxwyxevNiOm+WjMqfyk9oXUSalc96+a4DH
vJTRtaQSLjIOnY5J+zx//nybzTEcxy62T4gEkUyiSEpbDXGtkVo1fWhoyBw4cKAyPZYCNOvbV5hi
NLX9WErTcP2dkI60G0VSNs1tkXJVNAW0cqFotF4fpb1VoC2yL2VTOmft+44dO3JTRteSSjglEh2P
8pm4fVZmylAksX1CJIikEGEGOr8FosKnob8dsRSgWZUmTDGa2n4spWm4/k5IR9qNIimb5rZIuSqa
Anp0dNS2Stx0/V26dGllfal9KZvSuey+15JKuEiuHn0xzNvn1D4hEkSSSdmUtv63k1gK0KL3g2Pb
L5MitRPSkXajSLLKV5n0ukWyZcbWt3nzZvstXah1rFutRZctm9K57L7Xkko4tc6wwz/c5yK3xhAJ
IqmilpS2YUHMSwFapNKktl8213a7pyNFJOXT66YCX2p9Ki/qfxPqG1E5LLpsvWl9axFJLal8Y3UK
kUDdIimS0lbNf78ZrVsBWYQpQItUmtT2YylNYwWzXdORIpLy6XVTga9ICmh1LKu/Q7e1yuxL2ZTO
jRBJ2VS+YZ1StlH1jThev36NSKA+kRRJadvb22smJiZsQFfHot/ZHksBGkvLW3T7sZSm4fo7IR0p
IkmnuS1SrsqkgBbqQNdTV35HepFly6Z0LrvvtaQS9h86GRsbs7fqYp3tOh5EAnWJpEhKWz0Voscf
9a1HUvE74mIpQFNpeYtsP5bSNFx/J6QjRST/L7E0t0XKVZkU0EJflDTN/6ZedNkyKZ3L7nstqYTd
lyjVAwlG9SBcj+Sn/ZU8tc+xFg0igaRIAJF0+rYhjr6s5d2upgwAIgFEApNQ60kPGLjfxqh1MxUP
plAGEAkgEoJIh6Cn0vT7F93O0i/bjx07ZoVCGQBEAogEKH+ASACRAOUPEAlQkQkiQBlAJEBFJogA
ZQAQCSASoPxBJ4qkVdKMdmu603YUCemUKX/QBiJJXdxmpkj11+2SUrkh6uvdLulOO0Mk7XCtAJHQ
IpnCix9bV6OysBXZVremO21HkbTDtQJEQovE+7xI2tBY2lHNqwHhslJ05qUZTU0rsl3Snba3SPLO
Yy3XqkgZzbqWPqmUzfVc96zt56WTLnI87ZReGpF0iUhSaUOLpEDVoHaxtKGxCpY3jXSnjRnNuBVF
UvY8ps5LkTIaXstY6zhM2Vzvdc/afiyddOp42im9NCLpEpGk0oYWSYGaShtayzTSnTamIraiSMqe
x3rS6uYtHxJL2Vzvdc/afiyddOp42im9NCLpEpGkMqeVTYHaKJGQ7rRzRVL2PNabVrfIOYilbK73
uhfNeFj0eNopvTQi6VKRhNPLpkBtlEhId9q5Iil7HutNq1v0HOSlbK73upcVSep4YvuKSGBaRJJK
G1o2BWqjREK6084VSdnzWG9a3bLnIEzZXO91z9p+LJ10kTTBefuKSGBaRJJKG5pKO5qq5LE0o7GA
QbrTzhVJ6jw2Oq1ukXMQS9lc73XP2n4snXTqeNopvTQi6RKRiFTa0Fja0VQlj6UZTX3zJN1pZ4ok
dR4bnVa3yDlIpWyu57pnbT+WTjp1PO2UXhqRdLBIoDWYinSnjLUFiAQQSQcxHelOEQkgEkAkHcR0
pDtFJIBIAJEAIgHKHyASQCRA+QNEAlRkgghQBhAJUJEJIkAZAEQCiAQof9AJIiEVKhWZIAKUAURS
1wUPR7GlMFGRue5AGUAkplnzUpgQCVD+oANFkkpT+/HjRzu+jwbP01g+SgV6//79SsEIU6HG5nfL
aBA+l1p0+/btVWMLpZZPpRaNpSWlECASQCTQBJGk0tSuWbPGjq7rRh9VmlFlZcsrHEXmd9kBNX1o
aMgcOHCg8PKx1KKptKQUAkQCiASaIJKyaWpF2Yxz4fx+C0RBX9ndii4fSy2aSktKIUAkgEigCSIp
kqZWQ1UrZ8LevXvtkNWpYbHLzh/uQ2z5WGrRVFpSCgEiAUQCUyCS8ILfvHnTJs+5fv26HWhQuRBi
Yig7v/Cf/Eot70STlVoUaSASoPzBNIgklaZWnfB+qs9U6tAi84+Ojlb+17b9PByp5X2y0qAWTUtK
RSaQANceGiSSVJraJUuWVJ6akmSUazyWPjc1v9739vaaiYkJu0119Pud7anlU2lQY2lJKQT/Yx+A
aw6NF4mIpal9/vy57bBWwFYQV0d3LH1uan691za0LS0jqUhERbeXSi2aSslLhW6N/eDVPS/oEpEA
IgHOPwAiAQIZ5x8AkQCBjPMPgEiAQAacf0AkQCADzj8AIgECGecfAJEAgYzzD4BIgEAGnH9AJEAg
A84/QNuIJLWP03UM4a/rhcb0iv2K99u3b5UEXUqy1dfXZ4egcSgfy65du+wv8DXPnj17qqYTyBAJ
ACLpkIo2NjZmx+sK902jDyv456FMjRrm3o37devWLTt8i0Njmt29e7cyXe81XAyBDJEAtJ1I6kld
WyStrsbGUjIqJdASGtzRpdnV/CMjI1XzDw4O2oEb3VhaLhtiWBH1XtkQ8+Z1+65xt+bPn28zLaaG
s89CQ9W/f/9+0vwa6FL7moekoEEnHcrYqLTCjqzh+7M+I5AhEoCWF0k9qWuLpNXt7++309zgiUpY
5TIc6lu9Bmb059+xY0dlEMdwdN9QBJJY3rzab+UqcaMab9y4sXRFlix0TFlBYPfu3VYWkqxkdeLE
iarp+izM1qjPwhaJQ+dk8+bNBDJEAtB+Iml06towra4/sq+QOMJ1xubPa0Wk5nV54R1FUgj7/Pff
f1W3msJlFy1aZG9XCR3PtWvXrCSLtjiUk0UtJde3ovd+nhYCGSIBaBuR1Ju6tt60uqmKFhNJbF4/
66IL9kUr8o8fP+ytOF9EqWW1fsklS6hZx67WlPKluNachvJXK4dAhkgA2k4kTga1pK6tJa3uVImk
SC76PJRoa2hoqHQQ8M+Xfxsr6zOJzm+Z6b36jQhkiASgLUXiKJu6tmwaXrF8+fLora1GiUSZFf3H
aV+/fl24IhdJ0qNEYGq5OPQQgR4ecEjKP3/+rPz/69evqmyNoTR0TvRAA4EMkQC0nUjqSV1bJK1u
iG6D6XaaePr06aTO9kaJJOxsz3qEt54gcOzYMftUmDs3egjhypUrlema5p87tdr8W4d6CEGf6SEG
TR8YGDCHDx8mkCESgPYTST2pa4uk1Q3RN3P9/kLLaLvqBG+GSISeutJTVT09PfYJNL/fpGylDufX
cRw8eNCuUx3lkoaPzpOezHJpiPU0mn6k6C8vmbjpkog+I5AhEoC2E0m3oCC9ePFiAhlw/gEQSTHU
h6EHCNxvYPQ7D/9BAgIZcP4BEEkUPUWmR3jdrSf1aUgoBDLg/AMgEiCQcf4BEAkQyDj/AIgECGTA
+QdEAgQy4PwDIBIgkHH+ARAJEMg4/wCIBAhkwPkHRAIEMuD8AyASIJBx/gEQCRDIOP8AiAQIZMD5
B0QCBDLg/AMgEiCQcf4BGleGKcgEMeAaANQtEgozAQy4DgB1i8QVaF7d8wJEAtBwkVCRASh/AIiE
igyUPwBEQkUGyh8AIqEiA1D+AJFQkQEofwCIhIoMlD8AREJFBsofACKhIgNQ/gCRUJEBKH8AiISK
DJQ/AERCRQbKHwAioSIDUP4AkVCRASh/AIiEigyUPwBEQkUGyh8AIqEiA+WPkwCIhIoMQPkDREJF
BqD8ASASKjJQ/gAQCRUZKH8AiKQ9KzIvXtP5AkAkwDdqAEAkAIgEABAJIBIAQCSASAAAkQAiAQBE
AoBIAACRACIBAEQCiAQAEAkgEgBAJACIBAAQCSASAEAk0HoCYcwoAKDmAyIBAEQCrSETAEAkAIgE
ABAJIBIAQCSASAAAkUC3yQQAEAkAIgGAzhcJub158SIPPCASvvUCUGcAkVAhAJAJQBuJhIoAQB0C
REIlAKAOASKhEgAgEgBEAoBIABAJAFCHAJFQCQCoQ4BIqAStydu3b2uaBtNzzqbqmlCHAJHkVAJ9
fufOnSmrNK1QGR89emRmzpxp1q5dmzl91qxZufscm9bJXybqWTY8Z42m2etHJIBICohk3bp15tev
X10jEknk8ePHNe1jOA2RTP81n6prgEgAkUREcu3aNXPmzJnc+bOWDadfv37dLFiwwMyfP9/cvXvX
XLp0ycydO3dS0Na8nz9/Nvv37zezZ88227dvN69evapa99mzZ828efPMnDlzzNGjRydt9+XLl2bh
woVWgHmcOHHCLq9tbNmyxW7TLR8bRylruv83b1qRfXctoRkzZpjVq1ebZ8+e5e7/x48fzc6dO+3+
a5kVK1aY+/fvV+3njRs3zJIlS+z6wvP89+9fc/jwYXsNenp6bKszFgiLbC923fKOLe+chdcwtf3f
v39Xtq1pIyMjuesvc54RCSCSBolErF+/vhJsaxHJgQMHzJ8/f8yDBw9s8Dp48KD9X8FNldqfd8OG
DWZ8fNwGu6GhIbus4+rVqzZAapqWVwC8cOFC1fL9/f12+pcvXzKPSRK7fPmynUcvrVNBqGhAiLU6
YtNS++4H++HhYbNs2bLcfVizZo25fft25Rh0PAq8/nYVeN01C8/zwMCAOX/+vF3269evZtOmTdHj
LrK92HWLHVvWOQuvYWr7p0+fNvfu3bPvHz58aFauXJm7/jLnGZEAImmgSJ4/f276+vpqFkkooe/f
v+fO63+TVdDw+yr0Xp/5hEHJ31YWq1atst9g/W+zai01WySpfVdgdMGwFvQNO3Ye/H3RN33/HOic
lw2E4fZi1y12bFnnLHUNw+1LHOG5zVt/vecZkQAiqVEkQiKRUGoRSa2B2H2D9N+HtyvCgFYmAGVt
o1kiSe27vh3rMwXg8FZiFrr9o2/ie/futXIsc03843WBP3XcZbfnbyN2bEX7lWLbD48ntr6y5xmR
ACJpoEjGxsbsLa6pFon/1E2WBMpW5qygk9qHRogkte8uWOrWzLZt28zx48dz57t586b9Fq6+pydP
nthbQPWIJHXctWwvfFoq79iKiCS1/TIiKXOeEQkgkgaLROgbnDrfY0Hk06dPdYlkdHS06rbT4sWL
K/+rc9S/LVZLZdY6wltbftBrlkhS++7z5s2b6H6on8lfV+qch5+pP8M/B+/evat7e7HrFju2IiJJ
bX/58uWFb22VOc+IBBBJE0Six4B1SyD8Nug6L9VqUSdvPSLp7e01ExMTNjCoQ9jvtFVHuesk1kv/
66mrMpVZywwODlbWceXKFRuIiq5DTwbpHr4LxP78sWmpfdc3bj1RJMLO8RA9jeWeWpIE1FIsIxJ1
XJ87d67S2b5169bocRfZXuy6xY4tds6Kbl+3vHTLSjx9+rSqsz1cf5nzjEgAkTRBJCJ8VNRVRt26
UUBWJa1HJHq6SY/IqpWg4BR2vJ46dcp+Q9V0Sct/OqtoZXaP/+qlJ7Y+fPhQeB160krbdq0Yf/7Y
tNS+63aL7v27x3VdsMtCfVXqqNd8CozqPC4jEnHx4kX7kIHOtc557LiLbC923WLHljpnRbavLzh7
9uyx07Udv+M/XH+Z84xIAJFQCQCoQ4BIqAQAiAQAkQAgEgBEAgDUIUAkVAIA6hAgEioBAHUIEAmV
AACRACASAKAOASJpwUrQrmlqSa/LuUUkgEhMuV+2N6vyxNLUhulv691uPcuH+9LOqVwbuc4yA182
okwgEkAkHVIJmhWIQlLpb6dyv7OyOiKS1t8/RAKIpAVaJEXSs6bS4Oalf21mCttGppUN9yUvNW+9
6YDrPde1rLNIOgAN567xubRNZTHUGFepFkleGtyy5zprH/NSJqfKWzMCPyIBRFJAJKn0rEXS4MbS
vzYrhW0z0srGzl0j0gHXe65rWWcRkeh2nq6f1iGRHTlyJHm9Ymlw6znXRVImx8obLRJAJNMgklR6
1lrS4BaVRT0pbJuRVjZ27hqRDrjec13LOouIxG9N/Pz5syrnSN66Ymlw6znXRVImx8obIgFEMg0i
SaVnrSUNbiNEktpus9PKhv83Ih1wvee6lnUWuT6hEPJalEWzF9ZzrmtJmYxIAJG0mEiKVOzUNhoh
krIBNFXpy6aVDf+finTAsW3k9dvUkmK4TF72WkRSz7mu93gQCSCSaRBJKj1rLWlwGyGS1HabkVY2
dlyNSAdc77muZZ1FUiYrNa3j27dv9lylrlcsDW4957qWlMmIBBDJNIsklZ61ljS4RdPUpjpdY9tt
RlpZn3C/G5EOuN5zXcs6i6RM1ja0rNZx8uRJs3v37qRIYmlwU+c6lbq4bMpkRAKIZJpFIlLpWcum
wS2apjbVCohtt8h++5RNYxvudy3nIYt6znUt6yySMllBf9GiRfbJqmPHjtlWSUoksTS4qXOdSsNb
NmVyM340iUgAkVAJgDLC+QFEQiUAygjnBxAJlQBanqkaUwyRACASAEQCgEgAgDoEiIRKAEAdAkRC
JQBAJACIBACRACASAKAOASKpqxLo18P6BbWGq9AvlMfHx6uWi41Cq6HGDx06ZH95rMdHtbz/a2it
a9euXXaaW7+G4ABAJAAdIhINqeEnD9JYTbExnR48eGCH7nAo8ZHGQHLLS0qShUPjPd29e7cyXe97
e3spMYBIADpFJBoHSa0Kn7xhwSUCZbz78eNH5bP58+dXjfyqbH7+D9uy1tXMLHYAiAQQyTRWAg33
rfSqSkCUhQYB9FsjWWgUVz+VqmuRODRo3+bNmykxgEgAOk0kfX19lVFWX79+nTmPWiPKJxHj1q1b
dlhxx+joqG21uP4VvddnAIgEoANbJEJ9HEooFKLgr1wSMSYmJqyQdHvLoeHPlVfC9ZGoT8bPcQGA
SAA6TCSSQFYfhhIMSTKx5fbt2zfpiSz1l/h9KHqvp7cAEAlAh4hE/Rl+8FcfhxIjhagV8fDhw9yW
iB4BzrrtFUpDItHtMwBEAtAhIlEr48yZM5VbT0qvqleInu7KytD34sUL23nu//bEp7+/31y/ft22
WLT+gYEBc/jwYUoMIBKAThGJAryCvW5BqaWQd/tKt7v8W1SOxYsXZ/5o0aE0rG79ekki+gwAkQB0
iEgAgDoEiIRKAEAdAkRCJQCgDgEioRIAIBIARAIA1CFAJFQCAOoQIBIqAQB1CBAJlQAAkQAgEgCg
DgEioRIAUIcAkVAJAKhDgEioBACIBACRACASAEQCANQhQCRUAgDqECASKgEAIgFoP5FQEQCoO4BI
qBAA1BlAJK1TMXjx4lXsBYBIgG++AIBIAJEAACIBQCQAgEgAkQAAIgFEAgCIBBAJACASAEQCAIgE
EAkAIBJAJACASACRAAAiAUAkAIBIAJEAACIBRAIAiAQQCQAgEkAkAIBIABAJACASQCQAgEgAkQAA
IgFEAgCIBACRAAAiAUQCAIgEEAkAIBJAJACASAAQCQAgEkAkAIBIAJEAACIBRAIAiAQAkQAAIgFE
AgCIBBAJACASQCQAgEgAkQAAIgGoSSDhCwAQCQAiAQBEAtMjEwBAJACIBAAQCSASAEAkgEgAAJFA
t8kEABAJACIBAETSCgGVV/e8AACR8K0cuOYAiISAAlx7AERCIAHKAAAiIYgAZQAAkQBBBCgDAIiE
IAKUAQBEQhABygAAIiGIAGUAAJFAxwWRt2/f1jQNEAkAIpnGIHLixAkzd+5cM3v2bLNnzx4zPj5e
tVz4mjFjRmX6z58/zaFDh8ycOXPMrFmz7PLfvn2rTNe6du3aZae59X/9+jV3XzRf3n7HprXb+f/4
8aNZuXIlIgFAJO0vkosXL5rLly+bv3//2te5c+fMli1bctfz4MEDc+rUqcr/R44cMVeuXKksLylJ
Fo6tW7eau3fvVqbrfW9vb03BLpzWziIZHBy05wqRACCSthfJsmXLbKvCZ+bMmZnzSgRr1qwxP378
qHw2f/58+7njz58/VS2HrHXlrT9rjCj/b940x9mzZ828efNs6+jo0aNV0x49emS3q9bU6tWrzbNn
z3LPlVoLO3futC0oLbNixQpz//79qv28ceOGWbJkiV2f5nn8+HHVeTp8+LBt5fX09Jg7d+5M2lcJ
9sWLF1WtQu23timRf/78uWp7L1++NAsXLjTr1q1DJACIpLVE4vP9+3cbjPfu3Zs5/erVq1WtkSx+
//5tA17YInHcu3fPbN68uaZWR2ya9k3BXUFcMlPwvnDhQpW8XLAfHh62As1Dsrx9+3alFaUWm39M
2q5E44K91uvLcWBgwJw/f94uq9t4mzZtqtrXX79+WQE7Ll26VNUq1LHs37+/anv9/f122pcvXxAJ
ACJpTZH09fXZb8R6vX79OjfAfvr0KbqeW7dumdOnT1f+Hx0dtUHTtST0Xp81WiRr166tahm51pZD
IpDEasXvF9J2/RZDuC9qNUiojlevXlVNl1j37dtX+X/VqlVV8+v9ggULottDJACIpCVbJO4Wi279
hCj4r1+/PrrsxMSEFZJaBA59c9c3bvdtW30yu3fvbrhI1CKIPRSgVog+k3DOnDmTPA+6lSQhqnWm
QB/bj6x98dFx+9MlEV9q/n5mraNRAkAkgEhgSoKIJJDVh5HqHNZyCpDhE1nqL/FbCnqvfoBGiyQr
GGfJ4eHDh2bbtm3m+PHjufPdvHnTPlF1/fp18+TJE3s7qR6RhNPVKtPtraLzIxIARNLSItEtHz/4
h7dVHGpFKAjntUT0CHDWba9QGhKJbp81WiRqRamPpwhv3ryJBlV1kvvr0nGVEcmGDRuqblW9e/eu
Ml2d/BKZj/Y9vLXlP7CASAAQSUuLRK0M3epxt55OnjxpXyHqb8jq6NWTR+o893974qNOYn2zV4tF
61dHtJ5oykPiUX+AC6z+fsem6faZ6+DWS//7jzGrhaEnt0TYOR6ip7HcU1qSgG7plRGJOur1GLXr
bNcDB266zrdadz7aV33m9l2PUy9fvhyRACCS9hCJAryCvb4Bq6WQd/tKgTfszBaLFy+OpnfVLRy3
fr0kEf+2ToietHLzhvsdmyb0RJlaE5quvhlffLqtpb4O97iuk0oWz58/t+LUfBKQ+jPKiESoL0gt
Oz2OrKew3HStT48XZwndPeygJ7Y+fPiASJpQB3h1d4ppREIQAcoAxw51XXNKARUJKAMcN9R17SkJ
VCagDHDMUFcZoDRQoYAywDEDIqFCAWWAYwZEQoUCygDHDIiEkwmUAY4ZEAlQoYAywDEDIun8CtXs
1Lik3iWocsyASNqgQtVTEcPUuI2m2eunDHT2McdSTAvltFm6dKktZxomR2O0+euNjTbt0CgO/nA3
7XS9p3t5RIJIpqQg8W2T81XrMadSTP/333928E0N2KnpGj9Nw9vkEaagFhp+SIOdTtd5RySIZMoK
VZG0shooUeM/aZ7t27fbRE2OvBS2ealxw5Sxqe1rgEa3bU0bGRnJXX+ZdLqUge4+5lSKaeWhkWyK
kJWCWkhMY2Njhc97Xqpo5fh5+vRpVZ1TPYzVj0kBNDE+XJH00LFU1kWWRyQdXKGKpJXVNzM1+zV9
aGjIHDhwoKry5aWwzRr2PUwZm9q+kku5JFAaxt7/Vhiuv0w6XcoAx+zISjGtEaCL9sHlpaBWLpui
+xBLFa26oltrmqZbZSrXLsto0fqREkkqPXQqlXVqeUTShUEkTCvrt0BUUJRl0BFLYZslkiIpY/3t
q2JkjTqctf560+lSBrrvmPNSTOtLib6M6Fu+60P59u1b7pexWArqIuc9lSpagVzBWsH7yJEjpetH
SiSp9NCp/Ustj0i6oEKVTSvr3wKIpbCNJaIquv1Y3pBwfWXT6VIGOGZHmGJayylZm1orCqAK5H6L
xVEkBXWRfUilinbBXKkJlEiubP2oNz10av9SyyOSDq9QtaSVDZ+WykthW0Qkqe2XEUlsXwCRxAhT
TOtev/8NW4Ex6ynBVArqovtQJFX0jh07bF2ZCpGE01P7l1oekXR4hSqSVtbdjxWqXEpmlUWYwraI
SFLb16OTRW9txfYFOlMksSRGsWNOpZh2ndm+SMK00SKWgrrMeU+lilbWTPVR6AuXf2uraP0I9yGs
Z7H00EX2L7U8IunwIFIkrWxvb6/9FqQCqw41v7M9lsI2lhq36PZ1y0u3rISeXPE7E8P1l0mnSxno
LJHkZcerNcW0+tr0ctPV8si6hZWXgrrseY+litb6N27cWBXU379/n6wfYYvDPYiiJ8n0pGTR9NCp
/SuyPCLp8CBSJK2s7g/rsT817SUVv8M8lsI2lRq3yPb1lIo6OjVd2/E7/sP1l0mn281lgJSrxVJM
Sx5qubjUzS54h7d08loEZQWelypa5d9//FfvNT1VP/ztui9WqhtqxahuFE0Pndq/ossjEr6NAmWg
o1ok0J3lntJAEAHKQK5IKPeASAgiQBngmAGRUKGAMsAxAyKhQgFlgGMGRAJUKKAMUO4BkVChgDLA
MQMioUIBZYBjBkRChQLKAMcMiASoUAQSRAKUe0RCheK4ORccMyCSVq5QsfS0qTSeYdpcEUvHmZqu
dWqEUw3k6MbLcgPNFVm+ldN9ElQ5ZkAkHVuhYulpU2k8w7S5qXScqelapwaDc4NChiP4tnO6T4Iq
xwyIpGMrVCw9bSqNZ5g2N5WOMzU9a52dku6ToMoxAyLp2AoVS09bNjthkXScselFsri1a7pPgirH
DIikoytUXnrasiJJpeNMTU+JpJ3TfRJUOWZAJF1RocL0tGXT3KbScaamp0TSzuk+CaocN0z/tack
NKkyxdLTFk3j6Uil40xNT4mkndN9ElA5dpj+a04paFJFiqWnLZrG0yeVjjM2PSWSIutv1XSfBNPW
OH5e3Z1imWhAEAHKAEB9dYBTQBABygAAIiGIAGUAAJEQRIAyAIBICCJAGQBAJEAQAcoAACIhiABl
AACREESAMgCASAgiQBkAQCRAEAHKAAAiIYgAZQAAkRBEgDIAgEgIIkAZAEAkQBABygAAIiGIAGUA
AJEQRIAyAIBICCTAtQdAJEBA4ZpzzQEQSRMCC6/uTjkKgEgA+GYOAIgEEAkAIBJAJACASACRAAAi
AUAkAIBIAJEAACIBRAIAiAQQCQAgEgBEAgCIBBAJACASQCQAgEgAkQAAIgFAJACASACRAAAiAUQC
AIgEEAkAIBJAJACASAAQCQAgEkAkAIBIAJEAACIBRAIAiAQAkQAAIgFEAgCIBBAJACASQCQAgEgA
EAkAIBJAJACASACRAAAiAUQCAIgEAJEAACIBRAIAiAQQCQAgEkAkAIBIABAJACIBQCQAgEgAkQAA
IgFEAgCIBBAJACASAEQCAIgEEAkAIBJAJNA2159X97wQCSAS4NpDw685pQAIJsB1h7quPSUBCCjA
NYe6ygClAQgqwDUHRAIEFeCaAyIBggpwzQGRAAUKuOaASAAIKsA1B0QCBBXgmqd5+/ZtS62n2etE
JEBQgba65r9+/TLLly+f9PmPHz/M/v37zaxZs8yCBQvM0aNHzbdv33LX8+jRIzNz5kyzdu3a8sEt
sY/ah0bQqPXE1lm0jk1lXUQkgEigadf8z58/Zvfu3ZnzHDx40Fy4cMH8/fvXvgYHB+28eUgijx8/
ri24Jcplo8ptM8p/retEJIBIoCOu+ZYtW8zY2FjmPPqmLYE49H7u3Lm52wjHeMocniNHHrF9zBs/
6uzZs2bevHlmzpw5trXk6OvrM0+fPq1qKW3fvr3QOFQfP340O3fuNLNnz7ZiXLFihbl//37Vvrx8
+dIsXLjQrFu3Lnncv3//tq06rU/rGhkZyT3mvOPxW3szZswwq1evNs+ePUMkgEigNa75kydPcucJ
RaKgGLs1NGkojgaJJGv61atXzY0bN+z+qVV1584d23oSX758MevXr7fTdNtu2bJlZnR0tNB21qxZ
Y27fvl1phV2+fNlKw9+P/v5+O03bSR336dOnzb179+z7hw8fmpUrV2bOFzuesLU3PDxsjwmRACKB
lrrmWfPom7RuZ7mAfOTIEfuNuBVEon4YX3LCD64KzAMDAzYYa7/rKf/+MWv5z58/Fz5uiSPcz6z5
UscjmTkh1VsGiACASGDKRKKOdd0m0rdhdcbrm3CrtEi0T+FtpVByCs56SGBiYqLUudCtK7Uk9u7d
a1atWpXcz9hxaz+LHFPqeHTu9ZmO6cyZM4gEEAm0h0hC3r17Z3p6epoqkrx+jHBdsZaRY8eOHbZF
UEYkN2/etMtcv37d3vbT7aupEEmR45HgdHts27Zt5vjx44gEEAm0n0iGhobst/RaRfLp06eGtUjU
4fz9+/fc+a9cuWL7HCSEMre29DCBv97YPhc5brXkitzaSh2Pz5s3b0rXY0QCiASmRST6Zi55CD3N
pG/Cr169KrwOv4NYT4bpaahaRaKnntQ3oQ5/cenSJXP+/PlKp7j+1xNoQq2IjRs3VgXp9+/fZ64n
ZMmSJZWntNQCU6d9aj/DdYad7botJfQkWV5ne+x43LXQk1tC5zTW0kEkgEigZUQiaegRV9dHkurs
DdfhAp5u22h5BcJaRaJOc/XP+H00p06dsi0IfSZJuaeo9uzZU/X4r95ret56fJ4/f247ubXfCt46
5tR+huv059FDCtofrU/9Lb6Iw3XlHY/QbS0tr3OpdTmpIBJAJMA1hykvA5QGIKgA1xwQCRBUgGsO
iAQIKsA1B0QCFCjgmgMiASCoANccEAkQVIBrDogECCrANQdEAgQV4JoDIgEgqMC0X/N6tzXdyyMS
ACoaIBIuOCIBRAJTec3LpqsVRdPHpkbK1eCEhw8ftuNLaXh6ZQUsk362yPKASACRQBOvea3paoum
j02JRBkM3Yi3X79+NZs2bSqVfja1PCASQCTQ5Gtea7raouljUyLRyML+cO4aGbdM+tnU8oBIAJFA
k695relqi2b9S4kkXI+kUSb9bGp5QCSASKDJ17zWdLXNEkk4PbV/qeUBkQAigSZf81rT1RZNH5tK
tbthw4aqW1PKSFgm/WxqeUAkgEigyde81nS1RdPHplLt3r5925w7d67SWb5169ZS6WdTywMiAUQC
U3DNa0lXWzR9bCrVrrh48aLtg9EjvurcL5N+tsjygEgAkQDXHBAJEFSAaw6IBAgqwDUHRAJAUOGa
A2UAkQBBBbjmgEiAoAJcc0AkQFABrjkgEqBAAdccEAkAQQW45oBIgKACXHNAJEBQAa45IBIgqADX
HBAJAEEFuOaASICgAlxzQCRAUAGuOSASIKgA1xwQCQBBBbjmgEiAoAJcc0AkQFABrnkb8fbtW0QC
QFCBMtdcn9+5c2fay0irlEnlhUckAIgESopk3bp15tevX4ikw+sGIgEqCzRNJNeuXTNnzpyJzn/i
xAkzZ84cM3v2bLNlyxbz+fPn6LZevnxpFi5caCXlOHv2rJk3b55dz9GjR6Pby5r3x48fZvHixZOk
9/v3b7N69Wr7/uPHj2bnzp12P2fOnGlWrFhh7t+/X7WdGzdumCVLlpgZM2bYeR4/flyZ5r8QCQAi
gYIiEevXr6+Sgz//pUuXzOXLl83fv3/t6+rVq2b//v3RbfX399t5v3z5Yj/TMgrg+uzPnz/2dtqF
Cxcytxeb99ChQ3Z/fAYGBqx4xJo1a8zt27cr+6r9ltD87Ug07lglEcmEFgkAIoE6RfL8+XPT19eX
Of+qVavst36/BbBgwYLotsIWy9q1a21g91m2bFnm9mLzjo6O2laJm66/S5cujbaQ1PKI7VtVgEUk
AIgEahOJkEgklPBzPxA7/G/xRbal+cNbR2GALzrv5s2bbYtFqPWhFoaPbqudPn3a7N2710owJQpE
AoBIoEEiGRsbs7e4sgJ7mTKUNS1LRnnLpOZ9+PCh7fsQ6ht58uRJZdrNmzfNypUrzfXr1+3nurWG
SBAJIBKYIpEIdbqr893/XME6vLUVe0w2a1tax/fv3wstk5pXqLNcfSO6reUzd+7cqmU/ffqESBAJ
IBKYSpHoiSj1UYSd7YODg5UO7CtXrpjly5eX2pbWcf78+co69L+e/spaJjWvUOd7T09PVYe9E4x7
Suvdu3e2hVVGJHraS30ovjgRCQAigRIiEXpKKu/xX730xNaHDx9Kb+vUqVO2xaDWjPo13BNdWcvE
5hUTExN22tevX6s+Vx+POuZ1O063uO7du1dKJBKT1tuJP0xEJIBIgGsOiAQIKsA1B0QCBBXgmgMi
ASCocM0BkQAQVIBrDogECCrANQdEAgQV4JoDIgEKFHDNAZEAEFSAa16STk6pi0iAoAItc81rHYOq
UeWrmeW0k1PqIhJAJNCSIum0ctqNdQCRAJUImnLNNTihxs7SYIUamn1kZCTZIomlqw3nja2/SFrc
GLH0v7ExtbJS6sb2s8i2NGy9kn3Nnz/f3L171w40qbHCwnMjYimHHz16ZJfRedUoyM+ePWtYvUUk
gEigKddcCaA0sKFQng8NdFhEJEXT1cbWXyQtbh6p9L9lh4uP7WeRbR04cMCmBX7w4IEVyMGDB+3/
4blJpRz2xTM8PFyVRZIWCSASaMlrroAZprUtIpKi6Wpj688iL2tiSCr9b1mRxPazyLbCFoqfE6Vo
GmEhkTqhcWsLEAm0xTUvmjK31uRQsfWLsmlxs4STta2yIontZ9ltxf5PpRFWK0SfSThKMoZIAJEA
Iomsv5a0uLH11pMJMbafZbcV+z+VRtjJVbfXtm3bZo4fP45IAJFAa19zZTqs5dZW0Xlj668lLa4j
lf43XDa17th+lt1W7P8iaYQdb968aWhdRSSASKAp11y3lXQ7RTx9+rRwZ3tRkcTWX0taXEcq/a/f
aT02NmYfDoil1I3tZ2pbZUSSSiOs7erJLRF21CMSQCTQktdcOdr37NljA5b6KF69etVQkcTWX0ta
XJ9Y+l8XhHUrSUFfwTmWUje2n6ltlRGJiKUR1m0tbd89Vu2k0oh6i0gAkQDXHBAJEFSAaw6IBAgq
wDUHRAJAUOGaAyIBIKgA1xwQCRBUgGsOiAQIKsA1B0QCFCjgmgMiASCoANccEAkQVGB6r7l+2e0P
+5FF+MtzQCRAgQKuuUUJlnbv3h2dR+NVaUwoyg4iAUAkXPNJSBASRWweDWn+/v17yg4iAUAkXPPJ
KBdIbJ5z587ZVLOUHUQCgEi45qXn+e+//0xvby9lB5EAIBKueXmR/Pjxw6xbt86Mj49TdhAJACLh
mpcXyYEDB8zQ0BBlB5EAIBKoTST6P+8FiAQoUJwErnnT5gFEAgQVQCSUHUQCQDAArjkgEiCoANcc
EAkQVIBrDogECCrANQdEAkBQAa45IBIgqADXHBAJEFSAaw6IBAgqwDUHRAJAUOGaAyIBIKgA1xwQ
CRBUgGsOiAQIKsA1B0QCFCjgmgMiASCoANccEAkQVIBrDogECCrANQdEAgQV4JoDIgEgqADXHBAJ
EFSAaw6IBAgq0PLXfNWqVebz589Vn92/f9/O+/Dhw6rPNZ/mB0QCgEi45hVOnTplrl27VvVZf3+/
2bRpkzly5EjV55rv5MmTnEhEAoBIuOb/PyMjI+aff/6Z1Ep58eLFpNaH5tP8bl0vX740CxcuNOvW
ravMc+LECTNnzhwze/Zss2XLlqrWjpa5ceOGWbJkiZkxY4aZOXOmefz4cdU2zp49a+bOnWvmz59v
Ll++TDlFJIBIoB2ueU9Pj/n79699Pz4+blauXGnfr1ixwnz58sW+//Pnj1m0aFHVutRy0XJunkuX
Ltngr8/0unr1qtm/f3/VMjt37qzIRRKRTBySzPHjx+2yX79+NRs3bqScIhJAJNAO1/zff/81jx49
su/v3LlTuaWlv7dv37bv1V9y4MCBqnWFfStqwfz+/bvyv94vWLAguoy/Txs2bLAic7x69YpyikgA
kUA7XHN1rqt1Ifr6+szw8LB9r7/6Xxw+fNjOF1uXbleF+C2OrGX8z2bNmlU1TS0TyikiAUQCbXDN
ddtq+fLl9r1/m0t/582bV5nutzay1uVLIzNwJUQSLo9IEAkgEmija66+i3379pldu3ZVfa4Odn22
Y8eO5LpWr1496daW38pIiWT9+vW2b8Tx+vVryikiAUQC7XLN9WivpquDvMjnWetSZ/vg4GCls/3K
lSuVlk4RkYSd7Xrqi3KKSACRQJtccz15peljY2NVn+v/VCe5j3v8Vy89sfXhw4fCIhHnzp2zt9N0
i03yCvtNAJEAIgGueWF+/fplFi9ezIVDJEBQAa55MfSosB4z1q0tdfCrdaNbXYBIgKACXPNCPHny
xP5KXrez9Mv2Y8eOWaEAIgGCCnDNAZEAQQW45oBIAAgqXHOuOWUAkQBBBbjmgEiAoAJcc0AkQFCB
7r3mb9++beljbPX9QyRAUIGOvOZlykKr/9I83L+pLOc/f/40hw4dsr/q137s2bPHfPv2DZEAIgGu
eTuVm+ncP+Vv0fhibqwx/aBSMkEkQFCBrmqRxNLhapr/cig9rsbH0jfxo0ePTlq3S8m7du1aO+SJ
hj7x0SjBGjm46PrK7F94zPWkAk7VGf2I0g3BL/RjylZrwSESQCQwJSKJpcMN16GBFRV83bAmyrB4
4cKFqvn9lLy69aNRgn0GBgasPIqur8z++f/Xmwq4LBKkBIpIAJFA14kkNtJvuA61Mvxv4WLZsmW5
6xsdHbWtEj951tKlSyvzlF1fav/8/+tNBVyWW7dumdOnTyMSQCTQfSIpM13f2MNbSn7K3az1bd68
2bY6hHLCqxVQz/qKiqTeVMBlmJiYsGmKW22sMEQCiARaTiRZwTm1TY3wu2LFCvtefSMarLGe9RUV
Sb2pgIsieSjbpJ/tEZEAIgFEkjNdIvj+/XvpbapDW30juq1V7/qKiqTeVMBFWyLqB/r06VPLlwEi
ACASmBaR6Gkn9SO4gKwO7PPnz1c6sPW/noZKbVMd6MqC6Hek17q+2P6Fne31pAJO8eLFC3vbbnx8
vC3KABEAEAlMi0gU+PUt3v8mf+rUKTN37lz7mfo79HRWapv65q75s27/lF1fbP/yHv+tJRVwqs7o
IYKwf6fV6hkiAUQCXHNAJEBQAa45IBIgqADXHBAJAEGFaw6IBICgAlxzQCRAUAGuOSASIKgA1xwQ
CVCggGsOiASAoAJcc0AkQFABrjkgEiCoANccEAkQVIBrDogEgKACXHNAJEBQAa45IBIgqADXHBAJ
EFSAaw6IBICgAlxzQCRAUAGuOSASIKhAB1/zt2/fcoIRCRBUoFuvuT6/c+dOXWXEz+HeqH31XzNn
zrR53A8dOmR+/PhRNa/yvx89etQsXLjQzrdq1apJx5OVS73WnOq/fv0yy5cvRyQAiIRr7n++bt06
GyBrLSONLk9Z65NAjh8/bg4fPlz1mfb9xo0b5vfv3/az//77zyxdutTcvHmz4fv6588fs3v37rat
P4gEEAk0TSTXrl0zZ86cic5/4sQJM2fOHDN79myzZcsW8/nz58xv+1l8/PjR7Ny50y6rVsOKFSvM
/fv3S+/r379/7T44Tp8+bS5dujRpPslEgil7HlLouMfGxhAJACLhmmd9vn79+oocwvkVrC9fvmwD
uV5Xr141+/fvL1ye1qxZY27fvl1ZXuvSrahayqcvkpUrV9rAPlVl/8mTJ21dfxAJIBJoqkieP39u
+vr6MudXv4O7dST0fsGCBXWVpxkzZpTaVwljYGDA9Pf3Vz5T62Y6yj4iAUAkXPOczyUSCSX8PCvo
+0G8SHl6+fKlvRW1d+9eK6bYMlmd4j09Pfb2mvopHLpVhkgQCSASaCGR6Fu/bnGFn2d9868KSony
pI5v3Ya6fv26vT305cuXpEgc4+PjZvv27ebNmzeT5tMts69fv076XLLJ64NBJIgEEAk0USRCne7q
fPc/X7169aRbW/4jv6nypEd3v3//Xvn/06dPhUXixKDO+gcPHkzaVz2xFXLr1i2zceNGRIJIAJHA
dIhEjwGvXbt2Umf74OBgpbP8ypUrVb+l0C0mddT7svFZsmRJpYXw7t072+opIxLXMlm2bJmVkOPb
t2/2Npn25+fPn3bfhoaGzPz58yu36BAJIgFEAlMsEqEf9OU9/quXntj68OFDZdqFCxdsCyXvh4kK
6pKAbpHpFte9e/dKi0Q8ffrUbN68ueoz3Y7bt2+f3S/15eixX83XiPOASAAQCXDNAZEAQQW45oBI
gKACXHNAJEBQAa45IBIAggrXnJNAGUAkQFABrjkgEiCoANccEAkQVIBrDogEKFAEFa45IBIAggpw
zQGRAEEFuOaASICgAlxzQCRAUAGuOSASAIIKcM0BkQBBBbjmgEiAoAJcc0AkQFABrjkgEgCCCnDN
AZEAQQW45k3k7du3bbluRAIEFWipa75q1Srz+fPnqs/u379v53348GHV55pP83cKYX75RtaJvNz1
iAQQCXTcNT916pS5du1a1Wf9/f1m06ZN5siRI1Wfa76TJ09SB9q4fiESQCTQ8Gs+MjJi/vnnn0mt
lBcvXkxqfWg+ze/W9fLlS7Nw4UKzbt26yjwnTpwwc+bMMbNnzzZbtmypau1omRs3bpglS5aYGTNm
mJkzZ5rHjx9XbePs2bNm7ty5Zv78+eby5cvRcqppN2/eNAsWLLDblAB//fpVmf7x40ezc+dOuy/a
1ooVK2xryy3rv7LOj/Zl3rx5dt1Hjx6dtO28Y8laNyIBRAIdfc17enrM379/7fvx8XGzcuVK+16B
98uXL/b9nz9/zKJFi6rWpcCt5dw8ly5dssFfn+l19epVs3///qplFNidXBR4FYAdCszHjx+3y379
+tVs3LgxKZK1a9fa9WkZBX6/FbVmzRpz+/btyv5o3yS+vPPh/6991/5oOR37nTt3zIULFwofCy0S
QCTQVdf833//NY8ePbLvFTBdMNZfBWKh/pIDBw5UrSvsW1EL5vfv35X/9V6thdgy/j5t2LDBiszx
6tWrpEhcC0n8/PnTLF68OHoO1HooIhIJysnVsWzZssLHgkgAkUBXXXPd7lHrQvT19Znh4WH7Xn/1
vzh8+HDltlDeuvwg7Uh9S/c/CzuoFchTIgmDvb89odtvp0+fNnv37rWiiwV7/3+tJ7xFFZMQIgGC
CnT1Ndetm+XLl9v3/m0u/VUfgZvutzay1hUG8SLBNQzeZUUS2wf1n+g23fXr182TJ0/sLbiiIsmS
YmrbiAQIKtDV11z3+/ft22d27dpV9bk62PXZjh07kutavXr1pFtbfisjFXzXr19v+0Ycr1+/Tork
zZs3lf+/fftmO+odev/9+/fK/58+fSosEh2LvywiAUAkkLjmerRX09XJXOTzrHWps31wcLDSuX3l
ypVKS6dI8A072/XUV0okmkfzahk9mrx79+7KdD1R5W7HvXv3zorKX5+e5lI/h5OfP03Hcv78+cqx
6H9tq+ixhOtGJIBIoOOvubvtMzY2VvW5/k91LPu4x3/10hNbHz58KBx8xblz5+ztNN1ik7xiP+zT
shKFnibT01jHjh2zrRLH8+fPbQe5bnfpFte9e/eqtqensLR+t41wX/QbG7VqNF0tNvd0WpFjCdeN
SACRANd8GtBvQmJPYVGGEQlMY0Fq5R9MQfeKRI8K6zFj99sNtW50qwuRIBJAJIBICqEnq/Qred0O
0i/bdatKQsmjVcezQiTQdTIBRAKIBACRACIBRAKIBBAJIBJAJIBIAJEAQQW45oBIAAgq0MHXvFVT
2CISTiyvLnoRRNp7v5qZHrco+qGkP/QLIkEinASuOcfeRvs13ceg37VoPK92LUeIhIACXPumHHcq
Za1IpdCNLV9mpNx60+PWk+q3SLnQOt34Y4iEQMJJoAxwzN7nsZS1RVLoxpYvI5J60uPWm+q3CPr1
fTuXH0RCEAHKQNNEEktZWySFbmz5enN3FE2PW2+q324oP4iEIAKUgaaJJJaytkgK3djyZUVSa3rc
elP9IhIgiABloA6RxAJwLSl0axVJPelx6031i0iAIAKUgTpEEktZWySFbmz5cLuxlLf1psetJ9Uv
IgGCCFAG6hBJLGVtkRS6seX9p6P0xJM6vPPkUG963HpS/SIS6Log0qhf+Dbjl8Lt8OtjRFL9eSxl
rUil0I0t756OUh+GAvujR49yRVJvetx6Uv220+9ZEEkLVyg1qWO/hs6altXB51CFUYXQo5GlL3Ki
oDYqqU8zkgPV+uvjqayciKRx54IWPiJBJB5K87lnz57C63nw4IE5depU7vTwB0+NFEmjKm8zgkA7
3C5AJIgEkUBTCv65c+fsPdYi6B6sfjz148eP3G2kfoUbk0escua1mPRDsHnz5tlm/dGjRyuf9/X1
madPn1a1lLZv315oHKrYL43dvuhxTd3SUJrU1HHr3rZuOWh9Wpf/+4NwH/KOx2/tqUWoTtZnz54R
/Go85npbpaS8RSSIxEMdhL29vTZ46ekR3W/NQ7+ajbVGsrbTKJFkTdf+aPgHCU7jAd25c8feTxZ6
hFKdlpqmoSt0D3p0dLTQdor80lhDYmiatpM6bv0+QPe9XQtQ98Gz5osdT9jaGx4etseESDhmQCTT
XqHUWXjr1q1Ki+PatWs28OUFWD2a2CoiUT9M+KMwP7gqMA8MDNhgnBq+IkX4S+PUr4X9/yWOcD+z
5ksdj2TmhERQ5ZgBkbRshVIgk1xC9G1e3/DLbqeZItE39NSDAArOGjJiYmKi1Lko80vj1HHHxjYK
54sdj1ohboynM2fOEFQ5ZkAkrVuhsp7KUj9K7LZXI0USe4IstZ8hO3bssC2CMiIp+0vjRomkyPFI
cLo9tm3bNnP8+HGCKscMiGT6K5S+rfud5+oYVodwiPpSFMDqFUnsV7tlWyTqcPZ/ERyiH2epz0FC
KHNrq+wvjVPHrd8RFLm1lToeH/2qumyQRCSASKApFUo/pNKTQq5jWf0JCsAhulfvOpbLbKfML3xT
lT78ha9+1Xv+/PnKvut//dpYaF83btxYFaTfv3+fuZ6Q1C+Ns/Yz9utj3SLTbSmhJ8nyOttjxyO0
nJ7cErUMB45IAJFAUyqUnmg6ePCgfZxx/vz5NpBloaCV9606tp0yv/BNVfrwF75CT5GpBaHPJCkn
O/02xn/8V+81PW89PqlfGmftZ+zXxzrH2h+tT/0tr169yl1X3vEI3dbS8i5BkZMKQZVjBkRChQLK
AMcMiIQKBZQBjhkQCRUKKAMcMyASoEIBZYByD4iECgWUAY4ZEAkVCigDHDMgEioUUAY4ZkAkQIUC
REK5p9wjEioUUAY4ZkAkVKhWPvayqYEpA+1/zBodIEwDoCFxNG84npzm0/yASACR5E4rmxqYMtD+
x6xhaJR3x0eJyjZt2lQ1uKfQfCdPniSAIBKIBZFUWtlYetdU6tda08bWs16NB3b48GE7XlVPT4/N
MhjL2501XL2Gy9e6dU40aKL/7TVMs4tI2u+Yler4n3/+mdRKefHixaTWh+ZzqZHzrn2qvGgEag0E
6sZIC7+4qDyrvGqsO2Xj5HYcImm7IJJKKxtL7xqbVk/a2HrWq4yIbgTdr1+/2m+ZqVzwPhpxV+fA
nQ9tT/nW/fnDNLuIpP2OWV8y3CCk4+PjlRGZ9UXKXVeVLz/JW9a1L1Je9EXNySUctVllWXllXHnV
iNWIBJF0RBDxEyzF0rvGptWTNrae9eqboj88vEbaLSMSfSP1l9d75Wzx5w/vryOS9jvmf//9tzJ6
sr6MuFta+qsvVkL9JQcOHIhe+1rKi79PGzZssCIrWl4BkbRsEImllY2ld41NqydtbD3rDXN0SDpl
RJKVpdBfZztXckTy/6Pbt2pdiL6+vkq+GP3V/0K3SP3bvFnrqqW8+J+FqQxS5RUQSUtWqFRaWSea
vPSuedPqTRtb63qzkj2VEUlqeUTSGces21bKjxPe5tJf9b+56X5rI2tdtZSXWBpmRIJI2rJCpdLK
+sTSu4bTGpU2tux6davAr/zKcFhGJFp/eKvC/9aISFrvmMpcXx/1Xezbt8/s2rWr6nN1sOuzHTt2
JNdVS3nxP1P2TfWNOF6/fo1IEEn7BZFUWtlYetfYtHrSxtazXt3fPnfuXKXzcuvWraU72wcHByvr
V9ph980VkbSuSPKewIsdsx7t1XR1kBf5PGtdtZQX/7Ows11lGZEgkrYLIqm0srH0rqnUr7Wmja1n
veLixYu2w1O3KBQMyn5jdY9z6qUncD58+NBRIskLvp36ysPdxh0bG6v6XP+nOsnrKS/hZ/rio7Kq
W2wqr3kpoAGR8G0UKAMt1iJpRX79+mUWL15MYUUkBBGgDEy1SNr1mNVy1kMl7ndRat2ED54AIiGI
AGWAY85FT0rqt0+6naVfth87dswKBRAJFQooAxwzIBIqFFAGOGZAJECFAkRCuafcIxIqFFAGOGZA
JFQooAxwzIBIqFDTz9u3b7mIBFWOGRBJO1aoWn/cVWa5vHljo6QCQbVbj7nVjkk/ovSHhUEkVKim
FNpaBcQ3S4Iqx9za6Dcvu3fvbunzjEimqELFUtfGWhaxFKHhe41bpHGIlI50+/btNoFP0RZJOPyF
sjpmFWgNLfHjxw8uNkE1ecwapdeVR2VFdOl0Han0uUq7oF+lq+zfvXvXDt6ouhCm0tW8StWgebU+
5UDRN3hHKtV1Vnpf/5hSaanrSQNcpLxonW5sMkTSxRUqlbo2L8inUoSG710mOM0/NDQ0KfNcmfca
0TesMNqfgwcPcqERSaFjViI3l4VTQ5S4VLuiSPpclV/VlwcPHliBqOzp/3C0apegTQFc69KXL5eN
UaRSXWel9w3zmeSlpa43DXAR9Mv8Vi9biGQKKlQqdW1eME+lCA3f+y0QbU/brVUkLuGVj76tKZcD
IJIixyxxhOXeUTZ9rv73c+SE5dZv7fz8+TM5KKOfvC01CnEsLXW9aYA7pWwhkimoUKnUtUU7v8PM
bqnO9rx0pEXXoeb46OhoRWKu2Q+IpGi5LxLIU+U19b/eh8IKtx1LdZ0ahj6WlrreNMCIBApf6FTq
2rxCnUoRmqoMeVnkiq5DORwOHTpk36u5rmREgEgaIZKy6XNTIomtP5Xqukiwz0tLXW8aYEQChS90
KnVtXsFLpQgN37vWg2ti+837WkSibasDUbfX9KCA34EJiCR1zHpcNe/WVtn0uSmRKF2049u3b7ZP
xZFKdV0m2Gelpa4nDTAigcIXOpW6tmhne5giNHzf29trJiYm7PzaXtnOdklD93P9iqGWiPJrqzMS
EEmZY9atJN0WEk+fPp3U2V4mfW5KJKobqiNa18mTJ+3jso5UqutUsE+lpa4nDTAigVIXOpa6NnV7
KS9FaLicpmtezSOphJ2Vqfd6kkzL+ttQJ6bm4VfviKTsMasFu2fPHht41S/hPwwiyqTPTYlEoli0
aJHtGFe+EbVKHKlU16lgn0pLXU8a4Eb8/guREERKMR0pQiU8faMDRNKqx8wPIhEJFSrCdKcI1XbV
kgqfVAGCGiIBRNImBXq6U4Sqz0S3yOhkJ6i18jEzRhwioUIBZYBjBkQCVChAJEC5RyRUKKAMcMyA
SKhQQBngmAGRUKGAMsAxAyLhZAJlgGMGRAJUKKAMcMyASKhQQBngmAGRUKGAMsAxAyKhQgFlgGMG
RAJUKKAMcMyASKhQQBngmAGRUKGAMsAxAyKhUgHXnmOHzr72lAQqFXDNOQdQ1zWnFDT4BPPqnhdQ
7in3iAT4VgoAjYgBnAJAJACASACRAAAiAUQCAIgEEAkAIBIARAIAiAQQCQAgEkAkAIBIAJEAACIB
QCQAgEgAkQAAIgFEAgCIBBAJACASAEQCAIgEEAkAIBJAJACASACRAAAiAUAkAIBIAJEAACIBRAIA
iAQQCQAgEkAkAIBIABAJACASQCQAgEgAkQAAIgFEAgCIBACRAAAiAUQCAIgEEAkAIBJAJACASAAQ
CQAgEkAkAIBIoOUEEr4AAJEAIBIAQCQwPTIBAEQCgEgAAJEAIgEARAKIBAAQCXSbTAAAkQAgEgBA
JK0QUHl1zwsAEAnfyoFrDoBICCjAtQdAJAQSoAwAIBKCCFAGABAJEESAMgCASAgiQBkAQCQEEaAM
ACASgghQBgAQCXRVEHn79m1LrafZ66QMACCStgkiJ06cMHPnzjWzZ882e/bsMePj45Vper9r1y4z
a9asyvSvX7/mruvRo0dm5syZZu3ataX3KxXotA+NoFHria2zaNCeyuCOSACRQFOCyMWLF83ly5fN
379/7evcuXNmy5Ytlelbt241d+/erUzX+97e3tztSCKPHz+uab9Sga5RgbAZAbXWdSISAETS9iJZ
tmyZ+fnz5yQZZL2Pfea2EY7xlLXdPHnEAl3e+FFnz5418+bNM3PmzDFHjx6tfN7X12eePn1a1VLa
vn17oXGoPn78aHbu3GlbYDrWFStWmPv371fty8uXL83ChQvNunXrksf9+/dvs3//frs+rWtkZCT3
mPOOx2/tzZgxw6xevdo8e/YMkQAgkukXic/3799tINu7d++kFonj3r17ZvPmzYW30yiRZE2/evWq
uXHjhm0p/fnzx9y5c8dcuHDBTvvy5YtZv369nfbr1y8rzNHR0ULbWbNmjbl9+3alFaYWm6Th70d/
f7+dpu2kjvv06dP2vImHDx+alStXZs4XO56wtTc8PGyPCZEAIJKWEYm+wetbsF6vX7+ufK7gO3/+
/Mq3bb13AXm6RaJ+GAXdsIXlB+aBgQEbjI8cOVJXQFUrwF/+8+fPhY9b4gj3M2u+1PFIZk5Izfoy
AYBIoO4goo533TZx6BbPpUuXKt/O1aeye/fulhCJvqGHt5X8gO+C84IFC8zExESpc6FbV2pJqHW2
atWq5H7GjjvvVmDWfLHjUStEn+mYzpw5g0gAEElrikS3VPzAp6eR/G/Jeq97/c0USV4/RriuUBpZ
7Nixw7YIyojk5s2bdpnr16+bJ0+e2NtXUyGSIscjwen22LZt28zx48cRCQAimX6R6HaJ/zivOob1
Dd4RSkMi0e2vWkXy6dOnhrVI1HJSv04eV65csX0OEkKZW1t6FNpfb2yfixz38uXLC93aSh2Pz5s3
b0qLAZEAIoGmiES3snSbxN26OnnypH051KmsQKyWiqarz+Hw4cOFt+N3EI+NjdlbZbWKRFJT34Rk
J3TL7fz585V91//u0WW1IjZu3FgVpN+/f5+5npAlS5ZUntJ69+6d7bRP7We4zrCzXbelhJ4ky+ts
jx2P0HJ6ckvonMZaOogEAJFMmUgkCMlCt7DU0pBYfPTEk5uulySiz4puxwU83bbRN3MFwlpFok5z
tx+OU6dO2RaEPpOk3FNU+uGk//iv3mt63np8nj9/bju5td8K3urgTu1nuE5/Hp0v7Y/Wp/6WV69e
5a4r73jcbS0tr3OpdTmpIBIARDKtIgHKAAAiAYIIUAYAEAlBBCgDAIiEIAKUAQBEQhABygAAIgGC
CFAGABAJQQQoAwCIhCAClAEAREIQmUraIVUtZQAAkRBEWphaU9XWinJ9LF261G5XQ6Bo7CrKAAAi
gTYOIlO5f//995/ZsGGDHYxRY1opiZU//hVlAACRQIkgEqaNdcRSvmoZDbWuUYI1XWNxheNvacwu
TdNghhp40E8EVTZVrd5rFF8NpujGmQrzwmt/NUaVEm8po2EsaCrHiPKqlDl3Rbafdb7U6nFD2LtR
hCUyMT4+bqcjEgBE0vYiCdPGplK+uuRKkoPmURD1h2nXqLUK5m4UW61POctj24wNw673GsDQySgc
+Vb7qtwcWp+GxNeov7GgKSGU6ZNJbT92vvbt22eGhobse6Us1q00ze/+988LIgFAJG0rkjBtbCrl
q5YZGRmp/P/z50+zePHiyv8aodYfoj3McVI2VW1qft2m0rd7h0bXjQVNSUDDuq9YscK2mDQy77dv
36LnLrb92PlSy+3QoUP2/f/93//Z1pBe4sCBA1Y6iAQAkbS9SLICbSzlq/4PA6f/DT0r058/vWxi
qNT8YUe99i0WNDVNwV1JpFyLyQX3oueoaIpc5bdfs2aNfa+cKOrUd9KVyHS7C5EAIJKOE0kq5Wue
fLLe1yKGsvOH20uJRH0pfotJ8+flJimy/dT5Ur+Nbrk5gejWmhJm+a04RAKASDpKJKmUr1rGf1xW
t4UUnP3lw1tbfqButEj0+K6fLvj169fRoLl9+/ZJ4imThz78LHW+du/ebf79999Kq8fd3oq1ghAJ
ACJpa5GkUr5qGf2v4O3S8ypY+ssPDg5WllfudGVHjG0zlqo2FcjDznbtWyxoKuOhXm7/tK+SUa0i
SZ0vrV99RDoP4tq1a/Z4td+IBACRdKRIRCzlq5ZRTvNFixbZR3iPHTs2qbPaPf6rl55M+vDhQ3Sb
sVS1RVow586ds4/f9vT02D6P2K0qF9y17+74XD73WkSSOl8vXryoeuzXPQwQ2yYiAUAkbSOSTgxI
+k3LVPc/dFsZAEAkBJGOCki6bfTw4cPK7zjUGtKtLkAkAIikRYNI6rbRVPPkyRP7C3ntl56Q0q02
CQUQCQAiIYgAZQAAkRBEgDIAgEgIIkAZAEAkQBABygAgEiCIAGUAAJG0VxAh/S1lAACRQF1BpBGP
+aZ+od7O50s/fPSHfnHoV/76dbuGQdEv+/v6+qrGAkMkAIika0TSiMDTrsErtd/6nYrGF8uaT4m+
zpw5Uxl769atW3YIFUQCgEg6UiSPHj2yw7BrKHSNYvvs2bPK/LH0t1nrVdA8fPiwHXNKY14paVOs
RRJL55u3X1l8/Pix0gLQMsrzobHA/O3GUuWm9jsLDco4NjaWOV9vb68dJt6XTjjiMCIBQCQdIxI/
qCprYJgJMbUO/7OBgYHKKLi6lbNp06ZckaTS+cb2K0SJo27fvl1pASjNrwZk9LcbS5Wb2u8s9Gv6
vHMiIYWJv/xh9hEJACLpKJEo4GpI9SLLpESiYUr8PCRhytui6WlT+1WEMKNjLFVuar/LntesxF5Z
nyESAETSESLRt31NU2DXff16RJLKVFg0PW1qv7J4+fKlOX36tE0WpZzxzcywmDonqVTDiAQAkXSU
SFwQ1ui527Ztqxo1t16RhNPLpKeN7VfIzZs3zcqVK83169ftLSflAqlHJGWCbt6trSKfIRIARNIx
InEofW4sAIf/f/r0qeqzDRs2VN0iUodz3vpS6Wlj+5UVpP11hfuVEklqv8ueV4nv58+flf/1mLCf
MRGRACCSjhKJvsnrCSkRdkKH6W/9DnA9saQObH+96vBWpkLXab1169bcgJ5KTxvbrxA9jeWe0pIE
lDa3jEhS+132vOppNP/Y1FIqcnsOkQAgkrYUiW4fqU/BPRbrgrcI09+6gK559UM8zRuu9+LFizbR
lB7r1ZNZsYAeS08b26+Q58+f2456zScBqZO+bKre2H6XPa86DsnInbsdO3ZMSkWMSAAQSceIBCgD
AIgECCJAGQBAJAQRoAwAIBKCCFAGABAJQQQoAwCIBAgiQBkAQCQEEaAMACASgghQBgAQCUGEVLuU
AQBEAnUFkU5JtTsd223FoI1IAJHAlAeRTkm1i0gQCQAiaWIQ6ZZUu/57jeOlxFlKaFVkX1Lrzzvu
Dx8+2OyNIcoIuXjxYvPjxw9EAoBI2l8k3ZJq13/f399v53ODRKb2JbX+2HFr8MZQgtrWwYMHaZEA
IJLOEEm3pNr134dpd1P7klp/7LhdYi4fzf/69WtEAoBIOkMk3ZZqNy/HemxfUutPHbfypYyOjlYk
499SQyQAiKTtReKCZLek2i2aY73M+lPHraRZhw4dsu/3799vrl27hkgAEElnicTRDal2s9aT2pfU
+lPHrX4TddSPj4/bDn2l3kUkAIikY0TSbal2s85Dal9S6y+SqlctkX/++cd29LfylwkARAKlg0i3
pdrNOw+xfUmtP3XcYmRkxH42naMFIBJAJEAQaWMkJrVsKAMAiASRQGl0y0stniJPn1EGABAJIoFJ
qK+pt7d32jrZKQMAiIQgApQBAERCEAHKAAAiIYgAZQAAkRBEgDIAgEiAIAKUAQBEQhABygAAIumY
INKo4FLveqZ7eUQCgEhgmoMIIqEMACASWiT2vbL3aSgPN8aVG6RRaPBGDT6oH9gp3azGj8pbT2w7
qZS8Ipb6tsjygEgAEMk0iUQDFroMguGou0rs5LIWKk+IBjCsRSSplLyp1Lep5QGRACCSaRRJmIbW
ny5xhClpaxFJKiVvKvVtanlAJACIZBpFEpseywlSz3rC1LSp1Lep5QGRACCSLhNJOD2V+ja1PCAS
AETSoiJRMqtabm2VTU2bSn2bWh4QCQAiaVGRqLN9eHjYvn/69GluZ3u9KXlTqW+LpLYFRAKASFpQ
JMqnsWfPHisKpcFVJ3fWfPWm5BWx1LdFlgdEAoBICCJAGQBAJAQRoAwAIBKCCFAGABAJEESAMgCA
SAgiQBkAQCQEEaAMACASgghQBgAQCUEEKAMAiATaJIi8ffu2o7ZX7/qn+nwgEgBE0vZBRL9KL7Nf
9e5jke3Vc57qXX+4/FRfE0QCiATaLoiU3WYrpNuNraPR+4dIABBJR4gklj5XnDhxwqa71XQNnOgn
voql5g3zibjPXr58aRYuXGiTU2W1SLR+tz/bt2/PHc8r/Cxre6JRKXvz1h87P6nl9XdwcDA3tXFq
/xEJACJpCZHE0udq1N3Lly9XRuHV4IgK8v46Y6l5s76B9/f323W5QRhDkWiI+PHxcTvP0NCQOXDg
QCGRZE1vdMrecFrq/BRpkezYsSP3/KX2H5EAIJKWEEksfa5G+PXzfui9RtwNWxBFA3uR+f0WiPZL
aXdrFUmjU/aG01Lnp4hIYucjtf+IBACRtIRIYlkPszIVxlocRURSZv56t9folL3htNT5KSKS2Dyp
/UckAIik5UWSSmk7FSLxn3Qqu3yjU/Zmiaqe5VPHU480EAkAIpkykcTS5yrlbXjrpp7AXmT+0dHR
qu0tXrw4d/kwhW84vdEpe7PWHzs/9Yoktf+IBACRtIRIYulz1Zmsp4pcZ/KVK1eseIoGQj3JpD4A
F2yLiKS3t9dMTEzY7akj3O9sT6XwDbfX6JS9WeuPnZ/U8qnzkdp/RAKASFpCJLH0ucI93qqXnkj6
8OFDYZHoCSN9Q3ff0ouIRE8q6XFXLSOp+J3RqRS+4fZEI1P2Zq0/dn5Sy6fOR5H9RyQAiGTaRQKU
AQBEAgQRoAwAIBKCCFAGABAJQQQoAwCIhCAClAEARAIEEaAMACASgghQBgAQCUEEKAMAiIQg0kzK
pp2d7jS1lAEARMIJnKYgkjcWVtm0tdOdppYyAIBIOIEtIJJ69ocgiEgAEEkLBxGNF6XxnJQC9+bN
m6WGiv/48aMdA0oDEmocLKXrvX//frRFkpV2NraevDS1P378sKMDa7wwHw2KqJFzHY1MV4tIABAJ
QSRA6WbdCLgaEFBZA8uIZM2aNXYUXTdCrVLPSkgxkWStt8x6/P8PHTpkR8UNj0nyEI1OV4tIABAJ
IglQOlf/G/3IyEgpkWThJ2QqKpIy6/H/V/4StUpcThX9Xbp0aWXU4Eanq0UkAIgEkQSk0s0WEcnL
ly9tXpO9e/faoeiLyCNrvUXXE/6/efNm2+oQatXoFpl/fI1MV4tIABAJIkmIpEjA9z9Tn4qSYV2/
ft08efLE3h6rRSRl1hP+//DhQ9unItQ3ouWzWjWUAaoRIBJoQhDZuHGj+fbtW+X/MN1sKr2tOun9
dLCx9Lex9ZZZT9b/S5YssX0juq3l0+h0tYgEAJEQRAKGhobsU1t56WZT6W0VwN3TVZLQ+vXrC8kj
TDubWk8qTa060Ht6eiZ1pDc6XS0iAUAkiCQDPdmkJ6QWLVpkg7k/byq97fPnz23ntebRral79+4V
EkmYdja1nlSaWuV51zTJMKSR6WoRCQAiQSQEHMoAACIBRAKIBACRtHQQKTsOFiASAERCEAHKAAAi
AYIIUAYAEAlBBCgDAIiEIAKUAQBEQhABygAAIoHpDiKkxqUMACASgkhdTGVqXAIk5wkAkXRgEEkN
sgiIBACRdEgQ0dhZbiwtjZT77Nkz8+HDB5uxMEQZBpVESilutT7lANFgi1rWH9wxLzXu4OBg5vyO
WErcrP3MOrbYfJQBqhEgEmhCEPED+vDwcCV7oEYBDoOwxHHw4MHK+jQAostE6AZ3jLVIduzYkTt/
KiVu3n6G24rNRxmgGgEigSYEEY36q5F2Q5Qsatu2bVWfKZ/769evK+tzUsjaRpZIYvOnUuLm7We4
nth8lAGqESASaEIQ0bd2TVMgP3PmTNU03YZSTnTx6tUrK5LY+sokospqScRS4sb2019PbD7KANUI
EAk0KYgoV7prgRw/frzy+blz58yhQ4fs+/3795tr1641TSRFUuLm7WdWDvms+SgDVCNAJNDkIPLm
zZuq+ZQkSpkJx8fHbSf4r1+/miaSMilxw/3MO7ZwPsoA5wIQCTQhiCgboZ50EmEHuGuJ/PPPP6a/
v7+UGFKpccPPUilxY/vpryd1PJQBAEQCDQ4iug20atWqyiO5Lgg7RkZG7LLhL9VTYkilxs36LJYS
N7af/npSx0MZAEAkMMVBRMFcne6ASAAQCUGk9DK6xaRWAk8/IRIARAI1BRH1c/T29lZ1sgMiAUAk
BBGgDAAgEiCIAGUAAJEQRIAyAIBICCJAGQBAJAQRoAwAIBIgiABlAACREESAMgCASAgiQBkAQCQE
EaAMACASIIgAZQAAkRBEgDIAgEgIIkAZAEAkBBGgDAAgEiCQANceAJEQUIBrDoBIWi+w8OqeFwAg
EuCbOQAgEkAkAIBIAJEAACIBRAIAiAQAkQAAIgFEAgCIBBAJACASQCQAgEgAEAkAIBJAJACASACR
AAAiAUQCAIgEAJEAACIBRAIAiAQQCQAgEkAkAIBIABAJACASQCQAgEgAkQAAIgFEAgCIBACRACAS
AEQCAIgEEAkAIBJAJACASACRAAAiAUAkAIBIAJEAACIBRAIAiAQQCQAgEgBEAgCIBBAJACASQCQA
gEigIwUSvgAAkQAgEgBAJDA9MgEARAKASAAAkQAiAQBEAogEABAJdJtMAACRACASAEAkrRBQeXXP
CwAQCd/KgWsOgEgIKMC1B0AkBBKgDAAgEoIIUAYAEAkQRIAyAIBICCJAGQBAJAQRoAwAIBKCCFAG
ABAJdH0Qefv2LRcXkQAgkukOInfu3DFLly41s2bNMuvXrzdv3rxpm+PSPjfy3HRysEUkgEigKUHk
v//+Mxs2bDCfPn0yf//+Nbdv3zYrV67squDYLQEWkQAigaYEkb1795qLFy+WWs+NGzfMkiVLzIwZ
M8zMmTPN48ePq+Y5e/asmTdvnpkzZ445evRo5XO1eiYmJux7iUvrksjE+Pi4nZ7Fo0eP7Ha0vdWr
V5tnz55V9iUcUyrrOP3PJMvDhw+buXPnmp6eHtsai7VI8o4ltl+IBACRdJVIJIQy/Qxaz86dO83n
z5/t/5KIgqnj6tWrVjQK2H/+/LGB+sKFC3bavn37zNDQkH1/9+5de1tK87v/9+/fn7lNX1bDw8Nm
2bJluceVEsnAwIA5f/683b+vX7+aTZs25Yokdiyp/UIkAIika0SiYKgguGLFCjN79myzZ88e8+3b
t+h6nESy1r127VobeH1cgL1586Y5dOiQff9///d/tjWklzhw4IAN1FksXLjQ3Lt3r9BxpUSybt06
8/v378r/r169yhVJ7FhS+4VIABBJ14hEnyu4f//+3QZNfQt3wb3oevzPJKbwlpNu/YjR0VGzZs0a
+163gtSpv3jxYvu/RKbbXVlIdFqPAvuZM2fqEonfehI65jyRxI4ltV+IBACRdI1I1Ffgf0NXYI09
CZUK1H6gzWL+/Pn2lpITiG6tvXv3rvJ/Hi9fvjQPHz4027ZtM8ePH2+YSMLpZY4ltl+IBACRdI1I
tm/fPukbum5x1SoStTTUuslj9+7d5t9//620etztrVgryEetmFjnePi/69R36Ak1X5ySWN76UscS
2y9EAoBIukYkusevlwSi1+DgoP0tSa0iuXTpUqUzWy/9v2XLlsp0rX/BggXmypUr9v9r165ZcalT
Ow89jqwnpETYua9l1Wfj5OB3gI+NjdkHA/z90+PN586dq3S2b926NVckqWOJ7RciAUAkXSMSF9zV
caxbWgq879+/r1kk4tSpU/aWmVvfly9fKtNevHhR9div6+yObVO3j1atWlV53NgFb6GnqLQddzvO
BXTNu3z5cjtvuH963Fky02O96hOKtXBixxLbL0QCgEi6SiRAGQBAJEAQAcoAACIhiABlAACREESA
MgCASAgiQBkAQCRAEAHKAAAiIYgAZQAAkRBEgDIAgEgIIvUw1WlwWz3t7nTvHyIBRAJtF0SKpMFt
ZJrbRqfdbfT8jdg/RAKASLoqiDQzKDfrGJu5z9MdyBEJIBJoShDRYIfKTKjBD5UTZGRkpGr6iRMn
bJpZTdeAhX5Sq1ja3bw0uBqfSuN6KcFUVotE63f7o5GJNRZX7Bj8dYfbE7FUuam0uyGp+T9+/GjH
49K+61zofN6/fz93/2LzIxIARNI2Ijl9+nQly5/yamhEW4dGu718+XJl9FsNcOinw02l3c0a4r2/
v9+uyw1+GIpEw7wrf7vmUVpeZU4sIpKs6alUuam0uyGp+ZW0S6MLu/Olcydp5u1fan5EAoBI2kIk
EkeYTtahkW393B16r1FzwxZE0cBeZH6/BaL9UvbBWkWSSpWbSrsbUnZ+4SfHKhLIiyTTQiQAiKSl
RBLLoZEV1GItjiIiKTN/vdtLpcpNpd1Nnaus+XXrTq08JeqSiFPHF5sfkQAgkrYXSZm0tM0Sif+k
U9nlU9/uU8dXdv6bN2/aFt7169fNkydP7O272P6l5kckAIikLUSi5E95t7aUaja8tVVPYC8y/+jo
aNX2/FzuqTS64fRUqtxU2t2y86sT3t9eav9S8yMSAETSFiLRbZXh4WH7/unTp5M625U90XUGKz2u
xFNUDGEa3CIi6e3tNRMTE3Z76tj2O9tTaXTD7aVS5abS7oak5tfTa+6pK0lGKYtj+5eaH5EAIJK2
EMmvX7/Mnj17bJDWPXq/s1u4x3/10hNbHz58KCySMA1uEZHoSSs9rqtlJBW/cz6VRjfcnoilyhWx
tLtZxOZ//vy57czXPkrIehoutn+p+REJACJpC5EAZQAAkQBBBCgDAIiEIAKUAQBEQhABygAAIiGI
AGUAAJEAQQQoAwCIhCAClAEAREIQAcoAACLpjiBSb/rXVk9vWy/1HF+rnRtEAogEmhJE6k3/Gi7f
acGqnuNrtXODSACRQFOCSKPT23ZasKrneFrtXCASQCTQ8CCSl542ll43tbz+aqDHrPS7jlj62yy0
PxovS9kDNfR6maHsU+lsa0kXXGTdecv++PHDjmisMc58NJCjRiuu9RwhEgBE0jItklR63SItkh07
duSm302lvw1Rels34q4GXFSWwjIiKZL+tmy64DLrzlr20KFD9jyHxyl51HKOEAkAImkpkaTS6xYR
SSydbir9bYjm97+9j4yMlBJJFmH627LpgsusO2tZ5VxRq8SdB/1dunRpZT/KniNEAoBIWkokqfS6
RUQSmyeV/ja17TC9bRGRlE1/W0YkZdbt/79582bb6hBq1ahVVOs5QiQAiKSlRFI2/WxZkZQNiPWm
+y2b/raMSMqu2///4cOHtk9FqG9Ey9d6jhAJACJpKZGk0uvWK5JU+tuQjRs3mm/fvlX+D9PbptLv
lk1/W0YkZdcd/q8OfvWN6LZWeA3KnCNEAoBIplUkWelpY+l1U8unAnMq/W3I0NCQfWorL71tKv1u
Kp1tPemCy6bWDbelDvSenp5JHellzxEiAUAk0yqSrPS0sfS6qeWL9Fmk0t+G6CkmPQ21aNEiG7j9
9aXS76bS2daTLrhsat1wW8pNr2kSZEjZc4RIABDJtImEY6EMACASQCTAeQNAJASRMtQ7PhhlAACR
AEEEKAMAiIQgApQBAERCEAHKAAAiIYgAZQAAkQBBBCgDAIik84JIp6fgpQwAIBKCSJOZyjSzBEjO
EwAi6cAg0ukpeCkDAIiEIPL/obGp3FhVGnX22bNndmwtZf8LUbY+JWRSuthaUtTWk4I3az+zji02
H2WAagSIBJoQRPyAPjw8XMnEp1F2wyAscRw8eLCyvrIpautJwZu3n+G2YvNRBqhGgEigCUFEo+pq
1NoQJV7atm1b1WfKl/769evK+sqmqK0nBW/efobric1HGaAaASKBJgQRfWvXNAXyM2fOVE3TbSjl
FxevXv0/7d2xLjVBGMbxa5C4B4VepdTrVVqFqLQqd6CSKBQKnaglChHV1yhOKVG6A+XKO7Ky1jkz
u+ziW79/IkH2XXvG63nszJ55/iUjyZ2vb9Z5nwje3HU2z5M7Tg/4MwIjwUgiErnj9R3I/v7+2/cP
Dw+rnZ2d9HnkkhwfH49mJF3iZRdd57wc9XnH6QF/RmAkGFlE7u/v3x0XgUuR8vf09JQWwZ+fn0cz
kj7xsu3rXPTa2sfpAWMBRoIRRCSS/eJJp6C9AF7fiWxubla7u7u9jGHoCN7cdTbPU3o9egBgJBhY
RGIaaHV19e2R3FqEa+7u7lJt+53qX4moXXSOXLxs7jqb5ym9Hj0AMBJ8s4iEmMeiOxgJwEiISO+a
mGKKuwRPPzESgJHgUyIS6xwbGxvvFtnBSABGQkSgBwBGAiICPQAwEiICPQAwEiICPQAwEiICPQAw
EvxmERG5qwcARvIHRCR2zI2skDFoR+5OVWC7niPesX99fc1IAEYyLSOJLdfr7eL/onh95zXGODe3
42ckACP5743k9vY2vemwfezJyUm1vLxcLS0tVefn52kTxdgHq09E7rzI3YeHh/RfebzZMc61srJS
XVxcZK+9VJOL/e1a3yVeeKi43xjvGHdGAjCSSRjJ3t5edXp6+uHY7e3tJKKXl5fJQCJiN77uG5Hb
/rkh1mdnZ2+7/B4dHaVUwxylmlLsb5f6oBQvPFTcb5h0jDsjARjJJIxkbW2tms1mH45txuLG182s
kD4RuV3Eq0uoVa6mFOPbpT4oxQsPFfcb4x3jzkgARjIJI4npnrYRlEKp+kTkzvu5sdX7wcFBtbW1
lbZ87yJwuZouW9R3rc/FCw8V9xvjHdOAjARgJJMwknl3A32MpHQ30a6NabQIn4rpnaurq7RNfX3M
vDWVUk0XI+lTn4sXrg1piLjfnwjcYiRgJPiVdySliNx2bay3NI9/fHwsClyppmQkfepz8cJNvhL3
G2tJ7kgARjIZI4m5+pjC+ayRlCJy25G7MXVUPzFVrxWUBK5UUzKSvvWL4oWHivuNNRdrJAAjmYyR
xNND8eTVZ40kyEXktiN3b25u0mJ8iGsIbixKlwSuVFMykr71i+KFh4r7jekyT20BjGQyRhKi2byD
wPjxwuvr68lsGAnASCZhJEE8XWRPrFfGjheOqbUY79/WAwAjwZdEJObxY00A48cLxzjbawtgJJMz
EugBgJGAiEAPAIyEiEAPAIyEiEAPAIyEiEAPAIwERAR6AGAkRAR6AGAkRAR6AGAkRAR6AGAkICLQ
AwAjISLQAwAjISLQAwAjISLQAwAjISTwuwcYCQgK/M4BRvLjwuLj73wAeOUF6q62rcwWnlMAAAAA
SUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-03-06 13:42:06 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Process of study selection for the updated review</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAhQAAARrCAYAAADb3j/LAACAAElEQVR42uydD2SX3f//b263JLdE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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-02-03 12:28:38 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>
<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>: Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-02-03 12:28:38 +0000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>: Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU8AAAOPCAIAAADE2NQ4AAAtuklEQVR42u3dvW4cN//28QUCBC5U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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-03-04 19:06:25 +0000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-003.01" SETTINGS="SHOW_CI_LINES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: Hormone therapy versus placebo in primary and secondary prevention, outcome: 5.1 Death (all-causes).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-08-19 11:58:22 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-08-19 11:58:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-08-19 11:56:20 +0100" MODIFIED_BY="[Empty name]">Jim Thornton</TITLE>
<DATE_SUBMITTED>
<DATE DAY="18" MONTH="4" YEAR="2015"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2015-08-19 11:56:36 +0100" MODIFIED_BY="[Empty name]">
<P>I have two concerns with your analysis of the HRT &#8220;timing hypothesis&#8221; in this review.<BR/>
<BR/>Firstly, I fear you underestimate the problem of publication bias and selective reporting, especially of small trials performed by pharmaceutical companies in younger women.<BR/>
<BR/>You mention that &#8220;two trials (ERT II 1979; HALL 1998) may have been subject to selective reporting. The remaining 17 trials reported all expected outcomes.&#8221;<BR/>
<BR/>This is not an adequate description of the problems of selective publication and selective reporting of adverse outcomes by pharmaceutical companies in this area prior to 2000. I refer you to the following two papers, not cited in your reference list.<BR/>
<BR/>Hemminki E and McPherson K (1997) Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials BMJ 1997; 315 doi: http://dx.doi.org/10.1136/bmj.315.7101.149 (Published 19 July 1997)<BR/>
<BR/>Hemminki E and McPherson K (2000) Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease The Lancet<BR/>355: 566&#8211;569<BR/>
<BR/>Both studies identified selective reporting and publication bias of both cardiac events and cancer.<BR/>
<BR/>This is potentially a big problem. I note that your &#8220;Characteristics of excluded studies&#8221; table includes, by my count, 45 papers reporting randomised trials of HRT in postmenopausal women which were excluded because &#8220;no outcomes relevant to the review&#8221; were reported. I don&#8217;t know what efforts you have made to find cardiac events in those trials, or how many were sponsored by individuals or organisations with a vested interest in minimising harms. I would suggest that until that has been done and publication bias ruled out, it would be safer to conclude that there is a high risk of publication and selective reporting of adverse outcomes in this area.<BR/>
<BR/>Secondly, I fear, by missing the above to papers you have also missed some relevant trials with informative cardiac endpoints. The relevant studies are reported in detail in the above two papers, and you have included some. I would particularly note:<BR/>
<BR/>Writing group for PEPI trial JAMA 1995. This is included in the list of included studies in your review but I could not find the cardiac events reported by Hemminki and McPherson (1997) namely 5/875 HRT v 0/174 placebo included in any analyses. Forgive me if I missed them.<BR/>
<BR/>Derman et al, 1995 is not mentioned at all in your review. According to Hemminki and McPherson (1997) cardiac events were reported, albeit there were none.<BR/>Derman RJ, Dawood MY, Stone, S. Quality of life during sequential hormone replacement therapy. A placebo-controlled study. Int J Fertil 1995;40:73-8.<BR/>
<BR/>Svendsen et al, 1992 is excluded for &#8220;no relevant outcomes&#8221; in your review. According to Hemminki and McPherson (1997) cardiac events were reported, albeit there were none.<BR/>Svendsen OL, Hassager C, Marslew U, Christiansen C. Changes in calcanean bone mineral occurring spontaneously and during hormone replacement therapy in early postmenopausal women. Scand J Clin Lab Invest 1992;52:831-6.<BR/>
<BR/>Resch et al, 1990 is not mentioned at all in your review. Hemminki and McPherson (1997) reported cardiac events 1/16 placebo, 1/15 estradiol 2mg/NETA 1mg<BR/>Resch H, Pietschmann P, Krexner E, Woloszczak W, Willvonseder R. Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. Acta Endocrinol 1990;123:14-8.<BR/>
<BR/>Christiansen et al, 1990 is excluded for no placebo group in your review. Hemminki and McPherson (1997) say there was a placebo group.<BR/>Christiansen C, Riis BJ. 170-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990;71:836-41.<BR/>
<BR/>Coope, 1981 is excluded from your review because of &#8220;not post-menopausal and most suffered from depression&#8221;. Could you check this? I don&#8217;t have a copy of the paper but the title &#8220;Is oestrogen therapy effective in the treatment of menopausal depression?&#8221; suggests that it might be relevant. Hemminki and McPherson (1997) report cardiac events 0/26 placebo v. 1/29 oestrone<BR/>
<BR/>Nachtigall et al, 1979 is not mentioned at all in your review. Hemminki and McPherson (1998) state cardiac events 3/84 placebo versus 1/84 CEE 2.5 mg+MPA 10 mg/7 days<BR/>
<BR/>Lindsay et al, 1984 is excluded for &#8220;no relevant outcomes&#8221;. According to Hemminki and McPherson (1997) cardiac events were reported, albeit there were none.<BR/>
<BR/>Aitken et al, 1973 is excluded for &#8220;no relevant outcomes&#8221;. But Hemminki and McPherson (1997) report 3 cardiac events mestranol v 0 placebo<BR/>
<BR/>In total Hemminki and McPherson (1997) reported total cardiovascular events<BR/>12/1818 HRT versus 5/1041. Can you check that all of these which should have been included in your review were?<BR/>
<BR/>In their second paper Hemminki and McPherson (2000) described a search of unpublished drug company reports of early phase trials of HRT. 17 reports were found. They included 198 trials, of which nine were placebo controlled trials in which cardiovascular events were reported. Six had not been included in their previous BMJ paper.<BR/>
<BR/>These six trials were all randomised. Participants were &#8220;healthy, recently menopausal women&#8221;. Their ages ranged from 35-66. The investigational drugs were oestradiol (2 trials), tibolone (3 trials) and conjugated equine estrogens (1 trial). Among these six new trials there were 5 cardiovascular events out of 348 in the hormone groups and 1 out of 297 in the control groups.<BR/>
<BR/>Again, can you check that all of these which should have been included in your review were?<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-08-19 11:57:49 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Prof Thornton for his letter regarding our recent publication on Hormone therapy for preventing cardiovascular disease in post-menopausal women1. We appreciate his concerns regarding publication bias that affects the accuracy of reviews, particularly those which have been funded by or include studies funded by pharmaceutical companies. Our strategies for identifying and minimizing publication bias are designed to be as robust as possible and a full description of our methods is described in our review1. In brief we carried out extensive searches of healthcare databases (CENTRAL, MEDLINE, EMBASE and LILACS), trial registers and checked references of relevant systematic reviews not limiting our searches by language. Funnel plots show symmetrical distributions of study effects across the range of outcomes.<BR/>
<BR/>Specifically within the subgroup analysis of the effect of timing of initiation of hormone therapy we acknowledge one limitation of our analysis is that we cannot be confident that the Estonian Postmenopausal Hormone Therapy Trial2 (1178 participants out of 9629 of the subgroup analysis) are all attributed correctly to starting treatment within 10 years of the menopause due to the trial population starting hormone therapy or placebo a mean of 8.8 years after the menopause. It is likely that this underestimates the associations with treatment, a reduction in mortality and coronary heart disease, and an increase in venous thromboembolism.<BR/>
<BR/>We acknowledge that there may be data on trials which are not published which we have not found in our search and are grateful for information about any that might be relevant so that we can assess them for the next update of the review. We also accept that it is more likely that these types of studies might show no association or an association with harmful outcomes. However the majority of the weight of our analyses comes from 3 large well conducted trials (WHI I3, WHI II4 and HERS5, total number of participants 30 110 out of a total of 40 410). We do not think that we have missed any studies of comparative size or quality and feel that the addition of small unpublished studies is unlikely to change markedly the overall balance of effect that we have found. However in future updates of this review we will provide a more detailed description of this limitation as well as an assessment of any eligible unpublished data we are able to include. We welcome the assistance of those who have an interest in the field to identify any difficult to locate, unpublished studies which we can include in future updates of our review to give us greater confidence in the results of future analyses.<BR/>
<BR/>Prof Thornton identifies several studies reported in Hemminki and McPherson (1997)6 and PEPI7 which he queries as to whether they should be included in our review. Our pre-specified method states that trials greater than a pre-specified size (see paper1 for details) were reviewed to see if relevant outcomes were reported as adverse events. Also outcomes with zero events in one or more arms of a trial were not included from the trial in question. These methodology designs were chosen to limit the inclusion of small trials with limited power to detect relevant outcomes and therefore minimise bias. The following studies identified do not meet these inclusion criteria and are therefore not included in our analysis: Derman et al8; Svendsen et al9; Lindsay et al10 and Aitken et al11. Christiansen et al12 was excluded as there was no true placebo or control group. The paper reports &#8220;After an initial examination the women were randomly allocated to one of three main treatment groups: 1) estrogen/gestogen; 2) anabolic steroids; 3) nasal calcitonin&#8221;. Coope et al13 was excluded as it used a cross over design using piperazine oestrone sulphate and placebo with a washout period in the middle. Although there were 2 deaths reported in the study population, due to the cross over design, it is not possible to know how these were associated with the intervention or placebo. Nachtigall et al14 is included in the review (ERT II). Resch et al15 reports a participant randomised to estrogen who had a transient ischaemic attack, this is not a pre-specified outcome in our review. The control group had no reported cardiovascular outcomes.<BR/>
<BR/>Prof Thornton identifies a second review by Hemminki and McPherson (2000)16 which describes a search of unpublished drug company reports and includes a few additional cardiovascular events attributed to hormone therapy which are unpublished. This paper was not found in our search and we thank Prof Thornton for drawing it to our attention. Some of the papers assessed synthetic oestrogens which were excluded in our review. In addition cardiovascular events were not described in any detail. Without further detail of the cases and interventions in the 3-5 events (&#8220;conservative &#8211; best estimates&#8221;) in the hormone group and 1-2 events (&#8220;conservative &#8211; best estimates&#8221;) in the control group we are at present unable to assimilate them into our meta-analysis. However, due to the relatively small number of events compared to those already included, not including these data at present seems unlikely to make the current overall findings misleading.<BR/>
<BR/>1.Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. The Cochrane database of systematic reviews. 2015;3:CD002229.<BR/>2.Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas. Sep 20 2006;55(2):162-173.<BR/>3.Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama. Jul 17 2002;288(3):321-333.<BR/>4.Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Jama. Apr 14 2004;291(14):1701-1712.<BR/>5.Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama. Aug 19 1998;280(7):605-613.<BR/>6.Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. Bmj. Jul 19 1997;315(7101):149-153.<BR/>7.Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Jama. Jan 18 1995;273(3):199-208.<BR/>8.Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy -- a placebo-controlled study. International journal of fertility and menopausal studies. Mar-Apr 1995;40(2):73-78.<BR/>9.Svendsen OL, Hassager C, Marslew U, Christiansen C. Changes in calcanean bone mineral occurring spontaneously and during hormone replacement therapy in early post-menopausal women. Scandinavian journal of clinical and laboratory investigation. Dec 1992;52(8):831-836.<BR/>10.Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstetrics and gynecology. Jun 1984;63(6):759-763.<BR/>11.Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. British medical journal. Sep 8 1973;3(5879):515-518.<BR/>12.Christiansen C, Riis BJ. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. The Journal of clinical endocrinology and metabolism. Oct 1990;71(4):836-841.<BR/>13.Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? The Journal of the Royal College of General Practitioners. Mar 1981;31(224):134-140.<BR/>14.Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics and gynecology. Jul 1979;54(1):74-79.<BR/>15.Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R. Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. Acta endocrinologica. Jul 1990;123(1):14-18.<BR/>16.Hemminki E, McPherson K. Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease. Lancet. Feb 12 2000;355(9203):566-569.<BR/>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2015-08-19 11:58:22 +0100" MODIFIED_BY="[Empty name]">
<P>Henry MP Boardman, Louise Hartley, Anne Eisinga, Caroline Main, Marta Roqué i Figuls, Xavier Bonfill Cosp, Beatrice Knight</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2015-02-03 15:30:55 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-02-10 14:46:53 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-02-10 14:42:46 +0000" MODIFIED_BY="[Empty name]">Search strategies original review</TITLE>
<APPENDIX_BODY MODIFIED="2014-02-10 14:42:58 +0000" MODIFIED_BY="[Empty name]">
<P>#1 CARDIOVASCULAR-DISEASES*:ME<BR/>#2 CEREBROVASCULAR-DISORDERS*:ME<BR/>#3 CHOLESTEROL*:ME<BR/>#4 BLOOD-COAGULATION-FACTORS*:ME<BR/>#5 CARDIOVASCULAR<BR/>#6 CORONARY<BR/>#7 ANGINA*<BR/>#8 MYOCARDIAL<BR/>#9 STROKE<BR/>#10 HYPERTENSION<BR/>#11 CHOLESTEROL<BR/>#12 EMBOLI*<BR/>#13 THROMBO*<BR/>#14 CEREBROVASCULAR<BR/>#15 ATHEROSCLERO*<BR/>#16 ARTERIOSCLERO*<BR/>#17 LIPIDS*:ME<BR/>#18 LIPID*<BR/>#19 HYPERLIPIDEMIA*:ME<BR/>#20 (HYPERLIPIDEMIA or HYPERLIPIDAEMIA)<BR/>#21 FIBRIN*<BR/>#22 ((((((((#1 or #2) or #3) or #4) or #5) or #6) or #7) or #8) or #9)<BR/>#23 ((((((((((#10 or #11 or #12) or #13) or #14) or #15) or #16) or #17) or #18) or #19) or #20) or #21)<BR/>#24 (#22 or #23)<BR/>#25 ESTROGEN-REPLACEMENT-THERAPY*:ME<BR/>#26 HRT<BR/>#27 (HORMONE near REPLAC*)<BR/>#28 (OESTROGEN near REPLAC*)<BR/>#29 (ESTROGEN near REPLAC*)<BR/>#30 ((MENOPAUS* or POSTMENOPAUS*) or POSTMENOPAUS*)<BR/>#31 OESTROGEN<BR/>#32 ESTROGEN<BR/>#33 (#31 or #32)<BR/>#34 (#30 and #33)<BR/>#35 ((((#25 or #26) or #27) or #28) or #29)<BR/>#36 (#34 or #35)<BR/>#37 (#24 and #36)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-02-10 14:46:53 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-02-10 14:43:13 +0000" MODIFIED_BY="[Empty name]">Search strategies 2010</TITLE>
<APPENDIX_BODY MODIFIED="2014-02-10 14:43:53 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Cochrane Controlled Trial Register, Issue 1, April 2010 (search date: 20/04/2010)</HEADING>
<P>#1. MeSH descriptor Cardiovascular Diseases explode all trees<BR/>#2. MeSH descriptor Cerebrovascular Disorders explode all trees<BR/>#3. CARDIOVASCULAR*<BR/>#4. CORONARY<BR/>#5. ANGINA*<BR/>#6. MYOCARD*<BR/>#7. HEART NEAR/3 ATTACK<BR/>#8. STROKE*<BR/>#9. MeSH descriptor Embolism and Thrombosis explode all trees<BR/>#10. EMBOL*<BR/>#11. THROMBO*<BR/>#12. CEREBROVASCULAR<BR/>#13. MeSH descriptor Hypertension explode all trees<BR/>#14. HYPERTENSION<BR/>#15. MeSH descriptor Arteriosclerosis explode all trees<BR/>#16. ARTERIOSCLER* OR ARTHEROSCLER*<BR/>#17. ISCHAEMIC OR ISCHEMIC<BR/>#18. MeSH descriptor Hyperlipidemias explode all trees<BR/>#19. HYPERLIPIDEMIA* OR HYPERLIPIDAEMIA*<BR/>#20. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19)<BR/>#21. MeSH descriptor Hormone Replacement Therapy explode all trees<BR/>#22. HRT OR ERT OR ORT<BR/>#23. HORMONE NEAR/4 (REPLAC* OR THERAP* OR SUPPLEMENT*)<BR/>#24. ESTROGEN NEAR/4 (REPLAC* OR THERAP* OR SUPPLEMENT*)<BR/>#25. OESTROGEN NEAR/4 (REPLAC* OR THERAP* OR SUPPLEMENT*)<BR/>#26. (#21 OR #22 OR #23 OR #24 OR #25)<BR/>#27. (menopaus* OR postmenopaus* OR post-menopaus*)<BR/>#28. MeSH descriptor Postmenopause, this term only<BR/>#29. (#27 OR #28)<BR/>#30. oestrogen OR estrogen<BR/>#31. (#29 AND #30)<BR/>#32. (#26 OR #31)<BR/>#33. (#20 AND #32)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE search 20/04/2010</HEADING>
<P>1. CARDIOVASCULAR-DISEASES#.DE.<BR/>2. CEREBROVASCULAR-DISORDERS#.DE.<BR/>3. CARDIOVASCULAR.TI,AB.<BR/>4. CORONARY.TI,AB.<BR/>5. ANGINA$2.TI,AB.<BR/>6. (MYOCARDIAL OR HEART NEAR ATTACK).TI,AB.<BR/>7. STROKE$4.TI,AB.<BR/>8. EMBOLISM-AND-THROMBOSIS#.DE.<BR/>9. EMBOL$5.TI,AB.<BR/>10. THROMBO$6.TI,AB.<BR/>11. CEREBROVASCULAR.TI,AB.<BR/>12. HYPERTENSION.W..DE.<BR/>13. HYPERTENSION.TI,AB.<BR/>14. ARTERIOSCLEROSIS#.W..DE.<BR/>15. (ARTERIOSCLERO$5 OR ARTHEROSCLERO$5).TI,AB.<BR/>16. (ISCHAEMIC OR ISCHEMIC).TI,AB.<BR/>17. HYPERLIPIDEMIAS#.W..DE.<BR/>18. (HYPERLIPIDEMIA$4 OR HYPERLIPIDAEMIA$4).TI,AB.<BR/>19. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10<BR/>20. 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18<BR/>21. 19 OR 20<BR/>22. HORMONE-REPLACEMENT-THERAPY#.DE.<BR/>23. (HRT OR ERT OR ORT).TI,AB.<BR/>24. HORMONE NEAR (REPLAC$6 OR THERAP$4 OR SUPPLEMENT$6)<BR/>25. ESTROGEN NEAR (REPLAC$6 OR THERAP$4 OR SUPPLEMENT$6)<BR/>26. OESTROGEN NEAR (REPLAC$6 OR THERAP$4 OR SUPPLEMENT$6)<BR/>27. 22 OR 23 OR 24 OR 25 OR 26<BR/>28. MENOPAUS$4 OR POSTMENOPAUS$4 OR POST-MENOPAUS$4<BR/>29. POSTMENOPAUSE.W..DE.<BR/>30. 28 OR 29<BR/>31. (ESTROGEN OR OESTROGEN).TI,AB.<BR/>32. 30 AND 31<BR/>33. 27 OR 32<BR/>34. PT=RANDOMIZED-CONTROLLED-TRIAL<BR/>35. PT=CONTROLLED-CLINICAL-TRIAL<BR/>36. (SINGL$4 OR DOUBLE$4 OR TRIPLE$4 OR TREBLE$4) AND (BLIND$4 OR MASK$4)<BR/>37. RANDOM$5 OR PLACEBO$2<BR/>38. RANDOM-ALLOCATION.DE.<BR/>39. DOUBLE-BLIND-METHOD.DE.<BR/>40. SINGLE-BLIND-METHOD.DE.<BR/>41. (CLINIC$3 NEAR TRIAL$2).TI,AB.<BR/>42. RETRACT$5 NEAR PUBLICATION<BR/>43. 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42<BR/>44. ANIMAL=YES NOT HUMAN=YES<BR/>45. 21 AND 33 AND 43<BR/>46. 45 NOT 44<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE search 20/04/2010</HEADING>
<P>1. CARDIOVASCULAR-DISEASE#.DE.<BR/>2. CEREBROVASCULAR-DISEASE#.DE.<BR/>3. CARDIOVASCULAR.TI,AB.<BR/>4. CORONARY.TI,AB.<BR/>5. ANGINA$2.TI,AB.<BR/>6. MYOCARDIAL.TI,AB. OR (HEART NEAR ATTACK).TI,AB.<BR/>7. STROKE$4.TI,AB.<BR/>8. EMBOL$5.TI,AB.<BR/>9. THROMBO$6.TI,AB.<BR/>10. CEREBROVASCULAR.TI,AB.<BR/>11. HYPERTENSION.W..DE.<BR/>12. HYPERTENSION.TI,AB.<BR/>13. ARTERIOSCLEROSIS#.W..DE.<BR/>14. (ARTERIOSCLERO$5 OR ARTHEROSCLERO$5).TI,AB.<BR/>15. (ISCHAEMIC OR ISCHEMIC).TI,AB.<BR/>16. (HYPERLIPIDEMIA$4 OR HYPERLIPIDAEMIA$4).TI,AB.<BR/>17. HYPERLIPIDEMIA#.W..DE.<BR/>18. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17<BR/>19. Hormone-Substitution#.DE.<BR/>20. (HRT OR ERT OR ORT).TI,AB.<BR/>21. HORMONE NEAR (REPLAC$6 OR THERAP$4 OR SUPPLEMENT$6).TI,AB.<BR/>22. ESTROGEN NEAR (REPLAC$6 OR THERAP$4 OR SUPPLEMENT$6).TI,AB.<BR/>23. OESTROGEN NEAR (REPLAC$6 OR THERAP$4 OR SUPPLEMENT$6).TI,AB.<BR/>24. (menopaus$4 OR postmenopaus$4 OR post-menopaus$4).TI,AB.<BR/>25. Postmenopause.W..DE.<BR/>26. 39 OR 40<BR/>27. (oestrogen OR estrogen).TI,AB.<BR/>28. 41 AND 42<BR/>29. 19 OR 20 OR 34 OR 37 OR 38 OR 43<BR/>30. 44 AND 18<BR/>31. factorial$<BR/>32. crossover$2 OR cross ADJ over$2<BR/>34. (RANDOM$ OR PLACEBO$).DE,TI,AB.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS search conducted 20/04/2010</HEADING>
<P>
<B>Search 1:</B>
</P>
<P>"HORMONE REPLACEMENT THERAPY" OR</P>
<P>((hormone OR oestrogen OR oestrogen) AND (replac$ or therap$ or supplement$)) or (hrt OR ert OR ort) AND ("clinical trials, RANDOMIZED" or "controlled clinical trials, RANDOMIZED" OR (( trial$ or ensa$ or estud$) AND (clin$)) OR ((singl$ or doubl$ or doble$ or duplo$ or trebl$ or trip$) AND (blind$ or cego$ or ciego$ or mask$ or mascar$)) OR (random$ or randon$ or casual$ or acaso$ or azar or aleator$)) = 318</P>
<P>
<B>Search 2:</B>
</P>
<P>(("POSTMENOPAUSE" OR menopaus$ or postmenopaus$ or post-menopause) AND (oestrogen or estrogen))</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-02-03 15:30:55 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-02-03 15:28:18 +0000" MODIFIED_BY="[Empty name]">Search strategies 2014</TITLE>
<APPENDIX_BODY MODIFIED="2015-02-03 15:30:55 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL </HEADING>
<P>#1 MeSH descriptor: [Cardiovascular Diseases] explode all trees<BR/>#2 MeSH descriptor: [Cerebrovascular Disorders] explode all trees<BR/>#3 MeSH descriptor: [Hypertension] this term only<BR/>#4 (cardiovascular or coronary or angina* or myocardial or stroke* or embol* or thrombo* or cerebrovascular or hypertension or arteriosclero* or atherosclero* or ischaemi* or ischemi*):ti,ab<BR/>#5 (heart near/2 attack):ti,ab<BR/>#6 MeSH descriptor: [Hyperlipidemias] explode all trees<BR/>#7 MeSH descriptor: [Cholesterol] explode all trees<BR/>#8 MeSH descriptor: [Blood Coagulation Factors] explode all trees<BR/>#9 MeSH descriptor: [Lipids] explode all trees<BR/>#10 (hyperlipidemia* or hyperlipidaemia* or cholesterol or lipid* or fibrin*):ti,ab<BR/>#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10<BR/>#12 MeSH descriptor: [Progestins] explode all trees<BR/>#13 (progestogen or medroxyprogesterone acetate or MPA or dydrogesterone or norethisterone or norethindrone or oestrogen or estrogen or estradiol or CEE or premarin or estriol or oestradiol):ti,ab<BR/>#14 (hormone* near/3 therap*):ti,ab<BR/>#15 (hormone* near/3 supplement*):ti,ab<BR/>#16 #12 or #13 or #14 or #15<BR/>#17 MeSH descriptor: [Climacteric] this term only<BR/>#18 MeSH descriptor: [Menopause] this term only<BR/>#19 MeSH descriptor: [Perimenopause] this term only<BR/>#20 MeSH descriptor: [Postmenopause] this term only<BR/>#21 MeSH descriptor: [Menopause, Premature] this term only<BR/>#22 (postmenopaus* or post-menopaus* or perimenopaus* or peri-menopaus* or climacter* or menopaus*):ti,ab<BR/>#23 #17 or #18 or #19 or #20 or #21 or #22<BR/>#24 #16 and #23<BR/>#25 #11 and #24<BR/>#26 MeSH descriptor: [Hormone Replacement Therapy] explode all trees<BR/>#27 (HRT or ERT or ORT):ti,ab<BR/>#28 (hormone near/3 replac*):ti,ab<BR/>#29 (estrogen near/3 replac*):ti,ab<BR/>#30 (oestrogen near/3 replac*):ti,ab<BR/>#31 #26 or #27 or #28 or #29 or #30<BR/>#32 #11 and #31<BR/>#33 #25 or #32<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE </HEADING>
<P>1 exp Cardiovascular Diseases/<BR/>2 exp Cerebrovascular Disorders/<BR/>3 cardiovascular.ti,ab.<BR/>4 coronary.ti,ab.<BR/>5 angina$.ti,ab.<BR/>6 (myocardial or (heart adj2 attack)).ti,ab.<BR/>7 stroke$.ti,ab.<BR/>8 embol$.ti,ab.<BR/>9 thrombo$.ti,ab.<BR/>10 cerebrovascular.ti,ab.<BR/>11 hypertension.ti,ab.<BR/>12 Hypertension/<BR/>13 (arteriosclero$ or artherosclero$).ti,ab.<BR/>14 (ischaemi$ or ischemi$).ti,ab.<BR/>15 exp Hyperlipidemias/<BR/>16 (hyperlipidemia$ or hyperlipidaemia$).ti,ab.<BR/>17 exp Cholesterol/<BR/>18 cholesterol.ti,ab.<BR/>19 exp Blood Coagulation Factors/<BR/>20 exp Lipids/<BR/>21 lipid$.ti,ab.<BR/>22 fibrin$.ti,ab.<BR/>23 or/1-22<BR/>24 exp Progestins/<BR/>25 progestogen.tw.<BR/>26 (medroxyprogesterone acetate or MPA).tw.<BR/>27 dydrogesterone.tw.<BR/>28 (norethisterone or norethindrone).tw.<BR/>29 (oestrogen or estrogen).ti,ab.<BR/>30 estradiol$.ti,ab.<BR/>31 CEE.ti,ab.<BR/>32 premarin.ti,ab.<BR/>33 estriol.ti,ab.<BR/>34 oestradiol.ti,ab.<BR/>35 (hormone$ adj3 (therap* or supplement*)).ti,ab<BR/>36 or/24-35<BR/>37 climacteric/ or menopause/ or perimenopause/ or postmenopause/ or menopause, premature/ 38 (postmenopaus$ or post-menopaus$ or post menopaus$).tw.<BR/>39 (perimenopaus$ or peri-menopaus$ or peri menopaus$).tw.<BR/>40 (climacter$ or menopaus$).tw.<BR/>41 or/37-40<BR/>42 36 and 41<BR/>43 23 and 42<BR/>44 exp hormone replacement therapy/<BR/>45 (HRT or ERT or ORT).ti,ab.<BR/>46 ((hormone or estrogen or oestrogen) adj3 replac$).ti,ab.<BR/>47 or/44-46<BR/>48 23 and 47<BR/>49 43 or 48<BR/>50 randomized controlled trial.pt.<BR/>51 controlled clinical trial.pt.<BR/>52 randomized.ab.<BR/>53 placebo.ab.<BR/>54 clinical trials as topic.sh.<BR/>55 randomly.ab.<BR/>56 trial.ti.<BR/>57 or/50-56<BR/>58 49 and 57<BR/>59 exp animals/ not humans.sh.<BR/>60 58 not 59<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Embase </HEADING>
<P>1 exp cardiovascular disease/<BR/>2 exp cerebrovascular disease/<BR/>3 cardiovascular.ti,ab.<BR/>4 coronary.ti,ab.<BR/>5 angina$.ti,ab.<BR/>6 (myocardial or (heart adj2 attack)).ti,ab.<BR/>7 stroke$.ti,ab.<BR/>8 embol$.ti,ab.<BR/>9 thrombo$.ti,ab.<BR/>10 cerebrovascular.ti,ab.<BR/>11 hypertension.hw.<BR/>12 hypertensi$.ti,ab.<BR/>13 exp arteriosclerosis/<BR/>14 arteriosclerosis.hw.<BR/>15 (arteriosclero$ or atherosclero$).ti,ab.<BR/>16 (ischaemi$ or ischemi$).ti,ab.<BR/>17 (hyperlipidemia$ or hyperlipidaemia$).ti,ab.<BR/>18 exp hyperlipidemia/<BR/>19 hyperlipidemia.hw.<BR/>20 exp Cholesterol/<BR/>21 cholesterol.ti,ab.<BR/>22 exp blood clotting factor/<BR/>23 exp lipid/<BR/>24 lipid$.ti,ab.<BR/>25 fibrin$.ti,ab.<BR/>26 or/1-25<BR/>27 exp hormone substitution/<BR/>28 (HRT or ERT or ORT).ti,ab.<BR/>29 ((hormone or oestrogen or estrogen) adj3 replac$).ti,ab.<BR/>30 or/27-29<BR/>31 26 and 30<BR/>32 exp gestagen/<BR/>33 progestin$.ti,ab.<BR/>34 progestogen$.ti,ab.<BR/>35 (medroxyprogesterone acetate or MPA).tw.<BR/>36 dydrogesterone.tw.<BR/>37 (norethisterone or norethindrone).ti,ab.<BR/>38 (oestrogen or estrogen).ti,ab.<BR/>39 estradiol$.ti,ab.<BR/>40 CEE.ti,ab.<BR/>41 premarin.ti,ab.<BR/>42 estriol.ti,ab.<BR/>43 oestradiol.ti,ab.<BR/>44 progesterone$.ti,ab.<BR/>45 (hormone adj3 (therap$ or supplement$)).ti,ab.<BR/>46 or/32-45<BR/>47 exp "menopause and climacterium"/<BR/>48 (postmenopaus$ or "post menopaus$").ti,ab.<BR/>49 (perimenopaus$ or "peri menopaus$").ti,ab.<BR/>50 (climacter$ or menopaus$).ti,ab.<BR/>51 or/46-49<BR/>52 26 and 46 and 51<BR/>53 crossover procedure/<BR/>54 double blind procedure/<BR/>55 single blind procedure/<BR/>56 (cross over$ or crossover$).ti,ab.<BR/>57 placebo$.ti,ab.<BR/>58 (doubl$ adj blind$).ti,ab.<BR/>59 allocat$.ti,ab.<BR/>60 trial.ti.<BR/>61 randomized controlled trial/<BR/>62 random$.ti,ab.<BR/>63 or/53-62<BR/>64 63 and (31 or 52)<BR/>65 exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/<BR/>66 human/ or normal human/<BR/>67 65 and 66<BR/>68 65 not 67<BR/>69 64 not 68<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS</HEADING>
<P>
<B>Search A</B>
</P>
<P>((MH:"Estrogen Replacement Therapy" OR "MH:"Hormone Replacement Therapy") OR (terapeutica AND hormonal) OR (terapia AND hormona$) OR (terapia AND reposicao) OR (terapia AND estrogen$) OR (tratamiento AND hormonal) OR (terapia AND reemplazo) OR (hormone AND replac$) OR (hormone AND therap$) OR (hormone AND supplement$) OR (estrogen AND replac$) OR (estrogen AND therap$) OR (estrogen AND supplement$) OR (oestrogen AND replac$) OR (oestrogen AND therap$) or (oestrogen AND supplement$) OR (HRT OR ERT OR ORT OR THS)) limited to Controlled Clinical Trials Topic List</P>
<P>
<B>Search B</B>
</P>
<P>(MH:Climacteric OR MH:Menopause OR MH:"Menopause, Premature" OR MH:Perimenopause OR MH:Postmenopause OR pos-menopaus$ OR posmenopaus$ OR postmenopaus$ OR post-menopaus$ OR climacteric OR climaterio OR menopaus$ OR perimenopaus$) limited to Controlled Clinical Trials Topic List</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 new studies contributed data to the quantiative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;38 full-text articles reporting 6 new studies and 10 studies already included contributed to the qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;57 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3728 titles and/or abstracts screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of titles and abstracts identified after de-duplication: 3728&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Titles and abstracts identified through database searching: 4508&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Zero records retrieved through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3671 excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;19 full-text articles excluded&lt;/p&gt;&lt;p&gt;No relevant clinical outcomes: 14&lt;/p&gt;&lt;p&gt;Wrong intervention: 2&lt;/p&gt;&lt;p&gt;Not a RCT: 1&lt;/p&gt;&lt;p&gt;Wrong patient population: 1&lt;/p&gt;&lt;p&gt;Wrong comparison: 1&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 new studies provided data to the quantitative synthesis (meta-analysis). 19 studies in total provided data for quantitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 new studies included in the qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;37 articles reporting on 6 new studies and 10 studies already included in the review&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;97 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3963 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3963 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3698 records identified through database searching (December 2012)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;33 additional records identified through other sources (December 2012)&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;232 additional records identified through repeating search (February 2014)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3866 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;58 full-text articles excluded&lt;/p&gt;&lt;p&gt;2 studies identified in repeat search (February 2014). One study is ongoing and one study has completed and published in 2014.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>